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Summary 
Investigation of novel therapeutic strategies in B cell and antibody mediated disease 
Dr Gemma Deborah Banham  
Terminally differentiated B cells are responsible for antibody generation, a key component of 
adaptive immunity. IgG antibodies play an important role in defence against infection but can be 
pathogenic in some autoimmune diseases and in solid organ transplantation. In addition to antibody 
generation, there is increasing interest in the antibody-independent functions of B cells, including 
their ability to regulate immune responses via the production of IL10.  
In this thesis I firstly explored the therapeutic potential of belimumab, an anti-BLyS antibody, in an 
experimental medicine study in kidney transplant recipients. The rationale for this study was based 
on published studies showing that B cells activate alloreactive T cells and secrete human leukocyte 
antigen (HLA) and non-HLA antibodies that negatively affect graft function and survival, but may also 
play a protective role by regulating alloimmune responses promoting transplant tolerance. B-
Lymphocyte Stimulator (BLyS) is a cytokine that promotes B cell activation and survival. We 
performed the first randomized controlled trial using belimumab as early maintenance 
immunosuppression in kidney transplantation. In belimumab-treated subjects, we demonstrate a 
reduction in naïve and activated memory B cells, plasmablasts, IgG transcripts in peripheral blood 
and new antibody formation as well as evidence of reduced CD4 T cell activation and of a skewing of 
the residual B cell compartment towards an IL10-producing regulatory phenotype. This experimental 
medicine study highlights the potential of belimumab as a novel therapeutic agent in 
transplantation. 
In the second part of my project I performed a preclinical study investigating the potential efficacy of 
bromodomain inhibitors in reducing antibody-mediated immune cell activation. Immune complexed 
antigen can activate mononuclear phagocytes (MNP), comprising macrophages and dendritic cells 
(DCs), via ligation of Fc gamma receptors (FcγR), that bind the Fc region of IgG. FcγR-dependent MNP 
activation results in profound changes in gene expression that mediate antibody effector function in 
these cells. The resulting inflammatory response can be pathological in the setting of autoimmune 
diseases, such as systemic lupus erythematosus and in antibody-mediated rejection in 
transplantation. BET proteins are a family of histone modification ‘readers’ that bind acetylated 
lysine residues within histones and function as a scaffold for the assembly of complexes that 
regulate gene transcription. Bromodomain inhibitors (I-BET) selectively inhibit the transcription of a 
subset of inflammatory genes in macrophages following toll-like receptor stimulation.  Since MNPs 
         
make a key contribution to antibody-mediated pathology, we sought to determine the extent to 
which I-BET inhibits macrophage and DC activation by IgG.  
We show that I-BET delays phagolysosome maturation associated with build-up of immune complex 
(IC) whilst selectively inhibiting IC induced cytokine production. I-BET changed MNP morphology, 
resulting in a less adherent phenotype, prompting an assessment of its impact on DC migration. In 
vitro, in a three-dimensional collagen matrix, IgG-IC induced augmentation of DC chemotaxis to 
chemokine (C-C motif) ligand 19 (CCL19) was abrogated by the addition of I-BET. In vivo, two photon 
imaging showed that systemic I-BET treatment reduced IC-induced dermal DC mobilisation. Tissue 
DCs and transferred DC also had reduced migration to draining lymph nodes following I-BET 
treatment. These observations provide mechanistic insight into the potential therapeutic benefit of 
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Summary: Investigation of novel therapeutic strategies in B cell and antibody mediated disease 
Terminally differentiated B cells are responsible for antibody generation, a key component of 
adaptive immunity. IgG antibodies play an important role in defence against infection but can be 
pathogenic in some autoimmune diseases and in solid organ transplantation. In addition to antibody 
generation, there is increasing interest in the antibody-independent functions of B cells, including 
their ability to regulate immune responses via the production of IL10.  
In this thesis I firstly explored the therapeutic potential of belimumab, an anti-BLyS antibody, in an 
experimental medicine study in kidney transplant recipients. The rationale for this study was based 
on published studies showing that B cells activate alloreactive T cells and secrete human leukocyte 
antigen (HLA) and non-HLA antibodies that negatively affect graft function and survival, but may 
also play a protective role by regulating alloimmune responses promoting transplant tolerance. B-
Lymphocyte Stimulator (BLyS) is a cytokine that promotes B cell activation and survival. We 
performed the first randomized controlled trial using belimumab as early maintenance 
immunosuppression in kidney transplantation. In belimumab-treated subjects, we demonstrate a 
reduction in naïve and activated memory B cells, plasmablasts, IgG transcripts in peripheral blood 
and new antibody formation as well as evidence of reduced CD4 T cell activation and of a skewing of 
the residual B cell compartment towards an IL10-producing regulatory phenotype. This 
experimental medicine study highlights the potential of belimumab as a novel therapeutic agent in 
transplantation. 
In the second part of my project I performed a preclinical study investigating the potential efficacy 
of bromodomain inhibitors in reducing antibody-mediated immune cell activation. Immune 
complexed antigen can activate mononuclear phagocytes (MNP), comprising macrophages and 
dendritic cells (DCs), via ligation of Fc gamma receptors (FcγR), that bind the Fc region of IgG. FcγR-
dependent MNP activation results in profound changes in gene expression that mediate antibody 
effector function in these cells. The resulting inflammatory response can be pathological in the 
setting of autoimmune diseases, such as systemic lupus erythematosus and in antibody-mediated 
rejection in transplantation. BET proteins are a family of histone modification ‘readers’ that bind 
acetylated lysine residues within histones and function as a scaffold for the assembly of complexes 
that regulate gene transcription. Bromodomain inhibitors (I-BET) selectively inhibit the transcription 
of a subset of inflammatory genes in macrophages following toll-like receptor stimulation.  Since 
MNPs make a key contribution to antibody-mediated pathology, we sought to determine the extent 
to which I-BET inhibits macrophage and DC activation by IgG.  
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We show that I-BET delays phagolysosome maturation associated with build-up of immune complex 
(IC) whilst selectively inhibiting IC induced cytokine production. I-BET changed MNP morphology, 
resulting in a less adherent phenotype, prompting an assessment of its impact on DC migration. In 
vitro, in a three-dimensional collagen matrix, IgG-IC induced augmentation of DC chemotaxis to 
chemokine (C-C motif) ligand 19 (CCL19) was abrogated by the addition of I-BET. In vivo, two photon 
imaging showed that systemic I-BET treatment reduced IC-induced dermal DC mobilisation. Tissue 
DCs and transferred DC also had reduced migration to draining lymph nodes following I-BET 
treatment. These observations provide mechanistic insight into the potential therapeutic benefit of 
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1.1 B cell development and function 
1.1.1 B cells and antibody 
The immune system is comprised of an innate, rapidly responding component and an adaptive 
component. The latter is characterised by a capacity to adapt antigen-specific receptors to enhance 
immune responses as they develop and exhibit memory of previous exposure. B cells are the central 
mediators of humoral adaptive immunity. B cells are lymphocytes characterised by the surface 
expression of a B cell receptor (BCR), a membrane bound antigen-binding immunoglobulin (Ig) 
coupled with a signal transduction moiety. Immunoglobulins are made up of two heavy and two light 
chains, each of which contain variable and constant domains (Figure 1)(Janeway CA Jr 2001).  The 
crystal structure of the immunoglobulin domain reveals β strands which form a characteristic β 
sheet fold (Bork 1994). The fragment antigen binding (Fab) region is made up of one constant and 
one variable domain from each light and heavy chain. Hypervariable regions known as 
complementarity determining regions (CDR) are found in the loops that extend between the β sheet 
structures. Three CDR are found on each of the light (VL) and heavy (VH) chains of the variable 
domains. CDR are responsible for binding to antigen; variation in CDR largely determines the binding 
affinity of specific antibody-antigen combinations and allows for a broad range of antibody 
specificities (Sela-Culang 2013). 
 
Figure 1: Antibody structure. Immunoglobulins are made up of two heavy (H) and two light (L) chains, 
each of which contain variable (VH , VL ) and constant (CH , CL ) domains. CDR complementarity 
determining regions, Fab fragment antigen binding region, Fc fragment crystallizable region 
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The antibody constant domain allows for common effector functions, for example through binding 
of the fragment crystallizable (Fc) region to Fc receptors, receptors for Ig expressed on both innate 
and adaptive immune cells, and complement proteins. B cells are most widely known as the 
precursors to terminally differentiated B cells, known as plasma cells that secrete immunoglobulins, 
also known as antibodies, in response to activation following recognition of antigen via their BCR 
(Janeway CA Jr 2001). B cells can produce antibodies reactive not only to protein and peptide 
antigens (T-dependent antigens) but also to carbohydrate/polysaccharide antigens (T-independent 
antigens). Secreted antibodies are able to directly neutralize pathogens or toxins. They can also bind 
complement and activate it via the classical and alternative pathways (Karsten 2012). The resultant 
complement cascade can lead to direct lysis of microbes, phagocytosis of microbes opsonised by 
complement fragments e.g. C3b and induction of inflammation via secretion of anaphylotoxins e.g. 
C5a, with resultant recruitment of antibody, complement and mononuclear phagocytes to the site of 
infection.  
B cells have other effector functions besides antibody production which can influence the 
development of both humoral and cellular immune responses. B cells perform antigen presentation 
(Rodriguez-Pinto 2005) and organize the structure of lymphoid tissues, regulating lymphangiogenesis 
(Angeli 2006). B cells derived lymphotoxin (LT) and tumour necrosis factor alpha (TNFα) are 
important regulators of steady state lymphangiogenesis, supporting the development of follicular 
dendritic cells (Fu 1998) and regulating the development of secondary (Gonzalez 1998, Tumanov 
2002) and tertiary lymphoid organs (Weyand 2005). B cells control lymph node remodelling during 
acute immune responses via provision of LT; lymph node expansion following murine lymphocytic 
choriomeningitis virus (LCMV) was reduced in B cell deficient mice, inhibited by B cell depletion of 
wild type mice and restored in B cell deficient mice by B cell reconstitution (Kumar 2010). B cells also 
control the final steps of development of gut associated lymphoid tissues through LT and TNF 
signalling (Tumanov 2004) and direct interactions with Peyer’s patch stroma (Golovkina 1999) 
(reviewed in (Shen 2015)). B cell interactions with subepithelial dendritic cells in Peyer’s patches are 
critical for effective IgA mucosal responses against oral antigens and gut commensals (Reboldi 2016).    
B cells can be subdivided into ‘effector’ and ‘regulatory’ B cells depending on their cytokine profile 
(Figure 2)(Lund 2008). The environment in which a B cell is activated determines the cytokines they 
produce and the resultant immune response. Dendritic cells activated by toll like receptor (TLR) 
ligands secrete interleukin (IL)-12, promoting the differentiation of Th1 T cells. These Th1 cells 
provide help to naïve B cells, inducing the transcription factor T-bet and differentiation to a B 
effector 1 cell fate (Be1), prompting the release of the cytokines associated with type 1 immune 
responses, for example interferon γ (IFN-γ)  and IL-12. These B cells go on to present antigen to naïve 
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T cells promoting further Th1 differentiation, leading to a positive feedback loop, amplifying Th1 
responses (Harris 2005a). In contrast, T cell help delivered by Th2 T cells promotes the IL-4 
dependent differentiation of B cells into B effector 2 cells (Be2) that produce type 2 associated 
cytokines, for example IL-2, IL-4 and IL-13 (Harris 2005b). Under certain circumstances signals 
delivered by TLR ligands, CD40 crosslinking or antigen induce differentiation of B cells into IL-10 
producing regulatory B cells (Rosser 2015). 
 
Figure 2: B cell effector and regulatory functions. B cells have important roles as both effectors and 
regulators. Effector functions include antibody production, antigen presentation and secretion of pro-
inflammatory cytokines, including IL-6, that can activate T cells. Regulatory B cells are a recently 
described subset which inhibit T-cell responses via the production of IL-10. There are also thought to 
be regulatory B cells which act independently of IL-10, utilising contact mediated suppression and 
release of other anti-inflammatory cytokines for example TGF-β and IL-35. Regulatory B cells are also 
able to induce expansion of regulatory T cell populations. 
B cell effector responses are of great importance in the host defence against pathogens however, 
over-active or inappropriate effector responses can be pathogenic in the setting of autoimmunity, 
and undesirable when causing allo-immunity following transplantation. Tight regulation is therefore 
required to enable appropriate cellular responses; often achieved through systems involving a 
balance of activatory and inhibitory signalling.  
13 
 
1.1.2 B cell subsets and activation  
The B cell lineage comprises of two subtypes, B1 and B2 cells.  B1 cells reside primarily within the 
pleural and peritoneal cavity in mice and are capable of producing low affinity natural antibodies to 
T-independent antigens as a first line of defence. A human equivalent population has been identified 
in umbilical cord blood and adult peripheral blood (Griffin 2011). B2 cells are generated within the 
bone marrow. They develop from pro-B cells to pre-B cells to immature B cells that exit the bone 
marrow, entering the periphery migrating to the spleen where they go through several transitional 
stages (T1, T2) prior to reaching maturity (Loder 1999).  
Mature B cells can be divided into two subgroups: marginal zone B cells that are responsible for T 
independent responses, resident within the marginal zone of the spleen, an area specialized to filter 
blood borne antigens and follicular B cells responsible for T-dependent responses. Follicular B cells 
internalise antigen bound via their BCR, undergo activation and traffic to the border between the B 
cell follicle and T cell zone of secondary lymphoid organs, where they can present antigen to CD4+ T 
cells in the context of class II major histocompatibility complex (MHC) molecules. Activated, but not 
naïve B cells, express co-stimulation molecules required to provide the second signal needed for T 
cell activation. B cell activation is generally dependent on T cell help so in many cases an alternative 
innate antigen presenting cell, for example a dendritic cell, is required to provide the initial 
activating signal to CD4+ helper T cells. B cell antigen presentation is optimised to amplify high 
affinity antigen-specific responses. 
Following this B-T cell interaction, a proportion of B cells become short lived extra-follicular 
plasmablasts and the remainder enter the germinal centre; here antibody encoding genes are 
modified by class switch recombination and somatic hypermutation. Class switch recombination 
induces changes in the constant region of the heavy chain resulting in different antibody isotypes 
without inducing changes in the variable region that would affect antigen specificity (Stavnezer 
2008). Naïve B cells express only IgM. As they undergo maturation they co-express IgD. Class-switch 
recombination following antigen encounter renders cells capable of producing IgG, IgA or IgE, each 
having defined effector functions. During somatic hypermutation, mutations are induced within the 
CDR which alter binding specificity and affinity of the resultant BCR. These B cells then undergo 
clonal selection, competing for limited antigen and survival signals offered by follicular dendritic 
cells. Only those with the highest affinity for antigen will survive to become long lived memory B 
cells or plasma cells (Rajewsky 1996). A subset of CD4+ T cells known as T follicular helper (Tfh) cells 
are characterised by expression of the transcription factor Bcl6 (Nurieva 2009), located within B cell 
follicles and are essential for the development and maintenance of germinal centre B cells (Crotty 
2011). A small proportion of plasma cells arising from the germinal centre become established as 
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long-lived non-proliferative plasma cells in the bone marrow, secreting high affinity class switched 
antibodies and enabling a heightened antibody response on re-challenge with the previously 
encountered antigen (Radbruch 2006). 
B1 B cells and marginal zone B cells form an important part of the early innate immune response. 
They have the capacity to respond to antigens and inflammatory stimuli rapidly, terminally 
differentiating into short lived plasmablasts within three days of particulate bacterial antigen 
exposure (Martin 2001). Follicular B cells form an important part of the adaptive immune response, 
generating short-lived plasmablasts within three to five days, followed by long-lived memory B cells 
and bone marrow resident plasma cells that produce high affinity antibodies and are critical for 
rapid, specific and heightened secondary immune responses on rechallenge (Slifka 1998, Bernasconi 
2002, Nutt 2015). 
 
Figure 3: B cell development, based on figure from (Clatworthy 2011), permission for reprinting 
granted by John Wiley and Sons. A minor B-cell population, known as B1 cells, are found mainly in the 
pleural and peritoneal cavities and produce low affinity natural antibodies independent of T cell help. 
The majority of peripheral B cells are referred to as B2 cells and are produced in the bone marrow. B2 
cells pass through several stages of maturation as they exit from the bone marrow and pass into the 
periphery. Following antigen encounter, B cells obtain T-cell help and enter the germinal center 
where they undergo class switch recombination and affinity maturation. They compete for limited 
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antigen and survival signals offered by follicular dendritic cells, with only those with the highest 
affinity for antigen surviving to become long lived memory B cells or plasmablasts. Tfh are critical for 
germinal center formation, providing both contact and cytokine (IL-21) signals for germinal center B 
cells. Some plasmablasts find a suitable niche for long-term survival within bone marrow and tertiary 
lymphoid organs (TLO) within inflamed tissue, for example rejecting allografts.  
1.1.3 B cell development and tolerance 
As B cells mature they pass through multiple tolerance checkpoints, set periods of time where their 
fate can be influenced and determined, allowing for regulation of self reactive B cell clones resulting 
in an immunologically tolerant B cell compartment. Mechanisms of tolerance include clonal deletion, 
receptor editing, clonal anergy, and competition for extrinsic factors (Goodnow 2005). The first 
checkpoint occurs at the pre-B cell stage and requires expression of a pre-BCR. Induction of 
recombination activating genes (RAG1 and RAG2) initiates V(D)J recombination, enabling the 
developing B cell to produce heavy and light chain Ig receptors and form a functional BCR. Before 
exiting the bone marrow, immature B cells must pass through a central tolerance checkpoint 
(immature checkpoint). The strength of BCR signalling determines whether cells are allowed to 
progress (positive selection) or whether they undergo receptor editing or apoptosis (Tiegs 1993, 
Tussiwand 2009). Those expressing a non autoreactive receptor with an appropriate level of antigen 
binding receive optimal BCR signalling (tonic or basal BCR signalling) and are positively selected. 
Those expressing low levels of BCR may rearrange their light chain in an attempt to produce a more 
efficient BCR. Those expressing a BCR with high affinity for self antigen expressed in the bone 
marrow undergo receptor editing; RAG 1 and RAG2 are switched off only once a receptor that is not 
autoreactive is produced, allowing the immature B cell to be positively selected to exit the bone 
marrow. Cells that fail to be positively selected die by apoptosis. Peripheral tolerance mechanisms 
operate to control autoreactive cells reaching the periphery. Immature B cells that undergo positive 
selection and migrate from the bone marrow to the spleen are known as transitional B cells (TrB) 
and can be further subdivided into transitional type 1 (T1), transitional type 2 (T2) and transitional 
type 3 (T3) subsets. A further tolerance checkpoint occurs at the transitional to follicular stage. In 
contrast to central tolerance that is dependent on BCR binding affinity alone, the stringency of this 
peripheral tolerance checkpoint can be modulated by the cytokine BLyS as described in detail below.  
B cells may become activated when they encounter antigen that binds to their cognate BCR. The 
result of this interaction is dependent on the affinity of the antigen for the BCR, and the 
environmental context. The BCR signal transduction moiety is composed of the transmembrane 
proteins Igα (CD79a) and Igβ (CD79b), which signal via immunoreceptor tyrosine-based activation 
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motifs (ITAMs) located within their cytoplasmic domains (Clark 1992). The B cell co-receptor 
complex comprised of CD19, CD21 (CR2), and CD81 provides additional non-antigen specific signals 
that modulate BCR signal transduction (Fearon 1995). The B cell may receive additional co-activating 
and inhibitory signals that determine the net activation threshold and control the extent to which 
BCR cross-linking drives B cell activation (Poe 2001, Nitschke 2005), including signals through TLR 
(Lanzavecchia 2007). In murine B cells, generation of T-dependent antigen-specific antibody 
responses requires activation of TLRs in B cells in addition to CD4+ T-cell help (Pasare 2005). B cells 
may also receive activating signals from cytokines including BLyS (Mackay 2003).  
1.2  B cells and antibody in disease 
1.2.1 Immune complexes in disease 
When the immune response is directed against self-antigens autoimmune disease can result. 
Systemic lupus erythematosus (SLE) is an archetypal example of an autoimmune disease caused by 
the deposition of IgG immune complexes in tissues including the kidneys but also other tissues for 
example skin. Antinuclear antibodies and immune complex deposits can be identified by 
immunofluorescence, for example when they are deposited within the kidney (Toong 2011, Tsokos 
2011). Patient’s with SLE display impaired phagocytosis of apoptotic debris (Herrmann 1998), leading 
to an accumulation of apoptotic cells in patient blood, germinal centres and inflamed tissues (Emlen 
1994, Munoz 2010). Dying cells are prone to progress to secondary necrosis, exposing autoantigens 
which form immune complexes with circulating antinuclear autoantibodies. Deposited immune 
complexes activate plasmacytoid DCs, leading to the release of type 1 interferons that activate DCs 
and autoreactive B and T cells (Ronnblom 2008). An interferon-inducible gene expression signature 
in peripheral blood cells distinguishes those with SLE from controls and is associated with severe 
disease (Baechler 2003). Undigested secondary necrotic cell-derived material (SNEC) is captured by 
follicular dendritic cells within germinal centres, driving selection of autoreactive B cells. Deposited 
immune complexes activate complement, causing inflammation which attracts neutrophils and 
macrophages which bind via their Fcγ receptors. SNEC-containing immune complexes are cleared by 
blood-borne mononuclear phagocytes resulting in the secretion of inflammatory cytokines; 
potentiating inflammation and organ damage leading to further cell death and establishment of 
chronic inflammation (Munoz 2010).  
Other examples of antibody mediated diseases include Goodpasture’s Syndrome where antibodies 
to type IV collagen deposit within the kidneys and lungs (Bolton 1996), rheumatoid arthritis 
(Korganow 1999) and autoimmune thyroid disease (Nielsen 2004).  
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1.2.2 Antibody mediated pathology in kidney transplantation 
Antibodies forming following kidney transplantation have a deleterious role. Those who receive 
organs from HLA-antibody incompatible donors and have donor specific anti-HLA antibodies (DSA) at 
the time of transplantation have increased rates of graft loss, with risk of antibody mediated 
rejection (ABMR) correlated with the peak HLA-DSA strength (Lefaucheur 2010). Historically, 
transplantation in the setting of a positive crossmatch and preformed antibodies was often 
associated with hyperacute rejection (Patel 1969, Jeannet 1970). Desensitisation regimes that aim to 
reduce DSA prior to HLA-incompatible transplantation improve outcomes allowing successful 
transplantation across HLA antibody barriers with improved survival outcomes compared to 
remaining on dialysis or the deceased donor waiting list (Montgomery 2011), though the popularity 
of HLA-incompatible transplantation has decreased as the living donor kidney paired exchange 
scheme has grown. 
Recipients developing donor specific HLA-antibodies following transplantation have reduced survival 
of their grafts due to the development of chronic ABMR (Wiebe 2012). Those who develop antibody 
mediated vascular rejection are nine times more likely to lose their grafts than those experiencing T 
cell mediated rejection without vascular inflammation (Lefaucheur 2013). Allograft rejection is 
generally classified according to Banff histological criteria with recent revisions incorporating our 
increasing understanding of ABMR (Haas 2014, Haas 2016). 
The presence of non-HLA antibodies has also been associated with worsened graft outcomes. The 
presence of antibodies against MHC class I–related chain A (MICA) antigens is associated with 
increased rates of allograft rejection and reduced allograft survival (Zou 2007). The graft loss 
associated with anti-MICA antibodies appears to occur early in the post-transplantation period, a 
typical feature of rejection mediated by preformed antibodies. A subset of patients with severe 
allograft dysfunction associated with accelerated hypertension in the absence of anti-HLA antibodies 
were found to have antibodies against the angiotensin II type I (AT1) receptor (Dragun 2005). 
1.3 Regulatory B cells 
The last decade has brought increasing evidence for existence of B cells with a regulatory phenotype. 
Regulatory B cells (Breg) act primarily via secretion of the anti-inflammatory cytokine IL-10, but may 
also exert regulatory signals via other mechanisms including induction of regulatory T cells (Treg), 
contact mediated suppression and release of other cytokines including transforming growth factor 
beta (TGF-β) and IL-35 (Rosser 2015). 
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Initial reports of B cells with regulatory capacity came in murine models. Mice deficient in B cells are 
unable to recover from experimental autoimmune encephalomyelitis (EAE) (Wolf 1996), indicating a 
role for B cells in regulation of the immune response. Recovery is dependent on IL-10 release from 
autoantigen reactive B cells; mice with IL-10 deficiency restricted to B cells experience a severe non 
remitting form of EAE with an increased pro-inflammatory cytokine response to autoantigen, with 
rescue of the defect by transfer of B cells from normal mice that had recovered from EAE (Fillatreau 
2002). The first use of the phrase regulatory B cells came in 2002, with description of a subset CD1dhi 
Bregs that inhibited progression of intestinal inflammation in a murine colitis model (Mizoguchi 
2002). Soon after came a report of prevention and treatment of collagen induced arthritis (CIA) with 
transfer of IL-10 secreting B cells isolated from arthritogenic splenocytes (Mauri 2003).  
There is debate in the scientific community regarding the phenotype and origin of B cells with 
regulatory capacity, compounded by lack of a lineage-specific transcription factor to aid reliable 
identification. Identification of Bregs is therefore generally characterised by their capacity to secrete 
IL-10, although this may not capture all Breg. Breg have been identified within several different 
subsets of B cells in mice and men (summarised in table 1). One of the difficulties with identification 
and classification of Breg is that detection generally requires ex vivo stimulation. Stimulation may 
alter surface receptor expression hindering classification and the response may differ depending on 
the precise stimuli used. Alterations in the in vivo environment, as a result of inflammation and 
changes in gut microbiome, are known to influence Breg development (Rosser 2014). TIM-1 has 
been suggested as a murine marker for Breg, expressed by a large proportion of IL-10 secreting B 
cells including transitional, marginal zone, follicular and CD1d(hi)CD5+ B cells. Treatment with an 
anti-TIM antibody induced IL-10 producing TIM-1+ Breg and prolonged cardiac allograft survival 
(Ding 2011). Recently, a small case series has identified TIM+ Breg in humans, altered in number and 
function in systemic sclerosis patients (Aravena 2017). A transcriptomic analysis by Sun et al. 
highlighted CD9 as a robust marker of IL-10 competent Breg and their progenitors, allowing for the 
identification and study of cells capable of producing IL-10 without altering their phenotype by ex 
vivo stimulation (Sun 2015a). CD9+ B cells ameliorate inflammation in a Th1 cell mediated model of 
contact hypersensitivity (Sun 2015a) and in an allergic asthma model driven by Th2 and Th17 T cell 
responses (Braza 2015). Use of IL-10 reporter mice has allowed the identification of IL-10 secreting 
cells in vivo and identified plasmablasts as the predominant source of IL-10 during EAE (Matsumoto 
2014). A subset of Bregs characterised by the production of IL-35 and expression of plasma cell 
markers has been described that ameliorate the response in EAE (Shen 2014). Treatment of mice 




IL-10 producing B cells are enriched in a number of subsets in humans, particularly in transitional 
(CD24/CD38high)(Blair 2010) and memory B cell (CD24high/CD27+) (Iwata 2011) subsets. Van de 
Veen et al. utilised a whole genome expression analysis approach to characterise IL-10 producing Br1 
Breg cells, which included CD27- naïve B cells and CD27+ memory B cells and were enriched within 
the CD73-CD25+CD71+ B cell compartment (van de Veen 2013). To date a Breg specific transcription 
factor has not been identified. Breg may originate from a common or shared progenitor. Given the 
reports of Breg in multiple compartments, it is possible that a Breg phenotype is inducible, with the 
ability of a B cell to acquire regulatory capacity not based on the expression of a specific Breg lineage 





(human) Mechanism of suppression References 
B10 CD5+CD1dhi CD24hiCD27+  
 IL-10, suppress effector CD4+ 
T cells, monocytes and DC 







CD23hiCD24hi  - 
 IL-10, Treg induction, 
suppress effector CD4+ and 
CD8+ T cells 
(Evans 2007, Blair 
2009) 
Immature cells   CD19+CD24hiCD38hi 
 IL-10, Treg induction, inhibit 




(MZ) cells  
 CD19+CD21hi 
CD23− -  IL-10, induction of T cell IL10  (Gray 2007) 
Plasma cells 
CD138+MHC-11lo 
B220+  -  IL-10, IL-35 (Shen 2014) 
Plasmablasts CD138+CD44hi CD19+CD24hiCD27int IL-10 
 (Matsumoto 
2014) 
Tim-1+ B cells Tim-1+CD19+ - 
IL-10, suppress effector CD4+ 
T cells  (Ding 2011) 
Br1  - CD19+CD25hiCD71hi   IL-10, IgG4 
 (van de Veen 
2013) 
CD9+ B cells CD19+CD9+ -  IL-10, cell contact 
 (Braza 2015, Sun 
2015a) 
PD-L1hi B cells PD-L1hi  -  PD-L1, regulate Tfh function  (Khan 2015) 
Table 1: Breg subsets in mouse and man, adapted from (Rosser 2015); use with permission from 
Elsevier.  
It is clear that Breg can influence the development and recovery from autoimmunity in animal 
models (Fillatreau 2002, Mizoguchi 2002, Mauri 2003). Evidence for Breg involvement in 
autoimmune disease pathogenesis is mounting and manipulation of the Breg compartment may 
prove to be a useful therapeutic option (Mauri 2017). Breg are functionally impaired in SLE (Blair 
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2010) and rheumatoid arthritis (Flores-Borja 2013). Claudia Mauri’s group recently showed that the 
defect in SLE patients was due to failure of the normal regulatory feedback loop between 
plasmacytoid DC (pDC) and Breg, hypothesised to be secondary to increased exposure to IFN-α 
(Menon 2016). In healthy volunteers, pDC drive the differentiation of immature B cells into 
CD24+CD38hi Breg cell and plasmablasts by IFN-α release and CD40 engagement, and these Breg 
limit IFN-α release from the pDC via IL-10 release. However in SLE patients, pDCs promoted 
plasmablast differentiation but failed to induce Breg cells, leading to a loss in functional Breg and an 
increase in autoantibody producing plasmablasts.  
A number of lines of evidence suggest that regulatory B cells may be important in transplantation, 
regulating the immune response to the transplanted organ (Stolp 2014). The pathogenic roles of B 
cells in transplantation are well established. As the precursors to antibody secreting cells, B cells are 
responsible for the production of DSA and non-HLA antibodies that are associated with development 
of acute and chronic ABMR and poor graft outcomes (Dragun 2005, Zou 2007, Loupy 2013). B cells 
also act as antigen presenting cells, presenting allo-antigen to CD4+ T cells resulting in T cell 
mediated rejection (TCMR) and produce pro-inflammatory cytokines including IL-6 (Barr 2012) that 
can activate T cells driving TCMR. In addition, IL-6 promotes B cell differentiation into antibody-
forming plasma cells, contributes to the plasma cell niche (Kometani 2015), enhances Tfh cell 
development critical for germinal centre responses, and inhibits the generation of regulatory T cells 
(Jordan 2017). With these pathogenic B cell effector functions in mind, we began an open label 
randomised controlled trial where patients received two doses (day 0 and 7) of the B cell depleting 
agent rituximab or the anti-CD25 agent daclizumab, with a steroid free maintenance regime of 
tacrolimus and mycophenolate mofetil (MMF) (Clatworthy 2009). Surprisingly, rituximab was 
associated with an excess rate of TCMR (5/6 (83%) biopsy proven acute rejection (BPAR) in the 
rituximab group versus 1/7 (14%) in the daclizumab group (p=0.01)), leading to early cessation of the 
study. We hypothesised that the increased incidence of TCMR may in part have been due to 
inadvertent depletion of Breg. Two further randomised controlled trials have been conducted using 
a single dose of rituximab at induction in combination with a maintenance regime of tacrolimus, 
MMF and corticosteroids. A study by Tyden and colleagues (Tyden 2009) found no significant 
difference in TCMR at 6 months (8/68 (11.7%) in the rituximab group versus 12/68 (17.6%) in the 
placebo group; p=0.31), with similar rates of ABMR, TCMR and DSA at three years and worryingly a 
significantly increased mortality rate in the rituximab treated group (8/68 versus 0/68; p=0.006), 
with 6 cases being due to myocardial infarction/cardiac arrest (Tyden 2012). A study by van den 
Hoogan and colleagues used an identical regime to Tyden et al. and found no overall benefit of 
rituximab (BPAR 23/138 (16.7%) in the rituximab group versus 30/142 (21.2%) in the placebo group; 
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p=0.25) with no excess mortality at a median follow up of 4 years. A subgroup analysis suggested 
potential benefit in those with increased immunological risk; immunologically high-risk patients (PRA 
>6% or re-transplant) not receiving rituximab had a significantly higher incidence of rejection (13/34, 
38.2%) compared to other treatment groups (rituximab-treated immunologically high-risk patients, 
and rituximab- or placebo-treated immunologically low-risk (PRA ≤ 6% or first transplant) patients 
(17.9%, 16.4% and 15.7%, p = 0.004) (van den Hoogen 2015). Rituximab induction in the setting of 
cardiac transplantation is associated with accelerated cardiac allograft vasculopathy, with an 
increase seen in the percent change from baseline atheroma volume at 1 year measured by 
intravascular ultrasound (6.8 ± 8.2% rituximab group  versus 1.9 ± 4.4% placebo 
(p=0.0019)) (Chandraker 2016). 
An enrichment of B cell transcripts in peripheral blood mononuclear cells (PBMC), together with 
increased proportions of regulatory B cells in drug-free ‘tolerant’ kidney transplant recipients and a 
change in the balance of activated and regulatory T cells support the notion that B cells are a key 
player in the regulation of peripheral tolerance (Newell 2010, Pallier 2010, Chesneau 2014). Further 
support for a Breg role comes from immunophenotyping of those who do and do not experience 
rejection. Kidney transplant recipients with a higher number of TrB cells have a reduced frequency of 
rejection (Shabir 2015). The balance of pro-inflammatory (for example IL-6, TNFα) and anti-
inflammatory cytokines released from B cells is thought to be a factor in maintaining peripheral 
immune tolerance. Compared with TrB cells from patients with stable kidney graft function, TrB cells 
from patients with graft rejection displayed a reduced IL-10/TNFα ratio, did not inhibit in vitro 
expression of Th1 cytokines by T cells, and abnormally suppressed expression of Th2 cytokines. 
Furthermore, in patients with graft dysfunction, a low IL-10/TNFα ratio in TrB associated with poor 
graft outcomes after 3 years of follow-up (Cherukuri 2014). Patients with rejection following ABO 
incompatible transplantation had fewer CD24high/CD27+ memory B cells, a subset enriched for B10 





1.4.1 BLyS control of B cell development and tolerance  
BLyS (also known as B cell activating factor belonging to the TNF family (BAFF) and tumor necrosis 
factor ligand superfamily member 13B) is expressed as a membrane bound type II transmembrane 
protein on various cell types including macrophages, monocytes, dendritic cells and bone marrow 
stromal cells. It can be cleaved to a soluble form. BLyS binds to three receptors, BAFF receptor 
(BAFF-R), transmembrane activator and CAML interactor (TACI) and B cell maturation protein A 
(BCMA), binding to BAFF-R with high affinity and to BCMA and TACI with lower affinity. TACI and 
BCMA, but not BAFF-R, also bind the related TNF family cytokine APRIL (a proliferation-inducing 
ligand; also known as tumor necrosis factor ligand superfamily member 13 (TNFSF13)).  
BAFF-R is the most widely expressed, being found on all human peripheral B cells, as well as on 
human splenic naïve, memory and marginal zone B cells. BCMA and TACI are upregulated during B 
cell differentiation with TACI expression paralleling that of the memory marker CD27 (Darce 2007). 
BCMA expression is limited to antibody secreting B cells and is critical for the survival of long-lived 
plasma cells (Avery 2003, O'Connor 2004). Signalling through the APRIL-BCMA axis within the bone 
marrow induces expression of the anti-apoptotic factor myeloid cell leukaemia 1 (Mcl1), which is 
essential for the survival of all antibody secreting cells (Peperzak 2013). Splenic plasma cells were 
sustained at near normal frequency in BCMA deficient mice with normal levels of Mcl1 indicating an 
alternative BCMA independent survival pathway.  
B cells become dependent on BLyS signalling through BAFF-R at the transitional T1 stage and mice 
deficient in BLyS have reduced mature B cells within peripheral lymphoid systems, with near 
complete absence of follicular and marginal zone B cells (Schiemann 2001). A similar phenotype is 
shown in A/WySnJ mice that have a disrupted BAFF-R locus (Thompson 2001). Human BAFF-R 
deficiency is associated with adult onset antibody deficiency syndrome (Warnatz 2009). In contrast 
to the murine BLyS mutants, the human deficiency shows a late onset with variable penetrance and 
does not inevitably lead to a clinically overt immunodeficiency.  
BLyS is also important for maintenance of the germinal centre response; germinal centre B cells 
downregulate TACI following IL-21 mediated signalling with resultant reduction in surface bound 
BLyS. Tfh act as a local source of BLyS within the germinal centre that is required for normal affinity 
maturation and the persistence of high affinity germinal centre B cells (Goenka 2014). In addition, 
BLyS contributes to the plasma cells niche, selectively enhancing the survival of plasmablasts 
generated from human memory cells (Avery 2003). Mice overexpressing BLyS have marked B cell 
23 
 
expansion, with splenomegaly and lymphadenopathy, and develop autoimmune manifestations 
including an SLE like disorder characterised by circulating immune complexes, 
hypergammaglobulinemia, anti-double stranded DNA (anti-dsDNA) autoantibodies and 
immunoglobulin deposition within the kidneys (Mackay 1999, Gross 2000, Khare 2000).  
 
Figure 4: BAFF/BLyS control of B cell development, based on (Inaba 2016) and (Clatworthy 2011). 
BAFF-R is expressed on B cells as they mature through the T1 stage; B cells become dependent on 
BLyS signalling at the T1/T2 checkpoint. BLyS is important in maintaining the germinal centre 
response, with local production by Tfh. Plasma cells are supported by a niche which provides 
necessary survival signals including BAFF and APRIL, which both bind to the BAFF receptors, BCMA 
and TACI. Targeting of the plasma cell pool may therefore require dual blockade of BAFF and APRIL.  
BLyS signalling downstream of the BAFF-R activates the alternative nuclear factor kappa B (NF-κB) 
pathway, leading to upregulation of anti-apoptotic members of the Bcl-2 family and degradation of 
pro-apoptotic proteins such as Bim (Craxton 2005). TACI and BCMA signal via the classical NF-κB and 
Mek (mitogen-activated protein extracellular signal-related kinase) pathways leading to increased 
expression of anti-apoptotic proteins and downregulation of pro-apoptotic proteins, and through 
the JNK/p38 (c-Jun N-terminal kinase) pathway, driving class-switching (Bossen 2006). TACI and 
BAFF-R are both able to drive isotype switching through class switch recombination in response to 
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BLyS although induction of IgA switching appears dependent on TACI and class switching in response 
to APRIL is solely mediated by TACI (Castigli 2005b). Polymorphisms in TNFRSF13B, the gene 
encoding TACI, have been associated with human common variable immunodeficiency and IgA 
deficiency, diseases characterised by impaired class switching (Castigli 2005a, Salzer 2005). 
 
TACI may also have regulatory roles in B cell homeostasis; mice deficient in TACI have increased B 
cell numbers, with expanded populations of Tfh and germinal centre B cells following T dependent 
immunisation, secondary to up-regulation of inducible costimulator (ICOS) ligand on 
TACI-deficient B cells. However, these mice display defective antigen-specific antibody responses 
resulting from significantly reduced numbers of antibody-secreting cells (Ou 2012). TACI regulates 
the survival of plasmablasts and is required for efficient plasma cell differentiation in response to T 
independent antigens (Mantchev 2007). 
 
There is feedback between BCR and BAFF-R signalling. BCR signalling leads to generation of p100, a 
substrate for the alternative NF-κB pathway utilised by BAFF-R; BLyS mediated NF-κB signalling 
promotes survival. This underpins the dependency of B cells beyond the transitional stage for BLyS; 
T1 cell lipid rafts contain insufficient cholesterol to generate p100 and are subject to negative 
selection. BCR signalling in late transitional and follicular B cells generates sufficient p100 to support 
BLyS-mediated survival signals (Stadanlick 2008). Levels of BLyS can influence stringency of 
peripheral B cell negative selection at the transitional to follicular checkpoint; low levels lead to 
increased competition for signalling and negative selection of autoreactive B cells whereas excess 
BLyS facilitates escape from negative selection with survival of autoreactive clones that would 





Figure 5: The level of soluble BLyS (green) controls the stringency of peripheral B cell negative 
selection (orange) at the transitional to follicular (TR→FO) checkpoint. In the presence of high soluble 
BLyS levels, B cell clones normally subject to deletion (red cells) are permitted to enter the FO B cell 
pool. Under BLyS limited conditions a range of TR B cell clones normally capable of maturing (blue 
cells) do not survive. Adapted from (Parsons 2010); reprinted with permission from Elsevier. 
1.4.2 BLyS in disease 
Increased levels of circulating BLyS have been identified in patients with autoimmunity (Jonsson 
2005, Bosello 2008, Steri 2017) and may be associated with the development or maintenance of 
autoreactive B cells. A rise in serum BLyS can also be seen following B cell depleting therapy 
(Vallerskog 2007, Bloom 2009) which may contribute to the increased incidence of secondary 
autoimmunity seen following alemtuzumab treatment for multiple sclerosis (Thompson 2010), and 
increased levels of DSA and ABMR following alemtuzumab induction therapy in the setting of renal 
transplantation (Bloom 2009). A polymorphism in TNFSF13B, the gene encoding BLyS, has been 
associated with autoimmunity risk in a recent genome wide association study (Steri 2017). The 
causal variant was identified as an insertion–deletion variant, GCTGT→A (in which A is the risk 
allele), that yielded a shorter transcript which escaped microRNA inhibition and increased 
production of soluble BLyS, which in turn led to an increase in B cells and immunoglobulin. 
1.4.3 BLyS and transplantation 
Numerous studies have associated elevated serum BLyS levels in renal transplant recipients with a 
heightened humoral immune response. Patients with increased serum BLyS have a significantly 
increased risk of developing de novo DSA (Thibault-Espitia 2012) and increased presence and 
severity of transplant glomerulopathy (Sango 2016). We have shown in an HLA antibody 
incompatible cohort that increased levels of serum BLyS measured pre-transplant are associated 
with an increased frequency of ABMR (Banham 2013). Alterations in receptors for BLyS may also be 
important; Thibault-Espitia and colleagues detected an inverse correlation between serum and 
transcript levels of BLyS and expression levels of the receptors BAFF-R and TACI, and showed that 
stable patients with high BAFF-R levels had a higher risk of developing graft dysfuction (Thibault-
Espitia 2012). Tertiary lymphoid organs (TLO) may form within the allograft in the setting of chronic 
antibody mediated rejection. Here, BLyS may be an important local factor maintaining the niche. 
Indeed, BLyS protein and transcript levels were found to be overexpressed in chronically rejected 
grafts when compared with normal kidneys and lymph nodes (Thaunat 2008). BLyS has been 
detected by immunohistochemistry in renal allograft acute rejection and interstitial fibrosis/tubular 
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atrophy biopsies, correlating with C4d staining (Xu 2009), a marker of complement activation and 
hallmark of antibody mediated rejection. 
Furthermore, animal models of transplantation give further evidence of a pathogenic role for BLyS in 
alloimmunity and highlight the potential for therapeutic intervention. In a murine cardiac allograft 
model, mice with a mutation in the BAFF-R or with a targeted deletion of BLyS, showed prolonged 
cardiac allograft survival compared to wild-type or TACI deficient controls (Ye 2004). The effect of 
BLyS was shown to influence the T cell compartment in addition to the B cell compartment; binding 
of BLyS to BAFF-R expressed by a subset of primarily CD4+ T cells provided co-stimulation leading to 
T cell activation and allo-proliferation in vitro and in vivo. In a murine islet cell allograft model, BLyS 
blockade followed by a short course of rapamycin allowed for long term survival of MHC-disparate 
allografts (Parsons 2012). Induction therapy with rapamycin was necessary, but not sufficient, for 
the achievement of this long-term graft survival, which was associated with absence of DSA, 
impaired T cell activation, increased regulatory T cells and a regulatory cytokine milieu with low IL-2, 
high IL-5, high IL-10, and low IFN-γ production. Use of atacicept, a recombinant TACI-Ig fusion 
protein that blocks both BLyS and APRIL, prevented early DSA formation and ABMR development in 
a T cell depletion induced nonhuman primate ABMR model, although increased T cell rejection 
findings were observed, likely secondary to graft prolongation (Kwun 2015). Belimumab (Benlysta; 
GlaxoSmithKline, Rockville, MD, USA), a humanised anti-BLyS IgG1 antibody, is licensed for use in 
patients with SLE (Furie 2011, Navarra 2011). BLyS inhibition, used as monotherapy, had little impact 
on HLA antibody titres in sensitised subjects on the transplant waiting list (Naji , Mujtaba 2016), but 
to date this axis has not been targeted in human transplant recipients. 
1.5 Fc gamma receptors (FcγRs) 
1.5.1 FcγRs determine antibody effector function 
Many of the effects of IgG antibodies are mediated by cross-linking FcγRs, surface glycoproteins that 
bind IgG immune complexes, and are expressed by most immune cells, including mononuclear 
phagocytes. There are several different types of FcγR in mice and men that differ in their expression 
and binding affinity to different classes of IgG. FcγR are important in promoting and regulating the 
immune and inflammatory responses to immune complex (Nimmerjahn 2008). The human receptors 
comprise of 3 classes; FcγRI, FcγRII and FcγRIII (Figure 6). The murine receptors are simpler with an 
analogous FcγR1 and FcγRIIb but only two activatory low affinity receptors, FcγRIII which is similar in 
structure to human FcγRIIa and FcγRIV which is a homolog of FcγRIIIa. 
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Figure 6: Human FcγR expression (adapted from (Smith 2010), copyright © 2010, reprinted with 
permission from Springer Nature). Cell specific FcγR expression is shown, with each immune cell 
subset represented by a different colour block.  
FcγRII has three isoforms, A, B and C and FcγRIII has two, A and B. With the exception of FcγRIIb, 
these receptors are all activatory, containing immunoreceptor tyrosine-based activatory motifs 
(ITAM) within the cytoplasmic domain of the receptor (FcγRIIa and FcγRIIc) or in the associated FcR 
common γ-chain (FcγRI and FcγRIIIa). FcγR1 is a high affinity receptor that can bind monomeric IgG. 
The low affinity receptors FcγRII and FcγRIII bind immune complexes and mediate many of the 
effector functions of antibody. FcγRIIb, in contrast contains immunoreceptor tyrosine-based 
inhibitory motifs (ITIM) within its cytoplasmic tail and acts as the sole inhibitory FcγR. The ratio of 
binding to activatory and inhibitory receptors, known as the A/I ratio, determines the activation 
threshold of a particular cell. Cytokines differentially regulate the expression of the two opposing 
FcγR systems; IFN-γ increases monocyte FcγRIIa expression and reduces FcγRIIb expression whereas 
IL-4 increases FcγRIIb whilst reducing FcγRIIa (Pricop 2001). Mutations or polymorphisms affecting 
the expression or function of FcγR have been associated with the balance between susceptibility to 
infection and autoimmunity in mice and men (Smith 2010). 
B cells and plasma cells only express the inhibitory receptor, FcγRIIb. Crosslinking of FcγRIIb to the 
BCR increases the B cell activation threshold, regulating antibody production and reducing B cell 
mediated antigen presentation to T cells. Cross linking of FcγRIIb in the absence of BCR ligation in 
mature B cells and terminally differentiated plasma cells can induce apoptosis via non ITIM mediated 
signalling pathways (Nitschke 2005, Smith 2010). Mononuclear phagocytes express both activatory 




1.5.2 FcγR signalling 
The interaction between pathogen bound IgG and activatory FcγR on macrophages mediates 
pathogen clearance via phagocytosis and antibody dependent cellular cytotoxicity (ADCC). 
Crosslinking of activatory FcγR leads to phosphorylation of ITAMs, activation of the signalling 
molecule spleen tyrosine kinase (Syk) and the initiation of an activating signal cascade. This results in 
activation of various downstream targets including phosphoinositide 3-kinase (PI3K) and 
phospholipase Cγ (PLCγ) which lead to increased intracellular calcium levels and stimulation of the 
RAS–RAF–MAPK (mitogen activated protein kinase)-pathway. Downstream signalling events are 
triggered resulting in changes in the actin cytoskeleton leading to phagocytic cup formation, 
production of pro-inflammatory cytokines and chemokines as well as oxidative burst and ADCC 
(Nimmerjahn 2008). This inflammatory response assists in pathogen clearance but can potentially 
propagate tissue inflammation in the case of autoimmunity. Kidney resident macrophages detect 
and scavenge circulating IC and trigger a FcγRIV-dependent inflammatory response leading to the 
recruitment of monocytes and neutrophils. IC uptake is dependent on the unique anatomical 
position of kidney macrophages that are situated in close apposition to endothelial cells that 
transport circulating IC to them (Stamatiades 2016). FcyRIIb inhibits IC-induced pro-inflammatory 
cytokine production in macrophages (Clatworthy 2004). FcγRIIb may have an additional, non-
inhibitory role in macrophage function by mediating endocytosis and non-inflammatory clearance of 
immune complexes from arthritic joints by macrophages (van Lent 2003). 
1.6 Mononuclear phagocytes  
Monocytes, macrophages and DCs are professional phagocytes and antigen presenting cells found in 
most tissues, forming a network of immune sentinels specifically positioned to detect and respond 
to invading micro-organisms (Geissmann 2010), playing a pivotal role in the generation of an 
adaptive immune response. Mononuclear phagocytes express a range of immune receptors that 
recognise pathogen associated molecular patterns (PAMPs) and damage associated molecular 
patterns (DAMPS), known as pattern recognition receptors, including TLRs, C-type lectin receptors 
(CLR), scavenger receptors and nucleotide oligomerization domain (NOD)-like receptors (NLRs) in 
addition to the activatory FcγR receptors FcγRIIa and FcγRIIIa and the inhibitory receptor FcγRIIb.  
Monocytes circulate in the blood prior to entering tissues where they differentiate into 
macrophages or DC. Inflammatory monocytes are preferentially recruited to areas of inflammation, 
produce inflammatory cytokines and contribute to local and systemic inflammation. Resident 
monocytes enter tissues under steady state conditions (Gordon 2014).  
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1.6.1 Macrophages are tissue resident mononuclear phagocytes specialised for phagocytosis 
Macrophages reside within tissues throughout the body, positioned to ingest and process foreign 
materials, dead cells and debris, and recruit additional macrophages from the circulation and 
stimulate lymphocytes during infection or following injury. The majority are maintained through self 
renewal, derived from embryonic precursors (Schulz 2012, Hashimoto 2013, Ginhoux 2014). Tissue-
specific factors drive highly specialized macrophage functions irrespective of their ontological origin 
(Epelman 2014). Phagocytosis of pathogens by macrophages initiates the innate immune response 
and sets in motion the adaptive response. Pathogen bound IgG binds to activatory FcγR on 
macrophages, facilitating pathogen clearance via phagocytosis and ADCC as described above. 
Phagocytosis of IgG immune complexes initiates a similar inflammatory response (Gordan 2015). 
Phagocytosis can also be triggered following binding of complement opsonised pathogens to 
complement receptors, though the signalling downstream of receptor binding differs as does the 
resultant inflammatory response, with FcγR induced phagocytosis but not complement receptor 
mediated phagocytosis being tightly coupled to the generation of inflammatory metabolites 
(Aderem 1999).  
Macrophage phagocytosis does not always induce inflammation. Indeed macrophages induce 
immune tolerance toward self through removal of dying cells that have undergone apoptosis, 
without activating proinflammatory responses (Savill 1997, Kono 2008). Tissue macrophages also 
suppress inflammation mediated by inflammatory monocytes, thereby ensuring that tissue 
homeostasis is restored following infection or injury. Defects in apoptotic cell clearance are 
implicated in the pathogenesis of SLE (Munoz 2005, Munoz 2010). Historically, macrophages have 
been classified into classically activated M1 macrophages that secrete proinflammatory cytokines in 
response to pathogens and alternatively activated M2 macrophages that have anti-inflammatory 
functions and regulate wound healing and fibrosis. This nomenclature has lost popularity given that 
there is a range of macrophage activation states, with marked plasticity of macrophage populations 
in response to environmental cues; favouring classification on a spectrum according to macrophage 
function in host defence, wound healing or immune regulation (Mosser 2008).  
1.6.2 Dendritic cells are specialised for antigen internalisation, migration to draining lymph nodes 
and presentation of antigen to T cells 
DCs display a number of receptors, including FcγR, that enable internalisation of antigen and 
presentation to T cells (Banchereau 1998). Presentation of processed antigen to T cells may lead to T 
cell activation, if appropriate co-stimulatory signals are also provided by mature DC (Hawiger 2001). 
DC’s reside in an immature state in peripheral tissues where they act as sentinels to induce 
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protective immunity against incoming danger. When levels of captured self-antigen are low, or in the 
absence of appropriate co-stimulatory signalling, DCs contribute to the clearance of dying cells and 
provide tolerogenic signals to T cells (Hawiger 2001, Steinman 2003), maintaining homeostasis to 
self antigens. In steady state, heterogenous populations of DCs are localised to distinct anatomical 
sites according to their unique homing properties (Merad 2013). However during infection, and in 
the context of autoimmunity, DCs play a pivotal role in the activation of CD4 and CD8 T cells. DC 
maturation may be induced following activatory FcγR ligation (van Montfoort 2012), as well as 
through signalling induced by TLR ligands, CD40 ligation and pro-inflammatory cytokines (Roake 
1995, Reis e Sousa 2006). FcγRIIb inhibits FcγR-dependent internalization and presentation of 
antigen and exerts a basal level of inhibition to DC maturation in the presence of ICs, providing an 
important tolerance checkpoint (Boruchov 2005). Microarray analysis of unstimulated and IC-
activated bone marrow derived DC (BMDC) reveals a gene expression profile associated with 
effective T cell activation, dependent on the presence of activating FcγR and regulated by FcγRIIb. 
FcγRIIb-deficient DCs have an improved capacity to activate naïve T lymphocytes, displaying 
enhanced FcγR-dependent Ag presentation. In vivo induction of CD8+ T cell expansion was increased 
in mice selectively lacking FcγRIIb on DC (CD11cCre X FcγRIIb fl/fl mice) compared to wildtype 
controls (van Montfoort 2012). 
Dendritic cells can broadly be divided into plamacytoid DC (pDC) and conventional DC (cDC) (Merad 
2013). Plasmacytoid DC represent a small subset of DCs, with poor antigen presenting capacity, but 
that produce large quantities of type I interferon on recognition of foreign nucleic acids by TLR7 and 
9, particularly important in the antiviral response. All other subsets of DCs can be grouped together 
as cDC; cDC are uniquely specialized in processing exogenous antigen for presentation to T cells and 
T cell priming and are best characterized further by their location. Non lymphoid tissue cDC’s 
represent 1-5% of tissue resident cells, depending on the organ in question, and consist of two major 
subsets: CD103+CD11b- and CD11b+ cDCs. Skin resident DC can be divided into langerhans cells and 
dermal DC (Kaplan 2010). Langerhans cells are the only MHC II expressing cells within the epidermis; 
those that are transiting through the dermis or that have migrated to skin-draining lymph nodes can 
be identified based on expression of Langerin (CD207), EpCam and CD11b and the absence of CD8 
and CD103 expression. Dermal DC express CD103 but not EpCam, CD11b or CD8 and can be divided 
into Langerin+ and Langerin- subsets. Dermal DC migrate to skin draining lymph nodes in the steady 
state and in response to infection, and are able to present antigen acquired in the periphery to T 
cells. Non lymphoid tissue DCs that have migrated to tissue draining lymph nodes through the 
lymphatics are known as tissue migratory DC (Randolph 2005) in contrast to blood-borne lymphoid 
organ resident DCs. In the steady state, tissue migratory DC migrate through afferent lymphatics to T 
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cell areas of lymph nodes, carrying antigens phagocytosed in the periphery; this process is increased 
several fold following DC maturation in response to inflammatory signals. Most of these stimuli 
trigger downstream signalling pathways that activate NF-κB and induce proinflammatory gene 
expression. In contrast to steady-state tissue migratory cDCs, those that migrate in response to 
inflammation also produce inflammatory cytokines and upregulate costimulatory molecules such as 
CD40, CD80 and CD86, as well as MHC class II, optimising the DC for antigen presentation enabling it 
to drive adaptive immunity; the nature of the immune response being guided by the specific 
maturation signal received, the DCs ontogeny and environmental modifiers which determine 
whether the DC becomes immunogenic or tolerogenic (Reis e Sousa 2006). Lymphoid organ resident 
DCs reside permanently in lymphoid tissues including lymph nodes, mucosal associated lymphoid 
tissues such as Peyer’s patches and the spleen and mainly consist of CD8+ and CD11b+ subsets 
(Merad 2013). 
1.6.3 Control of dendritic cell migration 
The control of DC migration is complex since the process of migration relies both on a cell’s intrinsic 
capacity to migrate as well as signals guiding migration from the surrounding environment. DC 
maturation induces a switch in chemokine receptor expression, to allow migration of DC from 
peripheral tissue where they capture antigen to the lymph nodes where they can stimulate T cells. 
Immature DC express chemokine receptor 1 (CCR1), chemokine receptor 2 (CCR2), chemokine 
receptor 5 (CCR5) and chemokine (C-X-C motif) receptor 1 (CXCR1), allowing them to respond to 
their respective ligands which are chemokines produced at inflammatory sites. Maturation, induced 
by stimulation with LPS or TNFα, leads to upregulation of chemokine receptor 7 (CCR7) and 
chemokine (C-X-C motif) receptor 4 (CXCR4) and downregulation of CXCR1, CCR1 and CCR5 (Sallusto 
1998), allowing mature DC to undergo CCR7 dependent migration to draining lymph nodes. Mice 
deficient in CCR7 have similar numbers of DCs in their peripheral organs to wild type mice, but show 
reduced mobilisation of DC from dermal tissues in response to contact sensitisation induced by 
fluorescein isothiacyanate (FITC) skin painting (Forster 1999), indicating that CCR7 is not required for 
recruitment of DC progenitors to the skin and mucosal surfaces but is required for mobilisation in 
response to external stimuli. Activating FcγR-crosslinking by preformed IC or autoantibody 
containing serum provides a similar maturation signal inducing upregulation of CCR7, and this 
process is inhibited by FcγRIIb (Clatworthy 2014a).  
Various signalling modules act downstream of CCR7 ligation, leading to multiple points of regulation 
of DC migratory responses such as chemotaxis and migratory speed (Figure 7; reviewed in (Randolph 
2008)). The Rho family of GTPases act as an intermediate in the signalling pathway leading to 
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activation of the actin binding protein cofilin, which may regulate the basal migratory speed of DCs 
but not DC chemotaxis (Riol-Blanco 2005). CCR7 signalling also induces activation of PI3K, protein 
kinase C (PKC) and NF-κB, which are important for activation and survival of cells and phospholipase 
Cβ2 (PLCβ2) which breaks down plasma membrane lipids into diacylglycerol (DAG) and the calcium 
second messenger, inositol trisphosphate (IP3), leading to the release of intracellular calcium from 
stores in the endoplasmic reticulum, with effects on chemotaxis. Cdc42 and Rac, but not RhoA 
GTPases, coordinate actin polarization, cytoskeletal rearrangement, cell polarity, and ultimately 
motility in a c-Jun N-terminal kinase (JNK) dependent pathway (Iijima 2005).  
 
Figure 7: Various signalling pathway modules regulate distinct migratory responses induced by 
chemokines through CCR7 (Randolph 2008). Reproduced with permission from the Annual Review of 
Immunology, Volume 26 © 2008 by Annual Reviews, http://www.annualreviews.org. Upon agonist 
binding trimeric G proteins consisting of α, β, and γ subunits are uncoupled and a series of signal 
transduction events ensue that result in cell activation followed by enhanced motility. At least two 
non-overlapping independent signalling modules are activated upon CCR7 ligation.  
Migrating DCs secrete matrix metalloproteinases (MMPs) to facilitate movement through the 
extracellular matrix and across basement membranes (Ratzinger 2002). MMP release is also 
inhibited by FcγRIIb (Clatworthy 2014a). Prostaglandin E2 (PGE2), present at sites of inflammation 
induces DC migration by inducing MMP-9 which is required in addition to CCR7 for the migration of 
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mature DC to draining lymph nodes (Yen 2008). Mast cells are able to induce Langerhans cell 
migration from the skin to the draining lymph nodes following IgE mediated activation in vivo via a 
histamine dependent mechanism (Jawdat 2004). The cysteinyl leukotriene pathway also promotes 
DC migration. Migration of DC from skin to lymph nodes was reduced in mice lacking the leukotriene 
C4 transporter MRP1, and restored by exogenous cysteinyl leukotrienes. In vitro, these cysteinyl 
leukotrienes promoted optimal chemotaxis to chemokine (C-C motif) ligand 19 (CCL19), but not to 
other related chemokines, suggesting that triggering of DC by cysteinyl leukotrienes is required for 
maximal chemotaxis towards CCL19 (Robbiani 2000). Activation of DC, induces the downregulation 
of E-cadherin which permits their detachment from the epidermis (Schwarzenberger 1996) and the 
upregulation of various adhesion molecules including integrins (Price 1997) and CD44 (Weiss 1997), 
which facilitate migration. The absence of junctional adhesion molecule 1 (JAM1) expression by DCs 
facilitates their migration to lymph nodes (Cera 2004); it is unclear whether JAM1 supports 
prolonged cell–cell interactions, impeding the passage of DC across the lymphatic endothelium, or 
whether the increase in DC migration that is observed in the absence of JAM1 is associated with the 
positive regulation of 1-integrin expression by JAM1 (Mandell 2005), since 1-integrins mediate the 
interaction of DCs with extracellular-matrix components and may favour retention of DCs in the 
periphery. Although integrins are not required for interstitial migration of DC (Lammermann 2008), 
they are required for the transendothelial migration of DC (Maddaluno 2009, Gunawan 2015). 
CD38, a glycoprotein expressed on the surface of mononuclear phagocytes and other immune cells, 
is an ecto-enzyme, meaning that its active site is located on the outside of the cell, positioning it to 
respond to substrates found within the extracellular matrix. CD38 catalyses a reaction using NAD+ 
substrate, leading to the formation of the metabolites ADP ribose (ADPR) and cyclic ADP ribose 
(cADPR) that induce calcium flux via modulation of the cADPR- and ADPR-activated plasma 
membrane channel TRPM2. CD38 regulates the migration of DC precursors from the blood to 
peripheral sites and controls the migration of mature DCs from sites of inflammation to lymph 
nodes; mice lacking CD38 have impaired T cell dependent antibody responses. CD38 and cADPR 
modulate calcium mobilization in chemokine-stimulated DCs and are required for the chemotaxis of 
immature and mature DCs to CCL2, CCL19, CCL21, and C-X-C Motif Chemokine Ligand 12 (CXCL12) 
(Partida-Sanchez 2004). Of note, inflammatory signals and bacterial products that induce DC 
maturation and CCR7 expression often also induce upregulation of CD38. 
Cell migration requires the dynamic interaction between a cell and the substratum on which it is 
attached and over which it migrates. In order to migrate, cells must acquire a special asymmetry, 
enabling them to turn intracellularly generated forces into net cell body translocation, leading to 
forward propulsion (Lauffenburger 1996). Lamellipodia and filopodia are membrane projections that 
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can extend reversibly into three dimensions around the cell in response to migratory stimuli, driven 
by actin polymerisation. Once the membrane protrusion has become adherent to the substratum, a 
contractile force is required to move the cell body forward; this may be driven by myosin 
interactions with actin filaments. Rapid migration requires efficient mechanisms to release 
adhesions at the rear of the cell, in order to allow the cell to move forward (Figure 8).  
 
Figure 8: Reprinted from (Raftopoulou 2004) with permission from Elsevier. A migrating cell (seen 
from the top and side). A migrating cell needs to perform a coordinated series of steps to move. 
Cdc42 regulates the direction of migration, Rac induces membrane protrusion at the front of the cell 
through stimulation of actin polymerization and integrin adhesion complexes, and Rho promotes 
actin:myosin contraction in the cell body and at the rear. 
All these steps involve the assembly, the disassembly or the reorganization of the actin cytoskeleton, 
and each must be coordinated both in space and time to generate productive, net forward 
movement. Alterations in DC migration can therefore be induced by modification of the process of 
actin polymerisation. A complex of 7 proteins known as actin-related proteins 2 and 3 (Arp2/3) 
complex regulates the assembly of new actin filaments at the leading edge of moving cells. Vinculin 
is a cytoplasmic actin-binding protein that eukaryotic cells use to strengthen adhesions and promote 
cell spreading and lamellipodial extension. Assembly of vinculin-containing focal complexes at the 
leading edge allows transient adhesion of the cytoskeletal network to the extracellular matrix, 
enabling development of traction force and forward movement of the cell. Vinculin selectively 
recruits Arp2/3 to the leading edge of the lamellipodium, coupling the actin polymerization 
machinery to adhesion complexes to promote membrane protrusion (Craig 2003). Although vinculin 
seems to restrain migration in two-dimensional (2D) tissue culture systems, it is required for the 
generation of traction forces necessary for effective directional migration in three-dimensional (3D) 
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collagen systems that may more closely mimic the in vivo environment (Thievessen 2015). Proteins 
of the Wiskott–Aldrich syndrome protein (WASP) family bind directly to Arp2/3 and stimulate its 
ability to promote nucleation of new actin filaments. Murine DC deficient in WASP exhibited defects 
of attachment and detachment to fibronectin coated surfaces in vitro, leading to impaired net 
translocation and displayed impaired DC homing in vivo in a FITC paint hypersensitivity model (de 
Noronha 2005). Upstream of the WASP family members, receptor tyrosine kinases, G-protein- 
coupled receptors, PI3K and the Rho family of GTPases receive and transduce the signals that lead to 
actin nucleation through WASP-Arp2/3 action. The Rho family includes Rho, which regulates the 
assembly of contractile, actin:myosin filaments as well as Rac and Cdc42 that appear to regulate the 
polymerization of actin to form peripheral lamellipodial and filopodial protrusions (Nobes 1995, 
Raftopoulou 2004). Dock8 is a guanine nucleotide exchange factor that has been shown to activate 
the GTPase Cdc42 in mouse DCs and be critical for interstitial DC migration (Harada 2012, 
Krishnaswamy 2015, Eisenbarth 2016); DOCK8 mutations are associated with combined 
immunodeficiency in humans (Zhang 2009). Inhibitory signalling to the Arp2/3 complex mediated by 
a protein known as Arpin, provides a mechanism for directional persistence of migration and the 
ability for cells to steer (Dang 2013). Gadkin (also known as Ap1ar) negatively regulates Arp2/3 
function (Maritzen 2012); it’s loss impaired DC migration in vitro but not in vivo, suggesting 
compensatory mechanisms (Schachtner 2015). PI3K also controls the directionality of movement by 
controlling F-actin spatial localisation and leukocyte polarity towards chemoattractant (Rickert 
2000). The signalling adaptor Eps8 is an actin capping protein involved in the formation of a dense 
actin meshwork, essential for sustaining persistent and extended cell protrusions required for 
effective DC migration (Frittoli 2011). 
Although integrins are required for movement of leukocytes over two-dimensional surfaces, three-
dimensional movement within tissues is integrin independent, and reliant on forces generated from 
actin-network expansion, with myosin-II dependent contractility required for squeezing through 
narrow gaps (Lammermann 2008).  
DC are the only type of antigen presenting cell that have the capacity to stimulate the activation of 
naïve T cells, initiating a primary adaptive immune response. Naïve T cells collect in paracortical 
regions of lymph nodes and the spleen, migrating to these locations directly from the vasculature, 
not passing through peripheral tissues. Re-location of DC to lymph nodes increases their likelihood 
of encountering naïve CD4 T cells that express antigen receptors recognising the presented antigen 
peptide, and may potentially promote autoimmune T cell activation if autoantigen-containing 
immune complexes have been internalised (Figure 9). DC migration is also important once a DC 
reaches the lymph node; after establishing initial contact between their dendrites and naïve T cells, 
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mature DC migrate towards contacted lymphocytes and tightly entrap the T cells within a complex 
net of membrane extensions. DCs from Rac1−/− or Rac2−/− mice show severe alterations in dendrite 
formation, defective migration in vivo and impaired T cell priming (Benvenuti 2004).   
ICs also contribute to relocation of DC by driving lymph node lymphangiogenesis, in a VEGF-A 
dependent process, controlled by FcγRIIb (Clatworthy 2014b). 
 
Figure 9: Maturation of DC facilitates relocation and drives phenotypic change to meet altered 
functional requirements. FcγR expressed on the surface of DC (shown in green) recognise and bind 
the Fcγ portion of immunoglobulin, providing a pathway for the specific uptake of opsonized antigen. 
DC migrate from the periphery where they capture antigen to lymph nodes where they encounter T 
cells, following maturation signals inducing upregulation of the CCR7 receptor (shown in blue). DC 
expressing CCR7 are able to migrate towards a gradient of CCL19 which directs them to lymph nodes 
where they are more likely to encounter T cells expressing the TCR that recognises their internalised 
antigen. Upon maturation DC also secrete matrix metalloproteinases, promoting break down of the 
extracellular matrix facilitating forward migration and VEGF-A, supporting lymphangiogenesis. Once 
within the lymph node, DC present antigen in the context of MHC II (shown in red) to cognate T cells 
and provide co-stimulation signals, via ligation of co-stimulatory receptors with their respective 
ligands (shown in yellow), promoting T cell activation.   
1.6.4 Cell specific influence on autoimmunity 
DC specific effects play an important role in autoimmune disease. Collagen induced arthritis (CIA) 
(Yilmaz-Elis 2014) and nephrotoxic nephritis (NTN)(Sharp 2013) are murine models of antibody 
mediated autoimmune disease, where FcγRIIb expressed on myeloid cells rather than on B cells is 
37 
 
protective. Despite their comparable anti-mouse collagen autoantibody titers, full FcγRIIb knockout 
(KO), but not B cell-specific FcγRIIb KO mice showed a significantly increased incidence and severity 
of disease compared with wild-type (WT) control mice when immunized with bovine collagen. 
Following immunisation with chicken collagen, disease incidence was significantly increased in pan-
myeloid and full FcγRIIb KO mice but not in B cell-specific KO mice, compared with WT control mice; 
with an increase in disease severity only seen in full FcγRIIb KO mice. This suggests that anti-mouse 
collagen autoantibodies are a prerequisite for the development of CIA but their presence is 
insufficient for disease development, with FcγRIIb on myeloid effector cells controlling susceptibility 
by modulating the threshold for downstream Ab effector pathways (Yilmaz-Elis 2014). In a similar 
study, selective deletion of FcγRIIb from B cells did not increase susceptibility to NTN compared with 
WT mice, despite presence of increased antibody titres, but mice lacking FcγRIIb on myeloid cells 
had exacerbated disease. Where there was a lack of FcγRIIb on circulating myeloid cells, expression 
of FcγRIIb on intrinsic renal cells provided an additional level of protection from Ab-mediated 
glomerulonephritis (Sharp 2013). 
SLE is an autoimmune disease characterised by the deposition of IgG immune complexes and so B 
cells are clearly of great importance to disease pathogenesis. Mice with B cells but not secreted Ig 
have severe disease indicating that both antibody dependent and independent functions are 
important (Chan 1999). B cells act as antigen presenting cells (Giles 2015) and prime autoreactive T 
cells (Chan 1998). The immune response to deposited immune complex determines the degree of 
tissue damage and disease progression, with T cells and MNP playing an important role (Bagavant 
2009). DCs contribute to T cell pathogenicity following disease initiation, influencing tissue damage 
and are also an important source of BLyS (Teichmann 2010). The inducible T cell costimulator (ICOS) 
co-receptor stimulates Tfh cell differentiation in lymphoid tissue, supporting the germinal centre 
response. Local triggering of the ICOS coreceptor by CD11c+ myeloid cells drives organ inflammation 
in lupus prone mice by protecting Tfh and effector CD8+ T cells within inflamed tissues from 
apoptosis by signalling through the PI3K-Akt pathway, promoting cell proliferation and survival, with 
minimal effect on autoantibody titres (Teichmann 2015). Blockade of ICOS signalling could modulate 
pathogenic T cell responses, offering potential to attenuate destructive organ inflammation, 
regardless of the nature of the disease initiating event.  
1.7 Treatment strategies for antibody mediated disease 
1.7.1 Current strategies 
Several strategies exist for treating antibody mediated disease (Figure 10) including non-specific 
immunosuppressive regimes using corticosteroids, or other disease modifying agents for example 
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alkylating drugs such as cyclophosphamide, or anti-proliferative drugs such as methotrexate, 
azathioprine and mycophenolate mofetil. The development of more specific monoclonal antibodies 
has greatly impacted the treatment of autoimmune diseases. These include antibodies which target 
pro-inflammatory cytokines, for example TNFα (infliximab, adalimumab, etanercept) and IL-6 
(tocilizumab), or are cytotoxic to B cells, causing their depletion via complement or antibody 
mediated cellular toxicity, for example rituximab and alemtuzumab. Belimumab, a monoclonal 
antibody blocking BLyS has shown some efficacy in SLE (Furie 2011, Navarra 2011, Manzi 2012) and 
is being trialled for other indications (see chapter 3). Direct removal of antibody via plasmapheresis 
can be used in some acute presentations where rapid control of disease is required, for example in 
Goodpasture’s Syndrome (Bolton 1996).  
Intravenous immunoglobulin (IVIG) is a preparation of human polyclonal IgG derived from pooled 
plasma samples, widely used in the treatment of autoimmune disease (Nimmerjahn 2007a) and in 
transplantation, in the setting of desensitisation prior to HLA-incompatible transplantation and as a 
treatment for ABMR (Jordan 2006). IVIG is hypothesised to have multiples modes of action including 
competition with pathogenic IgG for activating FcγRs, blocking access to these receptors and 
inhibiting immune cell activation; upregulation of the inhibitory receptor FcγRIIb; high dose IgG 
saturation of the neonatal Fc receptor (FcRn), disrupting FcRn mediated recycling of pathogenic IgG 
from acidic lysosomal vesicles, resulting in increased lysosomal degradation and rapid clearance of 
IgG; neutralisation of antigen via Fab mediated binding and inhibition of complement activation 
(Nimmerjahn 2007a, Clatworthy 2011). 
Treatments focussed on increasing regulation of the immune response offer promise for 
autoimmune disease and transplantation (Wood 2012), for example by inducing or indeed 
transferring ex vivo manipulated tolerogenic DC (Morelli 2007, Hilkens 2013), Treg (Riley 2009, 
Miyara 2014), mesenchymal stem cells or Breg (Wang 2014). The One Study is a cooperative project, 
aiming to trial the use of cell based therapies in human renal transplantation (Geissler 2012).  
Activation of Fcγ receptors induces signalling that leads to the transcription of pro-inflammatory 
cytokines. Small molecules for example PI3K inhibitors that interfere with cell signalling are in 
development and may be beneficial in treating autoimmune disease (Banham-Hall 2012). Activation 
of B cells and mononuclear phagocytes by cytokines or antibodies requires gene transcription in 
these cells. Using small drug molecules to target epigenetic modifications that regulate transcription 




Figure 10: Therapeutic options for antibody mediated disease. Current commonly used therapies 
include B cell depleting drugs for example rituximab and alemtuzumab; removal of preformed 
antibodies using plasmapheresis; and inhibition of downstream cytokines for example TNFα 
(infliximab, etanercept, adalimumab), IL-6 (tocilizumab) and IL1 (anakinra). Newer strategies in 
development with potential for use in autoimmune disease include those targeting intracellular 
signalling pathways, for example PI3K and Syk inhibitors and epigenetic modulators that inhibit the 
transcription of pro-inflammatory cytokines.    
1.7.2 Epigenetic modulation and bromodomain inhibition 
Epigenetic marks are heritable post translational changes applied to deoxyribonucleic acid (DNA) or 
associated histones that do not affect the DNA sequence itself but have marked effects on 
chromatin structure, determining the likelihood of gene transcription due to changes in accessibility 
to the cell’s transcription machinery. Histones are globular proteins which associate with DNA and 
have flexible N-terminal tails which can be covalently modified, for example by acetylation or 
methylation (Bannister 2011). Histones that are heavily acetylated have an open chromatin 
structure, are more accessible to RNA polymerases and are generally transcriptionally active (Struhl 
1998). 
 
Bromodomains are highly conserved, left twisted bundles of four α-helices, linked by diverse loop 
regions, forming a hydrophobic pocket that recognises acetylated lysine residues (Dhalluin 1999). In 
humans, there are estimated to be 56 bromodomains encoded in 42 proteins (Sanchez 2009). The 
bromodomain and extra-terminal domain (BET) family are a group of proteins that contain two 
mutually related bromodomain motifs (BD1 and BD2) and an extra-terminal domain and function as 
chromatin readers. They bind to acetylated lysine residues, acting as scaffolds for the assembly of 
40 
 
protein complexes critical for gene transcription, for example the positive transcription elongation 
factor (P-TEFb) complex (LeRoy 2008). They regulate gene transcription via controlling the 
recruitment of transcription factors, transcriptional co-activators and transcriptional co-repressors. 
In mammals the BET family includes BrdT, Brd2, Brd3 and Brd4. Transgenic mice that overexpress 
Brd2 develop B cell lymphomas and transplantable leukaemia (Greenwald 2004), suggesting an 
important role for BET proteins in the expansion and maintenance of lymphocytes with potential 
implications for autoimmune disease. Brd4 reads inducible acetylation marks at H4K5, H4K8 and 
H4K12 on primary response gene promotors, recruiting pTEFb (a complex formed by cyclin-
dependent kinase 9 (CDK9) and its activator cyclin T1 which phosphorylates RNA-polymerase II (RNA 
Pol II) via CDK9, resulting in elongation of transcription, initiating a switch from basal RNA 
polymerase transcription of immature unspliced transcripts to productive transcription of protein 
coding mRNA (Hargreaves 2009) (Figure 11).  
 
Figure 11: BRD4 recruits P-TEFb and initiates gene transcription. Based on (Schaefer 2014). 
Inflammatory stimuli induce epigenetic changes, for example histone acetylation (illustrated as red 
triangles labelled Ac) and methylation (illustrated as green circles labelled Me), which lead to 
chromatin remodelling. Transcription factor binding sites (represented by rectangles marked TF) 
become exposed resulting in initiation of transcription. Induced acetylation of histones H3 and H4 
(H3/H4Kac) recruits BRD4 and P-TEFb to chromatin. P-TEFb phosphorylates RNA polymerase II (Pol II) 
(indicated by a yellow circle labelled P), releasing it from a paused state, resulting in elongation of 
mature RNA.  
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In addition, BET proteins regulate transcription of inflammatory genes at other levels. Brd4 is 
associated with regulating nuclear factor kappa beta (NF-κB) inducible responses (Figure 12). Binding 
of Brd4 to the acetylated lysine-310 residue of the RelA subunit of NF-κB is essential for the 
recruitment of Brd4 to the promoters of NF-κB target genes and subsequent coactivation of NF-κB. 
Brd4 further recruits CDK9 to phosphorylate RNA Pol II, activating the transcriptional activity of NF-
κB (Huang 2009). BET family proteins have also been shown to have roles in regulating cell division 
with dysregulation associated with malignancy (Belkina 2012). 
 
Figure 12: Brd4 enhances transcriptional activation of NF-κB and the expression of a subset of NF-κB 
responsive inflammatory genes in an acetylated lysine-310-dependent manner. Following 
inflammatory stimuli, p300 acetylates RelA at the lysine-310 (K310) residue, triggering the 
recruitment of Brd4. Brd4 further recruits CDK9 to phosphorylate RNA Pol II, activating the 
transcriptional activity of NF-κB. Brd4 is also recruited to the promoters of a subset of NF-κB target 
genes during the activation of NF-κB. 
Stimulus-dependent acetylation of RelA at lysine-310 by p300 triggers the recruitment of Brd4 to the 
promoter via its bromodomains. Brd4 further activates CDK9 to phosphorylate the carboxyl-terminal 
domain of RNA Pol II and facilitates transcription of NF-κB target genes (Huang 2009). 
The potential of BET proteins as a therapeutic target resulted in the development of BET-inhibitors, 
including the GlaxoSmithKline (GSK) compound I-BET762 (Nicodeme 2010) and JQ-1 (Filippakopoulos 
2010), small molecules that mimic acetylated histones and interfere with their binding to BET 
proteins (Figure 13). Bromodomain inhibitors bind to the bromodomains of BRD4, preventing them 
from binding to acetyl-lysine modifications. In the absence of BRD4 recruitment, P-TEFb is unable to 
dock and phosphorylate RNA polymerase II, leading to a failure to initiate gene transcription. These 
compounds are currently in early clinical trials for cancer (Andrieu 2016a). I-BET151 is a compound 
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that retains BET selectivity but is optimised pharmacokinetically for in vivo use and has potential for 
oral chronic dosing (Dawson 2011, Mirguet 2012, Seal 2012).   
 
Figure 13: Bromodomain inhibitors prevent BRD4 binding to acetylated lysine residues. I-BET bind to 
the bromodomains of BRD4, blocking their interaction with acetylated lysine residues. In the absence 
of BRD4 binding, P-TEFb is not recruited and RNA polymerase II remains stalled. I-BET selectively 
inhibits secondary response genes, including NF-κB and its target genes, that require stimulation 
induced chromatin remodelling prior to recruitment of RNA polymerase II.  
Selectivity of bromodomain inhibitors is in part based on the baseline epigenetic state of genetic 
loci. Affected genes generally have low levels of baseline H4 acetylation, H3K4 methylation, prior 
polymerase II recruitment and CpG, and belong to a group known as secondary response genes. 
Secondary response genes require new protein synthesis prior to induction, with formation of an 
initiation complex and recruitment of RNA polymerase for transcription. Genes affected by I-BET also 
have a greater reduction in BET recruitment following I-BET treatment compared to those not 
affected by treatment. In contrast, primary response genes initiate the early response, have higher 
levels of baseline H4 acetylation, H3K4 methylation, CpG and RNA polymerase II recruitment and are 
poised for immediate transcriptional activation and therefore are less dependent on BET protein 
recruitment for transcription. This does not explain all the differential selectivity of gene targets to I-
BET; knockdown of BET genes with small interfering RNA (siRNA) suppressed the expression of Tnf 
that was resistant to I-BET762 treatment suggesting an additional mechanism independent of 
interaction with acetylated histones (Nicodeme 2010).  
Super-enhancers are genomic regions with high numbers of enhancers identified by a concentrated 
region with high amounts of chromatin modification (Whyte 2013, Heinz 2015). Brown and 
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colleagues have described changes that occur in the endothelial cell epigenome associated with 
inflammation (Brown 2014) (Figure 14). Stimulation with TNFα prompted a dramatic and rapid NF-κB 
guided global redistribution of BRD4 away from basal endothelial super-enhancers to new 
inflammatory super-enhancers despite persistent histone hyperacetylation, leading to swings in 
transcriptional initiation and elongation and the transcription of key inflammatory genes. BRD4 is 
required to communicate enhancer remodelling to RNA Pol II, with the majority of enhancer bound 
BRD4 found within a small number of these super-enhancer regions. Bromodomain inhibition 
impedes NF-κB directed reorganisation of super-enhancers, suppressing super-enhancer dependent 
proinflammatory gene transcription, demonstrated by in vivo inhibition of atherogenesis, a 
pathogenic process dependent on inflammatory endothelial activation (Brown 2014).  
 
Figure 14: Graphical abstract from (Brown 2014), reprinted with permission of Elsevier. 
Bromodomain inhibitors have been shown to selectively inhibit genes associated with inflammation 
following murine BMDM treatment with LPS in vitro and protect mice from LPS induced septic shock 
in vivo (Nicodeme 2010, Belkina 2013). Reanalysis of the Nicodeme et al. data set (Nicodeme 2010) 
shows that the LPS induced inflammatory response in murine macrophages can be explained by 
redistribution of super-enhancers, with preferential I-BET151 mediated inhibition of gene 
transcription driven by proinflammatory super-enhancers compared to those driven by typical 
enhancers (Brown 2014). 
I-BET151 has also been shown to have effects on inflammatory responses in primary human 
monocytes. I-BET151 inhibited TLR4- and TNF-induced IFN responses and IFN-stimulated gene 
expression by both diminishing IFN-β expression and by suppressing transcriptional responses to 
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IFN-β. I-BET151 inhibited responses to cytokines (IFN-β, IFN-γ, IL-4, and IL-10) that activate the JAK-
STAT signalling pathway, by inhibiting cytokine-induced transcription of STAT targets in a gene-
specific manner without affecting STAT activation or recruitment, suggesting potential for effects on 
monocyte polarisation and inflammatory diseases (Chan 2014). Bromodomain inhibition inhibits the 
maturation of DC and enhances their tolerogenic properties (Toniolo 2015, Schilderink 2016). I-
BET151 treated murine BMDC and human monocyte derived DC (MoDC) show reduced LPS induced 
expression of co-stimulatory molecules, reduced cytokine production and reduced T cell activation. 
Treatment of BMDC with I-BET151 did not affect their ability to polarise ovalbumin specific CD4+ 
CD62L+ naïve T cells towards Th1, Th2, or Th17 phenotype, but increased induction of Foxp3 
expressing Treg with suppressive properties (Schilderink 2016). Similarly, JQ-1 impairs LPS-induced 
MoDC maturation, via a mechanism dependent on inhibition on LPS induced STAT5 phosphorylation 
and nuclear accumulation. JQ1 inhibited the expression of cytokines and cell surface markers 
associated with MoDC maturation leading to a decreased ability of MoDC to induce CD4+ and CD8+ 
T cell proliferation, reduced T-cell-mediated pro-inflammatory cytokine production and inhibition of 
Th1 polarization with maintained ability to induce Th2 cells and Tregs (Toniolo 2015).  
BET proteins are expressed ubiquitously in mammalian tissues so inhibition may have effects on 
multiple lineages of cells. Effects on T cell differentiation have been shown with effects on multiple 
lineages. Treatment of naïve CD4+ T cells with a BET inhibitor during the first two days of 
differentiation had long lasting effects on subsequent gene expression and cytokine production and 
inhibited the ability of antigen-specific T cells, differentiated under Th1 but not Th17 conditions in 
vitro, to induce pathogenesis in an adoptive transfer model of EAE (Bandukwala 2012). The BET 
inhibitor JQ1 was reported by Mele and colleagues to have a selective effect on human and murine 
Th17 cell differentiation in vitro, directly regulating production of effector cytokines such as IL-17, IL-
23 and granulocyte-macrophage colony-stimulating factor (GM-CSF). Therapeutic dosing inhibited 
EAE, a model induced by immunizing mice with myelin oligodendrocyte glycoprotein (MOG) peptide.  
In vitro stimulation of T cells obtained from the cervical lymph nodes of JQ1-treated EAE animals 
with MOG peptide produced normal levels of IFN-γ but reduced IL-17, suggesting a specific effect on 
Th17 cells (Mele 2013). Collagen induced arthritis was also inhibited by treatment with JQ1, 
although the mechanism of inhibition was not elicited in this study. JQ1 treated in vitro expanded 
antitumor T cells showed enhanced persistence and antitumour effects in murine models, 
maintaining features of stem cell–like and central memory T cells (Kagoya 2016). 
The innate immune response is critical in determining the response to tissue injury and whether this 
results in repair or fibrosis. JQ1 suppresses innate inflammatory and profibrotic transcriptional 
networks robustly enriched for NF-κB and TGF-β signalling in heart failure, improving outcomes in 
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mice with pre-established heart failure from chronic pressure overload and following induction of 
massive anterior myocardial infarction (Duan 2017). Bromodomain inhibition has also shown benefit 
in animal models of renal (Xiong 2016, Zhou 2017), lung (Tang 2013) and liver (Ding 2015, 
Zhubanchaliyev 2016) fibrosis.  
The broad range targets for bromodomain inhibition means that it is likely that effects on multiple 
pathways contribute to inhibition of inflammatory responses. Beatriz Suarez-Alvarez and colleagues 
show that JQ1 reduces inflammation in multiple models of renal injury; unilateral ureteric 
obstruction, anti-glomerular basement membrane antibody induced nephrotoxic nephritis and 
angiotensin II induced renal damage (Suarez-Alvarez 2017). Common findings included reduced 
proinflammatory mediators and reduced infiltration of inflammatory macrophages/monocytes. JQ1 
was shown to inhibit direct BRD4 binding to proinflammatory gene promotors including those for 
CCL2, CCL5 and IL6, inhibit canonical NF-κB pathway activation, reducing RelA nuclear levels in the 
injured kidneys across models, and target IL-17 production suggesting an effect on Th17 immune 
responses. JQ1 has also been shown to attenuate the progression of proteinuria and nephritis and 
improve survival in a MRL-lpr murine lupus model, with reduced levels of pro-inflammatory 
cytokines, BAFF and serum anti-dsDNA antibodies and reduced immune complex-mediated 
activation of human monocytes in vitro by JQ1 (Wei 2015).  
Targeting of integral pathways, for example the NF-κB pathway, may allow use of this class of drug in 
a broad range of inflammatory conditions, irrespective of the initial cause of injury. However, some 
argue that lack of specificity may limit use, and there is ongoing interest in developing new 
compounds with improved selectivity. The first bromodomain (BD1) functions to anchor the 
activated Brd4/transcription protein complex to target genes in chromatin through binding to lysine-
acetylated histone H4 (Zhang 2012), whereas the second bromodomain (BD2) of Brd4 is dedicated to 
interaction with lysine-acetylated transcription factors and p-TEFb (Schroder 2012). Selective 
inhibition of BD1 of BET proteins, with the newly described bromodomain inhibitor MS402, inhibits 
primarily Th17 cell differentiation with a little or almost no effect on Th1 or Th2 and Treg cells and 
prevents and ameliorates T-cell transfer-induced colitis in mice by blocking Th17 cell 
overdevelopment (Cheung 2017). Genomic sequencing analysis of BET inhibitor treated murine Th17 
cells confirmed a more selective effect of MS402 over JQ1; MS402 was similarly effective in releasing 
Brd4 genomic occupancy at Th17 signature genes and super-enhancers but had fewer effects than 
JQ1 at housekeeping genes. 
The timing of treatment may be critical in determining the effect on host immunity and whether 
beneficial host innate immune responses are affected. The Nos2 gene encoding inducible nitrous 
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oxide synthase (iNOS) is activated during infection with the intracellular organism Listeria. Inhibition 
of BET proteins by JQ1 treatment strongly reduced nitrous oxide production and immunity of mice 
to Listeria monocytogenes and influenza virus. JQ1 also exacerbated the colitogenic activity of 
dextran sodium sulfate where the host inflammatory response is protective (Wienerroither 2014). 
1.8 Hypotheses: 
1. Belimumab (an anti-BLyS antibody), given in conjunction with standard maintenance 
immunosuppression, will reduce B cell activation and antibody generation and B cell 
production of pro-inflammatory cytokine in renal transplant recipients   
 
2. Bromodomain inhibition will selectively inhibit FcγR-mediated MNP activation, providing a 
novel therapeutic strategy in IgG-immune complex-associated inflammation. 
1.9 Aims of the project:  
i. To perform an experimental medicine study in human kidney transplant recipients in 
order to characterise B cell activation post-renal transplant, and to determine if BLyS 
neutralisation is a useful therapeutic strategy to modulate B cell cytokine production, 
antibody formation and T cell activation in this clinical context. 
 
ii. To undertake pre-clinical studies in human and mouse cells in vitro, and to perform in 
vivo murine experiments, to determine if and how bromodomain inhibitors modulate: 
a. immune complex uptake and processing by macrophages and their generation of 
cytokines and chemokines. 
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2.1 BEL114424 clinical trial 
The clinical study was a collaborative project with clinicians, scientists and statisticians from 
Addenbrooke’s Hospital, the University of Cambridge and GSK all being critical for its design, 
implementation and completion. The human biological samples were sourced ethically and their 
research use was in accord with the terms of the informed consents under an institutional review 
board (IRB)/ethics committee (EC) approved protocol. 
2.1.1 Study design 
In this phase IIA, randomised, double-blind, sponsor unblind study (BEL114424; clinical trials.gov 
identifier NCT01536379; EudraCT number 2011-006215-56), subjects were recruited between 
September 2013 and February 2015 at a single UK transplant centre (Addenbrooke’s Hospital, 
Cambridge). Subjects were randomised 1:1 to receive 7 doses of intravenous (IV) belimumab 
10mg/kg or placebo (0.9% sodium chloride solution) by at days 0, 14, 28 followed by 4-weekly doses 
through to week 20, in addition to basiliximab (20mg IV days 0 and 3), tacrolimus (0.15mg/kg daily: 
target trough level 6-10μg/L first 6 months post transplantation, 5-8μg/L thereafter), mycophenolate 
mofetil (500mg twice daily) and prednisolone (20mg daily initially, weaning to 5mg daily in month 1-
2). Patients received infection prophylaxis with nystatin (1st month), co-trimoxazole (months 1-6) 
and valganciclovir (months 1-6), and were followed for 12 months.  
2.1.2 Study patients 
Patients aged 18 to 75 years receiving a kidney transplant were eligible for inclusion. Exclusion 
criteria included donor age <5 or >70 years, ABO blood type incompatibility, 0-0-0 HLA mismatch, a 
positive T and/or B cell cross-match, and previous recipient exposure to B cell targeted therapy (full 
eligibility criteria are in the study protocol available at www.gsk-
clinicalstudyregister.com/study/114424#ps).  
Initial study recruitment was slower than anticipated and my feedback on the recruitment process 
guided changes to the study protocol to allow targets to be met. Addenbrooke’s hospital specialises 
in transplanting kidneys donated after circulatory death (DCD). The majority of DCD donors did not 
meet initial tight donor exclusion criteria in view of their age and comorbidities; an amendment was 
sought to widen eligibility criteria (protocol amendment 4, dated 16 October 2013). The original 
protocol excluded DCD donors aged > 60 years old, or > 50 if they had died from a stroke, had a 
history of high blood pressure, or had a serum creatinine greater than 135µmol/L at the time of 
donation. We felt that including all DCD donors <70 would not impact on the quality of the study but 
may substantially improve recruitment. 
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Due to the nature of deceased donor transplantation there was often a restricted time window for 
gaining informed consent, compounded by the fact that this was a time of heightened emotions, not 
ideally suited to complex decision-making, where standard procedures required to facilitate timely 
transplantation took precedent. I observed a wide range of attitudes and risk behaviours towards 
clinical trials in patients with end stage kidney disease and placed high importance on ensuring that I 
maintained focus on protecting potentially vulnerable research participants. The trial involved a 
complex protocol with frequent sampling and dosing which was not well received by many patients 
who wished to receive their transplant and return to follow-up at local centres as soon as possible. 
The patient information sheet was lengthy and could not be shortened due to legal restraints. My 
experience consenting patients highlighted areas of common misunderstanding and guided minor 
amendments. The practicalities of obtaining and processing samples for multiple mechanistic studies 
and coordinating required study staff proved particularly challenging out of hours; a pharmacy out of 
hours rota was finalised to facilitate out of hours recruitment. Due to these challenges, recruitment 
was slower than initially anticipated and an additional centre at Guy’s Hospital was added to the 
study in August 2014. Study recruitment was completed in February 2015 with all subjects 
consented at Addenbrooke’s Hospital. 
2.1.3 Study endpoints 
Co-primary endpoints were safety and efficacy measured by change in naïve B cells from baseline to 
Week 24, a biomarker of functional BLyS neutralisation validated in patients with SLE (Navarra 
2011). Safety was measured via capture of adverse events and serious adverse events, classified 
using the Medical Dictionary for Regulatory Activities. 
Secondary and exploratory endpoints included pharmacodynamics, immunological biomarkers (e.g. 
regulatory B cells, assessment of peripheral blood transcriptional profiles, and non-HLA antibodies) 
and clinical endpoints. 
2.1.4 Study oversight 
The study was designed by the sponsor, GSK, in close collaboration with principal investigators at 
Addenbrooke’s Hospital. The study was approved by the local Research Ethics Committee and all 
patients provided written informed consent.  
2.1.5 Statistical analysis (Led by Mr Don Shanahan, GSK): 
Primary analyses were undertaken using a pre-specified modified intention to treat (MITT) 
population including all patients randomised who received at least one infusion of study drug. 
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Secondary and exploratory biomarker outputs were undertaken using a pre-specified per protocol 
(PP) population that included all MITT subjects who received at least five infusions of study drug, 
were followed up beyond week 24 and received no prohibited medications or plasma exchange 
(referred to as PP1 population in the study reporting and analysis plan (RAP)). 
No formal statistical hypotheses were defined in the RAP. For the primary and secondary biomarker 
endpoints, a mixed model for repeated measures (MMRM) approach was used to produce adjusted 
mean differences between belimumab and placebo with corresponding 95% confidence intervals. 
The MMRM approach used fixed categorical effects of treatment, visit, donor organ status (coded as 
live donor, donated after brain death, donated after circulatory death) and treatment-by-visit 
interaction and fixed continuous covariates of baseline values and baseline values-by-visit 
interaction. A compound symmetry variance structure was used to model the within-patient errors, 
shared across treatments. 
All post hoc analyses are labelled as such. Analyses were performed using SAS version 9.3 except for 
transcriptomic and protein microarray analyses, which were performed using R version 3.3.1. I 
recreated graphs for publication using Prism software. For exploratory analyses outside of the RAP, 
analysis was performed in Prism and the approach verified by the statistics team lead by Mr Don 
Shanahan, GSK. Data integrity was checked according to GSK internal procedures.  
The target sample size of 20 evaluable subjects was calculated to achieve a reduction in naïve B cell 
count from baseline to 24 weeks, based on naïve B cell data from a previous trial of belimumab in 
SLE (BLISS-76) (Stohl 2012) and n=93 renal transplant recipients at the Cambridge Transplant Unit 
(unpublished data). Interim re-estimations of sample size were performed in November 2014 and 
February 2015. 
2.1.6 Visit windows 
Assessments were assigned to visit windows (slots) according to the date of assessment (for study 
schedule see study protocol). For adverse events the on-treatment phase commenced from the start 
of the first infusion of belimumab/placebo and ended 28 days after the last dose. The post-
treatment phase began the following day. For other primary and secondary endpoints, the on-
treatment phase ended 35 days after the last dose to allow incorporation of the On-Trt Week 24 visit 
on day 168 +/- 7 days. 
The visit slotting intervals for the Pre-Treatment and On-Treatment (On-Trt) phases for biomarker 




Week Day relative to 
first infusion 
Day Visit Window 
Baseline 
On-Trt Week 4 
On-Trt Week 8 
On-Trt Week 12 







28 - 27 Days or + 14 Days 
56 - 13 Days or + 14 Days 
84 - 13 Days + 42 Days 
168 - 41 Days +7 Days 
≤0 
Days 1 to 42 
Days 43 to 70 
Days 71 to 126 
Days 127 to 175 
The visit slotting intervals for the Post-Treatment (Post-Trt) phase for biomarker endpoints were as 
follows: 
Week Day relative to 





Day Visit Window 
Post-Trt Week 12 





84 – 83 Days or + 56 Days 
196 – 55 Days or + 154 
Days 
Days 1 to 140 
Days 141 to 
350 
If more than one assessment fell within the same visit window, the assessment nearest to the 
scheduled time point was used. If two assessments were equally close, the latter was used. Samples 
for transcriptomic and protoarray analysis were collected at baseline, at week 24 (+/- 7 days) and at 
week 52 (+/- 7 days) according to the study schedule, irrespective of the last dose of study drug 
given, so data for these endpoints are presented without window fitting. On-treatment samples for 
the B cell stimulation assay were limited so the last available on-treatment result is displayed (‘Last 
On-Trt’). 
2.1.7 Immunophenotyping  
Immunophenotyping was performed by flow cytometry with absolute cell numbers calculated using 
TBNK counts.  
Sample processing, acquisition and blinded gating was performed by the GSK Clinical Unit Cambridge 
(CUC) team and QUEST; analysis of exploratory biomarker outputs was performed by Dr Gemma 




2.1.8 BEL114424 B cell stimulation assays  
B cell stimulation assays were performed by Dr Gemma Banham in collaboration with Ms Adele 
Gibson, GSK. 
For validation studies PBMC were isolated from human whole blood from healthy volunteers 
collected into Lithium Heparin Vacutainer tubes (BD Biosciences) (Blood Donation Units at GSK, 
Stevenage and GSK CUC Addenbrooke’s, Cambridge). Blood was diluted and layered on to 15ml 
Ficoll-Paque (GE Healthcare) in 50ml Accuspin tubes and centrifuged at 800g for 20mins without 
breaking. The mononuclear layer at the interface was harvested, washed and counted. For freezing, 
cell pellets were resuspended in freezing medium A (60:40 fetal calf serum (FCS):RPMI), followed by 
an equivalent volume of freezing medium B (80:20 FCS:DMSO added dropwise), to make a final 
concentration of 1 x 107 cells per ml.  Cells were transferred to cryovials in 1ml aliquots and frozen at 
-800C, and transferred to liquid nitrogen storage one week later until ready to be used. 
For the BEL114424 Breg assay, frozen PBMC samples were used from specified trial timepoints. 
These samples were processed following venepuncture by the GSK CUC according to standard 
operating procedures, in line with the BEL114424 study protocol and stored in liquid nitrogen until 
ready to be used.  
Frozen peripheral blood mononuclear cells were thawed, washed and resuspended in RPMI, 
supplemented with 1% L-glutamine (Gibco), 1% penicillin/streptomycin (Gibco) and 10% heat 
inactivated FCS (PAA Labs), and plated in flat bottom 48 well plates at a concentration of 1x106 cells 
in 200µl.  Cells were incubated at 37°C in a 5% CO2 humidified incubator for 48 hours with stimuli 
applied as described. CpG DNA Oligodeoxynucleotides (100nM; Hycult Biotech) and CD40L (1µg/ml; 
R&D Systems) were added at the beginning of the 48 hour incubation period (48 hour stimulation) or 
just for the last 5 hours (5 hour stimulation). Phorbol 12-myristate 13-acetate (PMA) (50ng/ml; 
Sigma-Aldrich), ionomycin (500ng/ml; Sigma-Aldrich) and brefeldin A (5µg/ml; BioLegend) (PIB) were 
added for the last 5 hours of culture. Following stimulation the cells were harvested, washed in FACS 
buffer (phosphate buffered saline (PBS) with 1% FCS and 0.1% NaN3), blocked with human FcX 
Trustain block (BioLegend), then stained with a surface antibody panel, followed by live dead 
discrimination using fixable aqua dead cell dye (Invitrogen), fixed and stored overnight at 4°C prior 
to permeabilization (Invitrogen) and intracellular staining prior to acquisition using a flow cytometer. 




2.1.9 B cell stimulation assays on healthy controls  
These assays were performed by Mr. Joseph Chadwick, GSK with guidance from Dr Gemma Banham 
and Ms Adele Gibson. 
CD19+CD27+ memory B cells were enriched from PBMCs of 16 healthy donors using a human 
memory B cell isolation kit (Miltenyi Biotec) and cultured in vitro in the presence of CpG (100nM; 
Hycult Biotech) and CD40L (1µg/ml; R&D Systems) with 0 to 200ng/ml BLyS (GSK) for 48 hours. 
Phorbol 12-myristate 13-acetate (PMA) (50ng/ml; Sigma-Aldrich), ionomycin (500ng/ml; Sigma-
Aldrich) and brefeldin A (5µg/ml; BioLegend) were added for the last 5 hours of culture and IL-6 and 
IL-10 quantified by flow cytometry. In 7 of these healthy donors, 15nM belimumab (GSK) was added 
in addition to 100ng/ml BLyS. 
2.1.10 Transcriptomic analysis  
Performed by Dr Shaun Flint (University of Cambridge/GSK) and Dr Paul Lyons, University of 
Cambridge. 
RNA was extracted from whole blood or from purified leukocyte subsets in Professor Smith’s 
laboratory (University of Cambridge), as described previously (Lyons 2007), and hybridised to Human 
Gene ST 2.1 microarrays (Affymetrix). Microarray data are available in the ArrayExpress database 
(http://www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-5906.  
Lysates (CD4+ T-cell) and PaxGene tubes (whole blood) were stored at -80°C until required. RNA was 
extracted from CD4+ T-cell lysates using an AllPrep Kit (Qiagen) and from whole blood using the 
PAXgene system (Qiagen). RNA was processed and hybridised to Human Gene ST 2.1 microarrays 
(Affymetrix) according to the manufacturer’s instructions. 
Affymetrix CEL files were imported into R/Bioconductor, normalised and summarised at the 
transcript cluster level using the oligo package (rma function, target = “core”). Transcript clusters 
were annotated using Ensembl biomaRt and manufacturer’s own annotation and Affymetrix control 
probes were removed. Non-protein coding probes were also removed. 
Weighted gene coexpression network analysis (WGCNA) was undertaken of the whole blood gene 
expression data using the WGCNA package in R/Bioconductor. One of the resulting whole blood 
gene expression modules was identified as representing a B-cell transcriptional programme on the 
basis of a unique overlap of module genes with the Gene Ontology class ‘GO:0050853 BCR signalling 
pathway’. Module expression was determined as the value of the first principal component 
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calculated from module gene expression, along standard analysis lines for WGCNA and using 
functions in the WGCNA package. 
Differential gene expression analyses were performed using the limma package in R/Bioconductor. 
The model incorporated time-point and treatment group interaction terms and accounted for the 
repeated measures nature of the analysis (study participants contributed gene expression samples 
at three different timepoints) using the duplicateCorrelation function. Contrasts were defined for 
differential expression at baseline, 24 weeks and 52 weeks (Belimumab – Placebo at each 
timepoint). Estimates were adjusted using the eBayes function. 
Where there was more than one transcript cluster per gene, differential expression was summarised 
into a single gene measure using the mean log-fold change. Immunoglobulin coding genes were 
identified from their Ensembl Biotype annotation. Cell cycle genes were identified using the Gene 
Ontology class ‘GO:0007049 Cell cycle’. 
2.1.11 ProtoArray® (Invitrogen) protein microarrays  
Assay run by Thermo Fisher, analysis performed by Dr Shaun Flint, GSK 
Serum samples were stored at -80°C until required. ProtoArray® Human Protein Microarray 5.1 
slides were blocked in blocking buffer (50 mM HEPES, 200 mM NaCl, 0.01% Triton X-100, 25% 
glycerol, 20 mM reduced glutathione, 1.0 mM DTT, 1X Synthetic Block) at 4 °C for 1 hour. After 
blocking, arrays were rinsed once with freshly prepared PBST buffer (1X PBS, 0.1% Tween 20, and 1 X 
Synthetic Block). Arrays were then probed with a 1:500 dilution of each sample diluted in 5 mL of 
PBST buffer. Arrays were incubated for 90 minutes at 4°C in QuadriPERM 4-well trays (Greiner) with 
gentle agitation. After incubation, slides were washed five times (5 minutes per wash) in 5 ml PBST 
Buffer in 4-well trays. An Alexa Fluor®647-conjugated goat anti-human IgG antibody diluted in 5 ml 
PBST buffer to a 1.0 µg/ml final concentration was added to each array and allowed to incubate with 
gentle shaking at 4°C for 90 minutes. After incubation, the secondary antibody was removed, and 
arrays were washed as described above. Arrays were dried by spinning in a table top centrifuge 
equipped with a plate rotor at 200x gravity for 2 minutes. Arrays were then scanned using a Tecan 
PowerScanner™ fluorescent microarray scanner. 
GenePix 7 software was used to overlay the mapping of human proteins in the array list file to each 
array image with a fixed feature size of 130 um (diameter). After aligning each of the 48 subarrays 
using spots from the AlexaFluor®-conjugated and murine antibodies printed in each subarray, the 
features were resized by the GenePix software to best fit the feature. Pixel intensities for each spot 
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on the array were determined. Arrays were normalised and a signal for each spot on the array 
calculated by subtracting the local background signal. Microarray hybridisation and these initial 
processing steps were performed by ThermoFisher. 
After removing data from control group spots and TNFSF13B (as bound by belimumab) the signal 
from duplicate spots was combined (mean) to give one value per unique antigen. This dataset was 
used to define a global threshold for ‘significant’ antibody binding (10,750) by maximising the signal-
to-noise ratio for the comparison of number of antigen with a signal above threshold in samples at 
baseline (no immunosuppression) versus Week 24 (maximal immunosuppression). This approach 
avoided defining a threshold based on the parameter of interest (treatment group), relying on the 
biologically plausible hypothesis that there would be differences in circulating auto-/allo-antibody 
pre- and post-transplant. 
This threshold was used to determine whether an individual antigen specificity had significant 
antibody binding (yes/no). New antigenic specificities post-transplant were defined as antigenic 
specificities with significant binding at week 24 post-transplant not observed at baseline (week 0). 
Patient serum was hybridised to ProtoArray (Invitrogen) protein microarrays according to 
manufacturer’s instructions. 
2.2 Investigation of the effect of bromodomain inhibitors on FcγR mediated MNP activation 
The human biological samples used were sourced ethically and their research use was in accord with 
the terms of the informed consents under an institutional review board/ethics committee approved 
protocol. 
2.2.1 Generation of macrophages from murine bone marrow 
Femurs and tibiae from C57BL/6 mice were removed and separated from the surrounding muscle 
tissue by blunt dissection. Intact bones were disinfected in 70% ethanol. The bone ends were cut 
with sterile scissors and the marrow flushed with sterile PBS using a 23G needle. Cells were spun at 
1300rpm for 5 minutes then re-suspended in RPMI 1640 media supplemented with 1% penicillin-
streptomycin and 10% FCS (all Sigma) in 10cm petri dishes (one leg per petri dish in 5ml media). To 
promote differentiation to a macrophage phenotype recombinant murine macrophage colony-
stimulating factor (M-CSF) (Peprotech; final concentration 10ng/ml) was added to the media. Media 
was supplemented on day 3 and changed on day 6 and cells seeded in 6, 12, or 24 well culture plates 
at an appropriate density suitable for individual experiments when displaying morphology consistent 
with a mature state (day 3-6)  
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2.2.2 Generation of bone marrow derived dendritic cells from murine bone marrow 
Femurs and tibiae were processed as above. The cells obtained from each mouse were resuspended 
in 60ml RPMI 1640 media supplemented with 1% penicillin-streptomycin and 10% FCS (all Sigma) in 
a 75cc tissue culture flask. To promote differentiation to a dendritic cell phenotype recombinant 
murine granulocyte-macrophage colony-stimulating factor (GM-CSF) (Peprotech; final concentration 
20ng/ml) was added to the media. Non adherent cells were removed with half the media on day 3, 
and the media replaced with murine GM-CSF (Peprotech; final concentration 40ng/ml). Non 
adherent cells were removed on day 6 and plated in appropriate tissue culture plates for use in 
media supplemented with murine GM-CSF (Peprotech; final concentration 20ng/ml). Cells were used 
between days 7 to 10.  
2.2.3 Generation of human monocyte derived macrophages 
The human biological samples used were sourced ethically and their research use was in accord with 
the terms of the informed consents under an IRB/EC approved protocol. ”Leukocyte “cones” were 
obtained from the National Blood Service (Cambridge, UK). Cell fractions were separated using 
Histopaque 1077 (Sigma-Aldrich, Gillingham, UK) and the monocyte layer retrieved. Cells were 
cultured in cRPMI with 0.1 mcg/ml MCSF (Peprotech, London, UK) and were supplemented every 72 
hr for 5-10 days. Adherent cells were lifted with a cell scraper. Mature macrophages were identified 
according to their distinctive forward/side scatter profile on flow cytometry. 
2.2.4 Reconstitution of I-BET 151 
I-BET151 was supplied by GSK. For in vitro assays, a stock solution of 10mM was prepared in DMSO 
(Sigma), and further diluted to desired concentrations in cell culture medium prior to addition to 
cells. For in vivo studies, I-BET151 was dosed at 30mg/kg and prepared by dissolving in normal saline 
containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB. 
2.2.5 Flow cytometry  
Cells were stained for flow cytometry according to standard protocols, briefly summarised here. 
1. Adherent cells were scraped off cell culture plates using the plunger of a suitably sized 
syringe and collected in a 12x75 mm round bottomed FACS tube. Following 
centrifugation for 5 minutes at 1300 rpm at 4oC, supernatants were discarded and the 




2. Non-specific Fc-mediated staining was inhibited by adding 1µl normal mouse serum to 
each tube and incubating for 15 minutes on ice prior to staining with specific antibodies. 
3. For directly conjugated antibodies (see appendices), an appropriate quantity of each 
primary antibody was added and the cells incubated on ice in the dark for 45-60 
minutes. Staining for CCR7 was performed at room temperature.  
4. Cells were washed with PBS (2ml/tube) and centrifuged at 1300rpm for 5 minutes at 
4oC. The supernatant was discarded and the pellet re-suspended 
5. Step 4 repeated. 
6. Cells were then stained for viability using LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit 
(Life Technologies; #L34957) according to the manufacturer’s instructions. 
7. Cells were fixed in FACS FICS (PBS containing 1% formaldehyde, 0.02% sodium azide, 2% 
glucose) 
8. FACS was performed using a BD LSRFortessaTM (Becton Dickinson) flow cytometer. Data 
were analysed with FlowJo software (Tree Star). 
Antibodies used are listed in the appendices 
2.2.6 Preparation of immune complexes for in-vitro stimulation 
LPS-free ovalbumin (OVA; Hyglos GmbH) was mixed in the following quantities with rabbit anti-OVA 
(Sigma) and PBS and incubated at 37 oC for 60 minutes: 
To stimulate 0.5-1 x106 macrophages in a volume of 300µl in a 24 well plate: 
0.4µl of 1mg/ml solution of OVA 
4µl of rabbit anti-OVA (3-5mg/ml) 
7.8µl of PBS 
For phagocytosis assays where half the amount of OVA-conjugate (Ovalbumin-647 (Invitrogen) or 
Ovalbumin-FITC (Invitrogen)) and rabbit anti-OVA were used to avoid oversaturation of the assay. 
2.2.7 Phagocytosis of immune complexes 
The phagocytic ability of macrophages treated with I-BET151 or DMSO was assessed using a flow 
cytometry based phagocytosis assay. Bone marrow derived macrophages (BMDM) were fed 
ovalbumin conjugated to alexa flour 647 (OVA-647) that had been opsonized with rabbit anti-
ovalbumin immunoglobulin (IC; prepared as described above). Cells were harvested at defined time 
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points and washed to remove free IC. Phagocytosis was assessed via flow cytometry following 
desired surface and viability staining. The percentage of cells containing phagocytic material were 
quantified using an untreated control to set the positive gate. In addition the geometric mean 
fluorescence in the alexa flour 647 channel of all live cells and phagocytic index (geometric mean 
fluorescence of live phagocytic cells) were calculated to quantify phagocytosis. 
Phagocytic degradation products were identified by substituting OVA-647 for DQ-OVA (Invitrogen), a 
conjugate that exhibits bright green fluorescence only after proteolytic degradation. 
2.2.8 Phagocytosis of apoptotic cells 
Thymi of C57BL/6 mice were removed and passed through a 70µm cell strainer. Thymocytes were 
labelled with cell tracker orange (ThermoFIsher) according to the manufacturer’s instructions, then 
rendered apoptotic via treatment with dexamethasone (Sigma; 1µM for 17 hours). Phagocytosis was 
assessed via flow cytometry and confocal microscopy. 
2.2.9 Confocal microscopy 
Murine BMDM were isolated from bone marrow and grown as described above. When mature, they 
were seeded onto glass cover slips sterilised in 70% ethanol prior to placing in 24 well culture plates. 
For assessment of immune complex phagocytosis, immune complexes were prepared as described 
above, and added to culture wells at defined time points prior to fixation of cells and staining. 
Staining was performed as follows: 
1. Cells were washed with RPMI to remove free IC 
2. Cells were fixed to cover slips by incubation with FACS FICS for 15minutes. 
3. Cells were blocked and permeabilised in blocking buffer made from 0.1M TRIS, 1%BSA, 0.1% 
Triton X-100, 1% normal goat serum (goat secondary antibodies used) 
4. Cells were incubated at room temperature with primary antibodies diluted in blocking buffer 
for 1-3 hours. 
5. Following washing with 0.1M TRIS, cells were incubated at room temperature for 1-2 hours 
with appropriate secondary antibodies diluted in blocking buffer. 
6. Slides were incubated with phalloidin diluted in blocking buffer for 45-60 minutes 
7. Following a further wash, cover slips were mounted onto slides using VectaShield Hardset 
Mounting Medium with DAPI (Vector Labs #H1500) 




For quantification of cell adhesion cells, following permeabilization, cells were stained with 
phalloidin alone and mounted using VectaShield Hardset Mounting Medium with DAPI (Vector Labs 
#H1500). 
Antibodies used are listed in the appendices 
2.2.10 Cytokine measurement 
TNF-α and IL-6 concentrations in culture supernatants were measured by ELISA (Duokit DY410 
(TNFα); DY206 (IL6); R&D Systems) according to the manufacturer’s instructions.  MCP3 levels were 
measured by ELISA (Peprotech #900-K123) according to the manufacturer’s instructions. Multiplex 
cytokine analysis on cell supernatants was performed by the Addenbrooke’s Hospital Core 
Biochemical Assay Laboratory using the MesoScale Discovery assay system (IFN-γ, IL-1 beta, IL-2, IL-
4, IL-5, IL-6, KC-GRO,IL-10, IL-12 & TNF alpha). 
2.2.11 Mice 
Wild-type C57BL/6 were obtained from Jackson Laboratories (Margate, UK) as were transgenic mice 
expressing enhanced yellow fluorescent protein (EYFP) under the control of the CD11c promoter 
(Lindquist 2004), enhanced green fluorescent protein (EGFP) under the control of the human 
ubiquitin C promoter (Schaefer 2001), and enhanced cyan fluorescent protein (ECFP) mice under the 
control of chicken beta actin promotor (Barnden 1998). Ovalbumin (OVA)-specific, MHC class II-
restricted alpha beta T cell receptor (TCR) transgenic mice (OTII mice)(Barnden 1998) were also 
purchased from Jackson Laboratories (Margate, UK). FcγRIIb-deficient mice on a C57BL/6 
background (Bolland 2000) were kindly provided by Jeff Ravetch (Rockefeller University, New York) 
and Silvia Bolland (National Institutes of Health, NIAID, Bethesda, MD). 
Mice were maintained in specific-pathogen-free conditions at a Home Office-approved facility in the 
UK. All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific 
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals. 
2.2.12 Tissue dissociation of murine kidneys  
Immediately following terminal procedure mouse kidneys were perfused with PBS. Organs were 
minced through a 70 μm cell strainer, digested in 1mg/ml collagenase A, 1mg/ml DNase I (both 
Roche, Burgess Hill, UK) and 2% heat inactivated FCS (Sigma-Aldrich, Gillingham, UK) in PBS for 20 
minutes, before red blood cell lysis and staining for flow cytometry.  
2.2.13 RNA extraction from murine kidneys  
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Samples of murine kidney were submerged after harvest in RNAlater™ Stabilization Solution 
(Invitrogen, UK), stored at 4oC for 24 hours prior to storage at -80oC, until ready for further 
processing. After thawing, tissue was removed from the RNAlater solution and homogenised in lysis 
buffer using Precellys®homogenisation technology (Bertin, France) and RNA extracted using 
PureLink RNA Mini Kit (Invitrogen, UK) according to manufacturer’s instructions.  
2.2.14 Reverse Transcriptase Polymerase Chain Reaction 
Tissue sections or cell suspensions were lysed in RNA lysis buffer. Subsequent RNA extraction was 
performed using Ambion RNA PureLink Kit (Life Technologies, Paisley, UK) and yields analysed using 
Nanodrop spectrophotometry (Thermo-Scientific, Loughborough, UK). Complementary DNA 
synthesis was undertaken using High Capacity RNA to cDNA (Life Technologies, Paisley, UK) and 
BioRad (Hemel Hempstead, UK) PCR machine. RT-PCR was performed using Taqman reagents 
(Thermo-Fisher, Paisley, UK) on the Viia 7 PCR machine (Life Technologies, Paisley, UK). For primers 
see Materials and Methods Appendix. Gene expression relative to GAPDH/HPRT was calculated 
using 2-ΔCT for DMSO and I-BET treated samples individually (Schmittgen 2008). 
2.2.15 Experimental protocol for murine bone marrow derived macrophage transcriptomic study 
BMDM were prepared from C57BL/6 mice as described above. BMDM treated with or without 
ovalbumin (OVA) or immune complexed ovalbumin (OVA-IC) in the presence of 3.3µm I-BET 151 or 
DMSO control for 1 hour, 4 hours and 14 hours. I-BET or DMSO was added 30 minutes prior to the 
addition of stimulus. RNA was extracted using Ambion PureLink RNA Mini Kits according to the 
manufacturer’s instructions. 
Samples were sent to Cambridge Genomics Service and assessed for concentration and quality using 
a SpectroStar (BMG Labtech, Aylesbury, UK) and a Bioanalyser (Agilent Technologies, Cheadle, UK). 
Array processing (Cambridge Genomic Services, University of Cambridge): 
Microarray experiments were performed at Cambridge Genomic Services, University 
of Cambridge, using a species specific Gene 2.1 ST Array Plate (Affymetrix, Wooburn Green, UK) in 
combination with WT PLUS amplification kit (Affymetrix) according to the manufacturer’s 
instructions. Briefly, 100ng Total RNA was amplified along with inline PolyA spike in control RNA, 
using the WT PLUS amplification kit (Affymetrix). Successfully amplified samples were labelled using 
the GeneChip WT terminal labelling kit (Affymetrix) using the in line hybridization controls. Plate 
arrays were processed on the GeneTitan instrument (Affymetrix) using the GeneTitan Hybridization, 
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Wash and Stain kit (Affymetrix). Samples were hybridized to the array, washed, stained and scanned 
using the array specific parameters provided by Affymetrix. Finally, basic visual quality control was 
performed using Command Console Viewer (Affrymetrix) prior to bioinformatic quality control. 
2.2.16 Bioinformatics  
Bioinformatic analysis was performed by Dr John Ferdinand. 
After scanning the files generated by the scanner (CEL files) were loaded in R using the oligo package 
from Bioconductor (Carvalho 2010). No background correction or normalisation was applied at this 
stage. To assess the quality of the data, plots of the control probes were generated along with 
boxplots, MA plots and intensity distribution plots. The raw data was then processed using the RMA 
method (Irizarry 2003). The data was background corrected, normalised using quantile and 
summarized. Once the data had been processed, comparisons were performed using the limma 
package with results corrected for multiple testing using False Discovery Rate (FDR) testing (Ritchie 
2015). Further analysis of normalised data was performed including Gene Set Enrichment Analysis 
(Subramanian 2005) and weighted correlation network analysis (Langfelder 2008). 
2.2.17 In vitro transwell migration assay 
Bone marrow derived dendritic cells were stimulated with IC for 16-24 hours in the presence of I-
BET151 or DMSO control. Following stimulation, cells were washed and re-suspended in serum free 
media. Migration was assessed in a three hours transwell migration assay through 8µm pore 
semipermeable membranes (Corning Life Sciences), by calculating the proportion of live cells that 
passed through the membrane. 
2.2.18 In vitro 3D chemotaxis assay 
Bone marrow derived dendritic cells derived from transgenic mice expressing a fluorescent tag were 
stimulated with IC for 16-24 hours in the presence of I-BET151 or DMSO control. After washing, cells 
were counted, resuspended to a concentration of 10-15 x 106 cells/ml and incorporated within a 
1.5mg/ml bovine collagen gel loaded into a μ-Slide Chemotaxis chamber (Ibidi, Germany) as per 
manufacturer’s instructions. A chemokine gradient of CCL19 (Peprotech, UK) was applied where 
indicated. 
Composition of 1.5mg/ml bovine collagen I gel (for total volume 300µl) 
- 20µl 10x Minimum Essential Media Eagle (MEM; Sigma) 
- 20µl water  
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- 10µl 7.5% sodium bicarbonate solution (Sigma) 
- 50µl RPMI 1640 
- 150µl 3mg/ml bovine collagen I (Sigma) 
- 50µl cell suspension (10-15 x 106 cells/ml) in RPMI 
Cell movement was imaged using time lapse confocal microscopy using a Zeiss LSM 780 inverted 
confocal microscope (Zeiss, Germany), with stacked images taken every 45-60 seconds, for a period 
of 2-4 hours. Image analysis was performed using the surface tracking function within Imaris 
software (Bitplane, Switzerland).  
2.2.19 In vivo models 
All procedures were conducted in accordance with the United Kingdom Animals (Scientific 
Procedures) Act 1986 
a) Accelerated nephrotoxic nephritis 
In the established model, female C57BL/6 mice are pre-immunized by intraperitoneal (IP) injection 
with 0.2 mg sheep IgG in a 50:50 mix of saline and complete Freund’s adjuvant (CFA) (Sharp 2013). 
Due to constraints of our home office licence, we attempted to induce disease, giving this injection 
subcutaneously. Five days later, the mice were injected intravenously via the tail vein with 0.2 ml 
nephrotoxic polyclonal sheep anti mouse glomerular basement membrane antibody (kind gift from 
Ruth Tarzi, Imperial College, London). 
 
Mice were monitored for the development of nephritis by collecting urine obtained when passed 
spontaneously upon handling. Mice were monitored daily for any weight loss and haematuria and/or 
proteinuria measured by dipstick and the experiments terminated if the mice showed signs of ill 
health. Mice were sacrificed at day 14 (or earlier if dictated my clinical phenotype) and kidneys and 
blood (post-mortem cardiac bleed) taken for analysis. Kidney samples taken for histological analysis 
in formalin (subsequent Hematoxylin and Eosin (H&E) and Periodic acid–Schiff (PAS)) or snap frozen 
and stored at -80 degrees Celsius for future RNA analysis or stored for future immunofluorescence 
staining following incubation in 0.05 M phosphate buffer containing 0.1 M L-lysine, pH 7.4, 2 
mg/mL NaIO4 and 10 mg/mL paraformaldehyde (12 hours), washing in phosphate buffer and 
dehydration in 30% sucrose in phosphate buffer (12 hours) and snap freezing in OCT. Blood urea and 
urine albumin creatinine ratios were quantified by Addenbrooke’s Hospital Core Biochemical Assay 
Laboratory. 
b) In vivo migration assay: FITC paint 
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Wild type C57BL/6 mice were treated with intraperitoneal injection of I-BET151 (30mg/kg) or solvent 
control. Dermal DCs were labelled by FITC painting, followed by local administration of IC to induce 
DC migration (as in (Clatworthy 2014a)). Forty eight hours later, the number of FITC+ MHC class II 
high CD11c+ cells in draining and non-draining LN was quantified by flow cytometric analysis of 
disrupted lymph nodes. Lymph nodes were disrupted by homogenizing through a 70-μm cell strainer 
(BD Falcon), and digested in PBS containing DNase I (1mg/mL; Roche, Burgess Hill, UK), collagenase A 
(1mg/mL; Roche, Burgess Hill, UK), and 2% FCS (Sigma-Aldrich, Gillingham, UK) at room temperature 
for 20 min. 
c) In vivo migration assay: DC transfer 
Fluorescently labelled BMDC (GFP or CFP) were stimulated with IC for 24 hours in the presence of I-
BET151 or DMSO. Cells were then washed in PBS to remove non-internalised IC and I-BET151/DMSO 
and injected subcutaneously in the flank or footpad (depending on the lymph node harvested) of a 
recipient C57BL/6. Draining and non-draining lymph nodes were harvested 48-72 hours following DC 
transfer and fluorescently labelled DC’s quantified via flow cytometry. 
d) In vivo migration assay: Intravital imaging of dermal DCs by two photon microscopy 
(performed with Dr. Menna Clatworthy) 
CD11c EYFP mice were injected intraperitoneally with DMSO or I-BET at a dose of 30mg/kg, 
followed 2 hours later by subcutaneous injection of 50 μl of 0.1mg/ml OVA solution to one hind 
footpad and 50 μl of OVA-IC solution (5μg OVA; 150μg rabbit anti ova)  to the contralateral footpad. 
Nineteen hours later following intravenous injection Qdot® 655 probe (Invitrogen Molecular Probes) 
to delineate dermal vasculature, mice were anaesthetised with isoflurane. Footpad dermal DCs were 
imaged using a Leica multiphoton microscope; a time-lapse sequence was generated by imaging 
stacks of the footpad every 45 seconds for up to 1 hour. Image analysis was performed using the 
surface tracking function within Imaris software version 7.4 (Bitplane, Switzerland). 
e) Intravenous Immune complex 
C57/BL6 mice were injected intraperitoneally with DMSO or I-BET at a dose of 30mg/kg. A second 
dose was given 24 hours later, followed by an intravenous dose of Immune complexes (6.5μg of 
ovalbumin opsonised with 63.75 μg of rabbit anti ova prepared as detailed above) via tail vein 
injection. Mice were sacrificed 60 minutes later, organs flushed with cold PBS and digested and 
stained for flow cytometry analysis or placed in RNA later for RNA extraction. In a modification for a 
repeat experiments, mice were injected with intravenous CD45 immediately prior to schedule 1, to 
allow identification of intravascular lymphocytes within kidney tissue.  
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f)  Intraperitoneal Immune complex 
C57/BL6 mice were injected intraperitoneally with DMSO or I-BET at a dose of 30mg/kg. A second 
dose was given 24 hours later, followed by an intraperitoneal dose of Immune complexes (6.5μg of 
ovalbumin-647 opsonised with 63.75 μg rabbit anti ova as detailed above). Mice were sacrificed 4 
hours later, and peritoneal lavage performed with 6ml ice cold supplemented with 2% FCS. Flow 
cytometric analysis of 3ml of peritoneal lavage fluid was performed. 
2.2.20 Image Analysis 
Both in vitro and in vivo migration movies were processed using Imaris software (Version 7.4). The 
surface tool was used to track individual DC and track statistics exported into Microsoft Excel and 
plotted in GraphPad Prism. The standalone version of Ibidi’s Chemotaxis and Migration Tool (Ibidi, 
Germany) was used to visualise tracks for the in vitro movies. Definitions of calculated parameters 
are shown below; i is the index of different single cells numbered from 1 to n (1 ≤ i ≤ n). 
  
Track displacement x (xi, end)= displacement of track in x axis 
Track displacement y (yi, end)= displacement of track in y axis 
Track displacement length = length of straight line between cell start 
and end point (euclidean distance) 
Track length = accumulated distance (di, accum) 
The x forward migration index (xFMI) and yFMI represent the efficiency of the forward migration of 
cells, in relation to the x- or y- axis. The larger the index on an axis, the stronger the chemotactic 
effect is on this axis. 
 
The center of mass (Mend) represents the averaged point of all cell endpoints. The x and y values 





2.2.21 DC:T cell co-culture assay 
BMDC were differentiated in vitro and plated in 96 well round bottomed plates at a density of 50000 
cells per well in RPMI media supplemented with 1% penicillin-streptomycin and 10% FCS. DMSO or I-
BET was added 30 minutes prior to addition of OVA or OVA-IC as indicated and cells were washed 
three times with tissue culture media five hours later. Meanwhile, a single cell OVA specific 
lymphocyte suspension was produced by mashing spleens from OTII mice through 70µm cell 
strainers. Following red blood cell lysis, CD4+ T cells were labelled with biotinylated anti-CD4 
antibody (1:200) and isolated using magnetic activated cell sorting. CD4+ T cells were then labelled 
with carboxyfluorescein succinimidyl ester (CFSE; eBiosciences) according to manufacturer’s 
instructions. CFSE labelled CD4+ T cells were washed three times and then co-cultured with the 
prepared DC at a ratio of 5:1 cells. T cell proliferation and activation was assessed 96 hours later via 
flow cytometry. 
2.2.22 Data analysis 
Graphs were compiled using GraphPad Prism. P<0.05 was taken to be statistically significant, 





Appendix 1: Murine antibodies  
Antigen Fluorophore Clone Species/Isotype Supplier 
Product 
number Dilution 
       Antibodies for flow cytometry: 
CCR7 PE 4B12  Rat/IgG2a, κ Biolegend 120106 1:100 
CD103 PE M290 Rat/IgG2a, κ 
BD 
Biosciences 557495 1:200 
CD11b eFluor® 450 M1/70 Rat/IgG2b, κ Biolegend 101224 1:200 
CD11c eFluor® 450 N418 
Armenian 
hamster/IgG eBioscience 48-0114-82 1:200 
CD11c PE N418 
Armenian 
hamster/IgG eBioscience MA5-16878 1:200 
CD11c PECy7 N418 
Armenian 
hamster/IgG Biolegend 117318 1:200 
CD16/32 PECy7 2.4G2 Rat/IgG2b, κ 
BD 
Biosciences 560829 1:200 
CD16/32 PE 2.4G2 Rat/IgG2b, κ 
BD 
Biosciences 553145 1:200 
CD19 PE 
eBio1D3 
(1D3) Rat/IgG2a, κ eBioscience 12-0193-83 1:200 
CD19 PECy7 
eBio1D3 
(1D3) Rat/IgG2a, κ eBioscience 25-0193-82 1:200 
CD19 PERCP Cy5.5  6D5 Rat/IgG2a, κ Biolegend 115534 1:200 
CD19 BV785 6D5 Rat/IgG2a, κ Biolegend 115543 1:200 
CD25 PERCP Cy5.5  PC61.5 Rat/IgG1, λ eBioscience 45-0251-82 1:200 
CD3  BV605 17A2 Rat/IgG2b, κ Biolegend 100237 1:200 
CD3  BV785 17A2 Rat/IgG2b, κ Biolegend 100231 1:200 
CD3e PERCP Cy5.5  145-2C11 
Armenian 
hamster/IgG eBioscience 45-0031-82 1:200 
CD32b APC AT130-2 Mouse/IgG2a, κ eBioscience 17-0321-82 1:200 
CD4 PECy7 GK1.5 Rat/IgG2b, κ eBioscience 25-0041-82 1:200 
CD4 APC GK1.5 Rat/IgG2b, κ eBioscience 17-0041-82 1:200 
CD40 APC HM40-30 
Armenian 
hamster/ IgM, κ eBioscience 17-0402-82 1:200 
CD45 FITC 30-F11 Rat/IgG2b, κ eBioscience 11-0451-85 1:200 
CD45 UV395 HI30 Mouse/IgG1, κ 
BD 
Biosciences 56427 1:200 
CD45.2 
APC-eFluor® 
780 104 Mouse/IgG2a, κ eBioscience 47-0454-82 1:200 





Biosciences 563290 1:200 
CD80 PECy7 16-10A1 
Armenian 
hamster/IgG eBioscience 25-0801-82 1:200 
CD86 FITC GL1 Rat/IgG2a, κ eBioscience 11-0862-82 1:200 
68 
 
CD86 PE GL1 Rat/IgG2a, κ eBioscience 12-0862-83 1:200 
CD8α ef450 53-6.7 Rat/IgG2a, κ eBioscience 48-0081-82 1:200 
CX3CR1 PE SA011F11 Mouse/IgG2a, κ Biolegend 149006 1:200 
EpCAM APC G8.8 Rat/IgG2a, κ eBioscience 17-5791-82 1:200 
F4/80 FITC BM8 Rat/IgG2a, κ eBioscience 11-4801-85 1:200 
F4/80 BV605 BM8 Rat/IgG2a, κ Biolegend 123133 1:200 
Ly-6C  PERCP Cy5.5  HK1.4 Rat/IgG2c, κ eBioscience 45-5932-80 1:200 
Ly-6G (Gr-1) PECy7 RB6-8C5 Rat/IgG2b, κ eBioscience 25-5931-82 1:200 
Ly-6G (Gr-1) 
APC-eFluor® 
780 RB6-8C5 Rat/IgG2b, κ eBioscience 47-5931-82 1:200 
MHC Class II-
1 eFluor® 450 AF6-120.1 Mouse/IgG2a, κ eBioscience 48-5320-82 1:200 
MHC Class II               
(I-A/I-E) BV650 M5/114.15.2 Rat/IgG2b, κ Biolegend 107641 1:400 
MHC Class II              
(I-A/I-E) A700 M5/114.15.2 Rat/IgG2b, κ eBioscience 56-5321-82  1:200 
       Antibodies for immunohistochemistry: 
anti Rab5  NA C8B1 Rabbit/IgG 
Cell signalling 
technology 3547 1:100 
anti Rab7 NA D95F2 Rabbit/IgG 
Cell signalling 
technology 9367 1:100 
anti-EEA1 NA C45B10 Rabbit/IgG 
Cell signalling 
technology 3288 1:100 
Rat anti 
LAMP1  NA Unknown Rat 























Appendix 2: Human antibodies  
Antigen Fluoroph
ore 
Clone Isotype Supplier Product 
Number 
Dilution 
CD27 FITC O323 Mouse/IgG1, κ Biolegend 302806 1:100 
CD16 ef450 CB16 Mouse/IgG1, κ EBioscience 48-0168-41 1:200 
CD19 APC Cy7 SJ25C1 Mouse/IgG1, κ BD Biosciences 557791 1:25 
CD24 PerCP-
Cy5.5 
ML5 Mouse/IgG2a, κ Biolegend 311116 1:20 
CD25 PE Cy7 BC96 Mouse/IgG1, κ Biolegend 302612 1:20 
CD3 AmCyan SK7 Mouse/IgG1, κ BD Biosciences 339186 1:20 
CD3 APC-Cy7 HIT3a Mouse/IgG2a, κ Biolegend 300318 1:100 
CD3 AF488 HIT3a Mouse/IgG2a, κ Biolegend 300320 1:100 
CD32A unconjugated Polyclonal R&D AF1330 1:100 
CD38 BV421 HIT2 Mouse/IgG1, κ Biolegend 303526 1:200 
CD71 PERP 
Cy5.5 
CY1G4 Mouse/IgG2a, κ Biolegend 334114 1:20 
CD73 BV421 AD2 Mouse/IgG1, κ Biolegend 344008 1:20 
IgD PE Cy7 IA6-2 Mouse/IgG2a, κ BD Biosciences 561314 1:100 
IgD APC IA6-2 Mouse/IgG2a, κ Biolegend 348222 1:100 
IL10 PE JES3-9D7 Rat/IgG1, κ BioLegend  501404 5µl/test 
IL10 PE JES3-19F1 Rat/IgG1, κ BioLegend  506804 5µl/test 
IL6 APC MQ2-13A5 Rat/IgG1, κ BioLegend  501112 5µl/test 
Rat IgG1, κ APC RTK2071 Rat/IgG1, κ BioLegend  400412 5µl/test 







Appendix 3: Other stain reagents 
Antigen Fluorophore Supplier 
Product 
Number Dilution 
Ovalbumin Alexa Fluor™ 647 Invitrogen O34784 As described 
Ovalbumin FITC Invitrogen O23020 As described 
DQ™ Ovalbumin 
 
Invitrogen D12053 As described 
LIVE/DEAD™ Fixable Aqua 
Dead Cell Stain Kit 
 
Invitrogen L34957 1:300 






Zombie UV™ Fixable Viability 
Dye 
 
Biolegend 423107 1:500 
Zombie Aqua™ Fixable 
Viability Dye 
 
Biolegend 423101 1:500 












Phalloidin Alexa Fluor™ 568 Invitrogen A12380 1:100 
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3.1. Chapter summary 
There is an increasing appreciation of the complex but important role of B cells in determining 
transplant outcomes. Activated B cells can present antigen to alloreactive T cells and secrete HLA 
and non-HLA antibodies that negatively affect graft function and survival. In contrast, B cells can 
regulate alloimmune responses and have been implicated in transplant tolerance. There is currently 
a significant unmet need in transplantation for immunosuppressants that inhibit B cell effector 
functions whilst promoting regulation. 
BLyS is a cytokine that promotes B cell activation and survival, and has not previously been targeted 
in kidney transplant recipients. We performed the first randomized controlled trial using belimumab, 
an anti-BLyS antibody, as early maintenance immunosuppression in kidney transplantation, 
performing comprehensive immunological characterization of the impact of BLyS neutralization on 
the peripheral B cell compartment. We demonstrate a reduction in naïve and in activated memory B 
cells, a reduction in plasmablasts, IgG transcripts in peripheral blood and in new antibody formation 
in belimumab-treated subjects. Furthermore, we present evidence of reduced CD4 T cell activation 
and of a skewing of the residual B cell compartment towards an IL10-producing regulatory 
phenotype following belimumab treatment.  
This trial provides a blueprint for proof of concept experimental medicine studies in transplantation, 
a field which has struggled to deliver randomised controlled trials (RCTs) using new 
immunosuppressants, in contrast to the field of autoimmunity. We recruited a relatively small 
number of patients to deliver information on safety, but performed intensive mechanistic studies on 
patient samples to generate robust data on relevant immunological readouts, providing the 
confidence to pursue this therapeutic target in future studies. 
A manuscript containing this work was accepted on 20th April 2018 for publication in the Lancet 





3.2.1 Rationale for a study of belimumab in renal transplantation 
In the UK, 913 people per million population require renal replacement therapy (MacNeill 2016). 
Renal transplantation offers the best treatment for most patients, optimising quantity and quality of 
life (Tonelli 2011). Despite advances in immunosuppressive regimes, long-term transplant function 
remains variable. Current immunosuppressive regimens carry an increased risk of infection but limit 
T cell activation such that TCMR occurs in less than 25% of kidney transplant recipients and is largely 
treatable. In contrast, there remain significant challenges in the field of humoral alloimmunity. De-
novo DSA and some non-HLA antibodies are associated with ABMR and allograft loss (Dragun 2005, 
Zou 2007, Loupy 2013). Furthermore, sensitised patients with pre-formed DSA have an elevated risk 
of acute and chronic ABMR, both of which reduce graft survival (Bentall 2013). B cells influence the 
immune response to the allograft through their capacity to produce antibodies, act as antigen 
presenting cells and secrete cytokines (Clatworthy 2011).  
Belimumab is a monoclonal antibody that binds soluble BLyS, a B cell survival factor, with high 
affinity, inhibiting its biological activity. We hypothesised that belimumab would reduce B cell 
activation and the associated allo-immune response. Since clinical end-points such as ABMR are rare, 
we sought to perform a small, mechanistic experimental study to assess the impact of BLyS 
inhibition on peripheral lymphocyte subsets as well as on standard transplant outcome parameters. 
The aim was to obtain safety and biomarker data to assess the potential for efficacy and safety of 
belimumab treatment in preventing allograft rejection.  
3.2.2 Recruitment of subjects to a phase two randomised controlled trial  
We conducted a phase 2 double-blind (sponsor unblind) randomised placebo-controlled trial 
(BEL114424; clinical trials.gov identifier NCT01536379; EudraCT number 2011-006215-56), to assess 
the safety and potential efficacy of belimumab, in addition to standard of care immunosuppression 
post-kidney transplantation. Subjects were randomised 1:1 to receive seven doses of belimumab 
10mg/kg or placebo (0.9% sodium chloride solution) by intravenous infusion at days 0, 14, 28 
followed by four-weekly doses through to week 20, in addition to standard of care 
immunosuppression and were followed for twelve months post-transplant (Figure 15; further details 
in materials and methods). 
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Figure 15: BEL114424 Treatment schedule. Schematic showing the timing of study infusions 
alongside standard of care induction (basiliximab) and maintenance immunosuppression 
(mycophenolate mofetil, tacrolimus and corticosteroids).  
A target sample size of twenty evaluable subjects (those with a week 24 assessment) was calculated 
to achieve a reduction in naïve B cell count from baseline to 24 weeks, based on naïve B cell data 
from a previous trial of belimumab in SLE (BLISS-76) (Stohl 2012) and n=93 renal transplant 
recipients at the Cambridge Transplant Unit (unpublished data). Interim re-estimations of sample 
size were performed in November 2014 and February 2015 by unblinded statisticians at GSK. 
The clinical study was a collaborative project with clinicians, scientists and statisticians from 
Addenbrooke’s Hospital, the University of Cambridge and GlaxoSmithKline all being critical for its 
completion. I had an instrumental role in getting the trial up and running; recruiting and consenting 
all study patients, coordinating study team members and overseeing adverse event reporting. In 
addition, with oversight from the Clatworthy lab, I worked alongside Adele Gibson and Robbie 
Henderson at the GSK Experimental Medicine Unit to design and validate a regulatory B cell assay, 
with subsequent optimisation for use in the clinical study. In collaboration with Adele Gibson, I was 
responsible for running the assay on clinical study samples in a blinded fashion. I led the analysis of 
this part of the study and was fully involved in the wider BEL114424 study analysis and reporting, the 
only non-GSK employee included in the primary study analysis team.  
3.3 Development and validation of a regulatory B cell assay in human peripheral blood 
The experimental plan for B cell phenotyping and B cell stimulation assays was developed in the 
Clatworthy Lab. The assay was optimised and validated with Adele Gibson, GSK Experimental 
Medicine Unit, Stevenage, UK. Data included is reported in a GSK internal report entitled 




Given the increasing evidence that regulatory B cells may be beneficial for the alloimmune response, 
we wished to determine the effect of belimumab treatment on this subset. No prior studies using 
belimumab had specifically looked at the effect of the drug on Breg or B cell cytokine production. 
We designed a regulatory B cell assay to align with published studies (Iwata 2011, Cherukuri 2014), 
optimised the assay to maximise detection of this rare population with limited frozen PBMC samples 
and thoroughly validated it prior to use in a clinical setting at the GlaxoSmithKline Clinical Unit 
Cambridge, using limited frozen PBMC samples stored from study timepoints, under good clinical 
practice (GCP) conditions. 
A two stage assay was performed. Stimulation of PBMC for 5 hours allowed for detection of 
circulating Breg, cells producing intracellular stored cytokines for which they are pre-programmed to 
synthesise. A longer stimulation with CpG/CD40L for 48 hours, with addition of PIB for the last 5 
hours, allows the additional detection of precursor Breg cells that have the capacity to produce IL-10 
with appropriate stimulation (pro-Bregs). 
3.3.1 Optimisation of experimental controls to allow definition of cytokine secreting B cells 
48 hours post-stimulation, we noted that cells changed in shape and size resulting in a change in 
autofluorescence. We therefore adopted an approach of using different controls for the 5 hour and 
48 hour assays. For the 48 hour assay, we used a sample stimulated for 48 hours with CD40L and 
CpG, with BFA only added for the last 5 hours to set the IL-10 gate since a negligible number of B 
cells secrete IL-10 in the absence of additional stimulation with PMA and ionomycin. In contrast, IL-6 
secreting cells could be detected following this stimulus; an isotype control antibody was therefore 
used in place of the IL-6 antibody to set the IL-6 gate (Figure 16). For the 5 hour assay we used a BFA 
only control to set the IL10 gate and an IL-6 isotype control to set the IL6 gate. 
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Figure 16: Use of an IL6 isotype control (middle) was better than stimulation with BFA only (left) for 
setting a gate for IL6 secreting B cells following full in-vitro stimulation for 48 hours (right).  
Full examples of gating can be seen in section 3.4.10. 
3.3.2 Optimisation of flow cytometry staining panel 
Initial experiments measured intracellular IL-10, IL-6 and TNF-α. A decision was made to drop TNF-α 
from the final panel since our stimulation conditions produced high levels of TNF-α across donors, 
with little inter donor variability. We noted that the expression of many surface markers, for 
example CD27, changed following 48 hours of stimulation, meaning that it was not possible to 
categorise cells into memory subsets following stimulation (data not shown). Given that inclusion of 
these surface markers on 48 hour stimulated cells was felt to be unhelpful, a change to the surface 
staining panel was proposed in response to the van de Veen et al. publication suggesting enrichment 
of Bregs in a B cell subset identified with the surface markers CD73-CD25+CD71+ (van de Veen 2013). 
Different surface staining antibody panels were investigated to establish whether there was any 
effect on IL-10 or IL-6 detection (Figure 17).   
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Figure 17: Effect of different surface staining panels on IL-10 and IL-6 detection following 48h 
stimulation. 48h stimulated PBMCs were surface labelled with different antibody panels.  ‘5hr panel’ 
refers to the standard panel used in all prior studies; ‘Basic’ panel refers to just CD3-FITC and CD19-
APC-Cy7; ‘CD73 CD25 CD71 panel’ refers to staining with CD3-FITC, CD71-PerCP-Cy5.5, CD25-PE-Cy7, 
CD19-APC-Cy7 and CD73-BV421.  Cytokine detection shown from 4 individual donors. IL-10 detection 
shown in panel A, IL-6 detection shown in panel B. 
With the exception of one outlier for IL-6 detection (Figure 17b), quantification of IL-I0 and IL-6, was 
similar, independent of the surface staining panel used. Confirming published results, B cells in the 
CD73-CD25+CD71+ subset were found to have the highest proportion of IL-10+ cells, followed by the 
CD73+CD25+CD71+ subset (Figure 18).   
A strong correlation between the percentage of CD73-CD25+CD71+ B cells in a resting sample and the 
percentage that go on to produce IL-10 following 48 hour stimulation was found (Figure 19c). 
Following stimulation CD25 and CD71 expression increases (Figure 19b) but a correlation remained 
between the % of CD73-CD25+CD71+ B cells and the % of B cells that produce IL-10 (Figure 19d). 
Therefore, we included these markers in the surface staining panel for the 48 hour stimulus and 
stained an aliquot of cells prior to stimulation. 
Figure 18: IL-10 production of subsets of B 
cells expressing different combinations of 
CD73, CD25 and CD71. PBMC samples from 
three donors were stimulated for 48 hours 
with CD40L and CpG, with PIB added in the 
last 5 hours. Following stimulation cells were 
stained for surface CD19, CD73, CD25, CD71, 
and CD3 and intracellular IL-10 and IL-6.  The 
percentage of CD19+ cells expressing IL-10 
within different surface marker subsets was 








































Figure 19: Staining of CD73-CD25+CD71+ B cells and correlation with IL10+ B cells following 
stimulation. Frozen PBMC samples from 3 donors were surface stained following thawing with 
antibodies recognising CD19, CD73, CD25, CD71, CD3. Cells from the same thawed aliquots were 
stimulated for 48h followed by surface staining and intracellular staining for IL-10 and IL-6.  
Representative surface staining, from one donor, (gated on CD19+ CD3- live singlets) to identify 
CD73-CD25+CD71+ B cells is shown for freshly thawed cells (a) and for 48h stimulated cells (b). IL-10 
positive B cells were quantified and correlated with the freshly thawed surface staining (c) and 
stimulated surface staining (d). c and d show mean +/- standard error of the mean with linear 
regression analysis 
3.3.3 Transfer of assay to CUC to enable processing of trial samples under good clinical practice 
conditions 
Prior to running the BEL114424 study samples, we transferred the assay to the GSK CUC. Assay 
transfer was assessed by carrying out the assay on samples from the same bleed in several donors 
(Figure 20). The 5h assay showed similar % IL-10+ B cells from two donors with the third donor 
showing higher levels of IL-10 producing cells at the CUC. IL-6+ B cells were greater in the CUC assay 
(Figure 20a). At 48h, both % IL-10 and IL-6+ B cells were similar in three donors with greater 
variability in one donor (Figure 20b). This donor had low cell recovery on thawing in the CUC assay 
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which may have affected performance. Given that differing reagent stocks and flow cytometers 











Figure 20: Comparison of IL-10 and IL-6 production from samples run at Stevenage and CUC, 
Addenbrooke’s site. PBMC samples from several donors, prepared and frozen at Stevenage were 
assayed at Stevenage and other vials from same bleed transferred and assayed at CUC. IL-10 and IL-6 
producing B cells were identified following 5h stimulation (a) and 48h stimulation (b). n=3 replicates 
for each donor with mean +/- SD displayed. 
3.4 BEL114424 study analysis 
3.4.1 Reference to source data at GSK 
The BEL114424 study results were analysed by the BEL114424 study analysis team, of which I was an 
integral part.  Analysis were defined prior to study unblinding as part of a statistical analysis plan. All 
post hoc analyses are marked as such. 
Raw data is referenced from the following internal GSK reports and electronic laboratory notebook 
entries. 
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2017N310877_00 Regulatory B cell exploratory flow cytometry analysis for belimumab in renal 
transplant study BEL114424 report – Gemma Banham, Adele Gibson 
2017N317074_00 Analysis of BLyS receptors and B cell activation markers for belimumab in renal 
transplant study BEL114424 – Gemma Banham, Adele Gibson, Shaun Flint 
N59855-1: Exploratory analysis of whole blood, CD4+ T-cell and CD14+ monocyte gene expression 
data from BEL114424 – Shaun Flint, Katie Foster, Robbie Henderson 
N59855-2: Pre-processing, QC and normalisation of whole blood, CD4+ T-cell and CD14+ monocyte 
gene expression data from BEL114424 - Shaun Flint 
N59855-3: A description of the pre-processing steps and plot generation using exploratory flow 
cytometry data from BEL114424 to support the publication plan - Shaun Flint, Adele Gibson 
N59855-4: Additional exploratory analysis of whole blood gene expression data from BEL114424 - 
Shaun Flint (work done in collaboration with Dr Paul Lyons, University of Cambridge) 
N59855-6: An exploratory analysis of ProtoArray auto/allo-antibody data from BEL114424 
(Belimumab in renal transplantation). Shaun Flint 
N60700-62: Figures and statistical analyses of final project report "Assessing the impact of BLyS 
neutralisation on the cytokine profile of memory B cells as an immunosuppressive therapy for renal 
transplantation". Joseph Chadwick 
2017N339717_00: Analysis of IL-6/IL-10 cytokine profile following BLyS stimulation and 
neutralisation by belimumab in memory B cells from healthy donors. Joseph Chadwick, Katie Foster. 
3.4.2 Study populations 
Two hundred and sixty patients admitted to Addenbrooke’s Hospital for a renal transplant between 
September 2013 and February 2015 were screened for study inclusion. Of these, 105 did not meet 
inclusion criteria for the study and 82 were unable to be approached for consent due to logistical 
reasons including unavailability of study staff or study drug, insufficient time to gain informed 
consent and the recipient being resident out of region. Forty-five subjects were approached and 
made an informed choice not to participate in the study; 30 subjects were consented for inclusion in 
the study however the transplant did not proceed in four due to donor organ unsuitability and one 
subject was found to be ineligible on screening. An additional 43 subjects were screened at Guy’s 
Hospital between August 2014 and February 2015, with 18 found to be ineligible, 24 unable to 
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participate due to logistical reasons and one refusing consent. The reasons for subjects not meeting 
inclusion criteria are shown in Table 2. 
A total of 28 subjects were randomised to the study, with 25 going on to receive a transplant and at 
least one infusion of study drug. This made up the modified intention to treat (MITT) population that 
was used for the analysis of the co-primary outcomes; safety and a change in naïve B cells from 
baseline to Week 24. Secondary and exploratory biomarker outputs were undertaken using a pre-
specified per protocol population (PP) that included all MITT subjects who received at least five 
infusions of study drug, were followed up beyond week 24 and received no prohibited medications 
or plasma exchange (referred to as PP1 population in study protocol). Figure 21 shows a consort 
2010 flow diagram (Moher 2001) describing the enrolment, randomisation and follow up 
populations. 
Table 2: Reasons for subjects not meeting inclusion criteria. 
 
 
Reason not meeting inclusion criteria Number 
Donor characteristic 36 
Alternative immunosuppression planned 21 
0-0-0 mismatch 16 
HLAi or ABOi transplant 15 
Other disease/condition judged unsuitable by PI 12 
Prior therapy 8 
Transplant other than kidney 3 
Recipient hepatitis 3 
Donor hepatitis 2 
Recipient unable to consent due to learning difficulties 2 
Recipient HIV+ 2 
Drug sensitivity 1 
Prior malignancy 1 
Poor venous access 1 
Total 123 
 
The two treatment groups were similar in terms of their baseline characteristics (Table 3). The 
majority were receiving their first renal transplant and were of low immunological risk. A single 
subject (subject 5) in the belimumab treatment group was found to have a positive flow cytometry 
cross-match with donor specific antibodies to DP1 and DP6 at baseline. This subject was receiving a 
second transplant and known to be sensitized against multiple HLA DP antigens. The HLA DP type of 
the donor was not known at the time of transplantation, and T and B lymphocyte CDC cross-match 
tests were negative. Both the donor DP type and flow cytometry cross-match result became 
82 
 
available following transplantation. Had this information been available the subject would have been 
deemed ineligible for the study and given lymphocyte depleting induction therapy in view of his 
increased immunological risk.  
Figure 21: BEL114424 study enrolment, randomisation and follow-up. The randomised treatment was 
given in addition to standard immunosuppression consisting of basiliximab, mycophenolate mofetil, 
tacrolimus and corticosteroids. 1260 at Addenbrooke’s Hospital, Cambridge (28 randomised); 43 at 
Guy's and St Thomas’ NHS Foundation Trust, London (0 randomised). 2Logistical reasons included 
unavailability of study staff or study drug, insufficient time for consent and recipient resident out of 
region. 3The pre-specified per protocol (PP) population used for biomarker and clinical endpoint 
analysis consisted of all subjects in the modified intention to treat (MITT) population who received at 
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least five infusions of study drug, no prohibited medications or plasma exchange and at least 24 
weeks follow-up. FSGS Focal Segmental Glomerulosclerosis, SAE Serious Adverse Event 
  Baseline demographic data, n 
Placebo (n=13) 
Belimumab 
10mg/kg (n=12)   
  Age (years), Mean (SD) 51.0 (14.0) 54.3 (11.0)   
  Range 24-73 32-72   
  Sex, n (%)        
  - Female 4 (31) 7 (58)   
  - Male 9 (69)  5 (42)    
  Race, n (%)          
  -White/Caucasian 12 (92)   11 (92)   
  -Asian 1 (8)   1 (8)   
  Mean number (SD) of HLA-A/B/DR mismatches   
  -HLA-A 1.7 (0.5) 1.8 (0.5)   
  -HLA-B 0.9 (0.6) 1.1 (0.3)   
  -HLA-DR 0.6 (0.5) 0.8 (0.6)   
  Number of previous kidney transplants, n (%)    
  -0 11 (85) 11 (92)   
  -1 2 (15)  1 (8)   
  Pre-transplant renal replacement modality, n (%)   
  -None 3 (23) 2 (17)   
  -Haemodialysis 7 (54) 7 (58)   
  -Peritoneal dialysis 3 (23) 3 (25)   
  HLA antibody at baseline (MFI>2000), n (%)   
  -Non-DSA 5 (38) 3 (25)   
  -DSA 1 0 1 (8)   
  Donor type, n (%)       
  -Living 3 (23) 4 (33)   
  -Donation after circulatory death 7 (54) 5 (42)   
  -Donation after brain death 3 (23) 3 (25)   
  Donor age (years)       
  Mean (SD) 52.9 (8.8) 58.3 (8.1)   
  Range 37-68 47-69   
  Donor creatinine-last value prior to transplant (μmol/L)   
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  Mean (SD) 64.8 (17.5) 84.3 (30.7)   
  Median (Min, Max) 66.0 (37-92) 78.0 (51-167)   
Table 3: Baseline demographics. 1One subject randomised to belimumab had a positive pre-
transplant MHC class II flow crossmatch (fulfilling an exclusion criterion but unknown at the time of 
enrolment and transplant). 
3.4.3 Belimumab pharmacokinetics and effect on circulating free BLyS  
Belimumab pharmacokinetic (PK) parameters were similar to those observed in previous studies in 
SLE (Navarra 2011) and were not affected by end-stage renal failure (ESRF) (Figure 22).  
 
Figure 22: Pharmacokinetic profile of belimumab. Median serum concentration of belimumab over 
time (left panel linear scale; right panel logarithmic scale). The lower limit of detection of 100ng/ml is 
marked with a dotted line. Error bars indicate range. PK population that consisted of all subjects 
randomised to belimumab treatment that were treated with at least one dose and had a PK sample 
that was analysed. 
Belimumab effectively removed circulating BLyS and levels remained suppressed up to week 12 




Figure 23: Serum BLyS levels. Serial measurements of serum BLyS concentration (µg/ml) in individual 
subjects. 
3.4.4 Belimumab and placebo groups demonstrate comparable safety with adverse events 
consistent with that expected for the study population and known safety profile of belimumab  
A key goal of this study was to determine the safety of belimumab in combination with standard 
transplant immunosuppression, in patients with ESRF. Belimumab has previously been used in 
patients with autoimmune diseases, in combination with steroids, and in some cases, an anti-
proliferative agent (for example azathioprine, MMF or methotrexate) but is has not been trialled 
alongside an immunosuppression regime including induction therapy with CD25 blockade and triple 
maintenance immunosuppression (tacrolimus, MMF and prednisolone) in patients with ESRF at 
baseline, a condition known to be associated with a heightened susceptibility to infection (Vanholder 
1993). It was therefore critical to assess the safety of the drug in this setting and this formed a co-
primary endpoint for the study. We observed similar rates of adverse events in the placebo and 
belimumab treatment groups, during both the on treatment and post treatment periods (Table 4). 
Post-transplant infection was an important end-point, particularly given its association with an 
increased risk of rejection and allograft loss (von Willebrand 1986, Almond 1993, Reinke 1994, Bohl 
2007). After 6 and 12 months follow-up, we observed similar rates of serious infection in belimumab 
and placebo groups (1/12 (8%) and 5/13 (38%) respectively during the 6 month on-treatment phase; 
0/13 (0%) and 2/13 (15%) during the 6 months post-treatment follow-up phase). We also found no 
excess frequency of viral infection (BK virus or cytomegalovirus (CMV)) in belimumab-treated 
subjects. There were no new diagnoses of malignancy in either group within during the follow up 
period and one death, from a cardiovascular cause, in the placebo group. In summary, belimumab 
was not associated with an excess risk of infection or malignancy when used with standard 
transplant immunosuppression. 
  On treatment 1 Post-treatment  
  Number (%) Subjects  Number (%) Subjects  
  
Placebo  Belimumab  Placebo  Belimumab  
(n=13)  (n=12)  (n=13)  (n=12)  
Any adverse event (AE)   10 (77)  11 (92)  9 (69)  10 (83)  
Any serious AE (SAE)  7 (54)  5 (42)  2 (15)  2 (17)  
Any severe AE  6 (46)  8 (67)  3 (23)  3 (25)  
Deaths 2 1 (8)  0 0 0 
Most common AE 3              
- Leukopenia 4 (31)  4 (33)  3 (23)  3 (25)  
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- Diarrhoea  3 (23)  5 (42)  1 (8)  1 (8)  
- Urinary tract infection 4 3 (23) 4 (33) 1 (8) 2 (17) 
- Anaemia 5 4 (31)  3 (25)  0 1 (8) 
- Lower respiratory tract infection 6 2 (15)  2 (17)  2 (15)  0 
- Dyspepsia7 2 (15)  2 (17)  2 (15)  0 
- Nasopharyngitis  2 (15)  1 (8)  1 (8)  2 (17)  
- Alanine aminotransferase increased  2 (15)  2 (17)  0 0 
- Diabetes Mellitus8  1 (8)  1 (8)  0 2 (17)  
- Endoscopic evidence upper GI inflammation9 2 (15)  1 (8)  0 0 
- Dizziness  0 2 (17)  0 1 (8)  
- Vomiting  0 2 (17)  0 0 
Infections              
- All  7 (54)  5 (42)  8 (62)  6 (50)  
- Serious infections (n≥1)  5 (38) 1 (8) 2 (15) 0 
- Severe infections (n≥1)  5 (38)  2 (17)  3 (23)  0 
- Opportunistic infections  3 (23)  2 (17)  3 (23)  3 (25)  
    - BK viraemia 2 (15)  1 (8)  1 (8)  1 (8)  
    - BK viraemia-associated nephropathy  0 1 (8)  1 (8)  0 
    - Cytomegalovirus (CMV) viraemia10 1 (8)  0 1 (8)  2 (17)  
Malignant neoplasm  0 0 0 0 
Depression/Suicide/Self injury  0 0 0 0 
Post infusion systemic reaction11 0 1 (8)  NA  NA  
Recurrence of focal segmental 
glomerulonephritis12 1 (8)  1 (8)  0 0 
Hypogammaglobulinemia of grade ≥3 (<4.0g/L) 2 (15)  3 (25)  0 0 
 
Table 4. Safety findings during on-treatment and post-treatment phases, by treatment group. 1The 
on-treatment phase commenced from the start of the first infusion of study drug and ends 28 days 
after the last dose. The post-treatment phase begun the following day. 2Death due to fatal 
myocardial infarction and acute cardiac failure. 3Includes all AEs (by grouped MedDRA preferred 
terms) occurring in more than one subject during the study not including opportunistic infections 
(listed separately), ordered by overall frequency. 4Grouped preferred terms include urinary tract 
infection, Escherichia urinary tract infection, urinary tract infection enterococcal and urosepsis. 
5Grouped preferred terms include anaemia, anaemia vitamin B12 deficiency and iron deficiency 
anaemia. 6Grouped preferred terms include pneumonia and lower respiratory tract infection. 
7Grouped preferred terms include dyspepsia and gastrooesophageal reflux disease. 8Grouped 
preferred terms include diabetes mellitus and type two diabetes mellitus; one post treatment AE was 
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worsening of diabetes, onset on treatment, in context of steroids for SAE (colitis). 9Grouped preferred 
terms include oesophagitis, duodenal ulcer, duodenitis and ulcerative gastritis. 10Grouped preferred 
terms include cytomegalovirus test positive, cytomegalovirus viraemia, culture positive (verbatim 
term CMV). 11The infusion reaction reported was mild, settled spontaneously and did not recur on 
subsequent infusions. 12Grouped preferred terms include focal segmental glomerulosclerosis (FSGS) 
and glomerulonephritis (recurrence of FSGS verbatim term). NA denotes not applicable.   
 
3.4.5 Belimumab and placebo groups demonstrate comparable clinical outcomes: acute rejection, 
allograft function and survival 
B cell depletion with the anti-CD20 antibody rituximab has been associated with increased TCMR 
(Clatworthy 2009) and cardiac allograft vasculopathy (Chandraker 2016). Since belimumab also 
depletes some B cell subsets, we sought to confirm that its use was not associated with an increase 
in alloimmune responses. The frequency of TCMR (including episodes classified as borderline 
according to the BANFF 2009 criteria (Sis 2010)) was similar in belimumab (n=1/12 (16.7%)) and 
placebo-treated subjects (n=3/13 (23%), Table 5). One subject was randomised to the belimumab 
group but withdrawn from the study due to a positive B lymphocyte flow cytometry cross-match (an 
exclusion criterion), the results of which became available post-transplant (donor specific antibodies 
to DP1 and DP6). This subject was receiving a second transplant and known to be sensitized against 
multiple HLA DP antigens. The HLA DP type of the donor was not known at the time of 
transplantation, and T and B lymphocyte CDC cross-match tests were negative. Both the donor DP 
type and flow cytometry cross-match result became available following transplantation. Had this 
information been available the subject would have been deemed ineligible for the study and given 
lymphocyte depleting induction therapy in view of his increased immunological risk. This subject 
experienced Banff IIA acute cellular rejection with features suspicious for early humoral rejection 
(day 6) associated with a rise in the titre of DP DSA and development of de novo DSA to HLA-A11 and 
HLA-B18. A further biopsy (day 34) demonstrated overt antibody mediated rejection. They were 
withdrawn from the study following a single dose of belimumab and the rejection responded to 
treatment with methylprednisolone, plasma exchange and anti-thymocyte globulin. Overall, 
transplant function at one year, graft and patient survival were not negatively impacted by the 





Clinical outcome data1, n 
Placebo (n=8) 
Belimumab 
10mg/kg (n=8)   
Acute transplant rejection by week 522,, n (%)   
- Borderline, not treated 2 (25) 0   
- Borderline, treated 1 (12.5) 0   
- Type IIa, treated 0 1 (12.5)   
Cumulative HLA class I (MFI >500)3 Sub 22 Sub 28 Sub 8 Sub 27   
Before treatment 39612 20046 127392 4894   
On treatment Wk 2 24658 14731 56453 4493   
On treatment Wk 4 26129 21466 33810 3438   
On treatment Wk 8 28930 19528 34420 4632   
On treatment Wk 12 26709 26500 25985 6320   
On treatment Wk 24 23152 18376 26491 8103   
Post treatment week 28 19204 18892 24607 4349   
Cumulative HLA class II (MFI >500)3 Sub 4   Sub 1     
Before treatment 2382   16009     
On treatment Wk 2 916   9305     
On treatment Wk 4 1211   12346     
On treatment Wk 8 768   12553     
On treatment Wk 12 606   10540     
On treatment Wk 24 577   13408     
Post treatment week 28 785   9075     
Graft survival, n (%) 8 (100) 8 (100)   
Creatinine at 52 weeks (μmol/L)   
Mean (SD) 142.5 (65.7) 110.6 (43.6)   
Median (Min, Max) 114 (86-282) 94 (68-201)   
eGFR at 52 weeks (ml/min/1.73m2),        
Mean (SD) 53.00 (22.10) 57.42 (15.08)   
Median (Min, Max) 54.03 (20.41-86.63) 56.77 (30.25-81.93)   
 
Table 5: BEL114424 clinical outcomes. 1Clinical outcome data described for the per protocol 
population. 2Acute rejection was defined on biopsy according to Banff 2009 criteria: Acute antibody 
mediated rejection (Grade I, II or III) or acute T cell mediated rejection (Borderline, Type IA, Type IB, 
Type IIA, Type IIB, Type III). An additional subject randomised to belimumab had a positive pre-
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transplant MHC class II flow crossmatch (fulfilling an exclusion criterion but unknown at the time of 
enrolment and transplant). They experienced Type IIA acute cellular rejection (day 6) and grade II 
antibody mediated rejection (day 34). They were withdrawn once the crossmatch was recognised 
following a single dose of belimumab. 3Cumulative HLA class I and class II MFI calculated by summing 
the normalised MFI values for any single antigen bead with a value above the level of detection 
(500). An additional subject in the belimumab group underwent adoptive transfer of donor HLA-
specific allosensitization following kidney transplantation from a highly sensitized donor, as described 
in (Maxfield 2015). SD standard deviation, n number of subjects, HLA human leukocyte antigen, MFI 
mean fluorescence intensity measured by Luminex assay, DSA Donor specific antibody, Min 
minimum, Max maximum, and eGFR estimated glomerular filtration rate. 
3.4.6 Belimumab targets naïve and activated B cells whilst sparing memory B cells  
BLyS is known to support the survival of transitional and naïve B cells (Mackay 2003). The second co-
primary endpoint for the study was the change from in naïve B cells from baseline to Week 24, a 
biomarker of functional BLyS neutralisation validated in patients with SLE (Navarra 2011). We 
observed a reduction in the number and proportion of naïve B cells in belimumab-treated subjects 
(Figure 24). In line with the statistical analysis plan, analysis of the primary endpoints was performed 
on the MITT population (Figure 24A). The magnitude of the treatment effect was diluted in this small 
study by those subjects who did not receive multiple doses of the randomised study drug; when only 
the PP population is considered there was a more marked difference in the change in naïve B cells 




Figure 24: Belimumab affects naïve B cells. Panel A shows the adjusted mean (95% CI) change from 
baseline in naïve (CD20+CD27-) B cell count, by visit and treatment (MITT population). Panel B shows 
naïve (CD20+CD27-) B cells expressed as a percentage of B cells by visit and treatment group (MITT 
population), with raw values at baseline for comparison and adjusted mean estimate +/- 95% 
confidence intervals at subsequent timepoint. Panel C shows the adjusted mean (95% CI) change 
from baseline in naïve (CD20+CD27-) B cell count, by visit and treatment (PP population). # indicates 
that the 95% confidence interval of the treatment difference does not include zero. 
Belimumab treatment altered the composition of the B cell compartment, with naïve B cells being 




Figure 25: Belimumab alters the B cell compartment. Median difference from baseline at week 24 in 
the labelled B cell populations by treatment group (PP population), with each population expressed 
as a percentage of B cells.  
In contrast, memory B cells were spared (Figure 26A) such that the proportion of memory B cells was 
increased (Figure 26B). In contrast to the effect of belimumab on the total memory pool, activated 
memory B cells were decreased, assessed using two different markers of activation, CD95 (Figure 





Figure 26: Belimumab spares memory B cells. Panel A shows the memory (CD20+CD27+) B cell count, 
by visit and treatment. Panel B shows memory (CD20+CD27+) B cells expressed as a percentage of B 
cells by visit and treatment group. Panel C shows activated memory (CD95+CD27+) B cell count 
(cells/ml) by visit and treatment group. Panel D shows the relationship between memory B cell count 
(cells/mm3) and activated memory B cell (CD95+CD27+) percentage at the post treatment week 12 
timepoint for individual subjects labelled by treatment group. A-C show PP population with raw 
values displayed at baseline for comparison, with adjusted mean estimate +/- 95% confidence 
intervals at subsequent timepoints. # indicates that the 95% confidence interval of the treatment 
difference does not include zero. D shows data for individual PP subjects labelled by treatment group. 
A, B and D are post hoc analyses. 
A low proportion of naïve B cells expressed the CD95 activation marker. The proportion expressing 
CD95 was not impacted by belimumab treatment but absolute numbers of CD95+ naive B cells 
decreased, reflecting the reduction in naïve B cells seen (Figure 27a). There was a clear decrease in 
the proportion of switched memory, non-switched memory and to a lesser degree double negative 
cells that were CD95+ positive from week 4 through to 36, with reductions in absolute numbers of 
these cells at week 36 and 52 (Figure 27b-d).  
Activation of B cells is associated with reduction of surface expression of the complement receptor 
CD21. A high proportion of memory B cells were CD21+ at baseline in both treatment groups (Figure 
28). In the placebo group, a number of subjects sharply downregulated CD21+ at week 24 and 36 on 
non-switched memory B cells (Figure 28b) and to a lesser degree switched memory B cells (Figure 
28c). In the belimumab group this effect was attenuated and delayed (Figure 28b-c). In the 
belimumab group compared to the placebo group, absolute counts of activated CD21 negative naïve 
B cells were reduced from week 4 onwards, in the most part due to reduced naïve B cell numbers 
(Figure 28a). Absolute counts of activated CD21 negative non-switched and switched memory 
populations were reduced at week 36 and 52 in belimumab compared to placebo group (Figure 28b-





Figure 27: Expression of the activation marker CD95 on B cell memory subsets. Graphs show the 
percentage of each subset expressing CD95 and absolute counts of CD95+ cells within each subset a) 
naïve B cells (CD19+CD27-IgD+) b) non-switched memory B cells (CD19+CD27+IgD+) c) switched 
memory B cells (CD19+CD27+IgD-) d) double negative memory B cells (CD19+CD27-IgD-). 1st and 3rd 
column plots show medians with interquartile range. 2nd and 4th column plots show individual subject 













































































































































































































































































































































































































































































Figure 28: Expression of the activation marker CD21 on B cell memory subsets. Graphs show the 
percentage of each subset expressing CD21 and absolute counts of CD21- cells within each subset a) 
naïve B cells (CD19+CD27-IgD+) b) non-switched memory B cells (CD19+CD27+IgD+) c) switched 
memory B cells (CD19+CD27+IgD-) d) double negative memory B cells (CD19+CD27-IgD-). 1st and 3rd 
column plots show medians with interquartile range; 2nd and 4th column plots show individual subject 
values over time.  
3.4.7 Belimumab alters BLyS receptor expression 
The BLyS receptor TACI is normally expressed at high levels on the surface of CD27+ memory B cells 
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period in belimumab treated subjects compared with controls (Figure 29), with similar effects seen 
in total memory, non-switched memory and switched memory populations (Figure 30).  
 
Figure 29: TACI expression on memory B cells is a strong pharmacodynamic marker of belimumab 
action. Geometric mean fluorescence intensity (MFI) of TACI staining on CD19+CD27+ memory B 
cells. PP population; raw values displayed at baseline for comparison, with adjusted mean estimate 
+/- 95% confidence intervals at subsequent timepoint. Note % confidence interval of the treatment 
difference not calculated for this endpoint. 
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Figure 30: TACI receptor expression. MFI of TACI staining on a) memory B cells (CD19+CD27+) b) non-
switched memory B cells (CD19+CD27+IgD+) c) switched memory B cells (CD19+CD27+IgD-). Left 
plots show medians with interquartile range. Right plots show individual subject values over time. 
Further characterisation of BLyS receptor expression was performed. There was a trend towards an 
increase in BAFFR expression in memory but not naïve B cells, with a clear difference between the 
treatment groups at Week 36 (Figure 31).  
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Figure 31: BAFFR receptor expression. MFI of BAFFR staining on a) memory B cells (CD19+CD27+) b) 
non-switched memory B cells (CD19+CD27+IgD+) c) switched memory B cells (CD19+CD27+IgD-) d) 
naïve B cells (CD19+CD27-IgD+). Left plots show medians with interquartile range. Right plots show 
individual subject values over time. 
There was no clear treatment effect on BCMA expression on plasmablasts, however plasmablast 








































































































































































Figure 32: BCMA receptor expression. MFI of BCMA staining on plasmablasts (CD19+CD27+CD38+). 
Left plot shows medians with interquartile range. Right plots show individual subject values over 
time. 
3.4.8 Belimumab impacts antibody producing cells  
There was also a reduction in circulating CD19+CD27+CD38hi plasmablasts measured by flow 
cytometry (Figure 33).  
 
Figure 33. Belimumab leads to a reduction in circulating plasmablasts. Adjusted mean (95% CI) of 
plasmablast (CD19+CD27+CD38+) count/ml. PP population with raw values displayed at baseline for 
comparison, with adjusted mean estimate +/- 95% confidence intervals at subsequent timepoints.  # 
indicates that the 95% confidence interval of the treatment difference does not include zero 
In order to further understand the potential impact of belimumab on B cell activation and 
differentiation into antibody-secreting cells, we assessed the whole blood transcriptome. Using a 
differential expression analysis approach, we compared whole blood gene expression in belimumab 
treated subjects compared to controls. Immunoglobulin coding genes were among the most 
differentially expressed. Figure 34A shows fold-change and unadjusted p-values at week 52. The 
distribution of differential gene expression for the whole transcriptome was symmetrical, indicating 
no global changes in gene expression (Figure 34A upper panel). In contrast, the volcano plot showing 
only immunoglobulin probes demonstrate a clear difference with lower expression of these 
transcripts in the belimumab 10 mg/kg group, compared with the placebo group (Figure 34A lower 
panel), although sample numbers were too small to demonstrate statistical significance for this 
comparison. In support of this observation, a weighted gene co-expression network analysis 
identified a B cell gene expression module (Figure 34B), the expression of which was attenuated in 
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belimumab-treated subjects (Figure 34C). The most attenuated genes in this module coded for 




Figure 34: Belimumab reduces the transcription of immunoglobulin coding genes. Panel A shows 
volcano plots demonstrating differentially regulated genes in belimumab vs placebo treated subjects 
at week 52. The upper panel shows all probes on the microarray; the lower panel shows only 
immunoglobulin coding probes. Panel B shows proportion of module genes within each module 
identified during weighted correlation network analysis of whole blood RNA in the GO:0050853 BCR 
signalling pathway. A single module (coloured red) was enriched for BCR signalling and analysed 
further for the effects of belimumab treatment. Panel C shows expression (arbitrary units) of this 
expression module by treatment group at baseline, end of on-treatment phase (Week 24) and end of 
follow-up (Week 52). Horizontal lines correspond to median and interquartile ranges. Panel D shows 
a heat map of differential gene expression (Belimumab versus Placebo groups) for genes in the B cell 
module at baseline, Week 24 and Week 52. Genes are ordered by fold-change at Week 24 and 
immunoglobulin-coding transcripts are highlighted. Colour corresponds to log2-fold change, with blue 
indicating higher expression in Placebo relative to Belimumab. Analysis performed on MITT 
population at baseline and PP thereafter.  
3.4.9 Belimumab treatment inhibits new non-HLA antibody production but study underpowered 
to detect changes in HLA antibodies 
Eight study participants had detectable anti-HLA antibodies (non donor-specific) at transplantation 
(3/12 in the belimumab group and 5/13 in the placebo group, Table 3). Belimumab treatment was 
associated with a reduction in HLA antibody titre post-transplant in some subjects (Figure 35). Two 
patients recruited to the study developed de novo DSA during follow-up; both had been withdrawn 
following a single dose of belimumab for reasons unrelated to antibody development. Subject 5 was 
withdrawn due to a positive cross-match; subject 13 withdrew consent for study drug (Figure 35C). 
Non-HLA autoantibodies can also have a deleterious effect on allograft function (Dragun 2005, Zhang 
2016). Antibodies against MHC class I–related chain A (MICA) antigens are associated with renal 
allograft rejection and reduced allograft survival, particularly amongst those well matched for HLA 
antigens (Zou 2007). One patient in each treatment group had positive anti-MICA antibodies at 
baseline; subject 19 received one dose of placebo and had positive levels throughout the first year 
post transplant; in contrast subject 27 received 5 doses of belimumab and antibody levels fell below 
the positive threshold. Subject 13 received a single dose of belimumab and developed de novo anti-
MICA antibodies in addition to low titre de novo DSA. The small numbers of subjects with positive 
anti-MICA antibodies prevents us from being able to draw firm conclusions, however this data 











Figure 35: Serum samples before and after treatment were screened for HLA antibodies using 
Luminex HLA class I and class II antibody detection beads (LABScreenTM Mixed, One Lambda) and 
HLA antibody specificities were determined using Luminex single antigen HLA-specific antibody 
detection beads (LABScreen Single Antigen HLA Class I and Class II, One Lambda). The normalized 
mean fluorescence intensity (MFI) for each single antigen bead with an MFI above the detection limit 
of 500 at any timepoint is shown in individuals from the per protocol population (A) and those not in 
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the per protocol population (B). Risk categories refer to the clinical interpretation assigned to MFI 
levels by the Histocompatibility and Immunogenetics laboratory for donor specific HLA antibodies. 
Vertical lines show when doses of study drug were received. Subject 6 received plasma exchange for 
FSGS between days 31 and 64. Subjects 3 and 13 withdrew consent for study drug following a single 
dose. Adoptive transfer donor HLA specific allosensitization as described in (Maxfield 2015). Panel C 
shows the relationship between serum BLyS and de-novo donor-specific HLA antibody over time for 
subject 13 who received a single dose of belimumab on day 0 prior to withdrawal of consent for study 
drug. Serum was sampled for BLyS levels at Day 0, week (W) 4, W8, W16, W24, W36 and W52 within 
time windows specified in the study protocol. The first increase in serum BLyS was detected at W24 
(day 167), with a fall in levels thereafter to baseline by W52 (day 370). Antibodies were measured 
using Luminex single antigen HLA-specific antibody detection beads (LABScreen Single Antigen HLA 
Class I and Class II, One Lambda); donor specificity was determined manually by comparison of donor 
and recipient HLA-types. A low MFI MHC class I B37 antibody became detectable at W24 (day 167), 
and a further A3 antibody at W52 (day 370), the latter in the context of a falling serum BLyS level.   
De novo HLA and non-HLA IgG autoantibodies can have a deleterious effect on allograft function 
(Dragun 2005, Sigdel 2012, Jackson 2015). In order to sensitively measure the ability of belimumab 
to inhibit the development of de novo IgG antibodies, we tested serum taken at time zero and week 
24 for antibody binding to a human protein array. This demonstrated that the addition of 
belimumab to standard of care immunosuppression significantly reduced de novo IgG antibody 
formation (Figure 36).   
 
Figure 36: Belimumab reduces new non-HLA antibody generation. The number of unique ProtoArray 
antigen specificities with significant antibody binding at Week 24 but not baseline. Horizontal lines 
on boxplot (left) correspond to median and interquartile ranges. Individual patient data shown 
(right), ordered by number. Patients are coloured by treatment group. The Wilcoxon rank-sum test 




In addition to effects on de novo antibodies, we also observed an effect on pre-formed non-HLA 
antibodies that have been implicated in allograft damage; at week 24 we saw reduced IgG specific 
for kidney antigens (Li 2009) following belimumab treatment (Figure 37A,B), and a significant 
reduction in anti-EDIL3 (EGF-like repeats and discoidin I-like domains 3) antibodies (Figure 37C), an 
endothelial cell-specific antibody associated with post-transplant glomerulopathy (Jackson 2015). 
The presence of antibodies to glial cell-derived neurotrophic factor (GDNF) at the time of 
transplantation has been associated with more severe chronic allograft injury (interstitial fibrosis 
and tubular atrophy) on 24 month biopsies (Sigdel 2012); we observed a reduction in the number of 
subjects with detectable anti-GDNF antibodies at week 24 compared with time 0 in the belimumab 
group (6/8 and 2/8 at time 0 and 24 weeks respectively), in contrast to the placebo group (6/8 and 
6/8 at time 0 and week 24 respectively) (Figure 37D). Together, these data emphasise that 
belimumab modulates a clinically important aspect of B cell function post-transplant.  
 
Figure 37: Belimumab reduced pre-formed kidney specific antibodies. The number (A) and mean 
protoarray signal (B) of kidney specific unique ProtoArray antigen specificities (defined in (Li 2009)) 
with significant antibody binding at Week 24. In A, horizontal lines on boxplot (left) corresponds to 
median and interquartile ranges. Individual patient data shown (right), ordered by number. Patients 
are coloured by treatment group. Panel C shows the distribution of the mean protoarray signal from 
two antigens on the array annotated to EDIL3 (BC053656.1; BC030828.1) by treatment group at 
week 24. Panel D shows the number of subjects in each treatment group with above threshold 
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protoarray binding to GDNF at baseline and week 24. PP population; Eight subjects were tested at 
each timepoint for both treatment groups. Horizontal lines on boxplots correspond to median and 
interquartile ranges. The Wilcoxon rank-sum test was used to compare the belimumab treatment 
group (BEL) and placebo treatment group (PBO) in post-hoc analyses; * denotes p<0.05; exact p 
values displayed where p ≥ 0.05. 
3.4.10 Belimumab treatment skews the residual B cell compartment towards an IL10-producing 
regulatory phenotype 
IL-10 producing B cells are enriched within transitional and memory subsets and associated with 
favourable outcomes in renal transplantation (Cherukuri 2013, Cherukuri 2014, Chesneau 2014, 
Shabir 2015). We observed a reduction in the number of transitional B cells following belimumab 
treatment (Figure 38A) with maintenance of memory B cells (Figure 38B).  
 
Figure 38: Belimumab reduced transitional B cells but not memory B cells. A shows the transitional 
(CD24brCD38brIgD+) B cell count/ml. B shows the memory (CD20+CD27+) B cell count (cells/cm3). PP 
population. Raw values shown at baseline with adjusted mean estimate +/- 95% confidence intervals 
at subsequent timepoints. # indicates that the 95% confidence interval of the treatment difference 
does not include zero. 
 
In order to further assess the effect on the regulatory B cell compartment, we sought to address 
how belimumab treatment affects B cell cytokine production post-transplant. PBMC were stimulated 
ex vivo with CpG and CD40L, and B cell IL-10 and IL-6 production assessed. Prior validation work with 
healthy controls showed that surface marker expression was not altered significantly by a short 5 
hour stimulation (data not shown). We were therefore able to quantify the cytokine production of 
subsets of B cells, based on their surface marker expression. Figure 39 shows representative flow 
cytometry plots to demonstrate the gating strategy used to define cytokine positive cells and 
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memory subsets. At week 12 post-transplant, subjects receiving belimumab had a reduction in IL-6-
producing B cells and an increase in IL-10+ B cells (Figure 40A, B), skewing the cytokine ratio toward 
a more regulatory profile compared with controls (Figure 40C). This skewing of cytokine production 
towards IL-10 was observed in both transitional and memory B-cell subsets (Figure 40D). 
 
IL-10 and IL-6 producing B cells were found within naïve (CD19+CD27-IgD+), transitional B (TrB) 
(CD19+CD24hiCD38hiIgD+), CD24+CD27+ memory (CD19+CD24+CD27+), switched memory (SM) 
(CD19+CD27+IgD-) and non-switched memory (NSM) (CD19+CD27+IgD+) subsets. Examining the 
surface markers expressed by B cells stained for intracellular cytokines revealed changes associated 
with belimumab treatment. In placebo-treated subjects, naïve B cells make up the majority of IL6+ B 
cells but a lesser proportion of IL10+ B cells (median 82.02% vs 51.12% at 12 week post treatment; 
Figure 41a). At 12 weeks post treatment, a reduced proportion of the IL-10 and IL-6 producing B cells 
from those treated with belimumab had a naïve phenotype and there was a concomitant rise in the 




Figure 39: Representative flow cytometry plots from 5 hour stimulation assay showing gating 
strategy used to define cytokine positive cells and memory subsets. The same cytokine gates were 
applied to each memory subset. Zebra plots are computed using equal probability contouring with 





Figure 40:  Belimumab treatment increases circulating regulatory B cells. PBMC were stimulated ex 
vivo for 5 hours and intracellular cytokine production quantified by flow cytometry (Panel A-D). 
Individual data points represent individual subjects with horizontal lines signifying the median for 
each treatment group. Wilcoxon rank-sum tests were performed to compare samples by treatment 
and visit. Panel A shows representative flow cytometry plots for IL-6 (upper) and the percentage of 
CD19+ B cells expressing IL-6 (lower). Panel B shows representative flow cytometry plots for IL-10 
(upper) and the percentage of CD19+ B cells expressing IL-10 by treatment group and timepoint 
(lower). Panel C shows the calculated ratio of IL-10/IL-6 with higher values indicating a more anti-
inflammatory cytokine milieu. Panel D shows the IL-10/IL-6 ratio for individual subsets of naïve 
(CD27-), transitional (CD24hiCD38hiIgD+), CD24+CD27+ memory, switched memory (CD27+IgD-), and 
non-switched memory (CD27+IgD+) B cells at post treatment Wk 12. PP population. P-values 
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calculated using Wilcoxon rank-sum tests. * denotes p<0.05, ** p<0.01. All analyses were performed 
post hoc. 
 
Figure 41: Post hoc backgating analysis of 5 hour stimulated samples shows that cytokine producing 
B cells are depleted for naïve B cells and enriched for memory B cells following belimumab treatment. 
a) Phenotype of CD19+IL10+ and CD19+IL6+ cells at 12 weeks post treatment. b) IL10+ B cells are 



































































producing and NOT IL10 producing cells at 12 weeks post treatment. c) IL6+ B cells are enriched for 
naïve B cells in placebo treated subjects. The proportion of naïve B cells in the peripheral blood falls 
following belimumab treatment. Comparison of IL6 producing and NOT IL6 producing cells at 12 
weeks post treatment. PP population. P values calculated using two-tailed mann whitney tests. * 
denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001. All analyses were performed post hoc. 
Naïve (CD27); TrB Transitional (CD24hiCD38hiIgD+); SM switched memory (CD27+IgD-); NSM Non-
switched memory (CD27+IgD+). 
Comparing the profile of B cells in the cytokine secreting and non-secreting populations gives an 
indication as to whether belimumab treatment effects on the regulatory B cell compartment mirrors 
that seen as a whole. The differences between the phenotype of IL10+ and NOT IL10+ populations 
were similar in the belimumab and placebo treatment groups at 12 weeks post treatment. IL10+ B 
cells were enriched for transitional B cells and CD24+CD27+, switched and non-switched memory 
cells in both treatment groups, representing a greater proportion in the IL10+ gate compared to the 
NOT IL10+gate in these subsets. In contrast, naïve B cells were under-represented in the IL10+ gate 
(Figure 41b). IL6+ B cells were predominantly comprised of naïve B cells in placebo treated subjects 
and naïve B cells were over-represented in placebo IL6+ cells compared to the NOT IL6+ cells. The 
proportion of naïve B cells fell to similar levels of IL6+ and NOT IL6+ cells following belimumab 
treatment (Figure 41c). 
To explore whether the effect of belimumab treatment on the regulatory compartment went 
beyond changing the proportion of cells from each subset, by altering the cytokine profile of the 
resultant B cell compartment, the ratio of IL10/IL6 producing B cell subsets were examined. 
Following belimumab treatment there was a trend for increased IL10 production relative to IL6 
across multiple B cell subsets including TrB and memory subsets (Figure 42). A summary of 
treatment effect across subsets at post treatment week 12 is shown in Figure 40D. During the ‘on 
treatment’ period, there was a strong negative correlation between the percentage of CD19+ cells 
that were naïve and the percentage that produce IL-10, but not with the percentage that produce IL-
6 (Figure 43). There was a strong positive correlation between percentage of CD19+ cells that were 
of a memory phenotype and the percentage that produce IL-10 but not with the percentage that 
produce IL-6 (Figure 44 (CD19+CD27+); Figure 45 (CD19+CD24+CD27)). There was no correlation 
between cytokine production and the proportion of transitional B cells (Figure 46). These strong 
reciprocal correlations between the proportion of naïve and memory B cells with the proportion of 
IL-10 producing cells suggesting the importance of the phenotype of the circulating B cells in 




Figure 42: Belimumab appears to have a general effect across subsets of skewing cytokine 
production towards IL10 relative to IL6. Ratio of the percentage of cells secreting IL10 to the 
percentage of cells secreting IL6 (IL10/IL6) following a 5 hour stimulation. The subset displayed is 
denoted in the top left of each graph. Due to the low frequency of TrB cells, replicate files were 
concatenated to increase the TrB event number to improve the accuracy of cytokine reporting. PP 
population. P values calculated using two-tailed mann whitney tests. * denotes p<0.05, ** denotes 
p<0.01. All analyses were performed post hoc. TrB transitional B, SM switched memory, NSM non 









































Figure 43: Correlation between naïve B cells and 
IL-10 secreting B cells (top) and IL-6 secreting B 
cells (bottom). All readings collected during the 
on treatment phase are shown and colour coded 
by treatment group.  Cytokine data taken from 5 
hour stimulation. PP population, post hoc 






Figure 44: Correlation between memory B cells 
(CD19+CD27+) and IL-10 secreting B cells (top) 
and IL-6 secreting B cells (bottom). All readings 
collected during the on treatment phase are 
shown and colour coded by treatment group.  
Cytokine data taken from 5 hour stimulation. PP 











 Figure 45: Correlation between memory B cells 
(CD19+CD24+CD27+) and IL-10 secreting B cells 
(top) and IL-6 secreting B cells (bottom). All 
readings collected during the on treatment phase 
are shown and colour coded by treatment group.  
Cytokine data taken from 5 hour stimulation. PP 






Figure 46: Correlation between Transitional B 
cells (CD19+CD24b+CD38b+IgD+) and IL-10 
secreting B cells (top) and IL-6 secreting B cells 
(bottom). All readings collected during the on 
treatment phase are shown and colour coded by 
treatment group.  Cytokine data taken from 5 
hour stimulation. PP population, post hoc 






The impact of belimumab on the circulating regulatory B cell compartment can therefore be 
summarised as follows. In placebo-treated subjects, naïve B cells make up the majority of IL-6+ B 
cells but a lesser proportion of IL-10+ B cells. Depletion of naïve B cells with belimumab is associated 
with a reduction in the proportion of IL-6 secreting B cells but a rise in the proportion of IL-10 
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producing B cells. Belimumab appears to impact the regulatory capacity of the B cell compartment in 
two ways. It causes a reduction in the proportion of naïve B cells that have a low IL10/IL6 ratio, with 
a concomitant increase in the proportion of memory B cells that have a higher IL10/IL6 ratio. In 
addition, belimumab appears to have a general effect across subsets of skewing cytokine production 
towards IL-10 relative to IL-6. 
Some B cells may not produce IL-10 in their current state, but have the capacity to produce IL-10 in 
the right environmental context. A more prolonged period of ex vivo stimulation identified these 
Breg progenitors in addition to circulating Breg. Figure 47 shows representative plots demonstrating 
the gating strategy in a 48 hour stimulation assay. In this assay, subjects in the belimumab group had 
fewer IL-6 producing B cells than subjects in the placebo group with no difference in IL-10 producing 
B cells, indicating maintenance of Breg progenitors with resultant cells less likely to produce pro-
inflammatory cytokines (Figure 48). 
IL-10 producing regulatory B cells are enriched in the CD73-CD25+CD71+ B cell subset (van de Veen 
2013). This subset was quantified in freshly thawed PBMCs and following 48 hour stimulation with 
CpG and CD40L, with the addition of PMA, ionomycin and brefeldin A during the last 5 hours. 
Proportions of CD73-CD25+CD71+ B cells were similar in those treated with belimumab and placebo. 
In both treatment groups, levels fell during the first 8 weeks on treatment, however this likely 
represents downregulation of surface CD25 expression following basiliximab treatment (Wang 2009) 
and therefore cannot be interpreted as a reduction in the CD73-CD25+CD71+ B cell subset (Figure 
49a, b). CD73-CD25+CD71+ B cells from those treated with belimumab had a more regulatory 
phenotype during the 8 to 24 week on treatment period, with a greater proportion producing IL-10 




Figure 47: Representative gating for CD73-CD25+CD71+ B cells stained following stimulation for 48 




Figure 48: Belimumab treated subjects maintain cells capable of producing IL10 on 48 hour 
stimulation (Breg progenitors) with a reduction in the proportion of cells secreting pro-inflammatory 
IL6.  a) Representative flow cytometry plots gated on live CD19+ cells. Zebra plots are computed 
using equal probability contouring with the last 2% of events shown as dots. b) Percentage of CD19+ 
cells secreting IL-6 (IL6+) and IL-10 (IL10+) following a 48 hour stimulation and the ratio of IL10+ to 
IL6+ (IL10/IL6). Each point represents an individual subject; in the plots on the left the median of each 
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treatment group is shown by a horizontal line. The plots on the right show changes in individual 
subjects over time. PP population. P values calculated using two-tailed mann whitney tests. * denotes 
p<0.05, ** denotes p<0.01. All analyses were performed post hoc. 
 
Figure 49: CD73-CD25+CD71+ B cell analysis. a) Stained prior to stimulation. b) Stained following 
stimulation for 48 hours with CpG and CD40L with PMA, Ionomycin and brefeldin added during the 
last five hours. c) Ratio of percentage of CD19+CD73-CD25+CD71+ cells producing IL10 to the 
percentage producing IL6 (IL10/IL6). PP population. P values calculated using two-tailed mann 
whitney tests. * denotes p<0.05, ** denotes p<0.01. All analyses were performed post hoc. 
3.4.11 Memory B cell IL-10/IL-6 Ratio is BLyS Dependent 
To confirm that the effect of belimumab on B cell cytokine production was B cell intrinsic we 
cultured human memory B cells from healthy controls with BLyS in the presence or absence of 
belimumab. This demonstrated that BLyS stimulation significantly decreased B cell IL-10 relative to 
IL-6, indicating a more inflammatory milieu, and that this effect was blocked in the presence of BLyS 




Figure 50: Memory B cell IL-10/IL-6 Ratio is BLyS Dependent. PBMC from healthy volunteers enriched 
for CD27+ memory B cells and stimulated for 48 hours with increasing quantities of BLyS and in the 
presence or absence of belimumab. This figure shows the IL-10/IL-6 ratio (relative to 0ng/mL BLyS) in 
the different experimental conditions indicated. N, number of healthy volunteers tested for each 
experimental condition. T-tests were performed to determine whether the mean percentage change 
from baseline differed significantly from 0 for each experimental condition. * denotes p<0.05, ** 
denotes p<0.01. Experiments performed by Joseph Chadwick, GSK Experimental Medicine Unit.  
3.4.12 Belimumab inhibits T cell proliferation 
We also investigated whether T cell activation was altered by belimumab treatment, since B cells are 
potent antigen presenting cells (Yuseff 2013) and IL-6 is known to augment T cell activation (Jordan 
2017) whilst IL-10 can regulate T cell responses (Maynard 2008). There was no difference in the 
number of circulating T cells by treatment (Figure 51A, B) but transcriptomic analysis of purified 
circulating CD4 T cells revealed reduced cell cycle gene expression in belimumab-treated subjects 
suggesting that BLyS neutralisation may also inhibit T cell proliferation. Figure 51C shows volcano 
plots demonstrating no differences in the expression of cell cycle genes 
(WHITFIELD_CELL_CYCLE_G2_M gene list from MSigDb v5.1) at baseline (top panel) but a co-
ordinated reduction in this geneset in subjects treated with belimumab 10 mg/kg compared with the 
placebo group at week 24 (bottom panel). Furthermore, numerous genes from this geneset were 
present in the list of genes most downregulated in the belimumab group relative to the placebo 





Figure 51: Belimumab inhibits T cell cell cycle genes. Panel A shows activated T cell 
(CD4+CD25hiCD45RA-IL 7Rhi) count/ml. Panel B shows regulatory T cell (CD4+CD25hiIL-7Rlo) 
count/ml. Raw values shown at baseline with adjusted mean estimate +/- 95% confidence intervals, 




Weeks 4 and 8 excluded due to known effects of basiliximab on CD25 surface expression. Panel C 
shows volcano plots demonstrating differentially regulated CD4+ T cell cell cycle genes in belimumab 
vs placebo treated subjects at week 0 (upper) and week 24 (lower). Panel D shows a heatmap of 
differential gene expression in blood CD4+ T-cells for the most downregulated genes at Week 24 in 
the Belimumab group relative to Placebo, ordered by fold-change at Week 24. Cell-cycle genes 
(GO:0007049) are highlighted. Colour corresponds to log2-fold change, with blue indicating higher 
expression in Placebo relative to Belimumab. Panels A-B use the PP population and panels C-D uses 
the MITT population for baseline and PP population thereafter. P-values in Panels A-D were 
calculated using Wilcoxon rank-sum tests and in Panel E using student’s t-test 
3.5 Discussion  
A key goal of this study was to determine the safety of belimumab in combination with standard 
transplant immunosuppression, in patients with ESRF. Although belimumab has previously been 
used in patients with SLE with renal involvement, it has not been used in patients with established 
ESRF. ESRF confers an increased risk of infection (Vanholder 1993), with impaired humoral immunity 
and reduced antibody vaccine responses (Eleftheriadis 2014). An added concern was the 
concomitant immunosuppression burden, which was significantly greater than that used in previous 
trials. Despite this burden of immunosuppression in an immunocompromised patient group, we 
observed no excess infections with the addition of belimumab. 
Secondary and mechanistic end-points in this study provide evidence for beneficial effects of 
belimumab post-transplantation. In particular, despite depletion of B cell subsets known to contain 
regulatory B cells, the residual B cell compartment post-belimumab treatment demonstrated an 
increased capacity to produce the immunoregulatory cytokine IL-10 relative to IL-6. Since B cells are 
the major source of IL-6 in secondary lymphoid organs (Barr 2012), this observation is significant and 
of potential benefit in transplantation; IL-6 promotes B cell differentiation into antibody-forming 
plasma cells, contributes to the plasma cell niche (Kometani 2015), enhances T follicular helper cell 
development – cells critical for the germinal centre response, whilst inhibiting the generation of 
regulatory T cells (Jordan 2017). Indeed, an IL-6R antagonist has been used to treat patients with 
chronic ABMR (Choi 2017). We provide novel insights into the mechanism of action of belimumab, 
identifying for the first time the maintenance of a beneficial Breg subset on belimumab treatment, 
likely to be relevant in the setting of autoimmunity where belimumab use is common. 
We present transcriptomic and protein microarray data suggesting that BLyS neutralisation reduced 
antibody-forming cells and resulted in a lower incidence of de novo non-HLA autoantibody formation 
post-transplant, both of which might positively affect transplant outcomes (Dragun 2005, Jackson 
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2015, Zhang 2016). Whether these effects were due to a reduction in B cell IL-6 production, or a 
direct effect of BLyS neutralisation on plasma cell survival (Benson 2008), was not addressed. Our 
study also highlights the role of BLyS in memory B cell activation, raising the possibility that 
belimumab may have utility in sensitised transplant subjects with pre-formed memory B cells. 
Finally, there was also a decrease in T cell proliferation markers demonstrating the potential for 
belimumab to impact both cellular and humoral alloimmunity. 
 
Our study has several limitations; the sample size was not powered for clinical efficacy. We used 
belimumab in combination with non-lymphocyte depleting induction therapy (basiliximab), rather 
than thymoglobulin or alemtuzumab, agents that previously associated with an increase in serum 
BLyS (Bloom 2009). Whether belimumab would have the same pro-regulatory effect on the 
reconstituted B cell pool when used in combination with lymphocyte-depletion remains to be 
determined. Of note, we observed a rebound in serum BLyS following cessation of belimumab. 
Although this was not associated with any clinically overt effects, it raises the question of whether 
belimumab should be administered for a more extended period post-transplant. Belimumab is now 







Chapter 4: Bromodomain inhibitors modulate FcγR mediated macrophage activation, suggesting 
therapeutic potential in immune complex-mediated disease  
 Page number 
4.1 Chapter summary 123 
  
4.2 Background 124 
  
4.3 Results 125 
4.3.1 I-BET inhibits gene expression induced by FcγR cross-linking in bone marrow 
derived macrophages 
125 
4.3.2 Bromodomain inhibitors reduce FcγR expression on macrophages and dendritic 
cells, lowering their capacity to respond to IC. 
138 
4.3.3 I-BET151 leads to accumulation of phagocytic material within MNP 141 
4.3.4 I-BET151 delays phagosome maturation 144 
4.3.5 I-BET selectively inhibits cytokine production in response to IC stimulation 146 
4.3.6 Failure to induce accelerated nephrotoxic nephritis without the use of IP CFA 149 
4.3.7 I-BET reduces spleen size following immune complex peritonitis and leads to 
accumulation of phagocytosed IC in vivo 
151 
4.3.8 I-BET reduces recruitment of mononuclear phagocytes to the kidney and reduces 
pro-inflammatory gene expression in response to circulating immune complex 
154 
  





Chapter 4: Bromodomain inhibitors modulate FcγR mediated macrophage activation, suggesting 
therapeutic potential in immune complex-mediated disease 
4.1 Chapter summary 
Immune complexed antigen can activate MNP via ligation of FcγR. FcγR-dependent MNP activation 
results in profound changes in gene expression that mediate antibody effector function in these 
cells. The resulting inflammatory response can be pathological in the setting of autoimmune 
diseases, such as systemic lupus erythematosus and in antibody-mediated rejection in 
transplantation. BET proteins are a family of histone modification ‘readers’ that bind acetylated 
lysine residues within histones and function as a scaffold for the assembly of complexes that 
regulate gene transcription. Bromodomain inhibitors (I-BET) selectively inhibit the transcription of a 
subset of inflammatory genes in macrophages following toll-like receptor stimulation. Since MNPs 
make a key contribution to antibody-mediated pathology, we sought to determine the extent to 
which I-BET inhibits macrophage activation by IgG.  
Following FcγR stimulation of BMDM we detected changes in the expression of 1779 genes in the 
presence of DMSO, but only 172 genes in the presence of I-BET, suggesting that I-BET significantly 
attenuates IC-induced changes in gene expression. Numerous immune pathways induced by OVA-IC 
were downregulated by I-BET, including cytokine-chemokine signalling and cell adhesion pathways 
as well as antigen presentation pathways. Many of the LPS inducible genes that were significantly 
suppressed by I-BET (sI-BET) are also induced by IC and similarly suppressed by I-BET. Bromodomain 
inhibitors reduce FcγR expression on macrophages and dendritic cells in vitro and in vivo, potentially 
lowering their capacity to respond to IC. I-BET delays phagolysosome maturation associated with 
build-up of phagocytosed immune complex within BMDM and DC, whilst selectively inhibiting IC 
induced cytokine production, potentially promoting non-inflammatory clearance of ICs by tissue-
resident cells. 
We also showed efficacy of I-BET in murine models of IgG mediated inflammation. I-BET reduced 
spleen size following immune complex peritonitis and caused accumulation of phagocytosed IC 
within macrophages and neutrophils, with a trend towards reduced neutrophil recruitment in the 
peritoneal exudate. In response to circulating IC, I-BET reduced recruitment of mononuclear 
phagocytes to the kidney, reducing pro-inflammatory gene expression.  
These findings support the hypothesis that bromodomain inhibition may be of benefit in the setting 




IgG antibodies propagate inflammation in a number of autoimmune diseases and in organ 
transplantation. Many of their cellular effects are mediated by cross-linking FcγRs, surface 
glycoproteins that bind IgG immune complexes, and are expressed by most immune cells, including 
MNPs. FcγRs may be activating (in humans, FcγRIIA, IIIA, IIIB), or inhibitory (FcγRIIB) and their relative 
expression sets the activation threshold for a cell encountering IC (Nimmerjahn 2007b, Smith 2010). 
IgG-opsonised cargo may be phagocytosed by MNPs in an FcγR-dependent manner and degraded, in 
the case of macrophages, or processed for antigen presentation in the case of DCs. FcγR cross-linking 
in macrophages also results in the production of inflammatory cytokines, that assist in pathogen 
clearance but can potentially propagate tissue inflammation in autoimmunity. Deficiency or 
dysfunction of the inhibitory receptor FcγRIIB results in susceptibility to SLE in both mice and 
humans (Bolland 2000, Floto 2005, Kono 2005, Brownlie 2008, Smith 2010, Boross 2011), identifying 
the importance of this pathway in disease pathogenesis.  
FcγR-dependent MNP activation results in profound changes in gene expression that mediate 
antibody effector function in these cells, including changes in genes associated with cytokine 
production, co-stimulation, antigen presentation and cell migration. Epigenetic marks such as DNA 
methylation and histone modifications control the expression of these genes. BET proteins (BRD2, 
BRD3 and BRD4) govern the assembly of histone acetylation-dependent chromatin complexes 
required for gene transcription (LeRoy 2008). Given the pivotal role of BET proteins in transcriptional 
regulation, small molecule compounds that inhibit binding of acetylated histones to BET proteins (I-
BET) have been developed as potential anti-cancer and anti-inflammatory drugs (Prinjha 2012).  
Treatment options in autoantibody-mediated disease such as SLE remain limited. B cell-targeted 
therapy may reduce antibody generation, but limiting FcγR-associated immune cell activation by 
existing autoantibodies remains an unmet need. I-BET have shown some utility in animal models of 
autoimmunity (Bandukwala 2012) including those with a proven antibody-dependent component, 
such as collagen-induced arthritis (Mele 2013) and selectively inhibit the transcription of a subset of 
inflammatory genes in macrophages following TLR4 stimulation (Nicodeme 2010, Belkina 2013).   
Since MNPs make a critical contribution to antibody-mediated inflammation, we sought to 






4.3.1 I-BET inhibits gene expression induced by FcγR cross-linking in bone marrow derived 
macrophages 
We first sought to gain a global overview of the extent to which changes in gene expression induced 
by FcγR cross-linking were altered by I-BET. We performed a transcriptomic analysis using affymetrix 
microarray analysis. BMDM were stimulated with IC (IgG-opsonised ovalbumin (OVA)) or control 
protein (OVA alone), as described previously (Clatworthy 2014a), with I-BET or DMSO solvent control 
added 30 minutes prior to the stimulus (Figure 52). 
 
Figure 52: Schematic describing experimental setup for microarray experiment. BMDM were 
stimulated with OVA-IC or OVA in the presence or absence of I-BET. RNA was extracted and 
transcriptomic analysis using an affymetrix microarray system was performed.  
Microarray analysis was performed by Dr John Ferdinand (post-doctoral fellow, Clatworthy Lab). Of 
the samples analysed one was rejected at the quality control (QC) stage, since it was a clear outlier 
with technical issues (Figure 53). Principal component analysis across the whole dataset showed that 
the greatest influence on the cell transcriptome was drug treatment, i.e. the presence or absence of 
I-BET (Figure 54). The second principal component separated samples that underwent stimulation 
for one hour from those stimulated for four hours or longer. This can be explained by the fact that 
these samples were prepared in an independent experiment at a different time.  
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Figure 53: QC plots identifying sample that failed QC. Boxplot of intensity (left); principal component 
plot (right). PC1 principal component 1; PC2 principal component 2; D DMSO; I I-BET. 
 
Figure 54: Principal component plots of whole dataset coloured by timepoint (A), treatment (B) and 
stimulation (C). PC1 principal component 1; PC2 principal component 2; D DMSO; I I-BET; IC OVA-IC; 
O OVA; US unstimulated. 
Few changes were observed following OVA-IC stimulation at one hour. The principal component 
determining differential expression was the biological replicate from which the sample was derived. 
The second principal component was the drug treatment given prior to stimulation, with minimal 
effect of the stimulation itself (Figure 55A-C). At this early timepoint, few genes were differentially 
regulated when comparing the samples treated with OVA-IC and those treated with OVA in the 















































Figure 55: Minimal effect of IC following one hour stimulation. Principal component plots of 1 hour 
dataset coloured by mouse (A), treatment (B) and stimulation (C). Venn diagram (D) describing genes 
differentially expressed (padj < 0.05 either direction) by immune complex in the presence of DMSO 
(IC.D vs O.D) and I-BET (IC.I vs O.I) and the effect of I-BET on IC stimulation (Diff). PC1 principal 
component 1; PC2 principal component 2; D DMSO; I I-BET; IC OVA-IC; O OVA; US unstimulated. 
Treatment of cells with I-BET for 1 hour did induce changes in the transcriptome; 389 genes were 
upregulated and 398 genes downregulated following the addition of I-BET to cells treated with OVA 
alone. Geneset enrichment analysis identified downregulation of immune pathways including 










































Figure 56: I-BET induces changes in the transcriptome in the absence of FcγR crosslinking. A. Volcano 
plot showing the fold change and statistical significance of differential expression in the presence of 
I-BET (I-BET OVA vs DMSO OVA). B. Heat map showing the 35 top upregulated and downregulated 
genes. C. Gene set enrichment analysis using the Hallmark (i) and Kegg genesets (ii).  
Following a four hour stimulation with IC, many more changes in gene expression were induced; the 
principal determinant being drug treatment, followed by stimulation condition. No differential gene 
expression was observed between those samples treated with OVA and media alone (Figure 57D); 
therefore we used the OVA treated samples for statistical comparisons with OVA-IC. Following FcγR 
stimulation we detected changes in the expression of 1779 genes in the presence of DMSO. With the 
addition of I-BET, only 172 genes were differentially expressed, suggesting that I-BET significantly 
attenuates IC-induced changes in gene expression (Figure 57E). Volcano plots showing the effect of 
adding IC in the presence and absence of I-BET (Figure 57 F-G) and a scatter plot demonstrating the 
interaction (Figure 58) demonstrate the impact of I-BET. The significance of the effect of I-BET on 
FcγR induced changes can be assessed by looking at the interaction of the effect of IC and the effect 
I-BET i.e. the effect of I-BET on the effect of IC stimulation, calculated using a difference of 
differences approach ((IC.D vs O.D) minus (IC.I vs O.I)) in limma (Ritchie 2015). Of the 1779 genes 
impacted by OVA-IC, only 20 were found to be significantly impacted by the addition of I-BET with a 
threshold of padj<0.05 (Figure 57E), however the small number of samples processed limits the 




Figure 57: I-BET dampens IC induced differential expression. Principal component plots of 4 hour 
dataset coloured by mouse (A), treatment (B) and stimulation (C). Venn diagram describing genes 
differentially expressed (padj < 0.05 either direction) by OVA vs US (D) and OVA-IC vs OVA (E) in the 
presence of DMSO and I-BET. Diff indicates the effect of I-BET on IC stimulation and is calculated as 
the difference of the difference. Volcano plots showing the fold change and statistical significance of 
IC dependent differential expression in the presence of DMSO (F) and I-BET (G). PC1 principal 
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component 1; PC2 principal component 2; D DMSO; I I-BET; IC OVA-IC; O OVA; US unstimulated. 
Figure 58: Scatter plot demonstrating OVA-IC induced differential expression in the presence of 
DMSO (x axis) and I-BET (y axis). Genes are coloured based on the interaction, with genes 
differentially expressed on addition of OVA-IC and significantly impacted by I-BET coloured in red. 
The 75 top differentially regulated genes (ordered by adjusted p value) are shown in the heatmap in 
Figure 59. The bottom cluster of genes are upregulated with OVA-IC in the presence of DMSO; with 
quenching of the effect with the addition of I-BET. In order to identify pathways of genes impacted 
by the addition of I-BET, we performed gene set enrichment analysis (Figure 60). Numerous immune 
pathways induced by OVA-IC were downregulated by I-BET, including cytokine-chemokine signalling 
and cell adhesion pathways as well as antigen presentation pathways. Pathways that were 
upregulated by the addition of I-BET included pathways involving DNA and RNA remodelling.  
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Figure 59 : Heatmap showing 75 top differentially regulated genes (ordered by adjusted p value). The 
p value demonstrated refers to the diff comparison, showing genes for which I-BET significantly 











Figure 60: Geneset enrichment analysis of genes for which I-BET significantly impacts on the effect of 
134 
 
OVA-IC. Hallmark genesets (A) and Kegg genesets (B) filtered to show pathways with FDR q value < 
0.1. A negative NES indicates a pathway which is down regulated as a result of I-BET in IC 
stimulation.  
I-BET is known to impact LPS induced change in BMDM (Nicodeme 2010). We compared our dataset 
with the Nicodeme et al. dataset (deposited in Gene Expression Omnibus (GEO) database under the 
accession number GSE21764). Many of the LPS inducible genes that were significantly suppressed by 
I-BET (sI-BET) are also induced by IC and similarly suppressed by I-BET (Figure 61). This is illustrated 
by a heatmap showing a similar pattern of gene expression following IC treatment in the presence 
and absence of I-BET (Figure 61A) and the corresponding scatter plot (Figure 61B) where the 
majority of genes lie between the x axis and the line of equivalent gene expression, indicating that 
the log fold change following IC stimulation is positive in the absence of I-BET and suppressed by the 








Figure 61: I-BET has similar effect on IC-induced change as LPS-induced change. Heatmap (A) and 
scatter plot (B) showing the effect of FcγR crosslinking in the presence and absence of I-BET on those 
genes significantly impacted by I-BET following a 4 hour LPS stimulation (Nicodeme 2010). The p 
value demonstrated refers to the diff comparison, showing genes for which I-BET significantly 
impacts on the effect of OVA-IC. 
I-BET suppressed the IC induced transcriptional changes in numerous transcription factors (Figure 










4.3.2 Bromodomain inhibitors reduce FcγR expression on macrophages and dendritic cells, 
lowering their capacity to respond to IC. 
Our transcriptomic analysis showed that I-BET reduces the expression of FcγR genes (Figure 63A, B). 
Genes encoding activatory receptors and the inhibitory receptor FcγRIIb were affected. We 
performed reverse transcription polymerase chain reaction (rtPCR) analysis to confirm the changes 
in gene expression, and found a significant reduction in the expression of genes encoding FcγRIIb 
and the activatory receptors FcγRIII and FcγRIV (Figure 63C).  
 
 
Figure 63: I-BET reduces FcγR expression. Heatmaps showing row Z scores (A) and log expression (B) 
of FcγR genes in BMDM treated with DMSO or I-BET for four hours in the absence of additional 
stimuli. rtPCR confirmed reduced expression of FcγR genes following I-BET treatment (C). Groups 
compared using Wilcoxon matched-pairs signed rank test. 
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We confirmed reduced FcγR expression following in vitro I-BET treatment at the protein level using 
flow cytometry. Initial experiments were performed using a 24G2 antibody that reacts specifically 
with a common non-polymorphic epitope on the extracellular domains of the murine FcγRIII (CD16) 
and FcγRII (CD32) receptors and is hence unable to distinguish between the activatory and inhibitory 
receptors. We observed reduced antibody binding with increasing concentrations of I-BET in murine 
bone marrow derived (Figure 64A) and peritoneal (Figure 64B) macrophages. At the time of later 
experiments, performed with bone marrow derived dendritic cells, a FcγRIIb (CD32b) specific 
antibody was available. I-BET treatment led to a reduction of CD32b in a concentration dependent 
manner (Figure 64Ci); with no effect on total CD16 and CD32 expression in these experiments. 
Human monocyte-derived macrophages also demonstrated a reduction in FcγR expression with I-
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Figure 64: I-BET151 reduces surface expression of murine and human Fcγ receptors. Surface CD16 
and CD32 expression measured on murine BMDM (A) and peritoneal macrophages (B) treated with I-
BET151 or DMSO for 14-24 hours. Geometric mean fluorescence of 24G2 antibody which binds to a 
common epitope on CD16 and CD32 (CD16/32) normalised to average reading in DMSO replicates for 
individual replicates. A. Results of two independent experiments shown. Differences between means 
significantly different by one-way ANOVA. B. Results of three independent experiments shown. Mean 
+/- standard error of the mean displayed; means compared using paired t test. C. Surface CD32b (i) 
and combined CD16 and CD32 (CD16/32) (ii) expression measured on murine bone marrow derived 
dendritic cells differentiated from FcγRIIb-/- and wildtype mice, treated with I-BET151 or DMSO for 
12-16 hours; results from 3 independent experiments; mean +/- standard error of the mean 
displayed; differences between means compared by one-way ANOVA test. D. Human monocyte 
derived macrophages were differentiated in culture. Surface staining was performed on two donors 
following 24 hours treatment with DMSO or I-BET151. Plots show representative histograms and 
mean +/- standard error of the mean of geometric mean fluorescence for CD16 (a) and CD32A (b). 
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Our in vitro studies and transcriptomic analyses suggest that I-BET inhibits both activatory and 
inhibitory FcγR. The relative effect on different receptors may influence the activatory to inhibitory 
(A/I) ratio which determines the activatory threshold of cells. We also looked at the expression of 
FcγR on splenocytes in mice treated systemically with I-BET for a period of 3 days (mice used in FITC 
paint experiments in chapter 5). There was no change in the expression of FcγRIIb, the only FcγR 
expressed on B cells. However, in mononuclear phagocytes, we detected a significant reduction in 
combined CD16 and CD32 staining with only a marginal effect on CD32b, suggesting a greater effect 
on activatory FcγR expression, shifting the A/I ratio towards a less inflammatory state (Figure 65). 
 
Figure 65: In vivo treatment with I-BET for 3 days results in decreased FcγR expression on splenic B 
cells, DCs and macrophages. Plots show geometric mean fluorescence intensity for 24G2 antibody 
which binds to a common epitope on CD16 and CD32 (CD16/32) (A) and CD32A (B) with 
representative histograms. Data from four independent experiments; points represent individual 
mice; median values compared using mann whitney tests. NS p>0.05; *p<0.05; ***p<0.001. 
 
4.3.3 I-BET151 leads to accumulation of phagocytic material within MNP 
We hypothesised that I-BET151 treatment would inhibit Fc-mediated phagocytosis. However, we 
observed increased phagocytic material within cells treated with I-BET151 at a 16-24 hour time 
point, as evidenced by a significantly increased geometric mean fluorescence for OVA 647 and an 
increase in phagocytic index (Figure 66). This effect on phagocytosis was concentration dependent 
(Figure 66B). A similar result was seen with OVA alone suggesting that the effect of I-BET151 on 
antigen internalisation may not be specific to FcγR mediated phagocytosis but may be due to more 
generalised effects on endocytosis. 
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Figure 66: I-BET151 increases phagocytic material within cells at a late time point in a concentration 
dependent manner. Murine BMDM were stimulated with OVA or OVA-IC in the presence of absence 
of I-BET151. Panel A shows the results of five independent experiments. Geometric mean 
fluorescence of OVA 647 has been normalised to average reading in DMSO treated OVA replicates to 
allow comparison between individual experiments. Differences between means significant by student 
t tests. Panel B shows a single experiment where cells were stimulated for 24 hours. Differences 
between means significant by one way ANOVA test. NS p>0.05; *p<0.05; ***p<0.001; ****p<0.0001. 
 
The increase in phagocytic material within cells treated with I-BET151 compared to DMSO only 
became apparent at later time points, with the phagocytic index separating two hours after OVA-IC 
uptake. This suggests that I-BET151 effects the processing and degradation of material rather than 
its uptake (Figure 67A). A similar pattern was seen when cells were fed immune complexes of DQ-
OVA, a conjugate that only fluoresces following proteolytic degradation. I-BET151 caused an 
increase in the degradation products within phagocytic cells in a dose dependent manner, 
suggesting an impact in processing after the point at which DQ-OVA degradation products produce 
fluorescence (Figure 67B, 68). The action of I-BET was opposite to the effect of increasing the 
activation of cells by knocking out the inhibitory FcγRIIb receptor (Figure 68). Mice lacking FcγRIIb 
had lower levels of DQ degradation products within cells at a late timepoint compared to wildtype 
mice, likely due to more rapid clearance. I-BET treatment increased accumulation of DQ degradation 






Figure 67: I-BET151 leads to defect in the clearance of proteolytically cleaved phagocytic material 
within cells. Murine BMDM were stimulated with IC in the presence or absence of I-BET151.  IC 
present within cells was measured at various time points (results from 4 independent experiments 
shown). B) Immune complexes were made from DQ-OVA, a protein that only upon proteolytic 
digestion releases fragments that exhibit fluorescence. I-BET151 causes an accumulation of degraded 
immune complex (results from single representative experiment shown). 
 
 
Figure 68. Murine bone marrow derived dendritic cells derived from FcγRIIb-/- and wildtype mice 
were stimulated for 12 hours with IC made from DQ-OVA (DQ-IC) or DQ-OVA control (DQ-O) in the 
presence or absence of I-BET 3.3µM.  
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Results from single experiment; Mean +/- standard error of the mean displayed; means compared 
using unpaired t test (NS p>0.05; *p<0.05; **p<0.01).  
 
The effect of I-BET on phagocytosis is not limited to immune complexes. I-BET caused an increase in 
the presence of apoptotic cell debris within macrophages at a four hour time point (Figure 69). 
 
 
Figure 69: I-BET151 has similar effect on macrophage phagocytosis of apoptotic cells. Murine 
thymocytes labelled with cell tracker orange and rendered apoptotic by dexamethasone treatment 
were fed to murine BMDM that had been pre-treated for 17 hours with DMSO or I-BET151 0.5µM 
and phagocytosis was measured by confocal microscopy (A) and flow cytometry (B) 4 hours later. 
Phagocytic macrophages shown as percentage of F4/80 positive live cells. Means compared with 
unpaired student t tests (NS p>0.05; *p<0.05). 
4.3.4 I-BET151 delays phagosome maturation 
In order to further explore the effects of I-BET151 on phagocytosed antigen, we investigated the 
kinetics of phagosome maturation by staining cells for early and late endosome and lysosome 
markers (Figure 70). At early time points there was no difference in the co-localisation of the early 
endosome marker RAB5 with IC between control and I-BET151 treated cells. At later time points 
there was loss of RAB5 staining in DMSO treated cells and loss of co-localisation with vesicles 
containing IC, however in I-BET151 treated cells there was retained RAB5 co-localisation with IC 
containing vesicles. Similar results were seen at a late time point with EEA1, another marker of early 
endosomes. Both DMSO and I-BET151 treated macrophages show co-localisation of IC with RAB7, a 
marker of late endosomes at an early time point. At later time points, DMSO treated cells had 
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reduced RAB7 staining with limited co-localisation with IC whereas I-BET151 treated cells retain 
RAB7 with ongoing co-localisation with IC, suggesting a delay in phagolysosome maturation. I-
BET151 treated cells do acquire LAMP1, a marker of mature lysosomes, at later timepoints so there 








Figure 70: I-BET151 delays phagosome maturation. Murine 
BMDM were adhered to cover slips and treated with DMSO or 
I-BET151 2.5µM for 15hours prior to IC addition. Cells were 
fixed at defined time periods following addition of IC and 
stained for Rab5, EEA1, Rab7. Staining for LAMP1 was done in 
different experiment where I-BET 3.3µM was used. Rab5, a 
Rab7, EEA1, LAMP1 (red) as labelled. Phalloidin (white) was 




4.3.5 I-BET selectively inhibits cytokine production in response to IC stimulation 
GSEA demonstrated that I-BET significantly down-regulated IC-induced enrichment of genes involved 
in cytokine-cytokine receptor interactions (Figure 60). Numerous chemokine and cytokine genes 
were induced by FcγR crosslinking and inhibited by I-BET (Figure 71A). To further assess the impact 
of I-BET on IC-induced cytokine and chemokine production, we used a multiplex cytokine analysis kit 
to test supernatants obtained from macrophage cultures. MCP3, also known as CCL7 is a chemokine 
that attracts monocytes to sites of inflammation. It binds to the chemokine receptors CCR1, 2, and 3. 
I-BET151 inhibits the OVA-IC induced increase in MCP3 transcript in BMDM in a concentration 
dependent manner (Figure 71Bi). As with LPS stimulation (Nicodeme 2010), there was no effect on 
TNFα production (Figure 71Bii). Cytokine analysis on the supernatants from one experiment showed 
a trend towards a reduction in IC-induced IL10 and KC/Gro production with I-BET treatment (Figure 
71Biii-iv). IL6 was not detectable in the supernatants from BMDM treated with IC (data not shown); 
however Il6 RNA was measurable by qPCR. We observed a rise in Il6 transcripts one hour following 
FcγR crosslinking in the absence of I-BET; with inhibition of the response to baseline levels with the 
addition of I-BET (Figure 71Bv). A similar trend was seen in RNA extracted 4 hours following 
stimulation. Treatment of BMDC with I-BET151 throughout a period of immune complex stimulation, 







Figure 71: I-BET151 selectively inhibits cytokine release in response to immune complex stimulation. 
A Heat map showing cytokine genes most impacted by I-BET. Murine BMDM were stimulated in the 
labelled conditions and RNA extracted for transcriptomic analysis following 4 hours stimulation. 
Genes ranked by log fold change of the difference of the difference ((IC.D vs O.D) minus (IC.I vs O.I)) 
representing the effect of I-BET on the effect of IC stimulation; the p value demonstrated refers to the 
diff comparison, showing genes for which I-BET significantly impacts on the effect of OVA-IC. Bi-iv), 
immune complexed OVA (OVAIC) or LPS in the presence of I-BET151 or DMSO for 24 hours. 
Supernatants were collected and stated cytokines assayed via ELISA (i-ii; results from three 
independent experiments) or MesoScale Discovery Multiplex Assay (iii-iv; single experiment). iv) RNA 
was extracted from BMDM stimulated for the documented times and Il6 transcript levels quantified 
by qPCR. C: Murine bone marrow derived dendritic cells were treated with I-BET151 or DMSO for one 
hour prior to or throughout IC stimulation. Supernatants were collected and stated cytokines assayed 
via ELISA (results from four independent experiments). P values calculated by one way ANOVA (Ai) or 
student t test (other). NS p>0.05; *p<0.05; **p<0.01. 
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4.3.6 Failure to induce accelerated nephrotoxic nephritis without the use of IP CFA 
In order to determine the effect of I-BET151 on an in vivo model of IC-mediated inflammation, we 
sought to establish the nephrotoxic nephritis model. In this model of IC-mediated 
glomerulonephritis, sheep are immunised with ground up mouse glomeruli and their serum 
harvested following the development of sheep anti-mouse glomeruli antibodies. Mice are pre-
sensitised with an IP injection of sheep IgG mixed with CFA and produce anti-sheep IgG antibodies. 
When mice are subsequently given IV nephrotoxic serum, sheep anti-mouse glomerular antibodies 
deposit in glomeruli forming IC with preformed anti-sheep IgG results in a glomerulonephritis (Figure 
72). 
 
Figure 72: Established model of accelerated nephrotoxic nephritis 
There are increasing regulations surrounding the use of CFA and under the terms of our home office 
animal licence we are unable to give CFA via the IP route. I therefore attempted to adapt the 
established model by substituting IP CFA for subcutaneous (SC) CFA. Despite the use of increasing 
doses of nephrotoxic serum, mice developed only minimal proteinuria (Figure 73a, c), had normal 
blood urea nitrogen values (Figure 73b) and no histological features of established 
glomerulonephritis. Mice deficient in FcγRIIb are known to be more susceptible to accelerated 
nephrotoxic nephritis. We therefore attempted to induce disease in mice with one null allele for 
FcγRIIb that show intermediate expression of the inhibitory receptor. Although a number of these 
mice developed greater amounts of proteinuria compared to wild type mice (Figure 73d), there was 
still no glomerulonephritis evident on histological examination. An experienced histopathologist 
found one lesion consistent with non-specific focal segmental glomerulosclerosis in one mouse but 










Figure 73: Attempts to induce accelerated nephrotoxic nephritis. Female C57BL/6 mice were given an 
IV tail injection of sheep anti-mouse glomerular basement membrane five days following SC injection 
of sheep IgG in CFA. They were monitored for weight loss (a) and proteinuria (c) and sacrificed 14-15 
days following initial CFA injection with collection of blood for urea measurement (b) and urine for 
proteinuria quantification by albumin creatinine ratio (ACR) (d). 
 
Concerned that the mice were not developing sufficient anti-sheep IgG due to the absence of CFA, 
we decided to boost the immune response prior to giving nephrotoxic serum by the use of an IP 
injection of Incomplete Freund’s Adjuvant (IFA) seven days following initial SC sheep IgG/CFA. 
Unfortunately these mice developed anaphylaxis minutes following injection of nephrotoxic serum 
so the experiment was terminated (Figure 74). We therefore sought alternative models to assess the 
effects of I-BET on FcγR-mediated macrophage activation in vivo. 
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Figure 74: Boosting sensitisation to Sheep IgG resulted in anaphylaxis on subsequent injection of anti-
mouse glomerular sheep serum extract. 
 
4.3.7 I-BET reduces spleen size following immune complex peritonitis and leads to accumulation of 
phagocytosed IC in vivo  
In order to assess the impact of I-BET on the immune complex mediated pathology in vivo we 
studied two alternative models. Firstly, we used a model of immune complex peritonitis, enabling us 
to study acute neutrophil recruitment and also assess the phagocytic properties of infiltrating 
immune cells (Figure 75) 
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Figure 75: Experimental procedure (A) and gating strategy (B) for an intraperitoneal immune 
complex peritonitis model. Mice were given immune complexed OVA or OVA control by 
intraperitoneal injection and culled 6 hours later with peritoneal lavage for quantification of 
inflammatory cell recruitment and assessment of phagocytosis. 
We observed a trend towards increased spleen size in control mice treated with intraperitoneal 
immune complex; I-BET treated mice had smaller spleens that DMSO treated mice receiving the 
same stimulus (Figure 76A). Within the peritoneal exudate there was a significant increase in 
neutrophils following immune complex instillation compared to OVA control. There were trends 
towards reduced cell recruitment in I-BET treated animals but these did not reach statistical 
significance (Figure 76B). Neutrophils (Figure 76C), macrophages (Figure 76D) and dendritic cells 
(Figure 76E) phagocytosed variable amounts of immune complexed and soluble OVA. There were no 
differences in any of these subsets in the proportion of cells containing phagocytosed material at 
four hours, however mirroring our in vitro findings, macrophages from animals treated with I-BET 
contained more phagocytosed OVA and OVA-IC. Neutrophils were able to phagocytose OVA-IC but 
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Figure 76: I-BET treated phagocytes accumulate immune-complexed and soluble antigen in vivo. 
Spleen weight (A), peritoneal lavage cell composition (B), OVA-647 uptake in neutrophils (C), 
macrophages (D) and dendritic cells (E). For each population, the percentage of cells containing 
phagocytosed OVA is reported along with the geometric mean fluorescence for OVA-647, phagocytic 
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OVA fluorescence. Mann-Whitney tests are used to compare medians (NS p>0.05; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001). Results from three independent experiments; relative values are 
reported where the combining values from independent experiments directly was not possible due to 
interexperimental variation in OVA fluorescence.  
4.3.8 I-BET reduces recruitment of mononuclear phagocytes to the kidney and reduces pro-
inflammatory gene expression in response to circulating immune complex 
We utilised an intravenous immune complex model in order to investigate the response of kidney 
resident mononuclear phagocytes to circulating immune complex, as used previously (Stamatiades 
2016) (Figure 77). The experiment was repeated twice; on the first occasion the kidneys were 
flushed with cold PBS prior to harvest to remove intravascular cells, in the second experiment 
intravascular labelling of CD45+ cells was used. The results in both experiments were similar; pooled 
data is shown with the individual data points coloured according to whether intravascular labelling 
was used.   
Mice treated with I-BET showed a trend towards reduced neutrophil recruitment one hour following 
injection of circulating immune complex (Figure 77A). CX3CR1 positive tissue resident MNPs can be 
classified according to their MHCII and Ly6C staining which has been described as a ‘waterfall’ 
(Tamoutounour 2012); newly extravasated cells express Ly6C but low levels of MHC II and those that 
have been present for longer, ‘mature’ tissue resident MNP, lose their Ly6C expression and acquire 
MHCII. I-BET treated mice had a more mature mononuclear phagocyte composition, with a lower 
proportion and number of newly extravasated and intermediate MNPs compared to solvent treated 



























Figure 77.  Experimental procedure for an intravenous immune complex model (A). Experiment 
performed twice; on the second occasion mice were given an intravenous injection of CD45 
immediately prior to schedule one to label intravascular cells. B. Representative gating strategy used 
in the second experiment. 
Alternatively, tissue resident MNPs can be classified into subsets 1 to 4 according to their CD11b and 
F4/80 expression (Berry 2017) (Figure 78D). The MNP1 subset of F4/80hi CD11bint cells expresses high 
levels of CD11c, MHC II, CX3CR1 and Clec9A, largely consistent with a cDC phenotype. These cells 
may either be mature and well-differentiated tissue-resident macrophages or DCs originally of 
monocyte origin, or perhaps derived from an embryonic precursor. The MNP2 subgroup of CD11bhi 
F4/80int cells are a heterogeneous group that may reflect different maturational states of 



















































The MNP3 subgroup express MHC II, CD11b and CD103, and represent monocyte-derived 
macrophages with low level F4/80 expression. These cells correlate broadly with newly extravasated 
Ly6Chi MHClo monocyte population in the waterfall gating schema. I-BET treated animals had an 
increase in F4/80 bright tissue resident MNP1 subset, with a reduction in the number of CD11b 
positive MNP2 and 3 subset tissue resident MNPs (Figure 78D); in keeping with the observations 
seen using alternative gating. The reduced influx of newly extravasated monocytes following I-BET 
treatment was associated with a reduction in the transcription of pro-inflammatory genes on FcγR 











Figure 78: I-BET reduces recruitment of mononuclear phagocytes to the kidney and reduces pro-
inflammatory gene expression in response to soluble immune complex. Representative plots and 
summary data showing neutrophil recruitment (A), DC (B), MNP classified according to MHCII and 
Ly6C expression (C), and CD11b and F4/80 expression (D). E. qPCR in total kidney tissue for Il1β (i), 
Tnfα (ii) and Il6 (iii). Results from two independent experiments; data points coloured according to 
experiment; Mann-Whitney tests used to compare medians (NS p>0.05; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001). Median with interquartile range shown in C; statistics not performed on 







Given the effect of I-BET on MNP inflammatory responses to LPS, we hypothesised that I-BET may 
inhibit macrophage and DC activation by IgG, thus reducing antibody-mediated inflammation. Here 
we show I-BET inhibits the expression of many genes induced by FcγR crosslinking in murine BMDM, 
including genes involved in immune pathways identified by gene set enrichment analysis, such as 
TNFα signalling via NFκB, IFNα and IFNγ signalling, cytokine-chemokine signalling, cell adhesion 
pathways and antigen presentation. We also identified similarities in the effect of I-BET on IC-
mediated gene expression to that observed in LPS simulated macrophages treated with I-BET 
(Nicodeme 2010); many of the LPS inducible genes significantly suppressed by I-BET were also 
induced by IC and similarly suppressed by I-BET, giving further evidence for a potential role for I-BET 
in the treatment of autoantibody-mediated disease.  
Current therapies for antibody-mediated autoimmune diseases are imperfect, with treatment-
resistance and frequent disease relapse. There are established therapies that inhibit autoantibody 
production, principally by depleting or inhibiting B cells, but few treatments that modulate MNP 
responses to IC. Our data show that I-BET reduced FcγR expression on macrophages and dendritic 
cells, potentially lowering their capacity to respond to IC. We identified reduced expression of both 
activatory and inhibitory FcγR in vitro, however in vivo studies suggested a greater effect on 
activatory receptors leading to a reduction in the A/I ratio and an increase in the activation threshold 
of MNPs encountering IgG immune complexes. This would suggest that even if autoantibodies were 
present, in the presence of I-BET, they may not cause inflammation due to this change in activation 
threshold. Of note, the A/I ratio is also known to determine Fcγ receptor-facilitated T cell activation 
by dendritic cells (van Montfoort 2012). 
Furthermore, we show that I-BET leads to altered macrophage phagocytosis, with accumulation of 
phagocytosed IC and degradation products within cells associated with reduced inflammatory 
cytokine production. This would potentially promote non-inflammatory clearance of ICs by tissue-
resident cells, again of benefit therapeutically. 
Bromodomain inhibitors have been shown to have marked anti-inflammatory effects in numerous in 
vivo models, and have been associated with protection from autoimmune and inflammatory disease 
(Nicodeme 2010, Bandukwala 2012, Belkina 2013, Mele 2013, Brown 2014, Fu 2014, Meng 2014, 
Zhang 2015). The cellular mechanisms and immunological pathways mediating these anti-
inflammatory effects are likely to be multifactorial and individual studies have focussed on different 
aspects of the immune response. In an adoptive transfer model of EAE, treatment with I-BET762 
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inhibited the ability of antigen-specific T cells, differentiated under Th1 but not Th17 conditions in 
vitro, to induce pathogenesis with reduced recruitment of macrophages consistent with decreased 
GM-CSF production by central nervous system infiltrating T cells (Bandukwala 2012). In a different 
study, inhibition of EAE and CIA was attributed to inhibition of Th17 mediated pathology (Mele 
2013). Zhang et al. also showed JQ1 associated amelioration of CIA but attributed reduced joint 
inflammation and damage to effects on fibroblast-like synoviocytes, showing BRD4 silencing 
associated reductions in pro-inflammatory cytokine production from TNF-α stimulated rheumatoid 
arthritis fibroblast-like synoviocytes associated with reduced migration and invasion behaviour 
(Zhang 2015). Bromodomain inhibitors reduce levels of proinflammatory cytokines, protecting mice 
from endotoxin induced death and sepsis (Nicodeme 2010, Belkina 2013) and reduce the 
inflammatory response and bone destruction in experimental periodontitis (Meng 2014). JQ1 
treatment inhibited the immune complex-mediated activation of human monocytes in vitro and 
attenuated murine lupus development in vivo, increasing survival in MRL-lpr mice, reducing serum 
concentrations of BAFF, IL1β, IL6, IL17, and IFNγ and augmenting IL10 (Wei 2015). Reductions in 
BAFF and IL6 levels alongside increased IL10 were also seen following in vitro culture of murine 
splenocytes and human monocytes stimulated with IC, bringing into question whether the effects of 
bromodomain inhibition may overlap with those of belimumab. Furthermore, the effects of 
bromodomain inhibition are not limited to immune cells; inhibition of type one diabetes was shown 
to be due to a dual effect inducing an anti-inflammatory phenotype in pancreatic macrophages 
mediated via effects on NFκB target genes and eliciting regeneration of pancreatic beta cells, with 
minimal effect on the transcriptome of CD4+ T cells infiltrating the pancreas and within draining 
lymph nodes (Fu 2014).   
The capacity of bromodomain inhibitors to supress the macrophage inflammatory response to TLR4 
stimulation is well established (Nicodeme 2010, Belkina 2013) and thought to occur due to 
remodelling of the enhancer landscape, with development of thousands of de novo enhancers. Many 
of these enhancers reside in super-enhancer regions, with loss of a subset of pre-existing enhancers 
(Kaikkonen 2013). Transcription of super-enhancer associated RNAs is dynamically induced at most 
of the key genes driving innate immunity and inflammation (Hah 2015). The selectivity of I-BET for 
pro-inflammatory genes is thought to arise from inhibition of NF-κB directed reorganisation of 
super-enhancers leading to suppressed super-enhancer dependent proinflammatory gene 
transcription (Brown 2014), a process of regulation distinct from that which coordinates constitutive 
expression of housekeeping genes. 
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The redistribution of super-enhancers is not limited to TLR4 stimuli and has been described following 
a wide variety of stimuli in human macrophages. GM-CSF stimulated monocytes were incubated 
with IFNγ (acute inflammation model), IL4 (alternative acute inflammation model) or a combination 
of TNF, prostaglandin E2 and Pam3CyS (chronic inflammation model) for 72 hours prior to 
assessment of histone modifications by CHIP-seq (Schmidt 2016). Schmidt and colleagues defined a 
transcriptional and epigenetic regulator network distinct to human inflammation associated 
macrophage activation that was distinct from the network seen in human somatic tissues and 
murine tissue resident macrophages. The inflammation associated network was characterised by a 
more globally permissive histone modification state, with both common and stimulus specific 
regulatory elements. 
Epigenetic modifications induced by FcγR crosslinking have also been described. Chromatin 
remodelling of the Il10 promotor locus is responsible for inducing high levels of IL-10 secretion by 
macrophages stimulated in the presence of immune complexes. FcγR crosslinking results in rapid 
and enhanced activation of two MAPKs, ERK and p38. Activation of ERK leads to the phosphorylation 
of serine 10 on histone H3 at the Il10 gene, making the promoter more accessible to transcription 
factors generated in response to p38 activation. Immune complex stimulation alone was sufficient to 
activate ERK, modifying the Il10 locus to make it more accessible; however additional TLR signals 
from the addition of LPS were required to activate transcription factors that bind to the Il10 
promotor, increasing IL10 production (Lucas 2005). The chromatin precipitation studies used in this 
study only allow detection of phosphorylation and acetylation at specified gene loci of interest (the 
Sp1 and STAT3 binding regions of the Il10 promotor in addition to a control region and the IL-12p40 
promotor). It is likely that FcγR crosslinking induces more widespread epigenetic changes, which may 
influence the subsequent immune response and determine susceptibility to modulation by drugs 
including bromodomain inhibitors. Such changes might significantly influence the activation of 
macrophages by subsequent stimuli, so called trained immunity (Cheng 2014, Saeed 2014). We 
therefore propose a more comprehensive study of the epigenetic changes induced by FcγR 
crosslinking, detailed in chapter 6, and wish to determine which of these changes are impacted by I-
BET.  
The vast majority of single nucleotide polymorphisms (SNPs) associated with disease susceptibility in 
autoimmune disease in genome wide association studies (GWAS) are found in non-coding regions of 
the genome, localising preferentially within gene regulatory regions in immune cells (Farh 2015). 
Aberrant regulation of immune responses due to dysregulated gene expression may underpin 
susceptibility to autoimmune disease. Interactions between genetic susceptibility and epigenetic 
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changes caused by environmental factors may be responsible for inducing autoimmune disease. 
Processes controlling epigenetic modifications, superenhancer remodelling and the regulation of 
gene expression may offer new therapeutic targets, with potential to signpost inflammation 
associated targets (Tough 2017) 
Our work suggests that I-BET inhibits the immune complex associated macrophage inflammatory 
response, similarly to its known effect on LPS driven inflammation. FcγR crosslinking induces multiple 
changes in gene expression in macrophages, impacting a number of inflammation associated 
pathways. We show that I-BET treatment alters the expression of FcγR, potentially modifying the A/I 
ratio and threshold for cell activation. Changes in the cytokine milieu are known to differentially 
effect FcγR expression (Liu 2005). The degree of change in expression of activatory and inhibitory 
receptors varied across our experiments with a reduced A/I ratio following I-BET treatment in vivo; 
perhaps due to additional indirect effects of altered cytokine expression. 
A more detailed analysis of the epigenetic changes induced is required to fully understand I-BET 
targeting; however given the large number of inflammation associated genes impacted it is likely to 
involve reorganisation of super-enhancers. Our in vivo models further support the hypothesis that 
bromodomain inhibition may be of benefit in the setting of antibody mediated disease. Following 
administration of intravenous immune complex, I-BET treated animals recruited fewer newly 
extravasated monocytes to their kidneys compared to solvent treated controls, associated with a 
reduction in the transcription of pro-inflammatory genes. This suggests that I-BET may attenuate the 
immune response to deposited immune complex, for example in SLE or in the setting of donor 
specific antibody following renal transplantation, and may be a useful therapeutic tool alongside 
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Chapter 5: Bromodomain protein inhibitors modulate FcγR-mediated DC migration, suggesting 
therapeutic potential in immune complex-mediated disease  
5.1 Chapter summary 
Here, we explored the potential of BET protein inhibitors to limit FcγR-mediated DC activation and 
migration.  We show that I-BET reduced the upregulation of many genes in MNP following IgG IC 
stimulation, including those associated with DC maturation and antigen presentation. We also 
observed a reduction in activating FcγR expression on I-BET treated DCs, reducing their susceptibility 
to IgG-mediated activation. I-BET treatment changed MNP morphology and resulted in a less 
adherent phenotype, prompting an assessment of its impact on DC migration. In vitro, in a 3D 
collagen matrix, IgG-IC induced augmentation of DC chemotaxis to CCL19 was abrogated by the 
addition of I-BET. In keeping with this, we observed that I-BET treatment inhibited the upregulation 
of CCR7 associated with FcγR cross-linking. In vivo, two photon imaging showed that systemic I-BET 
treatment reduced IC-induced dermal DC mobilisation. These tissue DCs also had reduced migration 
to draining lymph nodes. We confirmed a DC-intrinsic effect on IgG IC-induced migration by 
transferring I-BET-treated DCs into the skin and tracking their subsequent trafficking to lymph nodes. 
Together, our data confirm that I-BET has a substantial impact on FcγR-mediated DC activation and 
migration, and highlight the therapeutic potential of bromodomain protein inhibitors in antibody-




Almost all tissues contain a network of DCs, poised to detect and respond to local immune 
challenges, including deposited IgG IC. DCs act as important antigen presenting cells that may 
activate CD4 T cells, and determine whether these cells become tolerogenic or immunogenic 
(Banchereau 1998, Steinman 2012). This fate decision is dependent on the presence of co-
stimulatory signals present on mature DCs (Hawiger 2001, Steinman 2003). DC maturation may be 
driven by stimuli such as TLR ligation and by activating FcγR cross-linking (Roake 1995, Reis e Sousa 
2006). In addition to a requirement for maturation, tissue-resident DCs must be geographically re-
located from peripheral tissues to lymph nodes to permit interactions with T cells (Sallusto 1998, 
Cyster 1999, Forster 1999, Randolph 2005). Most DCs enter tissues via the lymphatic vessels that 
drain peripheral tissues. The processes that govern this migratory pathway are therefore key 
regulators of the induction of immune responses. Central to DC migration is the expression of the 
chemokine receptor CCR7 and its interaction with CCL19 and CCL21, chemokines expressed by 
lymphatic endothelial cells that guide DCs to the T cell zone of lymph nodes (Sallusto 1998, Forster 
1999). Other factors that facilitate this process include the production of MMPs, particularly MMP-2 
and MMP-9 (Ratzinger 2002, Yen 2008), that allow movement through the extracellular matrix and 
across basement membranes. Indeed, pharmacological inhibition (Lebre 1999), antibody 
neutralization (Kobayashi 1999), or genetic deletion of MMPs (Ratzinger 2002, Ichiyasu 2004, Yen 
2008) reduces DC migration.  
Of note, abnormalities in monocytes and DCs have been observed in patients with SLE (Blanco 2001, 
Decker 2006, Ding 2006, Crispin 2012) and engagement of activating FcγRs on tissue DCs by 
autoantibody-containing IC in SLE leads to the upregulation of CCR7, and stimulates DC migration to 
draining lymph nodes (Clatworthy 2014a). Furthermore, the lupus-associated polymorphism in 
human FCGR2B (rs1050501) (Willcocks 2010) that results in receptor dysfunction (Floto 2005, Kono 
2005), is associated with increased CCR7 expression on DCs following IgG IC stimulation (Clatworthy 
2014a), driving enhanced migration to the T cell zone of lymph nodes, propagating autoimmunity 
and inflammation. Therefore, IgG IC-driven DCs migration may represent a useful therapeutic target 
in autoimmune diseases.   
DC activation by IgG IC requires substantial changes in gene expression (Dhodapkar 2007). 
Bromodomain inhibition with JQ1 is known to inhibit LPS-induced STAT5-dependent DC maturation 
(Toniolo 2015), leading to reduced co-stimulatory molecule expression and IL12 production, and 
decreased ability of DC to induce T cell proliferation in an allogeneic system. Here, we explored the 




5.3.1 I-BET alters mononuclear phagocyte morphology and adhesion  
We noted that compared to BMDM treated with DMSO in vitro, those treated with I-BET tended to 
float, being less adherent to tissue culture plastic, with more cells noted to float in the culture 
supernatant when examined via light microscopy. Analysis of these cells using a viability strain 
showed that similar proportions were alive compared to adherent cells treated with DMSO alone 
(Figure 79). 
Figure 79: I-BET151 does not affect viability at 
concentrations up to 5µM. BMDM were 
treated with DMSO or I-BET151 for 16-24 
hours, prior to assessment of viability using 
Live Dead Aqua viability dye. Results 
combined from three independent 
experiments; p value calculated using one 
way ANOVA test 
Examination of BMDM treated with I-BET151 using confocal microscopy, staining the actin 
cytoskeleton with phalloidin, revealed changes in cell morphology consisted with the observation of 
decreased adherence to cell culture plates. I-BET treated cells appeared more rounded and were less 







Figure 80: I-BET causes rounding of BMDM. Representative images of BMDM treated with DMSO (A) 
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Treatment with I-BET151 at a concentration of 5µM for 14 or 24 hours significantly reduced the 
adhesion of BMDM in vitro (Figure 81A, B). Fewer cells were adherent to cover slips following 
treatment, shown by significantly reduced numbers of cell nuclei per high power field examined 
(Figure 81Aiv; Biv). Cells were smaller in surface area and volume and more rounded in appearance, 
demonstrating increased sphericity (Figure 81Av-vii; Bv-vii). Phalloidin stains F-actin and can hence 
be used to image the actin cytoskeleton of cells. With increasing concentrations of I-BET151, there 
was a reduction in the actin contacts made with cover slips, with less dense phalloidin staining 
shown on maximum projection imaging. Treatment with DMSO alone induced some changes in cell 
morphology. Cells treated for only one hour and then given DMSO free media for 23 hours prior to 
fixation had greater phalloidin staining with clear demonstration of actin around each nucleus 
(Figure 81Ci). Treatment for one hour with I-BET151 at a concentration of 1µM or 5µM was 
sufficient to induce changes in adhesion, with reduced cell nuclei and phalloidin stain volume per 
high power field (Figure 81Civ-v), with no apparent change in average cell volume (Figure 81Cvi). 
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Figure 81: I-BET reduces adhesion of BMDM. BMDM were allowed to stick down to cover slips then 
treated with DMSO (i), I-BET151 1µM (i) or I-BET151 5 µM (iii) for 24 hours (A) or 14 hours (B), fixed, 
stained with phalloidin 568 (red) and DAPI (green) and imaged by confocal microscopy (maximum 
projection images shown). In C, DMSO (i), I-BET151 1µM (i) or I-BET151 5 µM (iii) were present for 
only the first hour of 24 hour culture. Adhesion was quantified by counting the number of nuclei per 
high power field (iv). Morphology was quantified by cell surface area (Av; Bv), cell volume (Avi; Bvi) 
and cell sphericity (Avii; Bvii). In C, a high proportion of overlapping cells made it difficult to add 
surfaces to individual cells, so the phalloidin volume per high power field was quantified as a 
measure of cell volume (Cv); average cell volume was calculated by dividing the phalloidin cell 
volume by the number of nuclei per high power field (Cvi). Five high power fields imaged per 
condition; means compared using unpaired student t tests (NS p>0.05; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001). 
We were interested in whether this observation of decreased mononuclear phagocyte adhesion 
would impair the ability of dendritic cells to migrate, a process dependent on adhesion molecule 
expression. We confirmed that I-BET induced similar changes in cell morphology and adherence in 
bone marrow derived dendritic cells, with reduced cell surface area and volume, increased cell 
sphericity and reduced adhesion to tissue culture plastic (Figure 82).   
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Figure 82: I-BET reduces adhesion of BMDC. Representative images of bone marrow derived dendritic 
cells allowed to stick down to cover slips then treated with DMSO (A) or I-BET151 3.3µM (B) for 15 
hours fixed, stained with phalloidin 568 (white) and DAPI (blue) and imaged by confocal microscopy 
(x25 lens high power field maximum projection image with 50µm scale bar (i); magnified with 20µm 
scale bar in (ii)). Quantification of cells from 10 high power fields per condition was performed by 
applying surfaces using Imaris software (C) with quantification of number of cells per high power 
field (i), cell surface area (ii), cell volume (iii) and cell sphericity (iv). Means compared using unpaired 
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5.3.2 I-BET alters expression of genes involved in cell adhesion and migration 
Multiple gene pathways are involved in the process of DC adhesion and migration, including those 
coding for chemokine receptors and ligands, such as CCL19 and CCR7, matrix metalloproteinases, 
genes involved in prostaglandin and cysteinyl leukotriene signalling, adhesion molecules, and genes 
involved in regulation of the actin cytoskeleton, for example the Rac family of GTPases. We 
undertook transcriptomic analysis of BMDM treated with I-BET or DMSO control. Gene set 
enrichment analysis identified that I-BET treatment alone caused downregulation of multiple 
immune pathways including those involved in regulation of the actin cytoskeleton, leukocyte 
transendothelial migration and chemokine signalling pathways (Figure 83). Numerous chemokine 
receptors in additional to some chemokine ligands, were significantly downregulated following I-BET 
treatment (Figure 84)  
 
Figure 83: Gene set enrichment analysis of genes differentially expressed following the treatment of 
BMDM with I-BET for 4 hours, using Kegg pathway terms. Genes ranked based on 1/p value with sign 
of log fold change. Pathways filtered to show those with a FDR q value < 0.1. Normalised enrichment 




Figure 84: Heatmap showing differential expression of chemokine receptor (left) and ligand (right) 
genes following a 4 hour treatment with I-BET 
 
Numerous pathways implicated in DC migration were significantly affected by the addition of I-BET 
(Figure 85). Genes encoding the cysteinyl leukotriene receptor 1 and 2 (Cysltr1, Cysltr2), 
prostaglandin E receptor 2 (Ptger2), integrin subunit alpha 4 (Itga4), platelet-activating factor 
receptor (Ptafr), PI3K catalytic subunit gamma (Pik3cg) and dedicator of cytokinesis 8 (Dock8) were 
all significantly downregulated with I-BET treatment. Other genes with functions in DC migration also 
appeared to be downregulated with I-BET treatment, though didn’t reach statistical significance, for 
example genes encoding the small Rho family GTPases Cdc42, RhoA, Rac1 and Rac2, components of 
the Arp2/3 complex (Arpc2, Arpc5, Actr2, Actr4), integrin subunit beta 2 (Itgb2), Eps8, CCR7 and 
MMP9. Vinculin (Vcl) and adaptor related protein complex 1 associated regulatory protein (Ap1ar, a 







Figure 85: Heatmap showing differential expression of genes implicated in DC migration following a 4 
hour treatment with I-BET or DMSO 
173 
 
A further analysis was performed on BMDM treated with OVA or OVA-IC for four hours, in the 
presence or absence of I-BET (Figure 86). Ccr7 is upregulated by the addition of OVA-IC only in the 
absence of I-BET. The prostaglandin receptor genes (Ptger1, Ptger2 and Ptger4) appear to be 
downregulated in the presence of I-BET; prostaglandin signalling is known to be important for the 
induction of Mmp9, which also appears to be downregulated by I-BET. I-BET downregulated 
leukotriene receptor genes, critical for the leukotriene mediated induction of capacity for DC to 
migrate towards CCL19. Additionally, I-BET downregulates the expression of the Rac family of 
GTPases (Rac1 and Rac2) and the adhesion molecules integrin alpha 4 (Itga4), as well as both 
integrin beta 1 (Itgb1) and CD38 (Cd38), that are upregulated in response to FcγR crosslinking in the 
absence of I-BET. 
5.3.3 Effect of I-BET on CCR7 protein expression unclear 
We measured the expression of surface CCR7 on bone marrow derived dendritic cells using flow 
cytometry. We saw significant interexperiment variability; on some occasions I-BET clearly inhibited 
IC dependent CCR7 upregulation as suggested by the microarray analysis (Figure 87A upper panel 
results type A) whereas in others I-BET caused a concentration dependent increase in CCR7 
expression (Figure 87A lower panel results type B), irrespective of whether IC was added. Figure 87B 
shows summary data from multiple experiments. Overall there was a trend towards increased CCR7 
expression following I-BET treatment but this did not reach statistical significance. We queried 
whether the I-BET used may have been contaminated with LPS but variability was seen with fresh 





Figure 86: Heatmap showing differential expression of genes implicated in DC migration following a 4 
hour treatment with I-BET or DMSO plus OVA or immune complexed OVA. The p value demonstrated 
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Figure 87: Surface CCR7 expression measured by flow cytometry. A: results from two representative 
experiments showing the different trends seen. B: Summary data from 14 independent experiments; 
each individual point represents the mean of technical replicates (up to three) within each 
experimental. I-BET was used at a concentration of 3.3µM in all but two experiments where it was 
additionally used at a concentration of 1µM (displayed by a separate point). Stimulation overnight in 
all but two experiments where it was only four hours. Groups compared using Wilcoxon matched-
pairs signed rank test (NS p>0.05; **p<0.01).  
5.3.4 I-BET151 inhibits CCL19 guided migration in vitro 
Due to the changes seen in cell morphology and adhesion, we hypothesised that I-BET151 would 
impact cell migration, a process that is also dependent on actin polymerisation. Initially we 
quantified cell migration in a simple transwell migration assay (Figure 88). We observed variation 
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between assays in the proportion of cells migrating, with a trend towards reduced migration 
following I-BET treatment (Figure 88B). The effect of I-BET appeared more marked when cells were 
exposed to a chemokine gradient (Figure 88C).  
 
Figure 88: Effect of I-BET on a transwell migration assay. BMDC were stimulated for 24 hours with 
OVA-IC in the presence of DMSO or I-BET151. Following washing their migration was assessed in a 
transwell migration assay (A). B shows results from of four experiments (I-BET used at a 
concentration of between 1 and 5 µM).; p NS via Mann-Whitney test. C shows results from single 
experiment where cells were exposed to a gradient of CCL19 (nM). P values calculated Wilcoxon 
matched-pairs signed rank test (NS p>0.05; *p<0.05). 
Due to concerns regarding the simplicity of this assay and its relevance to migration in vivo, along 
with concerns regarding its reproducibility, we went on to quantify the migration of dendritic cells in 
a 3D collagen matrix. Bone marrow was collected from fluorescently tagged reporter mice and 
differentiated into dendritic cells in vitro according to our standard protocol. Cells were treated with 
OVA-IC in the presence of DMSO or I-BET, then loaded into a collagen gel, which was allowed to set 
within an Ibidi® µ-Slide chemotaxis slide. Cell migration was imaged using time lapse confocal 
microscopy and cell movement tracked by applying surfaces to the images using Imaris image 
analysis software (Figure 89). FcγR crosslinking in the absence of I-BET led to an increase in CCL19 
guided chemotaxis with increased forward migration parallel to the chemokine gradient and 
increased track displacement. I-BET treatment appeared to dampen chemokine directed movement, 
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with trends suggesting reduced deviation of the average cell centre of mass, reduced average 
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Figure 89: An in vitro model of CCL19 guided migration. Bone marrow derived dendritic cells were 
stimulated for 24 hours with OVA-IC in the presence of DMSO or I-BET151 (3.3µM). Following 
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washing their migration was assessed in a 3D collagen matrix (A). B shows representative images 
following migration for 2 hours 43min (left) and the migration tracks of individual cells from two 
independent experiments (right), tracked using surfaces within Imaris image analysis software and 
plotted using the Ibidi Chemotaxis and Migration tool. Red tracks indicate cells with a negative final 
displacement in the x axis plane. I) DMSO treated cells in the absence of a chemokine gradient; ii) 
DMSO treated cells in the presence of a chemokine gradient; iii) I-BET treated cells in the presence of 
a chemokine gradient. The average centre of mass (C) and forward migration index parallel and 
perpendicular to the chemokine gradient (D) were calculated for the labelled conditions. 
Quantification of forward migration in the direction parallel to the chemokine gradient (E) and 
perpendicular to the chemokine gradient (F), track displacement length (G) and mean track speed 
(H). Results combined from of two independent experiments; red line indicates mean; p values 
calculated using unpaired student t tests (NS p>0.05; **p<0.01; ****p<0.0001).  
The Ibidi® µ-Slide chemotaxis slide allows concurrent imaging of three windows containing a collagen 
gel and therefore three chemokine gradients. We further optimised the assay by combining cells 
derived from two differently labelled fluorescent mice (Figure 90). This allowed us to test the 
migration of DMSO and I-BET treated cells, each with a different fluorescent tag within the same 
collagen matrix. Inconsistencies in the setting of collagen can affect the ease with which a cell can 
migrate through the gel; the optimisation therefore not only doubled the number of conditions that 
we were able to test in a single experiment, but also had the additional benefit of removing any 
inconsistencies related to the collagen itself, since cells were exposed to the same collagen matrix.  
In the absence of a chemokine gradient (Figure 90B), I-BET treated cells displayed increased random 
movement with increased track displacement, total track length and speed. However, chemokine 
directed migration (Figure 90C), was impeded in the presence of I-BET, demonstrated by reduced 
displacement of the average centre of mass (Figure 90D), reduced track displacement parallel to the 
chemokine gradient (Figure 90F), with a trend towards a reduced forward migration index parallel to 
the chemokine gradient (Figure 90E, G). This reduction in chemokine directed movement was 
observed despite an I-BET induced increase in overall movement, indicated by increased track length 
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Figure 90: I-BET151 inhibits CCL19 guided migration in vitro. BMDC were stimulated for 24 hours with 
OVA-IC in the presence of DMSO (GFP labelled) or I-BET151 3.3µM (RFP or CFP labelled). Following 
washing their migration was assessed in a 3D collagen matrix (A). B shows migration in the absence 
of a chemokine gradient with C showing migration in the presence of a 500ng CCL19 gradient 
(greatest to the left of the image. i) representative image following imaging for 2 hours, scale bar 
50µm, ii) migration tracks of DMSO treated cells iii) migration tracks of I-BET treated cells. The 
average centre of mass (D) and forward migration index parallel and perpendicular to the chemokine 
gradient (E) were calculated for the labelled conditions. Individual cell data and means are shown for 
track displacementx axis (F), forward migrationx axis (G), track displacementy axis (H), forward migrationy 
axis (I), track displacement length (J), track length (K), mean track speed (L) and maximum track speed 
(M). Data from two independent experiments. Red lines indicate the mean; boxplots show mean and 
standard error of the mean. P values calculated using unpaired student t test (NS p>0.05; *p<0.05; 
**p<0.01; ***p<0.001).  
5.3.5 I-BET151 inhibits dendritic cell mobilisation and migration in vivo 
Using two photon microscopy, with time lapse imaging of the movement of dermal DC within the 
hind footpad of mice expressing eYFP in CD11c+ cells (Figure 91), we showed that I-BET inhibits DC 
mobilisation in response to FcγR crosslinking. Imaging was performed in FcγRIIb null (FcγRIIb-/-) and 
wildtype C57B/6 (FcγRIIb+/+) mice; with pairs of age and sex matched mice imaged on the same day, 
one treated with I-BET and one treated with solvent control. In solvent treated mice, FcγR 
crosslinking by OVA-IC led to increased dermal DC movement with increased track length (Figure 
91Bi, Bii, Ci, Cii). In FcγRIIb-/- mice the effect of crosslinking of activatory FcγR was abrogated in I-BET 
treated animals; track length and displacement were reduced following I-BET treatment (Figure 
91Bii, iii) and an increase in cell migration speed was seen only in the absence of I-BET treatment 
(Figure 91Biv, v). In FcγRIIb+/+ mice, I-BET treatment actually led to an increase in mean track speed 
(Figure 91Cv), though movement was restricted and inefficient resulting in increased cumulative 
































Figure 91: I-BET inhibits DC migration in vivo in wildtype and FcγRIIb-/- mice.  A shows the 
experimental set up; following treatment with I-BET or solvent control, mice were injected with OVA 
in one hind footpad and OVA-IC in the contralateral footpad, with imaging under isoflurane 
anaesthesia 18 hours later.  B shows results from a representative experiment (1 of 2) using a pair of 
FcγRIIb -/- mice. C shows results from a pair of wildtype BLK/6 mice. i) Dermal DC in the field of view 
were surface mapped and tracked in Imaris image analysis software. DC visible at the end of imaging 
are shown in green alongside representative tracks (yellow) and 50µm scale bar; blood vessels were 
visualised via intravenous injection of Qdot probe, with surface mapping in Imaris software applied 
to the end time slice (shown in red (note injection and visualisation not successful in all mice)). Track 
length (ii), track displacement length (iii), maximum track speed (iv) and mean track speed (v) were 
quantified using surface tracking in Imaris image analysis software. Track lengths were calculated 
per minute imaged to account for differences in track duration. Red bars indicate medians; treatment 
groups were compared using Mann Whitney tests (NS p>0.05; *p<0.05; **p<0.01; ****p<0.0001).  
Immune complexes stimulate dermal dendritic cell migration to lymph nodes in a CCR7 and FcγR 
dependent manner (Clatworthy 2014a). In order to determine if I-BET151 has an effect on dendritic 
cell migration in vivo, we topically administered FITC to the skin in order to label dermal DCs, 
186 
 
stimulated them with IC, and harvested draining lymph nodes 48 hours later, as described in 
(Clatworthy 2014a) (Figure 92 & 93). I-BET151 reduced the number of migrating DCs identified in 
lymph nodes following IC stimulation. We observed no obvious systemic side effects in mice treated 
with I-BET 30mg/kg over a 48 hour period, with no difference in weight from those treated with a 
solvent control (Figure 93C). We found reduced numbers (Figure 92D) and proportion (Figure 92B, E) 
of FITC+, MHC class II high, CD11c+ dendritic cells in the draining and non draining lymph nodes of I-
BET treated animals, compared to those treated with a solvent control, with similar effects on both 
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Figure 92: I-BET inhibits DC migration in an in vivo FITC paint model. A shows the experimental set 
up. B shows representative flow cytometry plots. Summary of results showing animal weight (C), 
FITC+MHCII+CD11c+ DC numbers per lymph node (Di) and per 10000 CD3-CD19- cells (Dii), 
FITC+MHCII+CD11c+ EPCAM+ Langerhan DC (E) and FITC+MHCII+CD11c+CD103+ dermal DC (F). Data 
from 4 independent experiments. Line displays median value. P values calculated using Mann-
Whitney tests (NS p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). Dr draining lymph node. 




Figure 93: Representative plots of gating strategy used in FITC paint experiment 
We noted that mice treated with systemic I-BET151 for the 48 hour period used in our FITC paint 
model, had smaller lymph nodes. This associated with reduced live cell numbers when quantified by 
flow cytometry, suggesting a change in DC lymph node homeostasis (Figure 94).  
 
Figure 94: I-BET reduces lymph node size. Quantification of lymph node cell number following FITC 
painting. The non draining lymph nodes in I-BET treated mice were macroscopically smaller and 
contained fewer cells. Results from four independent experiments. Line displays median value; groups 
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Figure 95: Representative gating strategy used for quantification of splenic DC subsets 
Analysis of spleens by flow cytometry (Figure 95 & 96) revealed a reduction in the number of 
lymphoid organ resident DC (Figure 96B), with a specific loss of CD8+ cDC in mice treated with I-
BET151, leading to a reduced proportion and number of this subset (Figure 96C). There was relative 

























Figure 96: I-BET reduces the number of splenic DCs with preferential reduction in CD8+ DC. Results 
from two independent FITC paint experiments shown. Panel A shows representative plots with 
quantification of DC number (B), CD8 (C) and CD4 (D) expression. Lines represent medians; groups 
compared using Mann-Whitney tests (NS p>0.05; *p<0.05; **p<0.01; ***p<0.001). Where relative 
counts shown; results normalised to the mean solvent value in each individual experiment.    
We next wished to explore whether the effect of I-BET was DC intrinsic since systemic treatment of 
animals with I-BET may have effects on other cell populations as well as chemokine gradients. We 
transferred GFP expressing DC, stimulated with OVA-IC in vitro in the presence or absence of I-BET to 
wild type C57BL/6 mice and quantified the number of GFP+ DC in the draining and non draining 
lymph nodes 48 hours later (Figure 97 & 98). We observed a trend towards reduced migration of I-
BET treated DC, however there was marked variation in the number of GFP+ DC detected in different 
mice within the same experiment, who received the same amount of fluorescently labelled DC. We 


















































































































































































































































Figure 97: I-BET inhibition of DC migration appears to be DC intrinsic in a cell transfer model. A shows 
the experimental set up. B shows representative flow cytometry plots gated on live CD3-CD19- 
singlets. Positive control made by mixing GFP positive DC with homogenised lymph node suspension 
in vitro. Summary of results showing GFP+ cells per lymph node (Ci) and per 10000 MHCII+ cells (Cii). 
















Negative control Positive control
DMSO Draining IBET Draining



















1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
1 5 0 0 0






























































Figure 98: Representative plots of gating strategy used in GFP DC cell transfer experiment 
We optimised the experiment using DC differentiated from multiple mouse strains, each expressing 
a different fluorescent reporter protein (GFP and cyan-fluorescent protein (CFP) mice). This allowed 
us to transfer a mix of I-BET and solvent treated DC and quantify the numbers reaching each lymph 
node; each lymph node would serve as its own control, removing any bias caused by differences in 
injection efficiency (Figure 99 & 100). The GFP signal was brighter than the CFP signal used; so GFP 
cells were treated with I-BET to maximise the chance of detection. A sample of the transferred cell 
mix was stained to ensure that an equal mix of DMSO and I-BET treated cells were transferred 
(Figure 99B). We observed a significant reduction in the proportion of I-BET treated DC reaching the 



















Figure 99: I-BET inhibition of DC migration is DC intrinsic in an optimised cell transfer model. A shows 
the experimental set up. B shows representative flow cytometry plot demonstrating staining of the 
















live CD3-CD19-MHCII+ cells with controls used to set gates (labelled cells added manually to a lymph 
node suspension ex vivo). D shows the number of each cell population detected per 1000 MHCII+ cells 
in each lymph node. Representative experiment shown; treatment groups compared using Wilcoxon 
matched-pairs sign rank test (***p<0.001). 
 
Figure 100: Representative plots of gating strategy used in an optimised GFP/CFP DC cell transfer 
experiment 
5.3.6 I-BET inhibits co-stimulatory receptor expression 
In order to investigate the effect of I-BET on DC’s antigen presentation capacity, we measured the 
surface expression of DC markers and co-stimulatory receptor expression on murine bone marrow 
derived dendritic cells stimulated with immune complex in the presence and absence of I-BET.  GM-
CSF murine bone marrow cultures are known to consist of a heterogenous population of 
CD11c+MHCII+ macrophages and dendritic cells (Figure 101) (Helft 2015). Both undergo maturation 
upon stimulation with LPS but respond differentially to the stimulus and remain separable entities; 
MHCIIhiCD11bint population of BMDC were of a conventional DC phenotype whereas the 
MHCIIintCD11bhi fraction was shown to be monocyte-derived macrophages. The non-adherent cells 
at day 6 of culture contain a greater proportion of MHCIIhiCD11bint conventional DCs, so we used 























Figure 101. GM-CSF murine bone marrow cultures can be split into MHCIIhiCD11bint conventional DC 
and MHCIIintCD11bhi monocyte derived macrophages. Figure from (Helft 2015) 
Both LPS and immune complex were triggers for DC maturation with a trend towards an increased 
proportion of MHCII+ CD11c+ cells within the BMDC culture compared to cells not given a 
maturation stimulus (Figure 102A); though LPS induced a greater proportion of MHCIIhiCD11bint 
conventional DCs (Figure 102B). I-BET treatment did not affect the proportion of MHCII+ CD11c+ 
cells (Figure 102A) or the proportion of MHCIIhiCD11bint  conventional DCs for each maturation 




Figure 100: Quantification of the effect of I-BET on DC maturation using gating as in (Helft 2015). 
Single experiment with three replicates per condition; representative plots shown and summary data 
showing median and interquartile range. Due to the small samples numbers trends were observed. 
We went on to quantify the expression of co-stimulatory receptors. Levels of MHC II, as well as 
CD40, CD80 and CD86 were greatest following LPS maturation (Figure 103Ai-iv). In this experiment 
we did not see an increase in co-stimulatory receptor expression following FcγR crosslinking, but I-
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irrespective of the maturation stimuli used (Figure 103Aiii-iv; B), with a reduction in CD40 on 
unstimulated cells (Figure 103ii; B). 
 
Figure 103 I-BET inhibits co-stimulatory receptor expression. MHC II and costimulatory receptor 
expression on live CD11c+MHCII+ cells from a BMDC culture, stimulated for 16 hours with the 
labelled stimuli at day 7 of culture. Three replicates for each experimental condition; medians with 
interquartile range displayed in A; representative histograms shown in B. 
Repeat experiments revealed similar trends; though with shorter stimulation times changes in 
surface expression were less marked. The degree of response to immune complex stimulation was 
variable between experiments but where increased co-stimulatory receptor expression was seen 
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with addition of immune complex, the response was in general inhibited by the addition of I-BET 
(Figure 104).   
 
Figure 104: Further evidence for inhibition of co-stimulatory receptor expression with I-BET. CD40 (i), 
CD80 (ii) and CD86 (iii) were quantified in a series of experiments on live CD11c+MHCII+ cells from 
BMDC culture. Experiment A BMDC from five independent mice stimulated for five hours; Experiment 
B BMDC from a single mouse stimulated for four hours (two replicates per condition); Experiment C 
and D BMDC stimulated for 12 hours with two (Exp. C) or three (Exp. D) replicates per condition. 
Medians with interquartile range shown in bar graphs. Box and whiskers plots also show range.   
MHCII levels on CD11c+MHCII+ splenocytes were quantified following 48 hours of I-BET treatment in 
vivo in mice who had undergone FITC painting (Figure 105). Not only were CD11c+MHCII+ DC 
numbers reduced in the spleen of I-BET treated animals, but those that were present had reduced 
MHCII expression. Although this result was statistically significant, the reduction in MHCII expression 
was only marginal so the biological significance is uncertain.  
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Figure 105: I-BET treatment led to a reduction in DC numbers and reduced MHCII expression.  Results 
from five independent experiments. Lines represent median values with groups compared using 
Mann-Whitney test (*p<0.05; ****p<0.0001).  
5.3.7 I-BET has little impact on T cell activation by IC-stimulated DCs in vitro 
We used a DC:T cell co-culture assay in order to assess the ability of I-BET treated DC to activate T 
cells. Murine BMDC, were pulsed with immune complexed OVA in the presence or absence of I-BET. 
CD4+ T cells were isolated from OTII splenocytes that express T cell receptors specific for OVA and 
labelled with CFSE, according to a standard protocol. Following removal of I-BET from the culture, 
given that it is known to directly affect T cell differentiation, the CFSE labelled CD4+ T cells were 
added and activation status and proliferation assayed after 96 hours by flow cytometry (Figure 106). 
T cells cultured with IC stimulated DC’s demonstrated increased proliferation and activation (as 
measured by surface expression of CD25 and CD69). DC treatment with I-BET during antigen capture 
resulted in a trend towards increased T cell proliferation (Figure 106C) but less activation (Figure 
106D-E). However, these were not statistically significant across three independent experiments. I 
did attempt to assay T cell activation in vivo by transferring OTII T cells intravenously at the time of 
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Figure 106: Antigen presentation by immune complex stimulated DC leads to increased T cell 
proliferation and activation and is not significantly affected by I-BET treatment. Experimental 
protocol (A) and representative plots of gating strategy used for a DC:OTII cell co-culture assay. Panel 
C shows representative CFSE histograms and summary statistics for proliferative index and T cell 
count. The activation markers CD25 (D) and CD69 (E were measured on the T cells at the end of the 
co-culture. Five independent experiments with up to four replicates for each experimental condition. 
Box plots show median, interquartile range and range with representation of all replicates, relative to 
the mean DMSO US value for the relevant experiment, in C (three experiments) and E (two 
experiments) and experiment means in D (five individual experiments). Wilcoxon matched-pairs sign 
rank test used in D; Mann-Whitney test used to compare replicates in C & E. NS p>0.05; *p<0.05; 









































































Mononuclear phagocytes, including macrophages and DCs respond to stimulation by IgG immune 
complex; macrophages are specialised for phagocytosis and cytokine production whilst DCs are 
specialised antigen presenting cells, transporting antigen from the periphery to lymph nodes where 
they are more likely to encounter naïve T cells to which they can present antigen leading to T cell 
activation.  
In the previous chapter we showed that I-BET reduced the upregulation of many genes following IgG 
IC stimulation in murine BMDM. Bone marrow-derived MNP populations are known to be 
heterogenous and those differentiated as ‘dendritic cells’ using GM-CSF are actually composed of a 
mixed population of DCs and macrophages (Helft 2015). Although ideally one would base 
conclusions on the effect of DCs on a study of a pure DC population differentiated in vivo, studies in 
BMDM can still provide a useful experimental system for hypothesis generation and testing. Our 
microarray study showed that I-BET inhibited pathways upregulated by FcγR signalling relevant to DC 
phenotype, including cell adhesion pathways as well as antigen processing and presentation 
pathways (Figure 60). A reduction in FcγR expression was also observed in DCs cultured in vitro 
(Figure 64C) and within splenic DC in vivo (Figure 65), potentially reducing their susceptibility to IgG-
mediated activation.  
I-BET changed the morphology of both macrophages and DCs, resulting in a less adherent 
phenotype. I-BET treatment led to changes in gene expression in multiple genes that control cell 
adhesion and migration behaviour. Gene set enrichment analysis showed downregulation of 
pathways including regulation of actin cytoskeleton, chemokine signalling and cell adhesion 
molecules, with reduced expression of a number of chemokine receptor genes, as well as genes 
known to be important for DC migration including cysteinyl leukotriene receptor genes (Cysltr1, 
Cysltr2), critical for the leukotriene mediated induction of capacity for DC to migrate towards CCL19; 
prostaglandin E receptor 2 (Ptger2) known to be important for the induction of Mmp9; integrin 
subunit alpha 4 (Itga4), platelet-activating factor receptor (Ptafr), PI3K catalytic subunit gamma 
(Pi3cg) and dedicator of cytokinesis 8 (Dock8), a crucial CDC42 activator required for the amoeboid 
migration of DCs. Other important genes were downregulated but did not reach statistical 
significance including small Rho family GTPases Cdc42, RhoA, Rac1 and Rac2, components of the 
Arp2/3 complex (Arpc2, Arpc5, Actr2, Actr4), integrin subunit beta 2 (Itgb2), Eps8, CCR7 and MMP9.  
We were particularly interested in genes that were upregulated with FcγR and impacted by I-BET 
treatment since these may be particularly important in driving IC-mediated DC migration. The 
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heatmap in figure 86 identifies numerous genes that appear to fulfil this brief, including Mmp9, 
Itgb1, Itgb2, Ptafr, Rap1b, Icam1, Cd82, Fscn1, Cmklr1, Ccr7 and Cd38, although none reached 
statistical significance when considering both these requirements. In our transcriptomic analysis the 
effect of I-BET treatment at four hours was greater than that of FcγR crosslinking. Given the small 
sample size and limited power of our study we may have missed more subtle changes induced by 
FcγR crosslinking; the fact that I-BET clearly inhibits genes known to drive IC mediated migration is of 
interest.   
These findings prompted us to assess the impact of I-BET treatment on DC migration. The movement 
of DC’s was altered by I-BET treatment. In the absence of a chemokine gradient I-BET treated DC’s 
showed greater track displacement and speed than those treated with DMSO control; likely due to 
their rounded morphology and reduced adhesion to the collagen matrix. However IgG-IC induced 
augmentation of DC chemotaxis to CCL19 was abrogated by the addition of I-BET, with a reduced 
acceleration and chemokine guided migration following addition of IC. In-vitro assays are not perfect 
models given the highly complex regulation of DC migration that is affected my multiple factors 
including adhesion to the matrix, actin cytoskeletal change, chemokine signalling and matrix 
composition and degradation. In vitro migration assays may not accurately represent the complex in 
vivo milieu in which multiple external environmental factors also impact on DC migration, for 
example by inducing subtle changes in chemokine gradients (Haessler 2011). Furthermore different 
processes determine DC migration in 2D and 3D systems; integrin mediated adhesion is critical for 
migration over 2D surfaces but not required for DC migration in 3D environments (Lammermann 
2008). 
In vivo, two photon imaging showed that systemic I-BET treatment reduced IC-induced dermal DC 
mobilisation and a FITC paint model showed reduced migration of tissue DCs from I-BET treated 
animals to draining lymph nodes. We confirmed a DC-intrinsic effect on IgG IC-induced migration by 
transferring I-BET-treated DCs into the skin and tracking their subsequent trafficking to lymph nodes. 
We noted reduced numbers of splenic DC in I-BET treated animals injected with subcutaneous IC in 
the FITC paint model, with under-representation of CD8+ DC. CD8+ DC are a subset of non-migratory 
tissue resident DC that efficiently cross present exogenous antigens on MHC class I (Schnorrer 2006), 
holding immunoregulatory properties during steady state but producing IL-12 on activation, 
stimulating inflammatory responses. During infection with intracellular pathogens, they become 
major presenters of pathogen antigens promoting CD8+ T-cell responses to the invading pathogens 
(Shortman 2010). However, a proportion of circulating plasmacytoid DC in the spleen also express 
CD8α after microbial stimulus (O'Keeffe 2002) and our limited surface staining was insufficient to 
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fully characterise the subsets effected by I-BET. It appears that I-BET not only impedes the migratory 
capacity of DC, but may also alter lymphoid tissue resident subsets.  
DC maturation following antigen capture induces changes that facilitate migration for example 
upregulation of CCR7, a process mediated by NF-κB signalling (Baratin 2015). Since starting this 
work, others have shown that inhibition of bromodomains inhibits LPS driven DC maturation (Sun 
2015b, Toniolo 2015, Schilderink 2016), reducing expression of co-stimulatory molecules, inhibiting 
cytokine and chemokine production and attenuating T cell proliferation. An increase in functionally 
suppressive CD25+Foxp3+ T cells was hypothesised to result from a failure of maturation of I-BET 
treated DC or alternatively from an impaired capacity of these DC to uptake and process, or present 
antigen (Schilderink 2016), although the authors report uptake of dextran particles was not affected 
by I-BET151. Our work suggests that I-BET does indeed impact DC antigen uptake and processing; in 
chapter 4 we show that I-BET impacts phagocytosis leading to delayed phagolysosome maturation 
and IC clearance. Schilderink et al. observed some therapeutic benefit of I-BET151 in a T cell 
mediated colitis model. Interestingly, their most marked observation was of reduced spleen weight 
following I-BET treatment; similar to our observation in an immune complex peritonitis model. Sun 
et al. similarly showed that I-BET reduced LPS induced DC surface co-stimulatory molecule 
expression and cytokine secretion together with direct effects on T cells, both due to disruption of 
the association between BRD4 and acetyl-310 RelA of NF-κB, reducing graft versus host disease 
severity in an MHC-disparate allogeneic bone marrow transplant model (Sun 2015b). Treatment of 
human monocyte derived DC (Mo-DC) with JQ1 inhibited LPS-induced STAT5 phosphorylation, 
impairing maturation of Mo-DC. This reduced the ability of Mo-DCs to induce allogeneic CD4+ and 
CD8+ T cell proliferation and production of proinflammatory cytokines, reducing generation of 
inflammatory CD8+ T cells and decreasing Th1 differentiation (Toniolo 2015). We studied the effect 
of I-BET on DC maturation following IC stimulation and show that I-BET similarly inhibited DC co-
stimulatory receptor expression. Incomplete maturation of DC is associated with induction of T cell 
tolerance (Lutz 2002). In limited in-vitro co-culture experiments we observed a trend towards 
increased T cell proliferation with reduced T cell activation following addition of I-BET during DC 
priming with OVA and OVA-IC. We did not examine T cell polarisation or Foxp3 expression following 
co-culture; it would be of interest to study the impact of I-BET on DC production of T cell polarizing 
cytokines following IC challenge.   
To our knowledge this is the first account directly implicating bromodomains in the morphology or 
migration of MNP; though there are supporting reports in other cell types. Malignant cell migration 
similarly relies on actin polymerisation and molecules that link migratory signals to the actin 
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cytoskeleton are upregulated in invasive and metastatic cancer cells (Yamaguchi 2007). 
Furthermore, there are multiple descriptions of bromodomain mediated control of malignant cell 
migration and invasion (Andrieu 2016b, Wang 2017). Dendritic spines are small protrusions from 
many types of neuron that share similarities with dendrites of dendritic cells, utilising actin 
remodelling to drive changes in morphology (Vicente-Manzanares 2009). Bromodomains have been 
shown to regulate Drosophila dendrite morphology; a loss-of-function mutation in the single 
Drosophila BET protein encoded by female sterile 1 homeotic [fs(1)h] causes loss of fine, terminal 
dendritic branches (Bagley 2014). Lung fibroblasts isolated from patients with rapidly progressing 
idiopathic pulmonary fibrosis exhibit evidence of dysfunctional Brd4 activity with enrichment of Ac-
H4K5 and Brd4 at the IL-6 gene locus at baseline; BRD4 inhibition of these fibroblasts with JQ1 in 
vitro attenuated platelet-derived growth factor-BB medicated migration, proliferation, and IL-6 
release. JQ1 reduced bleomycin-induced lung fibrosis in an In vivo murine model, associated with 
reduced numbers of infiltrating lymphocytes and macrophages, reversing disease when commenced 
after onset of fibrosis (Tang 2013). JQ1 reduced the secretion of IL-1β, IL-6, IL-17 and IL-18 from TNFα-
stimulated human rheumatoid arthritis fibroblast-like-synoviocytes (RA-FLS), reduced FBS-induced 
migration and invasion of human RA-FLS and reduced the inflammatory response, autoantibody 
production and joint damage in a CIA model (Zhang 2015). Similarly, I-BET151 suppressed the 
inflammatory, matrix-degrading, proliferative and chemoattractive properties of RA-FLS (Klein 2016). 
BET bromodomain inhibition suppressed the expression of endothelial cell adhesion molecules 
induced by TNFα or LPS, including ICAM‐1, VCAM‐1 and E‐selectin, and inhibited leukocyte adhesion 
to activated HUVEC monolayers. In an acute lung inflammation model, In vivo treatment with JQ1 
attenuated the LPS-induced accumulation of leukocytes and expression of endothelial adhesion 
molecules in lung tissue (Huang 2017). This report focussed on the effects of bromodomain 
inhibition on the endothelium, without probing whether it directly influenced leukocyte migration.  
It is not surprising that we see I-BET induced changes in both phagocytosis and adhesion/migration 
since these processes share signalling pathways and cellular components, both reliant on 
remodelling of the actin cytoskeleton. Maturation of DCs in response to TLR4–MyD88 signalling 
increases their migration speed and persistence by regulating actin-nucleation machineries; 
favouring a RhoA-mDia1-dependent actin pool located at the cell’s rear, which facilitates forward 
locomotion; and limiting a Cdc42-Arp2/3-dependent actin pool present at the cell’s front, which 
limits migration but promotes antigen capture (Vargas 2016). Our microarray study showed that I-
BET impacts genes within both these pathways; differential effects could cause alterations in the 
distribution of the actin pool which may account for some of the I-BET driven changes in migration 
behaviour observed. We observed cell rounding associated with I-BET treatment, a feature observed 
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in adherent cells during phagocytosis; felt to arise in this setting due to competition for cytoskeletal 
and membrane components necessary for phagocytosis and adhesion, which become enriched in 
the phagocytic cup (Aderem 1999). Cell rounding is also described as a feature of pathogens 
manipulating the host cytoskeleton; the Yersinia species protein YopT is a cysteine protease that 
inactivates Rho, leading to inhibition of phagocytosis and chemotaxis (Schmidt 2011); the Vibrio 
parahaemolyticus protein VopS inactivates Rho by AMPylation, preventing the interaction of Rho 
GTPases with downstream effectors, thereby inhibiting actin assembly in infected cells (Yarbrough 
2009). In the case of I-BET treatment, rounding could result due to alteration in the dynamics of 
actin reorganisation following phagocytosis, where we see delayed phagolysosome processing and 
build-up of phagocytic debris within cells, or via direct effects on Rho GTPases or downstream 
effectors. 
The impact of I-BET on DC migration is likely multifactorial with effects on NF-κB mediated DC 
maturation, chemokine-chemokine receptor signalling, cell adhesion and motility. Our observations 
further support the hypothesis that I-BET inhibits the inflammatory response of myeloid cells to IC. I-
BET may therefore interfere with the uptake of IgG opsonised antigen by mononuclear phagocytes, 
antigen processing and DC trafficking to secondary lymphoid tissues, providing mechanistic insight 
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In this thesis I explored the impact of two therapeutic agents that influence the immune system, at 
different stages of clinical development. In the setting of a phase 2 experimental medicine study in 
kidney transplant recipients, we explored the therapeutic potential of belimumab, an anti-BLyS 
antibody, as an adjunct to standard immunosuppression. Therapeutic agents that limit humoral 
alloimmunity in kidney transplant recipients are currently lacking. We hypothesised that blocking 
BLyS, a cytokine that promotes B cell survival, may be beneficial. We provide the first data on the 
use of belimumab in kidney transplant recipients, showing no excess risk of infection or rejection 
and a reduction in naïve B cells, activated memory B cells, circulating plasmablasts, and kidney-
specific IgG. We also provide the first data on the impact of belimumab to reduce de novo IgG 
formation and increase regulatory B cell numbers in the peripheral blood.  
Preclinical studies were performed to investigate the potential efficacy of the bromodomain 
inhibitor I-BET in reducing antibody-mediated immune cell activation. We show that I-BET delays 
phagolysosome maturation associated with build-up of immune complex whilst selectively inhibiting 
IC induced cytokine production. I-BET changed MNP morphology, resulting in a less adherent 
phenotype and altered DC migratory capacity. In vitro, in a 3D collagen matrix, IgG-IC induced 
augmentation of DC chemotaxis to CCL19 was abrogated by the addition of I-BET. In vivo, two 
photon imaging showed that systemic I-BET treatment reduced IC-induced dermal DC mobilisation. 
Tissue DCs and transferred DC also had reduced migration to draining lymph nodes following I-BET 
treatment. We found that I-BET treatment led to reduced expression of co-stimulatory receptor 
expression, though in limited studies were unable to show a significant impact on subsequent T cell 
activation, but definitive conclusions on this will require further experiments. Together, these data 
provide mechanistic insights into the potential therapeutic benefit of I-BET in the setting of 
antibody-associated inflammation. 
6.2 Therapeutic implications of the BEL114424 study 
The BEL114424 study provides a useful platform from which to explore the further use of 
belimumab in renal transplantation. It gives a clear indication of the potential efficacy of belimumab 
as an immunomodulatory agent in transplantation that can limit new antibody formation and 
provides a blueprint for much-needed proof of concept experimental medicine studies in this field 
where the need for surrogate endpoints and innovative study design has been acknowledged by the 
community (O'Connell 2017). The knowledge we have gained from this study provides numerous 
options for future potential studies. In order to progress the drug to the clinic with a licence for use 
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in transplantation one would need to prove efficacy and demonstrate an effect on clinical outcomes. 
We hypothesise that by inhibiting new antibody production, limiting memory B cell activation and T 
cell proliferation and potentiating regulatory B cell function, belimumab would lead to less DSA 
production and improved graft function and survival. However chronic ABMR and graft loss take a 
number of years to develop and are therefore difficult to measure in a clinical trial setting. The 
transplant cohort we used was of low immunological risk and therefore the number likely to develop 
chronic ABMR and develop graft loss is low. Given the association between pre-transplant BLyS 
levels and risk of ABMR and the development of DSA, one may be able to stratify a population based 
on their pre transplant BLyS levels in order to determine those most likely to benefit from 
belimumab therapy.  
Belimumab’s effects in lowering activated memory B cells and on preformed IgG highlight an 
additional potential role in sensitised kidney transplant recipients or in those with antibody-
mediated rejection. One could consider using belimumab in a cohort with higher immunological risk 
who are likely to have a higher event rate and potentially could benefit more from treatment. 
However, in this subset of patients we currently use alternative immunosuppression approaches 
including lymphocyte depleting treatment with alemtuzumab or anti-thymocyte globulin (ATG) at 
induction. The safety of belimumab in combination with these regimes is not known. It is also 
uncertain if the observed effects would apply in the setting of B cell depletion. Following 
alemtuzumab treatment, a rise in serum BLyS is observed and this has been associated with rises in 
DSA (Bloom 2009). It would be interesting to follow treatment with alemtuzumab with belimumab 
during the reconstitution phase to see if this modulates the reconstituting B cell compartment, 
leading to a more tolerogenic compartment with increased IL-10/IL-6 cytokine production. The 
COMBIVAS trial combining rituximab with belimumab treatment is due to start in the setting of 
vasculitis and it will be interesting to see the effect of belimumab treatment following B cell 
depletion.  
There are currently no proven treatments for chronic ABMR. There is an isolated case report 
describing the successful use of belimumab in a case of rituximab resistant acute ABMR (Leca 2013). 
Belimumab treatment is effective in the setting of the autoimmune disease SLE, where preformed 
antibodies are present. Belimumab may therefore be an effective therapy in the setting of acute or 
chronic ABMR, an area with limited current therapies due to the difficulties of targeting long lived 
plasma cells. 
We are the first to describe an impact of belimumab on immunoregulatory cytokine release. Our 
study therefore informs those using belimumab outside of the field of transplantation in SLE. Plans 
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are in place to use the regulatory B cell assay developed as part of this work in future GSK studies 
using belimumab. 
6.3 Outstanding questions regarding the impact of bromodomain inhibition on FcγR mediated 
MNP activation 
6.3.1 Epigenetic changes induced by FcγR crosslinking 
We describe changes in phenotype induced following I-BET treatment and using a microarray 
platform with subsequent confirmation by quantitative PCR, in the case of FcγR expression levels, 
describe changes in gene expression which may account for the phenotypic changes observed. As 
yet we have not explored the epigenome of MNP; at baseline this may determine the susceptibility 
of individual genes to I-BET mediated inhibition; a comparison following I-BET treatment may explain 
the changes observed. To our knowledge no-one has yet studied epigenetic modifications in MNP 
induced by FcγR crosslinking. We have planned to perform a full analysis of the epigenetic state of 
MNP using ATACseq technology, focussing on changes induced by FcγR crosslinking in the presence 
and absence of bromodomain inhibition (Figure 107). We have chosen to use ATACseq analysis to 
assess epigenetic changes because this allows a broad assessment of the epigenome, in contrast to 
ChiP-Seq, in which specific histone marks are assayed. 
 
Figure 107: ATACseq analysis of epigenetic changes induced by FcγR crosslinking and the impact of 
bromodomain inhibition.  BMDM will be cultured and treated with/without I-BET together with 
immune complexes (IgG opsonised OVA-IC) or control protein (OVA). After four-hours, all stimuli will 
be removed, the cells washed and some harvested for ATACseq studies. A subset of the cells will be 
cultured for an additional five days in standard media and then harvested to assess the stability of 
epigenetic changes induced by IC. For accuracy and reproducibility, three technical replicates will be 
used for each condition. We will also assay three unstimulated samples to provide information on the 
baseline epigenetic landscape 
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6.3.2 Pinpointing the mechanism of bromodomain inhibitor action 
Through our work we have identified multiple ways in which bromodomain inhibition alters MNP 
gene expression and phenotype. The epigenetic study outlined above will further our knowledge of 
key regulators; we hypothesise that I-BET will impede enhancer and superenhancer landscape 
remodelling following FcγR crosslinking, similarly to that seen in other settings (Brown 2014), leading 
to changes in multiple key immune pathways.  
Given the multitude of potential effects of bromodomain inhibition and the presence of complex 
immune regulation networks, in vivo models are critical for understanding the implications of 
bromodomain inhibition. Unfortunately our attempts at setting up a nephrotoxic nephritis model 
were unsuccessful. We utilised alternative models to test the impact of I-BET. We showed reduced 
recruitment of mononuclear phagocytes to the kidney and reduced pro-inflammatory gene 
expression in response to circulating immune complex; using a FITC paint model, two photon 
microscopy and transfer of DC’s treated with I-BET ex-vivo, we confirmed that I-BET impedes DC 
migration. Ideally we would like to dissect the effect of bromodomain inhibition in a more 
conventional autoimmunity model and have discussed the potential for using a K/BxN serum 
transfer arthritis (Christensen 2016), where we would be able to assay the effect of I-BET on the 
MNP immune response to autoantibody, independently from potential effects on B cell 
autoantibody production itself. We would plan to observe any impact on disease severity within the 
joints whilst also studying joint draining lymph nodes. With a working model of autoimmune disease, 
one could then explore changing the timing of therapeutic intervention to see whether I-BET impacts 
the development and/or maintenance of an established immune response.  
Our work suggests that I-BET may have some impact on baseline MNP adhesion and migration 
independent from changes resulting following FcγR crosslinking, leading to changes in baseline 
homeostasis; we see alterations in unstimulated BMDM by microarray analysis, for example in 
cytokine and chemokine signalling pathways; see altered kidney MNP populations even in the 
absence of IC administration; and observed changes in the size of non draining lymph nodes and 
splenic DC populations in our FITC paint model. We report that the impact of I-BET on DC migration 
is likely multifactorial, with effects on NF-κB mediated DC maturation, chemokine-chemokine 
receptor signalling, cell adhesion and motility. Use of LifeAct–GFP mice would allow the generation 
of LifeAct–GFP density maps, as in (Vargas 2016), and would confirm whether changes in actin 
distribution underpin the alterations in adhesion and motility observed. It is important to further 
characterise changes observed in the absence of IC stimulation since they could have implications 
for side-effects associated with treatment.  
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6.3.4 Effect of bromodomain inhibition on B cell memory responses 
Bromodomain inhibition has been shown to impact the BAFF axis; JQ1 improved survival in a murine 
lupus model and reduced serum anti-dsDNA antibody, BAFF, IL-1β, IL-6, IL-17 and IFN-γ, whilst 
increasing the immunoregulatory cytokine IL10. In vitro, JQ1 caused similar changes in cytokine 
release in cultures of splenocytes from diseased MRL-lpr mice and human monocytes stimulated 
with IC (Wei 2015). The reciprocal change in IL-6 and IL-10 associated with reduced BAFF mirror our 
findings with belimumab; giving further support for a role of BAFF/BLyS axis in modulating the 
balance between proinflammatory and immunoregulatory B cell cytokine release; and prompting 
study of the effects of bromodomain inhibition on B cell subsets. However, Wei and colleagues 
found that JQ1 inhibits the recruitment of BRD4 and NF-κB p65 at the IL-10 promoter region upon 
LPS stimulation, inhibiting IL-10 release from LPS stimulated mouse splenocytes in a dose dependent 
fashion. They found no change in the frequency of CD1dhiCD5＋ regulatory B cells but JQ1 reduced 
the differentiation of precursor cells to mature IL-10-producing regulatory B cells (Lee 2017). 
Published data suggest that BET inhibition can limit the proliferation of malignant B cells, causing a 
G1 cell cycle arrest (Chapuy 2013). Brd2 binds the cyclin A promoter in B cells, increases cyclin A 
expression and S-phase progression in in vitro mitogen-stimulated non-malignant primary B cells and 
JQ1 reduces B cell mitogenesis (Belkina 2014). In lymphoma cell lines, BRD4 loading has been noted 
on the enhancers for a number of transcription factors that determine B cell fate including Bcl6, 
Pax5 and Irf8 (Chapuy 2013). An increase in BRD4 expression occurs in GC B cells and BRD4 inhibition 
in vivo results in the suppression of GC formation and reduced IgG titres following T-dependent 
antigen immunisation (Gao 2015). In keeping with this, BET inhibition led to a reduction in Bcl6 
expression, the master regulator of GC B cells, and of Irf8, Pax5 and Bach2 (Gao 2015). Brd4 is also 
critical for non-homologous end-joining repair of activation-induced cytidine deaminase (AID)-
induced DNA breaks and BET inhibition reduces class-switch recombination in vivo (Stanlie 2014). 
These data support the potential for BET inhibition as a therapeutic strategy targeting B cells in 
antibody-mediated diseases. Given that in most autoimmune disease, and in sensitised organ 
transplant recipients, it is not the primary antibody response that mediates disease but rather an on-
going recall response, we would look to determine the role of BET proteins and the efficacy of BET 
inhibitors in impacting humoral memory, specifically the activation of memory B cells and the 
generation and maintenance of plasma cells.  
6.3.3 Applicability as potential treatment in autoimmunity and transplantation 
Our work suggests that I-BET may have potential therapeutic benefit in the setting of antibody-
associated inflammation; limiting the MNP response to deposited IC and impeding DC migration to 
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secondary lymphoid organs, resulting in potential attenuation of any subsequent T cell response. 
However it is uncertain if such a treatment may be effective in people with pre-existing autoimmune 
disease. When considering use as a therapeutic agent the timing of administration is crucial. Apart 
from perhaps in the setting of transplantation, when the timing of introduction of the allograft is 
known; those with autoimmunity in general present following the initiation of the autoimmune 
response. In our experiments pre-treatment with I-BET shortly prior to IC stimulation was used to 
maximise the I-BET treatment effect whilst elucidating mechanisms of action. Further experiments 
where introduction of I-BET following initial stimulation would be of interest. 
The targets of bromodomain inhibition are influenced by the baseline epigenetic state of genes and 
autoimmunity itself can result from epigenetic modifications (Long 2016); there is no guarantee that 
MNP’s from those with autoimmunity will behave similarly to those from healthy controls. Aberrant 
histone acetylation has been implicated in the pathogenesis of SLE with a global site-specific histone 
H3 and H4 hypoacetylation detected in CD4+ T cells from patients with SLE, correlating with 
increased disease activity (Hu 2008), and splenocytes of MRL/lpr lupus mice; with improvement of 
disease phenotype associated with normalisation of acetylation state following in vivo 
administration of a histone deacetylase inhibitor (Garcia 2005). Increased H4 acetylation at the TNFα 
locus in monocytes from patients with SLE associates with increased TNFα transcripts and markers 
of disease severity (Sullivan 2007). Moreover, monocytes from those with SLE show increased 
promoter H4 acetylation at multiple gene loci; network analysis identified significant nodes as ERK, 
p38, NFκB, CREB1 and αIFN; the majority of genes with increased H4ac having upstream interferon 
regulatory factor 1 (IRF1) binding sites and exhibiting the potential to be regulated by IRF1, 
consistent with the previous knowledge of type-I interferon hyper-responsiveness in SLE (Zhang 
2010). Elevated basal levels of H3 and H4 acetylation is associated with an open chromatin state and 
resistance to I-BET treatment (Nicodeme 2010). The epigenetic changes observed in patients with 
SLE could therefore render their MNP more resistant to I-BET mediated inhibition. We would wish to 
expand our in vitro work using human monocyte derived macrophages and dendritic cells, ideally 
including cells from patients with established autoimmune disease. The responses of MNP from 
those with prior autoimmunity may also differ from those of healthy controls due to the 
phenomenon of ‘trained immunity’, whereby innate immune cells show an exaggerated response to 
secondary stimuli (Netea 2016); a process mediated itself by epigenetic reprogramming (Saeed 
2014), driven by a shift in metabolism with an increase in glycolysis dependent on the activation of 
mammalian target of rapamycin (mTOR) through a dectin-1/Akt/HIF1α (hypoxia-inducible factor-1α) 
pathway (Cheng 2014). It is unknown whether FcγR crosslinking induces a state of trained immunity; 
this is something we hope to address using our ATAC-seq experiment.  
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Bromodomain inhibition has proven efficacy in animal models of autoimmune disease; our research 
complements those of others, suggesting that this class of drug targets multiple immune effectors, 
with potential to modulate the development and maintenance of the allo/autoimmune response to 
IgG (Figure 108). Reducing DC migration at the time of tissue implantation and antigen exposure may 
suppress the development of alloimmune responses in the setting of transplantation. Impeding 
presentation of persistent self-antigen that accumulates in SLE, may impact maintenance of 
autoimmune responses. Reduced MNP activation in response to FcγR crosslinking may attenuate the 
response to deposited immune complex, giving potential for use in established autoimmune disease 
and ABMR. Early phase studies of bromodomain inhibitors in solid organ and haematological 
malignancy are recruiting (clinical trial identifier NCT01587703; NCT01943851); as we gain more 
experience of their clinical use, if their tolerability is acceptable, it is likely that they will be tested in 
the field of autoimmunity. 
 
Figure 108: Bromodomain inhibitors act at multiple sites and are of potential therapeutic benefit in 
the setting of antibody-associated inflammation. I-BET reduces expression of FcγR on macrophages 
and DC (1). Our in vivo studies suggest a greater reduction in activatory receptors compared to 
FcγR2b leading to a reduced A/I ratio and increased threshold for cell activation. I-BET delays 
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phagolysosome maturation associated with build-up of immune complex (2) whilst selectively 
inhibiting IC induced cytokine production (3). Following encounter with IC, in the presence of I-BET 
DC fail to mature fully, expressing reduced levels of costimulatory receptors CD80 and CD86; and 
migration towards draining lymph nodes is impaired (4). An altered pattern of DC cytokine release 
associated with reduced expression of co-stimulatory receptors may favour provision of tolerogenic 
signals to T cells (5) and has been associated with increased numbers of regulatory T cells 
(Schilderink 2016). I-BET treatment directly effects T cell polarisation, with documented effects of 
Th1 (Bandukwala 2012) and Th17 subsets (Mele 2013) (6). Reduced secretion of BAFF and 
proinflammatory cytokines together with direct effects on B cells (Belkina 2014, Stanlie 2014, Gao 
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Background: B cells produce alloantibodies and activate alloreactive T cells, negatively 
affecting kidney transplant survival. In contrast, regulatory B cells are associated with 
transplant tolerance. There is an unmet need for immunotherapies that inhibit B cell effector 
function, including antibody secretion, whilst sparing regulators and minimising infection risk. 
B lymphocyte stimulator (BLyS) is a cytokine that promotes B cell activation, and has not 
previously been targeted in kidney transplant recipients. 
Aim: We sought to examine the safety and activity (the latter measured by a reduction in 
naïve B cells from baseline to week 24) of an anti-BLyS antibody, belimumab, in addition to 
standard of care immunosuppression in adult kidney transplant recipients. We utilised an 
experimental medicine study design with multiple secondary and exploratory endpoints to 
gain further insight into the effect of belimumab on the generation of de novo IgG and on the 
regulatory B cell compartment. 
Methods: We conducted a phase 2 double-blind randomised placebo-controlled trial of 
belimumab, in addition to standard of care immunosuppression (basiliximab, mycophenolate 
mofetil, tacrolimus and prednisolone), in adults aged 18-75 receiving a kidney transplant. 
Subjects were randomised at a single centre, Addenbrooke’s Hospital (UK), stratified 
according to receipt of a living or deceased donor organ. Within each stratum subjects were 
randomised by telephone in a 1:1 ratio to receive intravenous belimumab 10mg/kg or 
placebo (day 0, 14, 28 and every four weeks thereafter for a total of seven infusions). Co-
primary endpoints were safety and change in naïve B cells from baseline to Week 24. This 
trial has completed and is registered as ClinicalTrials.gov number NCT01536379 and 
EudraCT number 2011-006215-56. 
Findings: 28 kidney transplant recipients were randomised to belimumab (n=14) or placebo 
(n=14) treatment between 13th September 2013 and 8th February 2015. Twelve belimumab 
and 13 placebo patients were transplanted and went on to receive at least one dose of 
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belimumab/placebo (modified intention to treat (MITT) population). We observed similar rates 
of adverse events in belimumab and placebo groups, including serious infection (1/12 (8%) 
and 5/13 (38%) respectively during the six month on-treatment phase; 0/13 (0%) and 2/13 
(15%) during the six month post-treatment follow-up phase). There was one death in the on-
treatment phase in a patient in the placebo group. The co-primary endpoint of a reduction in 
naïve B cells from baseline to week 24 was not met; treatment with belimumab resulted in a 
trend towards, but not a statistically significant reduction in naïve B cells from baseline to 
week 24 (adjusted mean difference -34·4 cells/mm3 (95% confidence interval (CI) -109·5 to 
40·7)).  
Interpretation: Treatment with belimumab in addition to standard of care immunosuppression 
in low immunological risk renal transplant recipients was not associated with an adverse 




Panel: Research in context 
Evidence before this study 
Therapeutic agents that limit humoral alloimmunity in kidney transplant recipients are 
currently lacking.  B lymphocyte stimulator (BLyS; also known as BAFF) is a cytokine that 
promotes B cell survival, and we hypothesised that this pathway may represent a useful 
therapeutic target in transplantation. We searched PubMed using the terms ‘BAFF’ and 
‘kidney transplantation’ and ‘Clinical trial’ and Clinicaltrials.gov using the terms ‘kidney 
transplantation and ‘BAFF’ to establish the current clinical evidence-base in this area. Of the 
six studies identified in this search, only two included agents that targeted the BAFF/BLyS 
pathway, using monoclonal antibodies that bind BAFF/BLyS (tabalumab and belimumab), 
and only one of these was completed and published (Mujtaba et al. 2016). In fact, neither of 
these studies attempted BAFF/BLyS blockade in kidney transplant recipients. Both used an 
anti-BAFF/BLyS antibody as monotherapy in patients with end-stage kidney failure, with the 
aim of reducing pre-formed HLA antibodies to a level that permitted safe transplantation, but 
observed little effect. No trial to date has addressed the question of whether blockade of 
BAFF/BLyS could be a useful addition to current maintenance immunosuppressive agents 
following kidney transplantation.  
Added value of this study 
This study adds value to the existing evidence base by delivering the first data on the use of 
belimumab in kidney transplant recipients, showing no excess risk of infection and a 
reduction in naïve B cells, activated memory B cells, circulating plasmablasts, and kidney-
specific IgG. We also provide the first data on the impact of belimumab to reduce de novo 
IgG formation and increase regulatory B cell numbers in the peripheral blood. Our study 
informs clinical trials modulating the BLyS/BAFF axis in transplant recipients, and those 




Implications of all the available evidence 
Our data suggest that belimumab may be a useful therapeutic strategy in standard 
immunological risk kidney transplant recipients to prevent de novo donor-specific antibody 
formation. The observed lowering of activated memory B cells and preformed IgG suggest an 
additional potential role in sensitised kidney transplant recipients or in those with antibody-
mediated rejection. Therefore, the use of belimumab warrants further study in these patient 




Transplantation is the optimal renal replacement therapy for most patients with end-stage 
renal failure (ESRF). Current immunosuppressive regimens carry an increased risk of 
infection but limit T cell activation such that T cell mediated rejection (TCMR) occurs in less 
than 20% of kidney transplant recipients and is largely treatable. In contrast, there remain 
significant challenges in the field of humoral alloimmunity. De-novo donor-specific human 
leucocyte antigen (HLA)–specific immunoglobulin G (IgG) antibodies (DSA) and some non-
HLA IgG antibodies are associated with acute antibody-mediated rejection (ABMR) and 
allograft loss1-3. Furthermore, sensitised patients with pre-formed DSA have an elevated risk 
of acute and chronic ABMR, reducing graft survival4. B cells are not only the precursors of 
antibody-producing plasma cells, but act as antigen presenting cells and secrete pro-
inflammatory cytokines, including interleukin (IL)-6, that can activate T cells driving TCMR. 
Indeed, the presence of B cells in TCMR biopsies is a negative prognostic factor associated 
with steroid resistance5. Hence, there is an urgent unmet need in solid organ transplantation 
for immunotherapeutic strategies that target B cells and plasma cells6, ideally without 
increasing infectious complications. 
Efforts to inhibit pathological humoral immunity are complicated by the fact that B cells may 
also regulate immune responses via IL-10 production7,8. These regulatory B cells are 
enriched in transitional (CD24/CD38high)7 and memory (CD24high/CD27+) B cell compartments 
in humans8. Several lines of evidence suggest that regulatory B cells may be important in 
transplantation. Firstly, although a single dose of the anti-CD20 antibody rituximab at 
induction had no impact on transplant outcomes9,10, the use of a second dose within one to 
two weeks of transplantation was associated with TCMR in kidney transplant recipients11 and 
cardiac allograft vasculopathy12. Secondly, B cell transcripts and IL-10 producing B cells are 
increased in the peripheral blood of tolerant kidney transplant recipients13-15. Finally, kidney 
transplant recipients with a higher number of transitional B cells have reduced rejection16. 
Similarly, patients with a higher B cell IL-10:TNF ratio have a slower decline in transplant 
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function and reduced allograft loss17,18. In contrast, patients with rejection following ABO 
incompatible transplantation had fewer CD24high/CD27+ memory B cells19. Together, these 
data show that B cells can play both a positive and negative role in transplantation and 
highlight the need to identify immunosuppressants that preserve the immunoregulatory 
aspect of B cell function.  
B lymphocyte stimulator (BLyS; also known as BAFF) is a cytokine that enhances B cell 
survival and proliferation20 and contributes to the plasma cell niche21. The humanised anti-
BLyS IgG1 antibody, belimumab, is licenced for use in patients with SLE22, a disease 
characterised by high circulating BLyS23. In renal transplant recipients, elevated serum BLyS 
is associated with the development of de novo DSA24, high-titre HLA antibodies25, and an 
increased frequency of ABMR26. Experimental models suggest that BLyS neutralisation may 
be effective in preventing rejection27,28. BLyS inhibition, used as monotherapy, had little 
impact on HLA antibody titres in sensitised subjects on the transplant waiting list29,30, but to 
date, this axis has not been targeted in human transplant recipients.  
Currently, only 10% of compounds entering clinical trials reach patients as medicines. 
Experimental medicine seeks to improve this by ‘identify(ing) mechanisms of 
pathophysiology or disease, or … demonstrat(ing) proof-of-concept evidence of the validity 
and importance of new discoveries or treatments’ (UK Medical Research Council), thus 
providing detailed, mechanistic phenotypic data that precedes and informs late phase clinical 
development. 
We undertook a phase 2 randomised, double-blind, placebo-controlled experimental 
medicine trial of belimumab in addition to standard of care immunosuppression in renal 
transplant recipients to assess its safety and activity, as measured by a reduction in naïve B 
cells from baseline to week 24, and its effect on a number of exploratory endpoints. The use 
of belimumab was not associated with increased infection but led to a reduction in naïve B 
cells and activated memory B cells. The residual B cell compartment in belimumab-treated 
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subjects was skewed towards cells with a regulatory phenotype, with an increased capacity 
to produce IL-10 relative to IL-6. Following belimumab treatment, whole blood gene 
expression and protein microarray analysis indicated fewer circulating plasmablasts, reduced 
de novo IgG antibody formation and a reduction in kidney and endothelial cell-specific 
antibodies known to negatively impact graft outcome. In addition, belimumab treatment had a 
significant effect on the CD4 T cell transcriptome, with a marked reduction in cell cycle gene 
expression. Our data suggest that belimumab may be a useful therapeutic strategy to 
explore further in standard immunological risk kidney transplant recipients.  
METHODS 
STUDY DESIGN: 
In this phase IIA, randomised, double-blind, sponsor unblind study, subjects were recruited at 
a single UK transplant centre (Addenbrooke’s Hospital, Cambridge). The study was 
approved by the local Research Ethics Committee (East of England - Cambridge East). The 
study protocol is available at www.gsk-clinicalstudyregister.com 
STUDY PATIENTS: 
Patients aged 18 to 75 years receiving a kidney transplant were eligible for inclusion. 
Exclusion criteria included donor age <5 or >70 years, ABO blood type incompatibility, 0-0-0 
HLA mismatch, a positive T and/or B cell cross-match, and previous recipient exposure to B 
cell targeted therapy (full eligibility criteria are in study protocol, supplementary material). All 
patients provided written informed consent. 
RANDOMISATION AND MASKING: 
Subjects were stratified according to whether the recipient received a living or deceased 
donor organ. Within each stratum, subjects were randomised in a 1:1 ratio to either 
belimumab or placebo. Randomisation was performed by the investigators using the 
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GlaxoSmithKline telephone based Registration and Medication Ordering System (RAMOS). 
This was a double-blind study in which the investigator, patient and sponsor (with the 
exception of statistics personnel unblinded for interim/sample size re-estimation) were 
blinded to the treatment assignment. An unblinded pharmacist prepared the infusion 
according to the subject’s randomised treatment. 
PROCEDURES: 
Subjects received seven doses of belimumab 10mg/kg (GlaxoSmithKline, Rockville, MD, 
USA) or placebo (0.9% sodium chloride solution) by intravenous infusion over one hour at 
days 0, 14, 28 and then every four weeks to week 20, in addition to basiliximab (20mg IV 
days 0 and 3), tacrolimus (0.15mg/kg daily: target trough level 6-10μg/L first six months post 
transplantation, 5-8μg/L thereafter), mycophenolate mofetil (500mg twice daily) and 
prednisolone (20mg daily initially, weaning to 5mg daily in month 1-2). Patients received 
infection prophylaxis with nystatin (1st month), co-trimoxazole (months 1-6) and 
valganciclovir (months 1-6), and were followed for 12 months (see study protocol in 
supplementary material). 
For adverse event reporting the on-treatment phase commenced from the start of the first 
infusion of belimumab/placebo and ended 28 days after the last dose. The post-treatment 
phase began the following day. For other primary and secondary endpoints the on-treatment 
phase ended 35 days after the last dose to allow inclusion of the On-Trt Week 24 visit on day 
168 +/- 7 days. Details of visit windows can be found in the supplementary appendix.  
OUTCOMES: 
The first co-primary endpoint was safety assessed by: review of AEs and SAEs, classified 
using the Medical Dictionary for Regulatory Activities (MedDRA) and including AEs of special 
interest; and change from baseline and number of subjects outside the normal range for vital 
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signs and safety laboratory assessments, including immunoglobulin levels and white cell 
count. 
The second co-primary endpoint was change in naïve B cells from baseline to Week 24, a 
measure of functional BLyS neutralisation validated in patients with SLE31. 
Secondary and exploratory endpoints included pharmacodynamics, immunological 
biomarkers (e.g. regulatory B cells, assessment of peripheral blood transcriptional profiles, 
and non-HLA antibodies) and clinical endpoints. Full details of the secondary and exploratory 
endpoints can be found in the supplementary appendix and study protocol. 
B CELL STIMULATION ASSAYS: 
Frozen peripheral blood mononuclear cells (PBMC) were thawed and cultured in vitro with 
CpG DNA Oligodeoxynucleotides (100nM; Hycult Biotech) and CD40L (1µg/ml; R&D 
Systems). Phorbol 12-myristate 13-acetate (PMA) (50ng/ml; Sigma-Aldrich), ionomycin 
(500ng/ml; Sigma-Aldrich) and brefeldin A (5µg/ml; BioLegend) were added for the last five 
hours of culture and IL-6 and IL-10 quantified by flow cytometry.  
MICROARRAY ANALYSES: 
RNA was extracted from whole blood or from purified leukocyte subsets as described 
previously32, and hybridised to Human Gene ST 2.1 microarrays (Affymetrix). Microarray data 
are available in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under 
accession number E-MTAB-5906. 
Patient serum was hybridised to ProtoArray (Invitrogen) protein microarrays according to 
manufacturer’s instructions. 




Primary analyses were undertaken using a pre-specified modified intention to treat 
population (MITT) including all patients randomised who received at least one infusion of 
belimumab/placebo. Secondary and exploratory biomarker outputs were undertaken using a 
pre-specified per protocol population (PP) that included all MITT subjects who received at 
least five infusions of belimumab/placebo, were followed up beyond week 24 and received 
no prohibited medications or plasma exchange (referred to as PP1 population in the study 
protocol). 
No formal statistical hypotheses were defined in the reporting and analysis plan (RAP). For 
the primary and secondary biomarker endpoints, a mixed model for repeated measures 
(MMRM) approach was used to produce adjusted mean differences between belimumab and 
placebo with corresponding 95% confidence intervals (details in supplementary appendix). 
For each of the primary and secondary endpoints, error diagnostics from the residuals were 
examined to ensure that the model did not depart from the assumptions underlying analysis 
of variance. If the assumptions were seriously violated, then non-parametric alternatives 
were performed as defined in the RAP. Non-parametric statistical analyses were performed 
on exploratory endpoints post hoc and these are marked as such. 
The target sample size of 20 evaluable subjects was informed by feasibility assessment but 
calculated with the aim of achieving a reduction in naïve B cell count from baseline to 24 
weeks. Assumptions for the sample size calculation are provided in the supplemental 
methods. 
Interim re-estimations of sample size were performed in November 2014 and February 2015. 
An extended safety review team, consisting at a minimum of a safety physician, a clinical 
development physician and a statistician, oversaw the study. 
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Analyses were performed using SAS version 9.3 except for transcriptomic and protein 
microarray analyses, which were performed using R version 3.3.1. 
ClinicalTrials.gov number NCT01536379; EudraCT number 2011-006215-56 
ROLE OF THE FUNDING SOURCE: 
The study was designed by the sponsor, GlaxoSmithKline, in close collaboration with 
principal investigators at Addenbrooke’s Hospital. Authors affiliated to GlaxoSmithKline, 
Addenbrooke’s Hospital and the University of Cambridge were jointly responsible for trial 
design, data collection, analysis and interpretation, report writing and the decision to submit 
the paper for publication. 
RESULTS 
Twenty-eight subjects were randomised to belimumab (n=14) or placebo (n=14) between 13th 
September 2013 and 8th February 2015. Twelve belimumab and 13 placebo patients went on 
to receive at least one dose of belimumab/placebo (Fig. 1) in addition to standard 
immunosuppression (Table S3). Baseline patient characteristics were comparable between 
groups (Table 1). Belimumab pharmacokinetic (PK) parameters were similar to those 
observed in SLE22 and were not affected by ESRF (Fig. S1A; Table S12). Belimumab 
effectively removed circulating BLyS, and levels remained suppressed up to week 12 post-
treatment, rebounding thereafter (Fig. S1B).  
The first co-primary endpoint was safety. We observed AE in 11/12 (92%) belimumab-treated 
subjects and 10/13 (77%) placebo-treated subjects during the 6 month on-treatment phase 
and 10/12 (83%) and 9/13 (69%) respectively during the 6 month post-treatment follow-up 
phase. AE occurring in more than one subject with a higher incidence in the belimumab 
group were diarrhoea, urinary tract infection, dizziness and vomiting (on treatment) and 
nasopharyngitis, urinary tract infection and type two diabetes (post treatment). For each 
event, the difference in frequency compared to placebo was no more than two subjects and 
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not considered to represent a new safety signal. The number of patients experiencing 
serious AE were similar (5/12 (42%) of belimumab-treated and 7/13 (54%) of placebo-treated 
subjects during the 6 month on-treatment phase and 2/12 (17%) and 2/13 (15%) respectively 
during the 6 month post-treatment follow-up phase). A key question we wished to address in 
this study was whether the use of belimumab in renal transplantation might be associated 
with an excess risk of infection. Belimumab has previously been used in patients with 
autoimmune diseases, in combination with steroids, and in some cases, an anti-proliferative 
agent (e.g., azathioprine, MMF or methotrexate)22. This is the first study to use belimumab 
with basiliximab induction and with triple maintenance immunosuppression (tacrolimus, MMF 
and prednisolone) in patients with ESRF at baseline, a condition known to be associated with 
a heightened susceptibility to infection33. Therefore, post-transplant infection was an 
important end-point, particularly given its association with an increased risk of rejection and 
allograft loss34. At 6 and 12 month follow-up, we observed no excess serious infection events 
in the belimumab group (1/12 (8%) and 5/13 (38%) in belimumab and placebo-treated 
patients respectively during the 6 month on-treatment phase and 0/13 (0%) and 2/13 (15%) 
respectively in the 6 month post-treatment follow-up phase). We also found no excess 
frequency of BK virus and cytomegalovirus (CMV) infection in belimumab-treated subjects 
(Table 2). There were no new diagnoses of malignancy in either group during the follow up 
period and one death, from a cardiovascular cause, in the placebo group (Table 2).  In 
summary, in this preliminary study, belimumab was not associated with an excess risk of 
serious infection or malignancy when used with standard transplant immunosuppression. 
BLyS is known to support the survival of transitional and naïve B cells20. Therefore, we 
assessed naïve B cell count as a co-primary endpoint. This co-primary endpoint of a 
reduction in naïve B cells from baseline to Week 24 was not met. When considering the 
MITT population, there was a trend towards a reduction, but no statistically significant 
difference in naïve B cells (adjusted mean difference naïve B cells from baseline to week 24 -
34·4 cells/mm3 (95% CI -109·5 to 40·7)) (Fig. 2A; Table S4). At later time points in the PP 
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population that included all MITT subjects who received at least five infusions of 
belimumab/placebo, significant differences in naïve B cell count were observed; adjusted 
mean difference naïve B cells from baseline to post treatment week 28 was -61.6 cells/mm3 
(95% CI -122.6 to -0·7) (Fig S1D; Table S4). A pre-specified non-parametric sensitivity 
analysis on the MITT population showed a greater reduction from baseline naïve B cell count 
with belimumab at post treatment week 12 and 28 (median difference at post treatment week 
28 -48.3 cells/mm3 (95% CI -144.7 to -13.0)) (Fig. S1E; Table S5). 
Biopsy proven TCMR (Banff grade I-III) occurs with a frequency of 15.3% in the 6 months 
post-transplant, in those receiving basiliximab-based induction therapy35. B cell depletion 
with the anti-CD20 antibody rituximab has been associated with increased TCMR11 and 
cardiac allograft vasculopathy12.  Since belimumab also depletes some B cell subsets, we 
sought to confirm that its use was not associated with an increase in alloimmune responses. 
The overall frequency of TCMR (including borderline episodes, Banff classification) was 
similar in belimumab (n=1/12 (16.7%)) and placebo-treated subjects (n=3/13 (23%), Table 1). 
One additional subject was randomised to the belimumab group and received a single dose 
at day 0 but was withdrawn from the study due to a positive B lymphocyte flow cytometry 
cross-match (an exclusion criterion), the results of which became available post-transplant. 
This subject subsequently developed Banff IIA TCMR rejection with features suspicious of 
early acute humoral rejection (day 6), with a further biopsy during treatment demonstrating 
grade II ABMR (day 34), both of which resolved following treatment with methylprednisolone 
(day 3-5), plasma exchange (day 8 & 38-52) and anti-thymocyte globulin (day 8-21) (details 
in supplementary appendix). In the context of pre-formed HLA antibodies and suboptimal 
induction immunosuppression their rejection episode was not unexpected; however given 
there was also one further episode of Banff grade IIA cellular rejection in the belimumab PP 
treatment group and only three Banff ‘borderline’ rejections in the placebo treated group (one 
was treated with corticosteroids), close monitoring for rejection episodes in larger studies will 
be required to better understand this observation. Overall, transplant function at one year, 
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graft and patient survival were not negatively affected by the addition of belimumab to 
standard of care immunosuppression (Table 1 & 2). 
Total B cell numbers were comparable throughout the study (Fig. S1C; Table S13). We 
observed fewer transitional (CD24brCD38brIgD+) B cells at post-treatment week 12 (adjusted 
mean difference -9156 cells/ml (95% CI -18307 to -6) (Fig. S1F; Table S14) with relative 
sparing of memory (CD20+CD27+) B cells (Fig. S1G; Table S15) such that the proportion of 
memory B cells was increased throughout the treatment and follow up period (maximal 
adjusted mean difference 25.7% (95% CI 16.0 to 35.5) at post-treatment week 12; post hoc 
analysis) (Fig. 2B, C; Table S7). In contrast to the effect of belimumab on the total memory B 
cell pool, activated memory (CD95+CD27+) B cells were decreased from post-treatment week 
12 to 28 (Fig. 2D, S1H; Table S16) (adjusted mean difference -14538.52 cells/ml (95% CI -
24875.4 to -4201.6) at post-treatment week 12). There was also a reduction in circulating 
CD19+CD27+CD38hi plasmablasts measured by flow cytometry at post-treatment week 12 
(adjusted mean difference -1055.5 count/ml (95% CI -1889.7 to -221.2; post hoc analysis) 
(Fig. S1I; Table S17). In order to further understand the impact of belimumab on B cell 
activation and differentiation into antibody-secreting cells, we assessed the whole blood 
transcriptome. Weighted gene co-expression network analysis identified a B cell gene 
expression module, identified as such based on the overrepresentation of genes annotated 
as part of the BCR signaling pathway in the Gene Ontology (Fig. S1L), with attenuated 
expression in belimumab-treated subjects (post hoc analysis; Fig. 2E). The most attenuated 
genes in this module coded for IgG, suggesting a strong effect on antibody-secreting cells 
and complementing our observation of fewer circulating plasmablasts and reduced de novo 
non-HLA antibody formation (described below).  
Eight study participants had anti-HLA antibodies (non donor-specific) at transplantation (3/12 
in the belimumab group and 5/13 in the placebo group, Table 1). We observed a variable 
reduction in pre-existing HLA class I and II antibody levels, but the small sample size 
precludes any definitive conclusions on the effect of belimumab (Fig. S2). Two patients 
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recruited to the study developed de novo DSA during follow-up; both had been withdrawn 
following a single dose of belimumab for reasons unrelated to antibody development (Fig 
S2C; see appendix for details).   
De novo HLA and non-HLA IgG autoantibodies can have a deleterious effect on allograft 
function2,3,36. In order to sensitively measure the ability of belimumab to inhibit the 
development of de novo IgG antibodies, we compared antibody binding to a human protein 
array in serum samples taken at time zero and week 24. This demonstrated that the addition 
of belimumab to standard of care immunosuppression significantly reduced de novo IgG 
antibody formation (median number new antibody specificities binding above threshold 55.5 
placebo vs 15.5 belimumab; post hoc analysis p=0.0474) (Fig. 2G; Table S8).  In addition to 
effects on de novo antibodies, we also observed an effect on pre-formed non-HLA antibodies 
that have been implicated in allograft damage; at week 24 we saw a trend towards reduced 
IgG specific for kidney antigens37 following belimumab treatment (median number antibodies 
binding kidney specific antigen above threshold 12.5 placebo vs 8.0 belimumab; post hoc 
analysis  p=0.0524 (Fig. 2H; Table S8); median mean protoarray signal 1307.3 placebo vs 
983.5 belimumab; post hoc analysis p=0.065 (Fig. S2D; Table S8), and a significant 
reduction in anti-EDIL3 (EGF-like repeats and discoidin I-like domains 3) antibodies at week 
24 (median of mean protoarray signal 353.6 placebo vs 261.9 belimumab; post hoc analysis 
p=0.0379) (Fig. S2E; Table S8), an endothelial cell-specific antibody associated with post-
transplant glomerulopathy36. The presence of antibodies to glial cell-derived neurotrophic 
factor (GDNF) at the time of transplantation has been associated with more severe chronic 
allograft injury (interstitial fibrosis and tubular atrophy) on 24 month biopsies3; we observed a 
reduction in the number of subjects with detectable anti-GDNF antibodies at week 24 
compared with time 0 in the belimumab group (6/8 and 2/8 at time 0 and 24 weeks 
respectively), in contrast to the placebo group (6/8 and 6/8 at time 0 and week 24 
respectively; post hoc analysis) (Fig. S2F). Together, these data emphasise that belimumab 
modulates a clinically important aspect of B cell function post-transplant.  
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Transitional B cells have been associated with good outcomes in renal transplant, and this 
has been proposed to be due to their enrichment with IL-10 producing regulatory B cells15-18. 
IL-10 producing B cells have also been identified within memory subsets8. We sought to 
address how belimumab treatment affects B cell cytokine production post-transplant. PBMC 
were stimulated ex vivo with CpG and CD40L, and B cell IL-10 and IL-6 production assessed 
(Fig. 3A, B; Table S9). Despite reductions in transitional B cells (Fig. S1F; Table S14), at 
week 12 post-treatment subjects receiving belimumab had a reduction in IL-6-producing B 
cells (median 42.62% placebo vs. 29.18% belimumab; post hoc analysis p=0.0379) and an 
increase in IL-10+ B cells (median 2.46% placebo vs. 4.56% belimumab; post hoc analysis 
p=0.0499) (Fig. 3A, B; Table S9), skewing the cytokine ratio toward a more regulatory profile 
compared with controls (median 0.059 placebo vs. 0.127 belimumab; post hoc analysis 
p=0.0070) (Fig. 3C). This skewing of cytokine production towards IL-10 was observed in both 
transitional and memory B-cell subsets (Fig. 3D; Table S10). To validate our findings and 
confirm that the effect of belimumab on B cell cytokine production was B cell intrinsic we 
cultured PBMC enriched for memory B cells from healthy controls with BLyS in the presence 
or absence of belimumab. This demonstrated that BLyS stimulation significantly decreased B 
cell IL-10 relative to IL-6 (mean % change from baseline with 100ng/ml BLyS -22.90% 
(95%CI -36.52, -9.28); post hoc analysis p=0.0029) and was abrogated by the addition of 
belimumab (mean % change from baseline with 100ng/ml BLyS + 15nM belimumab 0.63% 
(95%CI -18.28, 19.54); post hoc analysis p=0.9377) (Fig. 3E; Table S11) providing new 
insights for Breg biology.  
We also investigated whether T cell activation was altered by belimumab treatment, since B 
cells are potent antigen presenting cells and IL-6 may augment T cell activation38 whilst IL-10 
can regulate T cell responses39. There was no difference in the number of circulating T cells 
by treatment (Fig. S1J-K); Table S18-19) but transcriptomic analysis of purified circulating 
CD4 T cells revealed reduced expression of cell-cycle genes in belimumab-treated subjects 
274
18 
(post hoc analysis; Fig. 3F, Table S2) suggesting that BLyS neutralisation may also inhibit T 
cell proliferation. 
DISCUSSION 
A key goal of this study was to determine the safety profile of belimumab in combination with 
standard transplant immunosuppression. Although belimumab has previously been used in 
patients with SLE with renal involvement, it has not been used in those with established 
ESRF, which in itself confers an increased risk of infection33. Despite this, and a significantly 
greater burden of concomitant immunosuppression than used previously, we observed no 
excess infections with the addition of belimumab. Observed AEs were consistent with that 
expected for the underlying population, concurrent medications and known safety profile of 
belimumab.  
The co-primary endpoint of a reduction in naïve B cells from baseline to week 24 was not 
met in the MITT population, due to the impact of subjects that received only one dose of 
belimumab on a group with limited sample size. However, sensitivity and pre-specified 
analyses performed on the PP population that included subjects who received at least five 
doses of belimumab/placebo, confirmed that belimumab did have a significant biological 
effect, greatest at post treatment week 12. Sample size calculation relied on data from 
studies of belimumab in SLE; it is likely that the more intense immunosuppression given in 
the immediate post-transplant period masked earlier differences.  
Although the co-primary endpoint of a reduction in naïve B cells from baseline to week 24 
was not met, data from secondary and mechanistic end-points suggest but do not definitely 
prove, potential beneficial effects of belimumab post-transplant. Despite depletion by 
belimumab of the transitional B cell subset known to contain regulatory B cells, remaining B 
cells after belimumab treatment demonstrated an increased capacity to produce the 
immunoregulatory cytokine IL-10 relative to IL-6. Since B cells are the major source of IL-6 in 
secondary lymphoid organs40, this observation is significant and of potential clinical benefit in 
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transplantation: IL-6 promotes B cell differentiation into antibody-forming plasma cells, 
contributes to the plasma cell niche41, enhances T follicular helper cell differentiation (critical 
for the germinal centre response),  and inhibits the generation of regulatory T cells38.  Indeed, 
an IL-6R antagonist has been used to treat patients with chronic ABMR42.  
We present flow cytometry, transcriptomic and protein microarray data suggesting that BLyS 
neutralisation reduced antibody-forming cells and resulted in a lower incidence of de novo 
non-HLA autoantibody formation post-transplant. In particular, observed trends in kidney and 
endothelial specific IgG raise the possibility of improved longer-term transplant 
outcomes2,3,36. Our study also highlights the role of BLyS in memory B cell activation. 
Belimumab-treated subjects had fewer circulating activated (CD95+) memory B cells, 
suggesting a rationale for using belimumab as a longer-term adjuvant in sensitised transplant 
subjects with pre-existing donor-specific memory B cells, in addition to lymphocyte depletion 
and antibody removal. This strategy is currently being studied in a recently established 
clinical trial using belimumab in combination with bortezomib, plasma exchange and 
rituximab as a desensitisation therapy (ClinicalTrials.gov Identifier: NCT02500251). Finally, a 
decrease in T cell proliferation markers demonstrates the potential for belimumab to 
modulate both cellular and humoral alloimmunity. 
Our study has several limitations; the sample size was not powered for clinical endpoints, 
limiting the broader interpretation of our findings. Early phase studies with modest numbers 
cannot provide definitive data on safety; with this caveat we report no major adverse safety 
signal. Despite modest numbers, we were able to implement a range of assays measuring 
both clinical and immunological parameters so that our major findings are backed by multiple 
independent readouts, for example flow cytometry, transcriptional differences and antibody 




The study population (standard immunological risk transplant recipients without DSA) was 
selected in light of previous studies in SLE showing a significant effect of belimumab on 
naïve B cells; we therefore hypothesised that the depletion and inhibition of naïve B cells 
may prevent the development of de novo HLA antibodies in low risk patients. However, these 
patients have a low risk of developing DSA (around 10% per annum) and a trial powered to 
detect a difference would need several thousand patients, unfeasible for a Phase 2 
experimental medicine study. The transplant community has acknowledged that the unmet 
need for novel effective therapies for ABMR and to improve long-term graft outcomes may be 
best addressed through non-traditional trial designs that include surrogate endpoints43. 
Although our study did not include sensitised subjects at greatest risk of ABMR and graft 
loss, the occurrence of ABMR in the sensitised subject that was inadvertently included in the 
study provides valuable information for the design of future trials in this area, suggesting that 
such patients may well need antibody removal and pan-lymphocyte depletion in addition to 
belimumab. Further studies will be required to evaluate the safety and efficacy of belimumab 
alongside lymphocyte depleting treatments including thymoglobulin or alemtuzumab, agents 
that previously associated with an increase in serum BLyS44. Whether belimumab would 
have the same pro-regulatory effect on the reconstituted B cell pool when used in 
combination with lymphocyte-depletion remains to be determined. An observed rebound in 
serum BLyS following cessation of belimumab raises the question of whether belimumab 
should be administered for a more extended period post-transplant, with graduated 
discontinuation alongside monitoring of serum BLyS.  
This study exemplifies an experimental medicine approach and suggests potential efficacy of 
belimumab as an immunomodulatory agent in transplantation that can limit new antibody 
formation, providing a useful platform to support design of future clinical studies to explore 
the further use of belimumab in renal transplantation. In addition, our study provides new 
insights into BLyS biology and the mechanism of action of belimumab, including novel 
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preliminary data on its effect on the regulatory B cell compartment and autoantibody 
production, which are also of relevance in autoimmunity.  
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Baseline demographic data, n 13 12 
Age (years), Mean (SD) 51.0 (14.0) 54.3 (11.0) 
Range 24-73 32-72
Sex, n (%) 
- Female 4 (31) 7 (58) 
- Male 9 (69) 5 (42) 
Race, n (%) 
- White/Caucasian 12 (92) 11 (92) 
- Asian 1 (8) 1 (8) 
Mean number (SD) of HLA-A/B/DR mismatches 
- HLA-A 1.7 (0.5) 1.8 (0.5) 
- HLA-B 0.9 (0.6) 1.1 (0.3) 
- HLA-DR 0.6 (0.5) 0.8 (0.6) 
Number of previous kidney transplants, n (%) 
- 0 11 (85) 11 (92) 
- 1 2 (15) 1 (8) 
Pre-transplant renal replacement modality, n (%) 
- None 3 (23) 2 (17) 
- Haemodialysis 7 (54) 7 (58) 
- Peritoneal dialysis 3 (23) 3 (25) 
HLA antibody at baseline (MFI>2000)3, n (%) 
- Non-DSA 5 (38) 3 (25) 
- DSA 2 0 1 (8) 
Donor type, n (%) 
- Living 3 (23) 4 (33) 
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- Donation after circulatory death 7 (54) 5 (42) 
- Donation after brain death 3 (23) 3 (25) 
Donor age (years) 
Mean (SD) 52.9 (8.8) 58.3 (8.1) 
Range 37-68 47-69
Donor creatinine-last value prior to transplant (μmol/L) 
Mean (SD) 64.8 (17.5) 84.3 (30.7) 
Median (Min, Max) 66.0 (37-92) 78.0 (51-167) 
Clinical outcome data1, n 8 8 
Acute transplant rejection by week 522, n (%) 
- Borderline, not treated 2 (25) 0 
- Borderline, treated 1 (12.5) 0 
- Type IIa, treated 0 1 (12.5) 
Cumulative HLA class I (MFI >500)3 Sub 22 Sub 28 Sub 8 Sub 27 
Before treatment 39612 20046 127392 4894 
On treatment Wk 2 24658 14731 56453 4493 
On treatment Wk 4 26129 21466 33810 3438 
On treatment Wk 8 28930 19528 34420 4632 
On treatment Wk 12 26709 26500 25985 6320 
On treatment Wk 24 23152 18376 26491 8103 
Post treatment Wk 28 19204 18892 24607 4349 
Cumulative HLA class II (MFI 
>500)3 Sub 4 Sub 1 
Before treatment 2382 16009 
On treatment Wk 2 916 9305 
On treatment Wk 4 1211 12346 
On treatment Wk 8 768 12553 
On treatment Wk 12 606 10540 
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On treatment Wk 24 577 13408 
Post treatment Wk 28 785 9075 
Graft survival, n (%) 8 (100) 8 (100) 
Creatinine at 52 weeks (μmol/L) 
Mean (SD) 142.5 (65.7) 110.6 (43.6) 
Median (Min, Max) 114 (86-282) 94 (68-201) 
eGFR at 52 weeks (ml/min/1.73m2), 
Mean (SD) 53.00 (22.10) 57.42 (15.08) 





1Clinical outcome data described for the per protocol population. 
2Acute rejection was defined on biopsy according to Banff 2009 criteria: Acute antibody 
mediated rejection (Grade I, II or III) or acute T cell mediated rejection (Borderline, Type IA, 
Type IB, Type IIA, Type IIB, Type III). An additional subject randomised to belimumab had a 
positive pre-transplant MHC class II flow crossmatch (fulfilling an exclusion criterion but 
unknown at the time of enrolment and transplant). They experienced Type IIA acute cellular 
rejection (day 6) and grade II antibody mediated rejection (day 34). They were withdrawn 
once the crossmatch was recognised following a single dose of belimumab. 
3A cut-off of MFI>2000 was used to define preformed HLA antibody at baseline, since this is 
the threshold for clinical significance determined by the tissue-typing laboratory. Cumulative 
HLA class I and class II MFI calculated by summing the normalised MFI values for any single 
antigen bead with a value above the level of detection (500). An additional subject in the 
belimumab group underwent adoptive transfer of donor HLA-specific allosensitization 
following kidney transplantation from a highly sensitized donor. 
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SD standard deviation, n number of subjects, HLA human leukocyte antigen, MFI mean 
fluorescence intensity measured by Luminex assay, DSA Donor specific antibody, Min 
minimum, Max maximum, and eGFR estimated glomerular filtration rate. 
Table 2. Safety Findings During On-treatment and Post-treatment Phases, by Treatment 
Group. 
On treatment 1 Post-treatment 
Number (%) Subjects Number (%) Subjects 
Placebo Belimumab Placebo Belimumab 
(n=13) (n=12) (n=13) (n=12) 
Any adverse event (AE) 10 (77) 11 (92) 9 (69) 10 (83) 
Any serious AE (SAE) 7 (54) 5 (42) 2 (15) 2 (17) 
Any severe AE 6 (46) 8 (67) 3 (23) 3 (25) 
Deaths 2 1 (8) 0 0 0 
Most common AE 3 
- Leukopenia 4 (31) 4 (33) 3 (23) 3 (25) 
- Diarrhoea 3 (23) 5 (42) 1 (8) 1 (8) 
- Urinary tract infection 4 3 (23) 4 (33) 1 (8) 2 (17) 
- Anaemia 5 4 (31) 3 (25) 0 1 (8) 
- Lower respiratory tract infection 6 2 (15) 2 (17) 2 (15) 0 
- Dyspepsia7 2 (15) 2 (17) 2 (15) 0 
- Nasopharyngitis 2 (15) 1 (8) 1 (8) 2 (17) 
- Alanine aminotransferase increased 2 (15) 2 (17) 0 0 
- Diabetes Mellitus8 1 (8) 1 (8) 0 2 (17) 
- Endoscopic evidence upper GI inflammation9 2 (15) 1 (8) 0 0 
- Dizziness 0 2 (17) 0 1 (8) 
- Vomiting 0 2 (17) 0 0 
Infections 
- All 7 (54) 5 (42) 8 (62) 6 (50) 
- Serious infections (n≥1) 5 (38) 1 (8) 2 (15) 0 
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- Severe infections (n≥1) 5 (38) 2 (17) 3 (23) 0 
- Opportunistic infections 3 (23) 2 (17) 3 (23) 3 (25) 
- BK viraemia 2 (15) 1 (8) 1 (8) 1 (8) 
- BK viraemia-associated nephropathy 0 1 (8) 1 (8) 0 
- Cytomegalovirus (CMV) viraemia10 1 (8) 0 1 (8) 2 (17) 
Malignant neoplasm 0 0 0 0 
Depression/Suicide/Self injury 0 0 0 0 
Post infusion systemic reaction11 0 1 (8) NA NA 
Recurrence of focal segmental 
glomerulonephritis12 1 (8) 1 (8) 0 0 
Hypogammaglobulinemia of grade ≥3 
(<4.0g/L) 2 (15) 3 (25) 0 0 
1The on-treatment phase commences from the start of the first infusion of randomised study 
drug and ends 28 days after the last dose. The post-treatment phase begins the following 
day. 
2Death due to fatal myocardial infarction and acute cardiac failure. 
3Includes all AEs (by grouped MedDRA preferred terms) occurring in more than one subject 
during the study not including opportunistic infections (listed separately), ordered by overall 
frequency. 
4Grouped preferred terms include urinary tract infection, Escherichia urinary tract infection, 
urinary tract infection enterococcal and urosepsis. 
5Grouped preferred terms include anaemia, anaemia vitamin B12 deficiency and iron 
deficiency anaemia. 
6Grouped preferred terms include pneumonia and lower respiratory tract infection. 
7Grouped preferred terms include dyspepsia and gastrooesophageal reflux disease.
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8Grouped preferred terms include diabetes mellitus and type two diabetes mellitus; one post 
treatment AE was worsening of diabetes, onset on treatment, in context of steroids for SAE 
(colitis) 
9Grouped preferred terms include oesophagitis, duodenal ulcer, duodenitis and ulcerative 
gastritis. 
10Grouped preferred terms include cytomegalovirus test positive, cytomegalovirus viraemia, 
culture positive (verbatim term CMV). 
11The infusion reaction reported was mild, settled spontaneously and did not recur on 
subsequent infusions. 
12Grouped preferred terms include focal segmental glomerulosclerosis (FSGS) and 
glomerulonephritis (recurrence of FSGS verbatim term). NA denotes not applicable. 
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Figure 1. Enrolment, Randomisation and Follow-up. 
The randomised treatment was given in addition to standard immunosuppression consisting 
of basiliximab, mycophenolate mofetil, tacrolimus and corticosteroids (see methods for full 
details).  
1260 at Addenbrooke’s Hospital, Cambridge (28 randomised); 43 at Guy's and St Thomas’ 
NHS Foundation Trust, London (0 randomised). 
2Reasons for not meeting inclusion criteria shown in Supplementary Table 1. Logistical 
reasons included unavailability of study staff or randomised study drug, insufficient time for 
consent and recipient resident out of region.  
3The pre-specified per protocol (PP) population used for biomarker and clinical endpoint 
analysis consisted of all subjects in the modified intention to treat (MITT) population who 
received at least five infusions of belimumab/placebo, no prohibited medications or plasma 
exchange and at least 24 weeks follow-up.  
FSGS Focal Segmental Glomerulosclerosis, SAE Serious Adverse Event 
Figure 2. Belimumab Affects Naïve B Cells, Activated Memory B Cells and Circulating 
Plasmablasts, and Reduces Allo/Auto-antibody Generation. 
Panel A shows the adjusted mean (95% CI) change from baseline in naïve (CD20+CD27-) B 
cell count (cells/mm3), by visit and treatment.  
Panel B is a radar plot summarising the median difference from baseline to week 24 
compared to baseline (i.e. percentage at week 24 – percentage at week 0) for the labelled B 
cell populations by belimumab or placebo, where each B-cell population is expressed as a 
percentage of total B cells.  
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Panel C shows memory (CD20+CD27+) B cells expressed as a percentage of B cells by visit 
and treatment group.  
Panel D shows the relationship between memory B cell count (cells/mm3) and activated 
memory B cell (CD95+CD27+) percentage at the post treatment week 12 timepoint for 
individual subjects labelled by treatment group.  
Panel E shows expression (arbitrary units) of a B cell whole blood gene expression module 
by treatment group at baseline, end of on-treatment phase (Week 24) and end of follow-up 
(Week 52). Horizontal lines correspond to median and interquartile ranges.  
Panel F shows a heat map of differential gene expression (belimumab versus placebo 
groups) for genes in the B cell module at baseline, week 24 and week 52. Genes are ordered 
by fold-change at week 24 and immunoglobulin-coding transcripts are highlighted. Colour 
corresponds to log2-fold change, with blue indicating higher expression in the placebo group 
(Placebo) relative to the belimumab group (Belimumab).  
Panel G shows the number of unique ProtoArray antigen specificities with significant 
antibody binding at Week 24 but not at baseline. Horizontal lines on boxplot (left) correspond 
to median and interquartile ranges. Ordered individual participant data are also shown (right), 
with participants coloured by treatment group. The Wilcoxon rank-sum test was used to 
compare the belimumab treatment group (BEL) and placebo treatment group (PBO); * 
denotes p<0.05.  
Panel H shows the number of kidney-specific unique ProtoArray antigen specificities (as 
defined in 37) with significant antibody binding at Week 24. Horizontal lines on boxplot (left) 
correspond to median and interquartile ranges. Ordered individual participant data are also 
shown (right), with participants coloured by treatment group. The Wilcoxon rank-sum test 
was used to compare the belimumab treatment group (BEL) and placebo treatment group 
(PBO); exact p value displayed. 
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Panel A uses the MITT population. Panels B, C, D, G and H use the PP population. Panels E 
and F use the MITT population for baseline and the PP population thereafter. C shows raw 
values at baseline for comparison and adjusted mean estimate with 95% confidence intervals 
at subsequent timepoints. Adjusted mean estimates and 95% confidence intervals are 
obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and 
treatment-by-visit interaction and fixed continuous covariates of baseline and baseline-by-
visit interaction. A compound symmetry variance structure was used to model the within-
patient errors, shared across treatments. # indicates that the 95% confidence interval of the 
treatment difference does not include zero. D shows data for individual PP subjects labelled 
by treatment group. Panels B, C, D, E, F, G and H represent analyses performed post hoc. 
Figure 3. Memory B Cell IL-10/IL-6 Ratio is BLyS Dependent. Belimumab Treatment 
Increases Regulatory B Cells and is Associated with Reduced T cell Proliferation. 
Peripheral blood mononuclear cells (PBMC) were stimulated ex vivo for 5 hours and 
intracellular cytokine production quantified by flow cytometry (Panel A-D). Individual data 
points represent individual subjects with horizontal lines signifying the median for each 
treatment group. Wilcoxon rank-sum tests were performed to compare samples by treatment 
and visit.   
Panel A shows representative flow cytometry plots for IL-6 (upper) and the percentage of 
CD19+ B cells expressing IL-6 (lower).  
Panel B shows representative flow cytometry plots for IL-10 (upper) and the percentage of 
CD19+ B cells expressing IL-10 by treatment group and timepoint (lower).  
Panel C shows the calculated ratio of IL-10/IL-6 with higher values indicating a more anti-
inflammatory cytokine milieu.  
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Panel D shows the IL-10/IL-6 ratio for individual subsets of naïve (CD27-), transitional 
(CD24hiCD38hiIgD+), CD24+CD27+ memory, switched memory (CD27+IgD-), and non 
switched memory (CD27+IgD+) B cells at post treatment Wk 12.  
Panel E shows the mean IL-10/IL-6 ratio (relative to 0ng/mL BLyS) with 95% confidence 
intervals for PBMC from healthy volunteers enriched for CD27+ memory B cells and 
stimulated for 48 hours with increasing quantities of BLyS. In the presence of increasing 
quantities of BLyS a more inflammatory cytokine milieu was observed. This change was 
blocked by the addition of belimumab. N, number of healthy volunteers tested for each 
experimental condition. T-tests were performed to determine whether the mean percentage 
changes from baseline differed significantly from 0 for each experimental condition. 
Panel F shows a heatmap of differential gene expression in circulating CD4+ T-cells for the 
most downregulated genes at week 24 in the belimumab group relative to the placebo group, 
with genes ordered by unsupervised hierarchical clustering. Genes annotated to the cell-
cycle (GO:0007049) are highlighted. Colour corresponds to log2-fold change, with blue 
indicating higher expression in the placebo group (Placebo) relative to the belimumab group 
(Belimumab). 
Panels A-D use the PP population and Panel F uses the MITT population for baseline and 
PP population thereafter. P-values in Panels A-D were calculated using Wilcoxon rank-sum 
tests and indicated where significant; in all other cases the values are not statistically 
significantly different. P-values in Panel E were calculated using Student’s t-test. * p<0.05, ** 
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BEL114424 eligibility criteria and study protocol 
The BEL114424 study protocol, including full eligibility criteria is included as a separate file and will also be 
published at www.gsk-clinicalstudyregister.com. 
The original protocol excluded donation after circulatory death (DCD) donors aged > 60 years old, or > 50 if 
they had died from a stroke, had a history of high blood pressure, or had a serum creatinine greater than 
135µmol/L at the time of donation (i.e. extended criteria DCDs). An amendment to widen eligibility criteria 
was sought (protocol amendment 4, dated 16 October 2013), with the aim of increasing recruitment. The 
reasons for subjects not meeting inclusion criteria are listed in Table S1. 
Table S1: Reasons for subjects not meeting inclusion criteria. 
Reason not meeting inclusion criteria Number 
Donor characteristic 36 
Alternative immunosuppression planned 21 
0-0-0 mismatch 16 
HLAi or ABOi transplant 15 
Other disease/condition judged unsuitable by PI 12 
Prior therapy 8 
Transplant other than kidney 3 
Recipient hepatitis 3 
Donor hepatitis 2 
Recipient unable to consent due to learning difficulties 2 
Recipient HIV+ 2 
Drug sensitivity 1 
Prior malignancy 1 
Poor venous access 1 
Total 123 
Visit windows 
Assessments were assigned to visit windows (slots) according to the date of assessment (for study schedule 
see study protocol).  
For adverse events the on-treatment phase commenced from the start of the first infusion of belimumab/placebo 
and ended 28 days after the last dose. The post-treatment phase began the following day. For other primary 
and secondary endpoints, the on-treatment phase ended 35 days after the last dose to allow incorporation of 
the On-Trt Week 24 visit on day 168 +/- 7 days. 
The visit slotting intervals for the Pre-Treatment and On-Treatment (On-Trt) phases for biomarker endpoints 
were as follows: 
Week Day relative to 
first infusion 
Day Visit Window 
Baseline 
On-Trt Week 4 
On-Trt Week 8 
On-Trt Week 12 







28 - 27 Days or + 14 Days 
56 - 13 Days or + 14 Days 
84 - 13 Days + 42 Days 
168 - 41 Days +7 Days 
≤0 
Days 1 to 42 
Days 43 to 70 
Days 71 to 126 
Days 127 to 175 
The visit slotting intervals for the Post-Treatment (Post-Trt) phase for biomarker endpoints were as follows: 
Week Day relative to (last 
infusion + 35 Days) 
Day relative to 
last infusion 
Day Visit Window 
Post-Trt Week 12 





84 – 83 Days or + 56 Days 
196 – 55 Days or + 154 Days 
Days 1 to 140 
Days 141 to 350 
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If more than one assessment fell within the same visit window, the assessment nearest to the scheduled time 
point was used. If two assessments were equally close, the latter was used. Samples for transcriptomic and 
protoarray analysis were collected at baseline, at week 24 (+/- 7 days) and at week 52 (+/- 7 days) according 
to the study schedule, irrespective of the last dose of study drug given, so data for these endpoints are presented 
without window fitting. On-treatment samples for the B cell stimulation assay were limited so the last available 
on-treatment result is displayed (‘Last On-Trt’). 
Study objectives and endpoints 
Objectives Endpoints 
Co-primary 
Efficacy: To estimate the change in naive B cells 
following belimumab 10 mg/kg (or placebo) in 
addition to standard of care immunosuppressants in 
renal transplant patients from the time of 
transplantation up to 24 weeks 
Change from baseline in naïve 
 B cells from baseline to Week 24. 
Safety: To assess the safety and tolerability of 
belimumab 10 mg/kg (or placebo) in renal transplant 
patients in addition to standard of care 
immunosuppressants. 
AEs and SAEs, including AEs of special interest 
(opportunistic infections, malignancies, 
hypersensitivity and infusion reactions, all cause 
mortality and suicidality) 
Incidence and severity of infections 
Change from baseline and number of subjects 
outside the normal range for blood pressure, heart 
rate, and temperature 
Change from baseline and number of subjects 
outside the normal range for clinical chemistry and 
haematology parameters, with particular attention to 
white blood cell count and immunoglobulin levels 
Secondary 
To further assess the pharmacodynamic effect of 
belimumab in addition to standard of care 
immunosuppressants in renal transplant patients at 
24 weeks 
Percent change from baseline in memory B cells, 
Activated memory B cells, Transitional B cells 
To assess the phenotype and tolerogenic profile of 
the repopulating B cells after belimumab therapy at 
Week 52. 
To further assess the potential for efficacy of 
belimumab in addition to standard of care 
immunosuppressants in reducing the incidence of 
renal allograft rejection using biomarker and clinical 
outcomes. 
Activated T cells, regulatory T cells, and  ratio of 
activated: regulatory T cells  
All HLA-specific and donor HLA-specific antibody 
levels  
Proportion of subjects with episodes of acute 
rejection 
Serum creatinine 
Estimated glomerular filtration rate (eGFR)  
Immunosuppressant/corticosteroid use 
Exploratory 
To further assess the potential for efficacy of 
belimumab in addition to standard of care 
immunosuppressants in reducing the incidence of 
renal allograft rejection using exploratory 
biomarkers.   
Exploratory endpoints may include analyses of 
transcriptomic signatures, non-HLA antibody 
profiles, cytokine profiles and additional leukocyte 
subsets 
Other 
To determine immunogenicity and pharmacokinetic 
profile of belimumab, and to characterize genetic 
variability that may affect efficacy or safety 
endpoints in renal transplant patients. 
Incidence, titers, and specificity of anti-belimumab 
antibodies 
Serum concentrations of belimumab 




There were no formal statistical hypotheses tested in this study. An estimation approach was used to investigate 
the magnitude of the difference in the selected primary and secondary endpoints following treatment with 
belimumab relative to placebo. Because the study included no prospectively defined formal hypothesis testing, 
no adjustment for multiplicity was required for the primary and secondary endpoints. 
The primary and, where specified, secondary analyses utilised a mixed model for repeated measures (MMRM) 
approach with fixed categorical effects of treatment, visit, donor organ status (coded as live donor, donated 
after brain death, donated after circulatory death) and treatment-by-visit interaction and fixed continuous 
covariates of baseline values and baseline values-by-visit interaction. A compound symmetry variance 
structure was used to model the within-patient errors, shared across treatments. 
All post hoc analyses are labelled as such. Analyses were performed using SAS version 9.3 except for 
transcriptomic and protein microarray analyses, which were performed using R version 3.3.1. 
Enabling work in transplant patients (n=93 renal transplant recipients at the Cambridge Transplant Unit 
(unpublished data)) found that naive B cell counts at baseline in transplant patients were similar to SLE patients 
(Phase III BLISS-76 study1) after removing the top 5th percentile of SLE patients with highest baseline counts. 
By adjusting the SLE data in this way, and assuming transplant patients will vary in a similar way to SLE 
patients a standard deviation (SD) of 63.24 cells/mm3 was observed. Assuming a sample size of 10 per group, 
and mean difference of -59 cells/mm3 (observed in BLISS-76) we predicted a 95% confidence interval around 
the mean difference of (-114.43, -3.57).  
Interim re-estimations of sample size were performed in November 2014 and February 2015 to take into 
account drop-outs and inform the potential benefit and requirement for further study enrolment. An unblinded 
statistician examined the variability in naive B-cells and compared to BLISS-76, looking for trends over time 
with subject profile plots. The observed treatment difference of the change from baseline in naïve B cells at 
Week 8 was used to make a predictive probability statement about the probability of achieving success at Week 
24 for a particular total sample size. The predictive probability assessment suggested that "the benefit of 
recruiting an additional 10 evaluable subjects (30 evaluable overall) on the outcome of the study was 
negligible" 
Microarray analysis 
Leukocyte subsets were purified from whole blood then lysed as previously described 2. Lysates (CD4+ T-
cell) and PAXgene tubes (whole blood) were stored at -80°C until required. RNA was extracted from CD4+ 
T-cell lysates using an AllPrep Kit (Qiagen) and from whole blood using the PAXgene system (Qiagen). RNA
was processed and hybridised to Human Gene ST 2.1 microarrays (Affymetrix) according to the
manufacturer’s instructions.
Affymetrix CEL files were imported into R/Bioconductor, normalised and summarised at the transcript cluster 
level using the oligo package (rma function, target = “core”). Transcript clusters were annotated using Ensembl 
biomaRt and manufacturer’s own annotation and Affymetrix control probes were removed. Non-protein 
coding probes were also removed. 
Weighted gene coexpression network analysis (WGCNA) was undertaken of the whole blood gene expression 
data using the WGCNA package in R/Bioconductor. One of the resulting whole blood gene expression 
modules was identified as representing a B-cell transcriptional programme on the basis of a unique overlap of 
module genes with the Gene Ontology class ‘GO:0050853 BCR signalling pathway’ (Supplementary Figure 
1L). Module expression was determined as the value of the first principal component calculated from module 
gene expression, along standard analysis lines for WGCNA and using functions in the WGCNA package. 
Differential gene expression analyses were performed using the limma package in R/Bioconductor. The model 
incorporated time-point and treatment group interaction terms and accounted for the repeated measures nature 
of the analysis (study participants contributed gene expression samples at three different timepoints) using the 
duplicateCorrelation function. Contrasts were defined for differential expression at baseline, 24 weeks and 52 
weeks (Belimumab – Placebo at each timepoint). Estimates were adjusted using the eBayes function. 
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Where there was more than one transcript cluster per gene, differential expression was summarised into a 
single gene measure using the mean log-fold change. Immunoglobulin coding genes were identified from their 
Ensembl Biotype annotation. Cell cycle genes were identified using the Gene Ontology class ‘GO:0007049 
Cell cycle’. 
Table S2: Top 100 differentially expressed genes (by fold-change) in CD4+ T-cells comparing 
belimumab treated subjects and placebo at Week 24. P-values are unadjusted. Cell cycle column denotes 
whether a gene is annotated with GO:0007049 cell cycle in the Gene Ontology 
Affymetrix ID Gene Symbol 
Week 0 (Baseline) Week 24 Week 52 
Cell cycle 
gene log(2) FC P-value log(2) FC P-value log(2) FC P-value 
16996813 CD180 0.104 0.668 -1.081 0.018 0.615 0.125 
16844312 TOP2A 0.049 0.733 -1.032 0.028 -0.194 0.539 cell_cycle 
17016403 HIST1H3G -0.224 0.245 -0.973 0.110 -0.460 0.407 
16850477 TYMS -0.014 0.915 -0.967 0.035 -0.215 0.503 cell_cycle 
16976644 JCHAIN 0.106 0.651 -0.907 0.096 0.041 0.905 
16979515 CCNA2 -0.089 0.496 -0.895 0.073 -0.302 0.386 cell_cycle 
16697471 B3GALT2 -0.332 0.283 -0.882 0.036 -0.445 0.225 
16977052 CXCL10 0.679 0.012 -0.882 0.225 1.433 0.034 
17019728 PLA2G7 0.044 0.912 -0.882 0.022 0.265 0.533 
16826230 NETO2 -0.037 0.730 -0.850 0.001 -0.252 0.333 
16877019 RRM2 0.136 0.274 -0.848 0.054 -0.277 0.358 cell_cycle 
17075776 PBK -0.011 0.918 -0.845 0.003 -0.159 0.416 cell_cycle 
17101531 TLR7 0.264 0.271 -0.838 0.049 0.651 0.111 
16943181 GPR15 -0.595 0.074 -0.827 0.024 -0.629 0.086 
16912379 TPX2 0.033 0.827 -0.826 0.062 -0.427 0.106 cell_cycle 
16965268 CD38 -0.129 0.204 -0.821 0.021 0.031 0.883 
16767335 CPM 0.045 0.796 -0.813 0.011 0.199 0.496 
16980096 TBC1D9 0.078 0.666 -0.804 0.018 0.413 0.301 
16986913 VCAN 0.082 0.844 -0.771 0.224 0.665 0.261 
16707468 KIF11 -0.003 0.985 -0.771 0.036 0.012 0.957 cell_cycle 
16944618 CD86 0.221 0.356 -0.770 0.100 0.194 0.647 
16725227 MS4A14 -0.199 0.424 -0.770 0.017 0.340 0.376 
16968529 PTPN13 -0.257 0.188 -0.765 0.016 -0.339 0.133 
16851618 HRH4 -0.239 0.355 -0.764 0.043 -0.465 0.047 
16851397 RBBP8 0.064 0.713 -0.759 0.010 0.224 0.351 cell_cycle 
16721835 WEE1 -0.049 0.768 -0.758 0.011 -0.447 0.062 cell_cycle 
16801557 CCNB2 -0.116 0.379 -0.757 0.056 -0.341 0.311 cell_cycle 
16677201 DTL -0.081 0.319 -0.724 0.096 -0.194 0.483 cell_cycle 
16843627 CCL3L3 -0.163 0.261 -0.714 0.093 0.200 0.460 
16719515 MKI67 -0.120 0.273 -0.706 0.043 -0.079 0.729 cell_cycle 
16992744 FAM153B -0.732 0.002 -0.704 0.012 -0.089 0.704 
16707551 CEP55 0.094 0.381 -0.700 0.033 -0.036 0.868 cell_cycle 
16679349 KMO 0.290 0.203 -0.699 0.078 0.366 0.368 
17004518 LY86 -0.117 0.600 -0.696 0.054 0.351 0.345 
16696187 F5 -0.538 0.007 -0.693 0.009 -0.209 0.424 
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16875997 ZNF154 -0.719 0.001 -0.693 0.003 -0.357 0.105 
16725041 FAM111B -0.004 0.977 -0.692 0.100 -0.195 0.421 
16960577 P2RY12 0.168 0.318 -0.686 0.042 0.503 0.210 
16666509 IFI44 -0.065 0.809 -0.685 0.034 0.611 0.027 
16666326 ST6GALNAC3 0.157 0.225 -0.684 0.001 -0.099 0.723 
16852312 SKA1 -0.009 0.947 -0.683 0.048 -0.143 0.525 cell_cycle 
16875467 LILRA4 -0.216 0.435 -0.681 0.270 -0.028 0.943 
16940172 CCR2 -0.315 0.127 -0.677 0.007 0.196 0.508 
16826160 SHCBP1 0.089 0.505 -0.669 0.015 0.041 0.850 
16840245 SCIMP 0.186 0.427 -0.664 0.090 0.197 0.617 
16665878 IL23R -0.554 0.066 -0.652 0.066 -0.503 0.070 
17070229 ZC2HC1A -0.096 0.638 -0.650 0.003 -0.059 0.718 
16928428 GRK3 0.063 0.801 -0.645 0.032 0.355 0.288 
16793225 DLGAP5 -0.121 0.191 -0.645 0.100 -0.297 0.230 cell_cycle 
17094893 ALDH1A1 0.253 0.378 -0.644 0.168 0.686 0.228 
16747958 CLEC6A 0.468 0.221 -0.641 0.188 1.090 0.040 
17050350 LRRN3 -0.313 0.202 -0.640 0.089 -0.594 0.132 
16886105 HNMT 0.128 0.533 -0.636 0.091 0.540 0.161 
16663514 CDC20 -0.044 0.718 -0.635 0.037 -0.131 0.602 cell_cycle 
16828886 GINS2 0.067 0.703 -0.624 0.094 -0.153 0.491 cell_cycle 
16949625 CCDC50 -0.094 0.626 -0.621 0.051 -0.011 0.973 
16777685 FLT3 0.317 0.043 -0.620 0.096 0.503 0.263 
16789334 TDRD9 -0.292 0.288 -0.617 0.141 0.012 0.975 cell_cycle 
16677425 CENPF -0.147 0.200 -0.613 0.003 -0.148 0.331 cell_cycle 
16671139 S100A9 0.340 0.334 0.609 0.331 0.705 0.165 
16813206 ANPEP 0.202 0.499 0.609 0.254 0.603 0.285 
16940444 CAMP 0.044 0.711 0.612 0.013 0.242 0.301 
16743816 PDGFD 0.386 0.145 0.619 0.015 0.002 0.996 
16872978 CD177 0.035 0.824 0.624 0.491 0.853 0.079 
16660360 CDA 0.348 0.198 0.636 0.267 0.473 0.371 
16983451 BASP1 0.144 0.473 0.636 0.314 0.646 0.205 
16672462 FCRL6 0.621 0.139 0.640 0.137 0.047 0.927 
16784760 DACT1 0.371 0.320 0.645 0.111 0.407 0.272 
16865540 FCAR 0.269 0.133 0.677 0.309 0.796 0.077 
17012582 ARG1 0.063 0.628 0.681 0.235 0.374 0.206 
16933766 OSM 0.271 0.086 0.689 0.014 0.150 0.450 
17052550 MGAM2 0.109 0.393 0.701 0.007 0.059 0.743 
16947173 MME 0.335 0.184 0.721 0.186 0.023 0.958 
16761617 MANSC1 0.076 0.576 0.723 0.056 0.275 0.448 
16819563 ADGRG3 0.314 0.093 0.728 0.265 0.442 0.358 
16686040 SVBP 0.697 0.004 0.740 0.009 0.663 0.011 
16695715 FCGR3B 0.386 0.083 0.743 0.105 0.613 0.185 
16747969 CLEC4D 0.378 0.055 0.744 0.324 1.162 0.052 
17101698 BMX 0.166 0.050 0.745 0.180 0.498 0.124 
16792859 PYGL 0.266 0.234 0.757 0.191 0.674 0.161 
16660436 ALPL 0.375 0.026 0.758 0.215 0.234 0.567 
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16660059 PADI4 0.310 0.169 0.767 0.248 0.585 0.204 
16820937 HP -0.034 0.860 0.795 0.401 1.116 0.100 
16681278 UTS2 0.729 0.062 0.805 0.097 0.668 0.146 
16922759 KCNJ15 0.376 0.090 0.823 0.124 0.607 0.279 
16998551 SLCO4C1 0.757 0.085 0.844 0.217 0.962 0.137 
17052425 MGAM 0.549 0.044 0.850 0.275 0.633 0.328 
16974529 FGFBP2 0.984 0.079 0.906 0.156 -0.129 0.847 
16743686 MMP8 -0.086 0.809 0.914 0.398 1.323 0.068 
16968213 ANXA3 0.129 0.530 0.932 0.235 0.853 0.130 
16873501 PGLYRP1 0.187 0.181 0.947 0.140 0.649 0.173 
16919547 SLPI 0.070 0.525 0.983 0.145 0.340 0.482 
16956213 PROK2 0.376 0.254 0.984 0.109 0.330 0.553 
17019877 CRISP3 0.174 0.421 0.999 0.352 0.896 0.120 
16849400 SOCS3 0.314 0.320 1.022 0.005 0.485 0.173 
17099463 ABO 0.680 0.225 1.030 0.101 0.410 0.454 
16697370 PTGS2 0.384 0.332 1.041 0.153 0.361 0.590 
16914395 MMP9 0.366 0.062 1.539 0.098 0.786 0.232 
17017885 HLA-DRB5 1.863 0.125 1.548 0.181 1.218 0.320 
17017900 HLA-DRB1 1.566 0.192 1.706 0.151 1.534 0.224 
ProtoArray (Invitrogen) protein microarrays 
Serum samples were stored at -80°C until required. ProtoArray Human Protein Microarray 5.1 slides were 
blocked in blocking buffer (50 mM HEPES, 200 mM NaCl, 0.01% Triton X-100, 25% glycerol, 20 mM 
reduced glutathione, 1.0 mM DTT, 1X Synthetic Block) at 4 °C for 1 hour. After blocking, arrays were rinsed 
once with freshly prepared PBST buffer (1X PBS, 0.1% Tween 20, and 1 X Synthetic Block). Arrays were 
then probed with a 1:500 dilution of each sample diluted in 5 mL of PBST buffer. Arrays were incubated for 
90 minutes at 4°C in QuadriPERM 4-well trays (Greiner) with gentle agitation. After incubation, slides were 
washed five times (5 minutes per wash) in 5 ml PBST Buffer in 4-well trays. An Alexa Fluor®647-conjugated 
goat anti-human IgG antibody diluted in 5 ml PBST buffer to a 1.0 µg/ml final concentration was added to 
each array and allowed to incubate with gentle shaking at 4°C for 90 minutes. After incubation, the secondary 
antibody was removed, and arrays were washed as described above. Arrays were dried by spinning in a table 
top centrifuge equipped with a plate rotor at 200x gravity for 2 minutes. Arrays were then scanned using a 
Tecan PowerScanner™ fluorescent microarray scanner. 
GenePix 7 software was used to overlay the mapping of human proteins in the array list file to each array 
image with a fixed feature size of 130 µm (diameter). After aligning each of the 48 subarrays using spots from 
the AlexaFluor®-conjugated and murine antibodies printed in each subarray, the features were resized by the 
GenePix software to best fit the feature. Pixel intensities for each spot on the array were determined. Arrays 
were normalised and a signal for each spot on the array calculated by subtracting the local background signal. 
Microarray hybridisation and these initial processing steps were performed by ThermoFisher. 
After removing data from control group spots and TNFSF13B (as bound by belimumab) the signal from 
duplicate spots was combined (mean) to give one value per unique antigen. This dataset was used to define a 
global threshold for ‘significant’ antibody binding (10,750) by maximising the signal-to-noise ratio for the 
comparison of number of antigen with a signal above threshold in samples at baseline (no immunosuppression) 
versus Week 24 (maximal immunosuppression). This approach avoided defining a threshold based on the 
parameter of interest (treatment group), relying on the biologically plausible hypothesis that there would be 
differences in circulating auto-/allo-antibody pre- and post-transplant. 
This threshold was used to determine whether an individual antigen specificity had significant antibody 
binding (yes/no). New antigenic specificities post-transplant were defined as antigenic specificities with 
significant binding at Week 24 post-transplant not observed at baseline (Week 0). Kidney specific antigens 




Immunophenotyping was performed by flow cytometry with absolute cell numbers calculated using TBNK 
counts.  
Healthy control B cell stimulation assay 
CD19+CD27+ memory B cells were enriched from PBMCs of 16 healthy donors using a human memory B 
cell isolation kit (Miltenyi Biotec) and cultured in vitro in the presence of CpG (100nM; Hycult Biotech) and 
CD40L (1µg/ml; R&D Systems) with 0 to 200ng/ml BLyS (GSK) for 48 hours. Phorbol 12-myristate 13-
acetate (PMA) (50ng/ml; Sigma-Aldrich), ionomycin (500ng/ml; Sigma-Aldrich) and brefeldin A (5µg/ml; 
BioLegend) were added for the last 5 hours of culture and IL-6 and IL-10 quantified by flow cytometry. In 7 
of these healthy donors, 15nM belimumab (GSK) was added in addition to 100ng/ml BLyS. 
Subject with retrospective flow positive crossmatch 
A single subject (subject 5) in the belimumab treatment group was found to have a positive flow cytometry 
cross-match with donor specific antibodies to DP1 and DP6 at baseline. This subject was receiving a second 
transplant and known to be sensitized against multiple HLA DP antigens. The HLA DP type of the donor was 
not known at the time of transplantation, and T and B lymphocyte CDC cross-match tests were negative. Both 
the donor DP type and flow cytometry cross-match result became available following transplantation. Had this 
information been available the subject would have been deemed ineligible for the study and given lymphocyte 
depleting induction therapy in view of his increased immunological risk. This subject experienced Banff IIA 
acute cellular rejection with features suspicious for early humoral rejection (day 6) associated with a rise in 
the titre of DP DSA and development of de novo DSA to HLA-A11 and HLA-B18.  A further biopsy (day 34) 
demonstrated overt antibody mediated rejection. They were withdrawn from the study following a single dose 
of belimumab and the rejection responded to treatment with methlyprednisolone, plasma exchange and anti-
thymocyte globulin.  
Donor specific and anti-MICA antibodies 
Two patients recruited to the study developed de novo DSA during follow-up; neither were part of the PP 
population having been withdrawn following a single dose of study drug (belimumab). Subject 5 was 
withdrawn due to a positive cross-match; subject 13 withdrew consent for study drug (Fig. S2C). 
One patient in each group had positive anti-MICA antibodies at baseline; subject 19 received one dose of 
placebo and had positive levels throughout the first year post transplant; subject 27 received 5 doses of 
belimumab and antibody levels fell below the positive threshold.  Subject 13 received a single dose of 
belimumab and developed de novo anti-MIC antibodies in addition to low level de novo DSA.  
Subject with adoptive transfer of donor HLA specific allosensitization 
Subject 21 had no HLA antibodies detectable at baseline but received a kidney from a sensitised donor. Post-
transplant, high levels de novo IgG HLA class I- and class II-specific antibodies were measurable with no 
antibodies to donor HLA. A similar antibody profile was found in the recipient of the paired deceased donor 
kidney (not part of this study) and in stored donor serum4. 
304
10 
Figure S1: Belimumab Pharmacokinetics and Impact on Peripheral B and T Cell Subsets
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Panel A shows the median serum concentration of belimumab over time (left panel linear scale; right panel 
logarithmic scale). The lower limit of detection of 100ng/ml is marked with a dotted line. Error bars indicate 
range. Pharmacokinetics (PK) population that consisted of all subjects randomised to belimumab treatment 
that were treated with at least one dose and had a PK sample that was analysed (N=12). 
Panel B shows serial measurements of serum BLyS concentration (µg/ml) in individual subjects. 
Panel C shows B cell count (cells/mm3). 
Panel D shows the adjusted mean (95% CI) change from baseline in naïve (CD20+CD27-) B cell count, by 
visit and treatment in the PP population. 
Panel E shows the Hodges Lehman estimates and 95% CI for median difference (belimumab 10mg/kg (BEL) 
– placebo (PBO)) of percent change from baseline in naïve B-cell (CD20+CD27-) count by visit in the MITT
population (sensitivity analysis of primary endpoint).
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Panel F shows transitional (CD24brCD38brIgD+) B cell count/ml.  
Panel G shows memory (CD20+CD27+) B cell count (cells/cm3).  
Panel H shows activated memory (CD95+CD27+) B cell count (cells/ml) by visit and treatment group. 
Panel I shows plasmablast (CD19+CD27+CD38+) count/ml.  
Panel J shows activated T cell (CD4+CD25hiCD45RA-IL 7Rhi) count/ml 
Panel K shows regulatory T cell (CD4+CD25hiIL-7Rlo) count/ml 
B-D and F-K performed on PP population. E performed on MITT population. C and F-K show raw values at
baseline for comparison and adjusted mean estimate with 95% confidence intervals, obtained from the same
MMRM model as used for the primary endpoint, at subsequent timepoints. # indicates that the 95% confidence
interval of the treatment difference does not include zero. In J and K weeks 4 and 8 excluded due to known
effects of basiliximab on CD25 surface expression. C, G and I represent analyses performed post hoc. Where
n numbers are displayed, these represent the number of subjects assayed at each timepoint.
Panel L shows the proportion of module genes within each module identified during weighted correlation 
network analysis of whole blood RNA in the GO:0050853 BCR signalling pathway.  A single module 
(coloured red) was enriched for BCR signalling and analysed further for the effects of belimumab treatment. 
Analysis performed on MITT population at baseline and PP thereafter. 
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Figure S2: HLA and Non-HLA Antibodies 
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Serum samples before and after treatment were screened for HLA antibodies using Luminex HLA class I and 
class II antibody detection beads (LABScreenTM Mixed, One Lambda) and HLA antibody specificities were 
determined using Luminex single antigen HLA-specific antibody detection beads (LABScreen Single Antigen 
HLA Class I and Class II, One Lambda). The normalized mean fluorescence intensity (MFI) for each single 
antigen bead with an MFI above the detection limit of 500 at any timepoint is shown in individuals from the 
PP population (A) and those not in the PP population (B). Vertical lines show when doses of study drug were 
received. Subject 6 received plasma exchange for FSGS between days 31 and 64. Subjects 3 and 13 withdrew 
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consent for study drug following a single dose. Adoptive transfer donor HLA specific allosensitization as 
described in 4. 
Panel C shows the relationship between serum BLyS and de novo donor-specific HLA antibody over time for 
subject 13 who received a single dose of belimumab on day 0 prior to withdrawal of consent for study drug. 
Serum was sampled for BLyS levels at Day 0, week (W) 4, W8, W16, W24, W36 and W52.  The first increase 
in serum BLyS was detected at W24, with a fall in levels thereafter to baseline by W52. Antibodies were 
measured using Luminex single antigen HLA-specific antibody detection beads (LABScreen Single Antigen 
HLA Class I and Class II, One Lambda); donor specificity was determined manually by comparison of donor 
and recipient HLA-types. A low MFI MHC class I B37 antibody became detectable at W24, and a further A3 
antibody at W52, the latter in the context of a falling serum BLyS level.   
Panel D shows the mean protoarray signal from kidney specific antigens (defined in 3) at week 24. Horizontal 
lines on boxplot correspond to median and interquartile ranges. Patients are coloured by treatment group. The 
Wilcoxon rank-sum test was used to compare the belimumab treatment group (BEL) and placebo treatment 
group (PBO); exact p value displayed. 
Panel E shows the distribution of the mean protoarray signal from two antigens on the array annotated to EGF-
like repeats and discoidin I-like domains 3 (EDIL3) (BC053656.1; BC030828.1) by treatment group at week 
24. Horizontal lines on boxplot correspond to median and interquartile ranges. PP population. The Wilcoxon
rank-sum test was used to compare the belimumab and placebo treatment groups; * denotes p<0.05.
Panel F shows the number of subjects in each treatment group with above threshold protoarray binding to glial 
cell-derived neurotrophic factor (GDNF) at baseline and week 24. PP population; Eight subjects were tested 
at each timepoint for both treatment groups.  
D, E and F represent post hoc analyses. Where n numbers are displayed, these represent the number of subjects 
assayed at each timepoint. 
Table S3: Concomitant maintenance immunosuppression (post hoc analysis). 
1. In addition, for treatment of rejection (week 2), one subject in the placebo group received 500mg x 3 pulsed
iv methylprednisolone and one subject in the belimumab group received 1000mg x 3 pulsed iv
methylprednisolone.
2. One subject in the placebo arm switched to mycophenolate sodium (Myfortic) at week 52; one subject in
the belimumab group switched at week 4. mycophenolate sodium 720mg approximately equivalent to
mycophenolate mofetil 1g. One subject in the belimumab group was on azathioprine 50mg on day 231 through
to week 52, having stopped MMF on day 120.
Placebo (N=8) Belimumab 10mg/kg (N=8) 
n Mean (SD) Median(Range) n Mean (SD) Median (Range) 
Daily prednisolone dose (mg)1 
week 1 8 20.0 (0.0) 20.0 (20.0-20.0) 8 20.0 (0.0) 20.0 (20.0-20.0) 
week 4 8 8.8 (3.3) 8.8 (5.0 -15.0) 8 8.4 (2.3) 10.0 (5.0-10.0) 
week 12 8 5.0 (1.3) 5.0 (2.5-7.5) 8 4.7 (0.9) 5.0 (2.5-5.0) 
week 24 8 5.3 (2.1) 5.0 (2.5-10.0) 8 6.9 (5.8) 5.0 (2.5-20.0) 
week 52 8 4.3 (1.8) 5.0 (0.0-5.0) 8 4.7 (1.6) 5.0 (2.5-7.5) 
Tacrolimus daily dose (mg) 
week 1 8 10.3 (3.1) 8.5 (8-15) 7 7.8 (4.6) 6.5 (0-13) 
week 4 8 12.1 (5.8) 11.5 (5-24) 8 9.6 (3.7) 11.5 (4-14) 
week 12 8 9.6 (6.3) 9.0 (4-24) 8 8.3 (4.0) 8.0 (3-15) 
week 24 8 7.5 (3.9) 6.5 (4-16) 8 7.1 (4.1) 7.0 (3-15) 
week 52 8 6.1 (1.5) 6.0 (4-8) 8 6.1 (2.9) 7.0 (2.5-10) 
Tacrolimus level (µg/L) 
week 1 8 5.6 (2.8) 4.4 (2.8-10.5) 8 7.3 (1.8) 6.9 (4.9-10.8) 
week 4 7 10.7 (5.8) 9.3 (4.5 - 22.8) 7 8.3 (2.4) 8.7 (3.3-10.3) 
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week 12 8 7.9 (2.1) 8.5 (3.7 - 10.5) 7 8.6 (2.1) 7.4 (6.2-11.6) 
week 24 7 6.6 (1.0) 7.0 (4.5 - 7.6) 6 8.4 (3.5) 8.5 (3.5 - 13.0) 
week 52 5 4.8 (3.0) 6.0 (0.0 - 7.4) 8 6.1 (1.8) 5.9 (3.7 - 9.4) 
MMF equivalent dose (mg)2 
week 1 8 937.5 (176.8) 1000 (500-1000) 8 1062.5 (176.8) 1000 (1000-1500) 
week 4 8 1062.5 (176.8) 1000 (1000-1500) 8 1062.5 (267.3) 1000 (500-1500) 
week 12 8 812.5 (530.3) 1000 (0-1500) 8 875 (517.5) 1000 (0-1500) 
week 24 8 750 (534.5) 1000 (0-1500) 8 687.5 (530.3) 750 (0-1500) 
week 52 8 625 (443.2) 750 (0-1000) 8 687.5 (530.3) 750 (0-1000) 
Table S4: Analysis for change from baseline in naïve B cell count by visit (MITT and PP populations). 
1. Adjusted Mean Differences(treatment-placebo) and 95% confidence intervals for differences are obtained
from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit
interaction and fixed continuous covariates of baseline and baseline-by-visit interaction. A compound
symmetry variance structure was used to model the within-patient errors, shared across treatments. Naïve B
cell count = CD20+CD27- cells/mm3. This data is represented visually in Figure 2A (MITT population) and
Figure S1D (PP population)
MITT Population: Unadjusted baseline values naïve B cell count (cells/mm3) 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 13 13 97.5 58.22 84 25 196 
Belimumab 10mg/kg Baseline 12 12 119.2 104.87 78.5 11 357 
MITT Population: Change from baseline in naïve B cell count by visit 
Treatment Visit N n 
Adjusted 
mean (SE) 








13 12 29.0 (23.65) (-19.2, 77.2) 
-40.7 (33.79) (-109.5, 28.1) Belimumab 10mg/kg 12 11 -11.7 (24.24) (-61.0, 37.7) 
Placebo 
On-Trt Wk8 
13 6 35.0 (29.14) (-23.4, 93.4) 
-51.5 (40.58) (-132.9, 29.9) Belimumab 10mg/kg 12 8 -16.5(27.35) (-71.5, 38.6) 
Placebo 
On-Trt Wk12 
13 8 19.4 (26.54) (-34.1, 72.8) 
-16.3 (38.45) (-93.6, 61.0) Belimumab 10mg/kg 12 8 3.1 (27.31) (-51.9, 58.0) 
Placebo 
On-Trt Wk24 
13 9 4.0 (25.55) (-47.7, 55.6) 
-34.4 (37.24) (-109.5, 40.7) Belimumab 10mg/kg 12 7 -30.4 (27.50) (-85.8, 24.9) 
Placebo 
Post-Trt Wk12 
13 11 0.8 (24.11) (-48.3, 49.8) 
-58.7 (35.72) (-131.0, 13.6) Belimumab 10mg/kg 12 8 -58.0 (26.52) (-111.5, -4.5) 
Placebo 
Post-Trt Wk28 
13 10 5.4 (24.67) (-44.6, 55.5) 
-59.3 (37.12) (-134.1, 15.6) Belimumab 10mg/kg 12 7 -53.8 (27.83) (-109.7, 2.1) 
PP Population: Unadjusted baseline values naïve B cell count (cells/mm3) 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 8 8 91.9 56.26 79.5 25 184 
Belimumab 10mg/kg Baseline 8 8 96.1 87.55 61.0 11 274 
PP Population: Change from baseline in naïve B cell count by visit 
Treatment Visit N n 
Adjusted 
mean (SE) 








8 8 -18.4 (19.11) (-56.6, 19.9) 
-22.2 (26.75) (-75.7, 31.4) Belimumab 10mg/kg 8 8 -40.5 (19.02) (-78.6, -2.5) 
Placebo 
On-Trt Wk8 
8 4 14.2 (27.38) (-40.5, 68.9) 
-58.5 (35.75) (-129.9, 13.0) Belimumab 10mg/kg 8 7 -44.3 (21.66) (-87.6, -0.9) 
Placebo On-Trt Wk12 8 7 -7.1 (20.44) (-48.0, 33.8) -0.9 (29.93) (-60.7, 59.0) 
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Belimumab 10mg/kg 8 7 -8.0 (21.53) (-51.1, 35.1) 
Placebo 
On-Trt Wk24 
8 8 -22.9 (19.11) (-61.1, 15.4) 
-33.3 (27.64) (-88.6, 22.0) Belimumab 10mg/kg 8 7 -56.2 (20.47) (-97.1, -15.2) 
Placebo 
Post-Trt Wk12 
8 7 -14.0 (20.44) (-55.0, 26.9) 
-61.2 (29.08) (-119.4, -3.0) Belimumab 10mg/kg 8 7 -75.3 (20.44) (-116.2, -34.4) 
Placebo 
Post-Trt Wk28 
8 7 -26.7 (20.37) (-67.4, 14.1) 
-61.6 (30.49) (-122.6, -0.7) Belimumab 10mg/kg 8 6 -88.3 (22.82) (-133.9, -42.7) 
Table S5: Non-parametric analysis of percent change from baseline in naïve B cell count. 
1. Median difference and 95% CI of difference obtained using the Hodges-Lehman method. Naïve B cell count
= CD20+CD27- cells/mm3. This data is represented visually in Figure S1E.
MITT population 
Comparison  
N Visit n 
Median difference % change 
from baseline naïve B cell count1 






On-Trt Wk4 23 -18.7 (-88.8, 30.8) 
On-Trt Wk8 14 -36.1 (-81.4, 27.2) 
On-Trt Wk12 16 -11.5 (-65.5, 70.1) 
On-Trt Wk24 16 -20.1 (-90.9, 34.5) 
Post-Trt Wk12 19 -50.4 (-107.0, -18.0) 
Post-Trt Wk28 17 -48.3 (-144.7, -13.0) 
Table S6: B cell populations at week 24 expressed as percentage of total B-cells (post hoc analysis). 
Median difference from baseline to week 24 (percentage at week 24 – percentage at week 0) in the labelled B 
cell populations by treatment group with each population expressed as a percentage of B cells. This data is 
represented visually in Figure 2B.  




(%) IQR Range n 
Median 
difference 
(%) IQR Range 











-2.497) 8 26.284 
(12.117,
40.853) (-58.19, 48.231) 
Non switched 




72.622) 8 10.953 
(8.632,






-2.113) 8 20.653 
(13.785,
34.642) (-57.145, 49.29) 




2.285) 8 0.883 
(-1.082,
6.538) (-2.566, 9.761) 
Table S7: Analysis of memory B cell (%CD19) by visit. 
1. Adjusted mean differences (treatment-placebo) and 95% confidence intervals for differences obtained
from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit
interaction and fixed continuous covariates of baseline and baseline-by-visit interaction. A compound
symmetry variance structure was used to model the within-patient errors, shared across treatments. This data
is represented visually in Figure 2C.
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PP Population: Unadjusted baseline values 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 8 8 12.1 4.32 12.5 6 17 
Belimumab 10mg/kg Baseline 8 8 8.3 6.84 4.5 3 22 
PP Population: Change from baseline in memory B cell count by visit 
Treatment Visit N n 
Adjusted 
mean (SE) 











8 8 10.3 (3.13) (3.8, 16.9) 
20.7 (4.62) (11.0, 30.3) Belimumab 10mg/kg 8 8 31.0 (3.25) (24.2, 37.8) 
Placebo 
On-Trt Wk8 
8 4 12.2 (3.68) (4.8, 19.7) 
18.1 (5.00) (7.8, 28.4) Belimumab 10mg/kg 8 8 30.4 (3.25) (23.5, 37.2) 
Placebo 
On-Trt Wk12 
8 7 8.6 (3.20) (2.0, 15.2) 
20.3 (4.67) (10.6, 30.0) Belimumab 10mg/kg 8 7 28.9 (3.31) (22.0, 35.8) 
Placebo 
On-Trt Wk24 
8 8 9.6 (3.13) (3.1, 16.1) 
23.0 (4.70) (13.2, 32.8) Belimumab 10mg/kg 8 7 32.6 (3.36) (25.6, 39.6) 
Placebo Post-Trt 
Wk12 
8 7 12.3 (3.20) (5.6, 18.9) 
25.7 (4.69) (16.0, 35.5) Belimumab 10mg/kg 8 7 38.0 (3.31) (31.1, 44.9) 
Placebo Post-Trt 
Wk28 
8 7 13.5 (3.23) (6.8, 20.1) 
15.5 (5.10) (5.1, 26.0) Belimumab 10mg/kg 8 6 29.0 (3.68) (21.5, 36.5) 
Table S8: Analysis of non-HLA antibodies via ProtoArray (post hoc analysis) 
Patient serum from baseline and week 24 was hybridised to ProtoArray (Invitrogen) protein microarrays. P 
values relate to Wilcoxon rank-sum tests used to compare the belimumab and placebo treatment groups. 
Kidney specific auto/allo-antibodies were defined in (Li 2009). IQR interquartile range; EDIL3 - EGF-like 
repeats and discoidin I-like domains 3 (EDIL3) (mean signal of two probes annotated to EDIL3 on array 
(BC053656.1; BC030828.1)); GDNF - Glial glial cell-derived neurotrophic factor (GDNF). This data is 





Number new auto/allo-antibodies above threshold 
(median (IQR)(range)) 
55.5 (27.5-91)  
(3-130) 
15.5 (8.75-20)  
(1-44) 
0.0474 
Number new kidney specific auto/allo-antibodies above 
threshold (median (IQR)(range)) 
12.5 (10.25-14.75) 
(3-20) 
8.0 (5.75 - 10.0)  
(5-12) 
0.0524 








EDIL3 protoarray signal at week 24 (median (IQR)(range))  
353.6 (305-442)  
(221-550) 
261.9 (232-296)  
(191 - 350) 
0.0379 
Number of samples with above threshold GDNF binding 
 - baseline 6 6 
- week 24 6 2 
Table S9: Analysis of B cell intracellular cytokine production following ex-vivo stimulation (post hoc 
analysis). PBMC were stimulated ex vivo for 5 hours and intracellular cytokine production quantified by 
flow cytometry. IL-6 and IL-10 secreting B cells are expressed as a percentage of CD19+ cells. Wilcoxon 
rank-sum tests were performed to compare samples by treatment and visit. This data is represented visually 
in Figure 3A-C. 
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Treatment Visit N n Endpoint Median  p value 
Placebo 
Baseline 
8 6 IL-6 secreting B cells 29.833 
Belimumab 10mg/kg 8 2 IL-6 secreting B cells 35.833 0.8571 
Placebo 
Last On-Trt 
8 4 IL-6 secreting B cells 32.183 
Belimumab 10mg/kg 8 6 IL-6 secreting B cells 20.250 0.0667 
Placebo 
Post-Trt Wk12 
8 8 IL-6 secreting B cells 42.617 
Belimumab 10mg/kg 8 8 IL-6 secreting B cells 29.175 0.0379 
Placebo 
Post-Trt Wk28 
8 3 IL-6 secreting B cells 33.067 
Belimumab 10mg/kg 8 4 IL-6 secreting B cells 32.183 0.8571 
Placebo 
Baseline 
8 6 IL-10 secreting B cells 1.352 
Belimumab 10mg/kg 8 2 IL-10 secreting B cells 2.702 0.2857 
Placebo 
Last On-Trt 
8 4 IL-10 secreting B cells 1.575 
Belimumab 10mg/kg 8 6 IL-10 secreting B cells 4.307 0.0667 
Placebo 
Post-Trt Wk12 
8 8 IL-10 secreting B cells 2.458 
Belimumab 10mg/kg 8 8 IL-10 secreting B cells 4.555 0.0499 
Placebo 
Post-Trt Wk28 
8 3 IL-10 secreting B cells 2.960 
Belimumab 10mg/kg 8 4 IL-10 secreting B cells 3.750 0.8571 
Placebo 
Baseline 
8 6 Ratio of IL-10/IL-6  0.043 
Belimumab 10mg/kg 8 2 Ratio of IL-10/IL-6  0.076 0.2857 
Placebo 
Last On-Trt 
8 4 Ratio of IL-10/IL-6  0.049 
Belimumab 10mg/kg 8 6 Ratio of IL-10/IL-6  0.180 0.0095 
Placebo 
Post-Trt Wk12 
8 8 Ratio of IL-10/IL-6  0.059 
Belimumab 10mg/kg 8 8 Ratio of IL-10/IL-6  0.127 0.0070 
Placebo 
Post-Trt Wk28 
8 3 Ratio of IL-10/IL-6  0.093 
Belimumab 10mg/kg 8 4 Ratio of IL-10/IL-6  0.117 0.8571 
Table S10: Analysis of B cell subset intracellular cytokine production following ex-vivo stimulation 
(post hoc analysis). Peripheral blood mononuclear cells were stimulated ex vivo for 5 hours and intracellular 
cytokine production quantified by flow cytometry. The IL-10/IL-6 ratio for individual subsets of naïve 
(CD27-), transitional (CD24hiCD38hiIgD+), CD24+CD27+ memory, switched memory (CD27+IgD-), and 
non switched memory (CD27+IgD+) B cells at post treatment Wk 12.  Wilcoxon rank-sum tests were 
performed to compare samples by treatment. This data is represented visually in Figure 3D. 







Naïve 0.035 0.060 0.1327 
TrB 0.100 0.225 0.0109 
CD34+CD27+ memory 0.150 0.230 0.0780 
Switched memory 0.225 0.275 0.4880 
Non-switched memory 0.120 0.180 0.0185 
Table S11: Summary of percent change from baseline of IL10:IL6 ratio (relative to 0ng/mL BLyS) in 
PBMC from healthy volunteers enriched for CD27+ memory B cells and stimulated for 48 hours with 
increasing quantities of BLyS (post hoc analysis). In the presence of increasing quantities of BLyS a more 
inflammatory cytokine milieu was observed. This change was blocked by the addition of belimumab. N, 
number of healthy volunteers tested for each experimental condition. T-tests were performed to determine 
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whether the mean percentage changes from baseline differed significantly from 0 for each experimental 





Mean change from 
baseline (%) SD 95% CI of mean p value 
25 0 8 -18.47 13.850 -30.05, -6.89 0.0070 
50 0 6 -20.47 19.447 -40.88, -0.06 0.0495 
100 0 15 -22.90 24.595 -36.52, -9.28 0.0029 
200 0 7 -22.64 15.218 -36.72, -8.57 0.0077 
100 15 7 0.63 20.448 -18.28, 19.54 0.9377 
Table S12: Median serum concentration of belimumab over time. The lower limit of detection of 100ng. 
Pharmacokinetics (PK) population that consisted of all subjects randomised to belimumab treatment that 
were treated with at least one dose and had a PK sample that was analysed. Values at day 0 pre IV dose were 
imputed. This data is represented visually in Figure S1A-B.  










Day 0 (pre IV dose) 12 12 0.00 0.00 0.00 
Day 0 (post IV dose) 12 12 212.63 134.40 309.60 
Week 1 12 12 67.06 49.98 140.98 
Week 2 (pre IV dose) 12 12 45.76 28.56 73.10 
Week 2 (post IV dose) 12 9 291.94 207.19 468.23 
Week 4 (pre IV dose) 12 10 100.08 26.23 177.61 
Week 4 (post IV dose) 12 8 349.29 141.54 550.07 
Week 8 (pre IV dose) 12 10 103.19 9.55 210.42 
Week 12 (pre IV dose) 12 10 113.79 3.34 257.04 
Week 20 (post IV dose) 12 8 489.89 0.11 616.84 
Week 24 12 11 119.37 0.00 253.97 
Table S13: Analysis of B cell count by visit (post hoc analysis). 
1. Adjusted Mean Difference (treatment-placebo) and 95% confidence intervals for differences are obtained
from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit
interaction and fixed continuous covariates of baseline and baseline-by-visit interaction. A compound
symmetry variance structure was used to model the within-patient errors, shared across treatments. B cell
count = CD19+ cells/mm3. This data is represented visually in Figure S1C.
PP Population: Unadjusted baseline values B cell count (cells/mm3) 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 8 8 107.6 62.33 96 32 211 
Belimumab 10mg/kg Baseline 8 8 105.8 91.41 70 16 291 
PP Population: Change from baseline in B cell count by visit 
Treatment Visit N n 
Adjusted 
mean  








8 8 86.4 (39.4, 133.5) 
-15.2 (33.01) (-81.2, 50.7) Belimumab 10mg/kg 8 8 71.2 (24.4, 118.0) 
Placebo On-Trt 
Wk8 
8 5 115.8 (56.0, 175.7) 
-45.5 (39.90) (-125.3, 34.2) Belimumab 10mg/kg 8 7 70.3 (17.4, 123.2) 
Placebo On-Trt 
Wk12 
8 8 89.2 (42.1, 136.2) 
27.9 (35.19) (-42.4, 98.2) Belimumab 10mg/kg 8 7 117.1 (64.3, 169.9) 
Placebo On-Trt 
Wk24 
8 8 83.5 (36.4, 130.6) 





8 7 96.2 (45.4, 147.0) 
-63.6 (36.28) (-136.1, 8.9) Belimumab 10mg/kg 8 7 32.6 (-18.0, 83.2) 
Placebo Post-Trt 
Wk28 
8 7 84 (33.7, 134.2) 
-71.9 (37.58) (-147.0, 3.2) Belimumab 10mg/kg 8 6 12.1 (-44.2, 68.4) 
Table S14: Analysis of transitional B cell count by visit. 
1. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences are obtained
from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit
interaction and fixed continuous covariates of baseline and baseline-by-visit interaction. A compound
symmetry variance structure was used to model the within-patient errors, shared across treatments.
Transitional B cell count = CD19+CD24b+CD38b+IgD+ cells/ml. This data is represented visually in Figure
S1F.
PP Population: Unadjusted baseline values transitional B cell count (cells/ml) 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 8 8 10437.19 10071.917 7592.85 1233.2 32697.0 
Belimumab 10mg/kg Baseline 8 7 20380.89 25680.973 9931.33 1005.2 64790.5 
PP Population: Change from baseline in transitional B cell count by visit 
Treatment Visit N n 
Adjusted mean 
(SE) 








8 7 3738  (3123.2) (-2720, 10197) 
-498 (4433.1) (-9658, 8663) Belimumab 10mg/kg 8 8 3240 (3178.6) (-3350, 9831) 
Placebo 
On-Trt Wk8 
8 5 4309 (3429.8) (-2692, 11311) 
-3531 (4677.9) (-13120, 6059) Belimumab 10mg/kg 8 7 779 (3283.7) (-5993, 7550) 
Placebo 
On-Trt Wk12 
8 8 4092 (3055.0) (-2251, 10434) 
-1777 (4544.2) (-11129, 7576) Belimumab 10mg/kg 8 6 2315 (3446.5) (-4743, 9373) 
Placebo 
On-Trt Wk24 
8 8 5586 (3031.6) (-717, 11890) 
-5134 (4519.6) (-14442, 4174) Belimumab 10mg/kg 8 7 452 (3371.0) (-6469, 7374) 
Placebo Post-Trt 
Wk12 
8 7 9464 (3119.9) (3012, 15917) 
-9156 (4427.7) (-18307, -6) Belimumab 10mg/kg 8 7 308 (3178.8) (-6283, 6899) 
Placebo Post-Trt 
Wk28 
8 7 8348 (3141.0) 
-8382 (4847.8) (-18276, 1513) Belimumab 10mg/kg 8 6 -33 (3614.9) (-7396, 7329) 
Table S15: Analysis of memory B cell count by visit (post hoc analysis). 
1. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences are obtained
from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit
interaction and fixed continuous covariates of baseline and baseline-by-visit interaction. A compound
symmetry variance structure was used to model the within-patient errors, shared across treatments. Memory
B cell count = CD20+CD27+ cells/mm3. This data is represented visually in Figure S1G.
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PP Population: Unadjusted baseline values memory B cell count (cells/mm3) 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 8 8 12.9 7.75 13.0 2 23 
Belimumab 10mg/kg Baseline 8 8 5.8 3.11 4.5 2 10 
PP Population: Change from baseline in memory B cell count by visit 
Treatment Visit N n 
Adjusted 
mean (SE) 








8 8 11.5 (5.12) (1.2, 21.7) 
3.4 (8.16) (-12.9, 19.7) Belimumab 10mg/kg 8 8 14.9 (5.40) (4.1, 25.7) 
Placebo 
On-Trt Wk8 
8 4 15.8 (8.20) (-0.6, 32.2) 
0.3 (11.71) (-23.1, 23.7) Belimumab 10mg/kg 8 7 16.1 (6.06) (4.0, 28.2) 
Placebo 
On-Trt Wk12 
8 7 8.9 (5.92) (-2.9, 20.8) 
16.2 (9.57) (-2.9, 35.3) Belimumab 10mg/kg 8 7 25.1 (5.97) (13.2, 37.1) 
Placebo 
On-Trt Wk24 
8 8 10.7 (5.12) (0.5, 20.9) 
5.7 (8.22) (-10.7, 22.2) Belimumab 10mg/kg 8 7 16.4 (5.60) (5.2, 27.6) 
Placebo 
Post-Trt Wk12 
8 7 11.4 (5.98) (-0.6, 23.3) 
3.2 (9.91) (-16.7, 23.0) Belimumab 10mg/kg 8 7 14.5 (6.16) (2.2, 26.9) 
Placebo 
Post-Trt Wk28 
8 7 13.0 (5.31) (2.4, 23.7) 
-7.8 (8.59) (-25.0, 9.4) Belimumab 10mg/kg 8 6 5.3 (6.04) (-6.8, 17.4) 
Table S16: Analysis of activated memory B cell (CD95%+) count by visit. 
1. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences are obtained
from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit
interaction and fixed continuous covariates of baseline and baseline-by-visit interaction. A compound
symmetry variance structure was used to model the within-patient errors, shared across treatments. Activated
memory B cell count = CD19+ CD27+ CD95+ cells/ml. This data is represented visually in Figure S1H.
PP Population: Unadjusted baseline values activated memory B cell count 
(cells/ml) 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 8 8 24516.5 29798.59 12610.3 6091 93078 
Belimumab 
10mg/kg Baseline 8 7 10535.3 9295.42 7131.4 876 25999 
PP Population: Change from baseline in activated memory B cell count by visit 
Treatment Visit N n Adjusted mean (SE) 
















10mg/kg 8 8 12900.5 (3556.85) (5677.0, 20124.0) 
Placebo On-Trt 
Wk8 






10mg/kg 8 7 8189.6 (3850.17) (411.1, 15968.1) 
Placebo On-Trt 
Wk12 






10mg/kg 8 6 8833.6 (4112.07) (550.4, 17116.8) 



















10mg/kg 8 7 7354.3 (3560.25) (124.4, 14584.1) 
Placebo Post-Trt 
Wk28 






10mg/kg 8 6 4524.7 (4053.36) (-3642.2, 12691.5) 
Table S17: Analysis of plasmablast count by visit (post hoc analysis). 
1. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences are obtained
from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit
interaction and fixed continuous covariates of baseline and baseline-by-visit interaction. A compound
symmetry variance structure was used to model the within-patient errors, shared across treatments.
Plasmablast count = CD27+CD38+CD19+ (EVENTS). Values for this rare subset have been normalised and
converted to count/mL using the formula: normalised count/mL = [(event count) / (CD19+ event count)] *
(CD19+ count per mm3) * 1000 cells/ml. This data is represented visually in Figure S1I.
PP Population: Unadjusted baseline values plasmablast count 
(cells/mm3) 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 8 8 973.2 935.50 726.9 218 3143 
Belimumab 
10mg/kg Baseline 8 8 575.7 542.24 324.6 80 1629 
PP Population: Change from baseline in plasmablast count by visit 
Treatment Visit N n 
Adjusted mean 
(SE) 








8 8 63.5 (270.58) (-479.6, 606.7) 
-113.7 (386.43) (-889.3, 661.9) 
Belimumab 
10mg/kg 8 8 -50.2 (269.52) (-591.4, 491.1) 
Placebo On-Trt 
Wk8 
8 4 206.4 (376.37) (-546.1, 958.9) 
-307.2 (479.12) (-1265.9, 651.4) 
Belimumab 
10mg/kg 8 7 -100.8 (368.77) (-838.3, 636.7) 
Placebo On-Trt 
Wk12 
8 7 187.0 (289.06) (-392.5, 766.5) 
-116.7 (427.98) (-974.1, 740.7) 
Belimumab 
10mg/kg 8 7 70.3 (297.79) (-526.5, 667.1) 
Placebo On-Trt 
Wk24 
8 8 307.7 (270.90) (-236.0, 851.5) 
-233.0 (393.20) (-1021.8, 555.8) 
Belimumab 
10mg/kg 8 7 74.7 (283.62) (-494.1, 643.6) 
Placebo Post-Trt 
Wk12 
8 7 1259.1 (288.55) (680.6, 1837.7) 
-1055.5 (416.23) (-1889.7, -221.2) 
Belimumab 
10mg/kg 8 7 203.7 (286.98) (-371.8, 779.1) 
Placebo Post-Trt 
Wk28 
8 7 1032.8 (287.02) (457.3, 1608.2) 
-600.6 (425.67) (-1453.2, 252.1) 
Belimumab 
10mg/kg 8 6 432.2 (308.99) (-186.5, 1051.0) 
Table S18: Analysis of activated T Cell count by visit. 
1. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences are obtained
from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit
interaction and fixed continuous covariates of baseline and baseline-by-visit interaction. A compound
symmetry variance structure was used to model the within-patient errors, shared across treatments. Activated
T-cell count= CD4+ CD25hi CD45RA- IL7Rhi cells/ml. This data is represented visually in Figure S1J.
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PP Population: Unadjusted baseline values activated T cell count (cells/ml) 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 8 8 103344.1 47314.16 105357.3 31488 170276 
Belimumab 10mg/kg Baseline 8 8 100793.4 52470.57 103341.5 542 169844 
PP Population: Activated T cell count by visit 
Treatment Visit N n 
Adjusted mean 
(SE) 




(SE)1 95% CI of difference 
Placebo 
On-Trt Wk12 
8 5 51203.4 (14618.11) (21342.6, 81064.2) 
-15043.8 
(21896.18) (-59669.7, 29582.0) Belimumab 10mg/kg 8 4 36159.5 (16350.26) (2849.4, 69469.7) 
Placebo 
On-Trt Wk24 
8 8 57278.7 (11872.54) (32803.8, 81753.5) 
3881.2 
(17477.72) (-31954.2, 39716.7) Belimumab 10mg/kg 8 6 61159.9 (13288.02) (33935.5, 88384.3) 
Placebo Post-Trt 
Wk12 
8 6 41835.9 (13483.91) (14211.7, 69460.1) 
26387.0 
(18975.60) (-12451.7, 65225.7) Belimumab 10mg/kg 8 6 68222.9 (13529.41) (40540.1, 95905.8) 
Placebo Post-Trt 
Wk28 
8 7 63901.1 (12475.65) (38257.5, 89544.7) 
-650.8 
(19371.60) (-40233.6, 38932.0) Belimumab 10mg/kg 8 5 63250.3 15250.65) (32152.3, 94348.4) 
Table S19: Analysis of regulatory T cell count by visit. 
1. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences are obtained
from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit
interaction and fixed continuous covariates of baseline and baseline-by-visit interaction. A compound
symmetry variance structure was used to model the within-patient errors, shared across treatments. Regulatory
T-cell count = CD4+ CD25hi IL-7Rlo cells/ml. This data is represented visually in Figure S1K
PP Population: Unadjusted baseline values regulatory T cell count (cells/ml) 
Treatment Visit N n Mean SD Median Min Max 
Placebo Baseline 8 8 50119.4 24537.03 49473.7 12884 97360 
Belimumab 10mg/kg Baseline 8 8 37496.1 35027.59 26074.9 192 117226 
PP Population: Regulatory T cell count by visit 
Treatment Visit N n Adjusted mean (SE) 












34657.8) Belimumab 10mg/kg 8 4 13498.0 (15530.96) (-17942.7, 44938.8) 
Placebo On-Trt 
Wk24 
8 8 19196.7 (9437.89) (90.7, 38302.7) 3486.5 
(13654.12) 
(-24154.8, 
31127.8) Belimumab 10mg/kg 8 7 22683.3 (9933.17) (2574.6, 42791.9) 
Placebo Post-Trt 
Wk12 




14464.2) Belimumab 10mg/kg 8 7 20768.6 (9794.01) (941.6, 40595.5) 
Placebo Post-Trt 
Wk28 
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